<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1000">
  <query>disease | Closed Studies | Interventional Studies | Phase 1, 2, 3, 4, 0</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <title>Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ITF2357</intervention>
      <intervention type="Drug">Placebo capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Italfarmaco</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>88 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 14, 2008</first_received>
    <start_date>October 2007</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the ability of ITF2357 to induce complete healing of mucosal ulcerations of ileum and/or colon, assessed by endoscopy</outcome_measure>
      <outcome_measure>to evaluate: the effect of ITF2357 on endoscopic disease activity assessed using both the CDEIS and the SESCD; the efficacy on clinical disease, assessed using the CDAI; to assess drug safety and tolerability and pharmacokinetic properties.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00792740</url>
  </study>
  <study rank="2">
    <title>Contrast-Enhanced Ultrasound in Human Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Contrast Enhanced Ultrasound</intervention>
      <intervention type="Drug">Optison</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>February 6, 2014</first_received>
    <start_date>February 2015</start_date>
    <completion_date>January 2018</completion_date>
    <last_updated>June 12, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of bowel wall inflammation and fibrosis in patients with Crohn's disease using CEUS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02061163</url>
  </study>
  <study rank="3">
    <title>Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycystic Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lanreotide Autogel 90 mg and 120 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Universitaire Ziekenhuizen Leuven</lead_sponsor>
      <collaborator>Ipsen</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 11, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 7, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction of total liver volume after 6 months of treatment measured by means of CT-scan.</outcome_measure>
      <outcome_measure>Reduction of total liver volume after 12 months of treatment by means of CT-scan</outcome_measure>
      <outcome_measure>Reduction of total liver volume after 18 months of treatment by means of CT-scan</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volumes and cyst volumes at baseline.</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volumes and cyst volumes after 6 months of treatment by means of CT scan</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volume and cyst volume after 12 months of treatment by means of CT scan.</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volumes and cyst volumes after 18 months of treatment by means of CT scan</outcome_measure>
      <outcome_measure>Assessment of quality of life at baseline</outcome_measure>
      <outcome_measure>Assessment of quality of life after 6 months of treatment</outcome_measure>
      <outcome_measure>Assessment of quality of life after 12 months of treatment</outcome_measure>
      <outcome_measure>Assessment of quality of life after 18 months of treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01315795</url>
  </study>
  <study rank="4">
    <title>Anakinra for Behcet s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune/Connective Tissue Diseases</condition>
      <condition>Immune System Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 24, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess treatment response (number of oral ulcers/inflammatory eye disease) to anakinra over 12-16 months of observation.</outcome_measure>
      <outcome_measure>Clinical and biochemical indicators of inflammation, total number of responders, long term clinical and biochemical response, and safety.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01441076</url>
  </study>
  <study rank="5">
    <title>Phase 1 Study of Zoledronic Acid in Sickle Cell Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Zoledronic Acid</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Virginia Commonwealth University</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <first_received>March 14, 2008</first_received>
    <start_date>June 2007</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>November 10, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The long-term goal of this project is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease.</outcome_measure>
      <outcome_measure>The specific purposes of this study are to learn if Zoledronic Acid has serious side effects for subjects with sickle cell disease and to study the effects of Zoledronic acid in subjects with sickle cell disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00639392</url>
  </study>
  <study rank="6">
    <title>The COPD Patient Management European Trial (COMET)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Disease Management</intervention>
      <intervention type="Other">Usual site management</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Air Liquide Santé International</lead_sponsor>
      <collaborator>ITEC Services</collaborator>
      <collaborator>Lincoln Medical and Mental Health Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>346</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>November 9, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>January 13, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of unscheduled hospital days</outcome_measure>
      <outcome_measure>Number of hospital days due to severe COPD exacerbation</outcome_measure>
      <outcome_measure>Safety parameters</outcome_measure>
      <outcome_measure>Medico-economic data</outcome_measure>
      <outcome_measure>Health related quality of life</outcome_measure>
      <outcome_measure>Use of health care services</outcome_measure>
      <outcome_measure>Compliance to oxygen therapy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01241526</url>
  </study>
  <study rank="7">
    <title>Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F]MK-9470</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>June 8, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>November 8, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Dynamic uptake and washout of [18F]MK-9470</outcome_measure>
      <outcome_measure>To acquire safety data</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01462708</url>
  </study>
  <study rank="8">
    <title>Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cough</condition>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Capsaicin</intervention>
      <intervention type="Other">Healthy Older Adults</intervention>
      <intervention type="Other">Parkinson's Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 2, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Lung volume initiation</outcome_measure>
      <outcome_measure>Peak expiratory flow rate</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02183519</url>
  </study>
  <study rank="9">
    <title>Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
      <condition>Ophthalmologic Complications</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">graft versus host disease prophylaxis/therapy</intervention>
      <intervention type="Other">questionnaire administration</intervention>
      <intervention type="Procedure">optical coherence tomography</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fred Hutchinson Cancer Research Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>June 6, 2012</first_received>
    <start_date>June 2012</start_date>
    <last_updated>June 1, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in symptoms measured by the Lee eye subscale</outcome_measure>
      <outcome_measure>Change in patient-reported symptoms as measured by the Ocular Surface Disease Index</outcome_measure>
      <outcome_measure>Change in patient-reported symptoms as measured by the 11-point eye rating scale</outcome_measure>
      <outcome_measure>Perceived change in eye symptoms measure by the 8-level patient-perceived change</outcome_measure>
      <outcome_measure>Change in comprehensive ophthalmologic evaluations</outcome_measure>
      <outcome_measure>Change in optical coherence tomography</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01616056</url>
  </study>
  <study rank="10">
    <title>Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Disease</condition>
      <condition>Myocardial Ischaemia</condition>
      <condition>Coronary Disease</condition>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Hybrid revascularization</intervention>
      <intervention type="Procedure">Coronary Artery Bypass Grafting</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Silesian Centre for Heart Diseases</lead_sponsor>
      <collaborator>Ministry of Science and Higher Education, Poland</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 16, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>December 1, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Possibility defined by means of (1) a % of pts with complete hybrid procedure according to study protocol, and (2) a % of conversion to standard CABG. Safety defined as a occurrence of MACE such as death, MI, stroke, TVR, or major bleeding.</outcome_measure>
      <outcome_measure>Postprocedure and follow up angiographic measurements as patency of grafts and restenosis in revascularized segments</outcome_measure>
      <outcome_measure>Assessment of quality of life of alive study participants according to SF-36 Health Survey version 2</outcome_measure>
      <outcome_measure>Cost-effectiveness defined as a cost of revascularization procedure and costs of hospitalizations in both groups.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01035567</url>
  </study>
  <study rank="11">
    <title>Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Capsule Endoscopy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>June 2005</start_date>
    <completion_date>June 2006</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Compare capsule endoscopy (CE) finding with traditional findings (colonoscopy and small-bowel follow through [SBFT]) in patients with known Crohn's disease</outcome_measure>
      <outcome_measure>Evaluate the extent and severity of CE determined small-bowel involvement in patients with known Crohn's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00178438</url>
  </study>
  <study rank="12">
    <title>Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute GVH Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Umbilical Cord Derived MSC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Affiliated Hospital to Academy of Military Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 11, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>April 7, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of UC-MSC in patients with acute graft-versus-host disease</outcome_measure>
      <outcome_measure>Efficacy of UC-MSC in patients with acute graft-versus-host disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01754454</url>
  </study>
  <study rank="13">
    <title>STA-5326 in Crohn's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STA-5326</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Synta Pharmaceuticals Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 19, 2004</first_received>
    <start_date>February 2004</start_date>
    <completion_date>November 2004</completion_date>
    <last_updated>June 23, 2005</last_updated>
    <last_verified>May 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00088062</url>
  </study>
  <study rank="14">
    <title>GM1 Ganglioside Effects on Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GM1 ganglioside</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Thomas Jefferson University</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>39 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2002</first_received>
    <start_date>November 1999</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>December 18, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>July 13, 2011</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Scores From Baseline to Week 120 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Total Unified Parkinson's Disease Rating Scale (UPDRS)Score Assessed Off Medication</outcome_measure>
      <outcome_measure>Change in Total UPDRS Score From Baseline to Week 120 Assessed Off Medication</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 48 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 72 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 96 Assessed Off Medication.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00037830</url>
  </study>
  <study rank="15">
    <title>Home-based Disease Management Program to Improve Clinical Outcomes in Patients With Heart Failure</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Home-based disease management</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Japanese Heart Failure Outpatient Disease Management Evaluation Investigators</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>156</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 25, 2011</first_received>
    <start_date>January 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>May 31, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Psychosocial status (depression, anxiety)</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Readmission due to heart failure</outcome_measure>
      <outcome_measure>Hospital admission</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Physical activity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01284400</url>
  </study>
  <study rank="16">
    <title>A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CJH1 (CLR4001)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alexandra Marine and General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 11, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>September 12, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduced signs and symptoms of Parkinson's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01684475</url>
  </study>
  <study rank="17">
    <title>Lyme Disease Prevention Program</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lyme Disease</condition>
      <condition>Tick-Borne Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Education about disease prevention</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
      <collaborator>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</collaborator>
      <collaborator>Centers for Disease Control and Prevention</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 18, 2000</first_received>
    <start_date>April 1997</start_date>
    <completion_date>March 2001</completion_date>
    <last_updated>December 23, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2001</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00000432</url>
  </study>
  <study rank="18">
    <title>18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">18F-DTBZ</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 11, 2011</first_received>
    <start_date>May 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>December 25, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of PD and normality for drug safety assessment</outcome_measure>
      <outcome_measure>To analyze the correlation between the regionally reduced 18F-DTBZ binding and the severity of disease of PD.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01283347</url>
  </study>
  <study rank="19">
    <title>A Trial of Wellbutrin for Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Wellbutrin (bupropion)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Altschuler, Eric, M.D.</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 2, 2005</first_received>
    <start_date>May 2005</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>January 19, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with Crohn's disease activity index (CDAI) &lt; 150 at the end of twelve weeks</outcome_measure>
      <outcome_measure>Number of patients with CDAI drop of at least 70 points at the end of twelve weeks</outcome_measure>
      <outcome_measure>Time course of CDAI</outcome_measure>
      <outcome_measure>Effect of drug and/or placebo on tumor necrosis factor-alpha (TNF) levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00126373</url>
  </study>
  <study rank="20">
    <title>A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Crohn's Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ferring Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 22, 2005</first_received>
    <start_date>October 2005</start_date>
    <completion_date>February 2006</completion_date>
    <last_updated>May 18, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the acceptability of Pentasa Sachets in comparison with the reference Pentasa tablets 500mg in children with Cohn's disease.</outcome_measure>
      <outcome_measure>To compare the safety of both formulations of Pentasa.</outcome_measure>
      <outcome_measure>To compare the concentration of mesalazine and N-acetylmesalazine in urine and stool during the administration of both formulations of Pentasa.</outcome_measure>
      <outcome_measure>To compare the PCD activity index at Week 4 and 8 Phase IV Study design: instead of Single Blind use Open Total enrollment: 29 patients.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00225810</url>
  </study>
  <study rank="21">
    <title>A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">[123I]β-CIT and SPECT imaging</intervention>
      <intervention type="Drug">[123I]β-CIT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 10, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>July 12, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the mean striatal uptake of [123I]B-CIT in first-degree relatives with a loss of odor identification, compared to an established healthy control database (age 40-70; n=50)</outcome_measure>
      <outcome_measure>Estimate the frequency of olfactory loss of first-degree relatives of PD patients</outcome_measure>
      <outcome_measure>Compare striatal DAT imaging in first-degree relatives of PD patients without signs or symptoms of PD with olfactory loss to age matched healthy controls</outcome_measure>
      <outcome_measure>Determine if a reduction in DAT density using [123I]B-CIT and SPECT imaging in first-degree relatives of PD patients without signs or symptoms of PD at baseline predicts the onset of clinical PD at 2-year follow-up</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00387075</url>
  </study>
  <study rank="22">
    <title>Effect of Increlex® on Children With Crohn Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">rhIGF (Increlex)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nationwide Children's Hospital</lead_sponsor>
      <collaborator>Tercica</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 1, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 14, 2015</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary outcome variable for the monitoring study (baseline, six months and disease exacerbation) will be longitudinal growth as measured by height velocity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00764699</url>
  </study>
  <study rank="23">
    <title>Targeting Oxidative Stress in Chronic Beryllium Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Beryllium Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalamine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Jewish Health</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 15, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Beryllium lymphocyte proliferation responses (BeLPT)</outcome_measure>
      <outcome_measure>Th1 cytokines</outcome_measure>
      <outcome_measure>Steady-state GSH levels</outcome_measure>
      <outcome_measure>HDAC2 levels</outcome_measure>
      <outcome_measure>Glucocorticoid receptors</outcome_measure>
      <outcome_measure>Lung function</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01088243</url>
  </study>
  <study rank="24">
    <title>Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Adalimumab</intervention>
      <intervention type="Biological">Adalimumab</intervention>
      <intervention type="Biological">Adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>192</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 8, 2006</first_received>
    <start_date>April 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>July 11, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>May 18, 2011</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26</outcome_measure>
      <outcome_measure>Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 52</outcome_measure>
      <outcome_measure>Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 26</outcome_measure>
      <outcome_measure>Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 52</outcome_measure>
      <outcome_measure>Change From Baseline IMPACT III Scores at Week 26 (Observed Case)</outcome_measure>
      <outcome_measure>Change From Baseline IMPACT III Scores at Week 52 (Observed Case)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00409682</url>
  </study>
  <study rank="25">
    <title>Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Transdermal nicotine</intervention>
      <intervention type="Other">Usual drug treatment of Parkinson's disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 31, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>December 29, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparison of motor scores in defined off condition : UPDRS III motor score assessed in &quot;defined OFF&quot; condition in comparison with control group.</outcome_measure>
      <outcome_measure>Evaluation of UPDRS III motor score assessed in &quot;defined OFF&quot; condition</outcome_measure>
      <outcome_measure>Improvement of UPDRS III motor score assessed in &quot;defined ON&quot; condition</outcome_measure>
      <outcome_measure>Evaluation of motor benefit (UPDRS &quot;OFF&quot; and &quot;ON&quot;)</outcome_measure>
      <outcome_measure>Evaluation of neuroprotection, (SPECT DaTSCAN and UPDRS &quot;OFF&quot;)</outcome_measure>
      <outcome_measure>Persistence of motor benefit (UPDRS &quot;OFF&quot; and &quot;ON&quot;)</outcome_measure>
      <outcome_measure>Decrease of total daily L-Dopa dose (or calculated equivalent in case of polytherapy)</outcome_measure>
      <outcome_measure>Improvement of quality of life (ADL and PDQ 39 scales)</outcome_measure>
      <outcome_measure>Decrease of daily percentage of &quot;OFF&quot; phase</outcome_measure>
      <outcome_measure>Improvement of dyskinesia score, (UPDRS IV)</outcome_measure>
      <outcome_measure>Relation dose / effect of nicotine</outcome_measure>
      <outcome_measure>Estimation of the most effective and tolerated dose of nicotine per kg</outcome_measure>
      <outcome_measure>Improvement of cognitive functions assessed by Mattis scale</outcome_measure>
      <outcome_measure>Comparison of all parameters between the 2 groups of patients</outcome_measure>
      <outcome_measure>Compliance to nicotine treatment</outcome_measure>
      <outcome_measure>Tolerance of transdermal nicotine</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00873392</url>
  </study>
  <study rank="26">
    <title>Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CEP-1347 10mg</intervention>
      <intervention type="Drug">CEP1347 25mg</intervention>
      <intervention type="Drug">CEP-1347 50mg</intervention>
      <intervention type="Other">Placebo Comparator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cephalon</lead_sponsor>
      <collaborator>H. Lundbeck A/S</collaborator>
      <collaborator>The Parkinson Study Group</collaborator>
      <collaborator>Teva Pharmaceutical Industries</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>806</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 26, 2002</first_received>
    <start_date>March 2002</start_date>
    <completion_date>August 2005</completion_date>
    <last_updated>May 8, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with disability using United Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Change from Baseline to 22 months in ([123I]β-CIT) Uptake Participants</outcome_measure>
      <outcome_measure>Safety and Tolerability as assessed by the number of participants experiencing adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00040404</url>
  </study>
  <study rank="27">
    <title>A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sensorineural Hearing Loss</condition>
      <condition>Autoimmune Inner Ear Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Andrea Vambutas</lead_sponsor>
      <collaborator>National Institute on Deafness and Other Communication Disorders (NIDCD)</collaborator>
      <collaborator>Northwell Health</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>13 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 28, 2010</first_received>
    <start_date>June 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>March 23, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>September 16, 2014</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To Assess the Potential Efficacy of Anakinra in Improving Hearing Thresholds in Corticosteroid-resistant Patients With Autoimmune Inner Ear Disease</outcome_measure>
      <outcome_measure>To Assess the Safety and Tolerability of a Three Month (84 Day) Course of Anakinra in Corticosteroid Resistant Patients With Autoimmune Inner Ear Disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01267994</url>
  </study>
  <study rank="28">
    <title>Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Transcranial Magnetic Stimulation (TMS)</intervention>
      <intervention type="Procedure">Motor Physiology Testing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>November 1, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>June 9, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Motor Cortex Excitability</outcome_measure>
      <outcome_measure>Relation between Unified Parkinson's Disease Rating Scale outcomes and physiological measures</outcome_measure>
      <outcome_measure>Transcallosal Pathway Excitability</outcome_measure>
      <outcome_measure>Physiological Measures</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02012647</url>
  </study>
  <study rank="29">
    <title>Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab with azathioprine (IIFX + AZA)</intervention>
      <intervention type="Drug">Infliximab (IFX alone)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Memorial Health Institute, Poland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>7 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 19, 2012</first_received>
    <start_date>November 2008</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>April 2, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical disease activity</outcome_measure>
      <outcome_measure>endoscopic disease activity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01559142</url>
  </study>
  <study rank="30">
    <title>An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab 5 mg/kg</intervention>
      <intervention type="Drug">Infliximab 10 mg/kg</intervention>
      <intervention type="Drug">Infliximab 20 mg/kg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centocor, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 22, 2005</first_received>
    <start_date>June 1995</start_date>
    <completion_date>October 1996</completion_date>
    <last_updated>November 3, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 1996</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparison of the proportion of patients achieving a clinical response at Week 4</outcome_measure>
      <outcome_measure>Clinical response over time; Time to loss of response; Clinical remission over time; Changes in CDAI, Inflammatory Bowel Disease Questionnaire (IBDQ) and Crohn's Disease Endoscopic Index of Severity (CDEIS) scores and C-reactive protein values</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00269854</url>
  </study>
  <study rank="31">
    <title>Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F] PBR111</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>September 20, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>November 8, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the cerebral distribution of [18F]PBR-111 positron emission tomography (PET) for detection/exclusion of microglial activation in patients with Alzheimer Disease compared to healthy volunteers.</outcome_measure>
      <outcome_measure>To assess the dynamic uptake and washout of [18F]PBR-111, a potential imaging biomarker for inflammatory changes in brain, using positron emission tomography (PET) in Alzheimer disease subjects compared to healthy volunteers.</outcome_measure>
      <outcome_measure>To perform blood metabolite characterization of [18F]PBR-111 in AD subjects compared to Healthy volunteers to determine the nature of metabolites in assessment of [18F]PBR-111 as a single positron computed tomography (PET) brain imaging agent.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01209156</url>
  </study>
  <study rank="32">
    <title>Rapamycin for Prevention of Chronic Graft-Versus-Host Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rapamycin</intervention>
      <intervention type="Drug">Tacrolimus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 13, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>July 15, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement of the rate of graft versus host disease (GVHD) from the accepted rate of 74%.</outcome_measure>
      <outcome_measure>Overall survival and disease free survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00623012</url>
  </study>
  <study rank="33">
    <title>Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">bowel prep regimen first boost 6 oz. and second boost 3 oz.</intervention>
      <intervention type="Other">bowel prep regimen first boost 3 oz. and second boost 6 oz.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Given Imaging Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>April 5, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>October 5, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 5, 2014</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>• Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01576120</url>
  </study>
  <study rank="34">
    <title>Self-Management Addressing Heart Disease Risk Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Bipolar Disorder</condition>
      <condition>Cardiovascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Chronic care model for Bipolar Disorder</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>118</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>July 9, 2007</first_received>
    <start_date>May 2008</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>November 12, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>October 17, 2014</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Systolic and Diastolic Blood Pressure (SBP, DBP)</outcome_measure>
      <outcome_measure>Total Cholesterol</outcome_measure>
      <outcome_measure>Physical Health-related Quality of Life Score</outcome_measure>
      <outcome_measure>Manic Symptoms</outcome_measure>
      <outcome_measure>Depressive Symptom Score</outcome_measure>
      <outcome_measure>Disability Based on WHO-DAS Score</outcome_measure>
      <outcome_measure>Body Mass Index (BMI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00499096</url>
  </study>
  <study rank="35">
    <title>Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">I-123-MNI-168</intervention>
      <intervention type="Drug">123-I MNI-168</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 26, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>February 24, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the uptake and washout of {I123}MNI-168, a potential imaging biomarker for β-amyloid burden in brain,</outcome_measure>
      <outcome_measure>To acquire initial safety data following injection of (123I) MNI-168.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00870519</url>
  </study>
  <study rank="36">
    <title>Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sargramostim (Leukine)</intervention>
      <intervention type="Drug">Sargramostim (Leukine)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>December 2, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Characterize the safety profile of sargramostim treatment with concomitant corticosteroid induction therapy</outcome_measure>
      <outcome_measure>Characterize the pharmacokinetic, pharmacodynamics properties of sargramostim treatment with concomitant corticosteroid induction therapy</outcome_measure>
      <outcome_measure>Evaluate the efficacy of sargramostim treatment with concomitant corticosteroids as measured by the Pediatric Crohn's Disease Activity Index (PCDAI), Physician's Global Assessment (PGA), and IMPACT-III Questionnaire</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00206661</url>
  </study>
  <study rank="37">
    <title>Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">lipoic acid and fish oil concentrate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oregon Health and Science University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 27, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>May 7, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Activities of Daily Living and Alzheimer's Disease Assessment Scale - cognitive subscale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01058941</url>
  </study>
  <study rank="38">
    <title>Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, With Complications</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Intravenous Insulin on cardiac disease in diabetic pts</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Florida Atlantic University</lead_sponsor>
      <collaborator>Advanced Diabetes Treatment Centers</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 3, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>August 8, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00539435</url>
  </study>
  <study rank="39">
    <title>Topical Imiquimod for Bowen's Disease of the Head and Neck</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bowens Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Imiquimod</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 4, 2006</first_received>
    <start_date>November 2006</start_date>
    <last_updated>March 25, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>histologic clearance of Bowens disease in treated versus placebo group</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00384124</url>
  </study>
  <study rank="40">
    <title>Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 12, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>May 30, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Crohn's Disease Activity Index (CDAI)</outcome_measure>
      <outcome_measure>Clinical response; remission; change in C-reactive protein; reduction in steroid use; fistula response; change in Perianal Disease Activity Index (PDAI); change in plasma cytokine levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00130390</url>
  </study>
  <study rank="41">
    <title>ESCAP: Supervised Exercise for Patients With Coronary Heart Disease in the Primary Care Setting</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Supervised exercise on a stationary bicycle, 3-5 days a week</intervention>
      <intervention type="Behavioral">Secondary prevention program for coronary heart disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Basque Health Service</lead_sponsor>
      <collaborator>Preventive Services and Health Promotion Research Network</collaborator>
      <collaborator>Santa Bárbara and Cuenca primary care centers(Castilla La Mancha Health Service)</collaborator>
      <collaborator>Castilla-León Health Service</collaborator>
      <collaborator>Dalt Sant Joan primary care center (Balears Islans Health Service)</collaborator>
      <collaborator>Public Health Service of Cataluña</collaborator>
      <collaborator>Public Health Service of Madrid</collaborator>
      <collaborator>Public Health Service of Galicia</collaborator>
      <collaborator>Cantabria Health Service</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>97</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 6, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>May 31, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Functional capacity (exercise treadmill test)</outcome_measure>
      <outcome_measure>Health Related Quality of life (SF-36)</outcome_measure>
      <outcome_measure>Cardiovascular risk factor control</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00146315</url>
  </study>
  <study rank="42">
    <title>Umbilical Cord Mesenchymal Stem Cells Injection for Diabetes Secondary Peripheral Arterial Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes</condition>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">umbilical cord mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute of Hematology &amp; Blood Diseases Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 2, 2014</first_received>
    <start_date>February 2014</start_date>
    <last_updated>February 24, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Angiographic evaluation of angiogenesis at ischemic limb</outcome_measure>
      <outcome_measure>Ankle-Brachial pressure index</outcome_measure>
      <outcome_measure>Walking distance</outcome_measure>
      <outcome_measure>Pain</outcome_measure>
      <outcome_measure>Laser Doppler evaluation of blood perfusion at ischemic limb</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02287831</url>
  </study>
  <study rank="43">
    <title>Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft-Versus-Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cyclosporine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Universitario Dr. Jose E. Gonzalez</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>May 13, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>February 25, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Ocular graft versus host disease is manifested by dry eye syndrome and disruptions in corneal integrity. The study will asses the efficacy of topical cyclosporine for preventing OGVHD manifestations</outcome_measure>
      <outcome_measure>Characteristics and clinical presentation of ocular graft versus host disease in patients receiving allogeneic bone marrow transplantation using a reduced intensity conditioning regimen</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02144025</url>
  </study>
  <study rank="44">
    <title>New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glioblastoma</condition>
      <condition>Sarcoma</condition>
      <condition>Neuroblastoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">New Castle Disease Virus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hadassah Medical Organization</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 2, 2010</first_received>
    <start_date>July 2011</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>June 10, 2015</last_updated>
    <last_verified>August 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression-free survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01174537</url>
  </study>
  <study rank="45">
    <title>Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ONO-2506PO</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ono Pharmaceutical Co. Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>January 2004</start_date>
    <last_updated>October 10, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's disease rating scale (Part III)</outcome_measure>
      <outcome_measure>Unified Parkinson's disease rating scale (Part I, II, IV and total), revised Hoehn &amp; Yahr severity score and off time</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00212693</url>
  </study>
  <study rank="46">
    <title>Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Autologous mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Clinica Universidad de Navarra, Universidad de Navarra</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 5, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>November 7, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Security and tolerance</outcome_measure>
      <outcome_measure>therapeutic effect</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01157650</url>
  </study>
  <study rank="47">
    <title>A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SEN0014196</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Siena Biotech S.p.A.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>25 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 29, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 19, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the effect of food on the repeated dose pharmacokinetics of SEN0014196 at 100 mg once daily in subjects with Huntington's disease</outcome_measure>
      <outcome_measure>Pharmacodynamics</outcome_measure>
      <outcome_measure>To determine the safety and tolerability of repeated doses of SEN0014196 at 100 mg once daily in subjects with Huntington's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01485965</url>
  </study>
  <study rank="48">
    <title>Alzheimer's Disease: Therapeutic Potential of Estrogen</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Transdermal estradiol</intervention>
      <intervention type="Drug">Medroxyprogesterone</intervention>
      <intervention type="Drug">Placebo Patch</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Wisconsin, Madison</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 4, 2003</first_received>
    <start_date>September 2001</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cognition: delayed recall on Buschke Selective Reminding Test; Stroop Interference condition--completion time and errors; Clinician-rated Interview Based Impression of Change</outcome_measure>
      <outcome_measure>Skills of Independent Living: Physical functioning Performance (PFP)</outcome_measure>
      <outcome_measure>Bioassays (Estradiol, estrone, medroxyprogesterone, FSH, influence of ApoE genotype in responsivity to estrogen)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00066157</url>
  </study>
  <study rank="49">
    <title>Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F] CFPyPB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>September 27, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>June 2, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the dynamic uptake and washout of [18F] CFPyPB</outcome_measure>
      <outcome_measure>Perform blood metabolite characterization of [18F] CFPyPB</outcome_measure>
      <outcome_measure>To obtain safety data</outcome_measure>
      <outcome_measure>Obtain test/retest reproductibility</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01461109</url>
  </study>
  <study rank="50">
    <title>Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Isotretinoin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospitals Cleveland Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 15, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 27, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline to Six month timepoint in the score on the Alzheimer's disease Assessment Scale- Cognitive subscale</outcome_measure>
      <outcome_measure>Number and types of adverse effects</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01560585</url>
  </study>
  <study rank="51">
    <title>A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Placenta-Derived Cells PDA001 Intravenous Infusion</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Celgene Corporation</lead_sponsor>
      <collaborator>Celgene</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 26, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>July 14, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>A reduction from baseline by 25% and/or &gt; 100 points in the Crohn's Disease Activity Index (CDAI) scores at both Week 4 (Day 29) and at Week 6 (Day 43).</outcome_measure>
      <outcome_measure>The induction of a clinical remission defined as a Crohn's Disease Activity Index score of &lt; 150 points at both Week 4 (Day 29) and Week 6 (Day 43)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01155362</url>
  </study>
  <study rank="52">
    <title>Development of Cognitive Assessment Tools in Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I] IBVM and SPECT imaging</intervention>
      <intervention type="Drug">Subjects will undergo the 123-I IBVM imaging visit</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>University of Oklahoma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <first_received>November 8, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>February 8, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The overall goal of this proposal is to validate ANAM-PD as an assessment tool for cognitive status in PD</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00556764</url>
  </study>
  <study rank="53">
    <title>Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rheumatic Valve Disease</condition>
      <condition>Atrial Fibrillation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Cardioblate® Surgical Ablation System</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>China National Center for Cardiovascular Diseases</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 11, 2009</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>November 16, 2009</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>At 3rd, 6th and 12th month's follow-up, to evaluate the rhythm status by ECG and 24-hour Holter and cardiac hemodynamic status by transthoracic echocardiography</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01013688</url>
  </study>
  <study rank="54">
    <title>Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Certolizumab pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 25, 2006</first_received>
    <start_date>January 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>August 26, 2014</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>February 23, 2011</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks)</outcome_measure>
      <outcome_measure>Disease Remission (Crohn's Disease Activity Index, CDAI≤150) at Week 34 in Patients Who Completed/Did Not Complete C87059 (COSPAR I, NCT00349752) and Remained Off Corticosteroids.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00356408</url>
  </study>
  <study rank="55">
    <title>Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Hematopoietic stem cell transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>7 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 28, 2013</first_received>
    <start_date>February 2014</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>April 13, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary outcome to be measured is safety and clinical benefit of lymphoablation followed by autologous HSCT rescue in therapy refractory Crohn's disease.</outcome_measure>
      <outcome_measure>Disease remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01932658</url>
  </study>
  <study rank="56">
    <title>Vaccination Against Influenza in Autoimmune Diseases</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Evaluation of vaccines against flu</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>234</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 21, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>January 5, 2016</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Protection against H1N1 influenza, defined by antibody level of 1/40, measured by hemagglutination, 3 weeks after the first injection and after the second injection</outcome_measure>
      <outcome_measure>Antibody levels against H1N1 in the different groups of patients, defined according diseases and their treatment (comparison of patients treated by immunosuppressants or not treated)</outcome_measure>
      <outcome_measure>Number of side effects related to vaccination</outcome_measure>
      <outcome_measure>Number of local side effects related to vaccination (erythema and/or pain at injection site)</outcome_measure>
      <outcome_measure>Number of patients who will develop influenza despite vaccination</outcome_measure>
      <outcome_measure>Number of patients who had antibodies against H1N1 before vaccination</outcome_measure>
      <outcome_measure>Number of hospitalisations and deaths related to influenza</outcome_measure>
      <outcome_measure>Number of flares of the autoimmune diseases that could be related to vaccination</outcome_measure>
      <outcome_measure>Determine if the induction of LT-CD4 to J21-28 anti-jams is correlated to the concentrations of antibody anti-vaccines measured in 6 months</outcome_measure>
      <outcome_measure>Determine if the basal concentrations of LT-CD4 anti-jam to J21-J28 are correlated to the concentrations of antibody anti-vaccines measured in 6 months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01065285</url>
  </study>
  <study rank="57">
    <title>Trial of a Treatment Algorithm for the Management of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Treatment Algorithm for Crohn's Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Western Ontario, Canada</lead_sponsor>
      <collaborator>Abbott</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1999</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 9, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>March 19, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients in remission at the end of the 24 month followup period. Remission is defined as a HBS&lt; or = 4 without use of steroids for the treatment of CD. the primary analysis will be performed at the level of the practice.</outcome_measure>
      <outcome_measure>Proportion of patients in remission over study, change in mean HBS; use of CD meds, occurrence of surgery/hospitalization for CD and complications, patients' health related QOL measured by SF-36 &amp; EQ-5D; physician/patient satisfaction with therapy.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01030809</url>
  </study>
  <study rank="58">
    <title>Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">CERE-110: Adeno-Associated Virus Delivery of NGF</intervention>
      <intervention type="Procedure">Placebo Surgery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ceregene</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
      <collaborator>Sangamo Biosciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 3, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>March 2020</completion_date>
    <last_updated>October 27, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</outcome_measure>
      <outcome_measure>Neuropsychological Test Battery</outcome_measure>
      <outcome_measure>Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00876863</url>
  </study>
  <study rank="59">
    <title>A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">QAX576</intervention>
      <intervention type="Drug">Infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 16, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assessment of efficacy of QAX576 to induce complete closure for at least 4 weeks of all perianal fistulas in patients suffering from Crohn's disease by: clinical observation and cutaneous photodocumentation</outcome_measure>
      <outcome_measure>Assessment of safety and tolerability of QAX576 in patients suffering from Crohn's disease as measured by lab assessments, ECG, physical exam etc</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01355614</url>
  </study>
  <study rank="60">
    <title>Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Influenza vaccination: Influvac (SolvayPharma)</intervention>
      <intervention type="Biological">placebo influenza vaccine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute of Cardiology, Warsaw, Poland</lead_sponsor>
      <collaborator>Solvay Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>658</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 31, 2006</first_received>
    <start_date>October 2004</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>October 21, 2007</last_updated>
    <last_verified>October 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>cardiovascular death</outcome_measure>
      <outcome_measure>First composite study end point was Major Adverse Cardiac Event (MACE). MACE was combined of: cardiovascular death, acute myocardial infarction (MI), coronary revascularization (PCI or coronary bypass).</outcome_measure>
      <outcome_measure>Second composite study end point was Ischemic Event (MACE or hospitalization for ischemia).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00371098</url>
  </study>
  <study rank="61">
    <title>Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">adalimumab</intervention>
      <intervention type="Drug">prednisone</intervention>
      <intervention type="Drug">azathioprine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>255</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 4, 2010</first_received>
    <start_date>February 2011</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of mucosal healing as defined by the Crohn's Disease Endoscopic Index of Severity (CDEIS) score at 48 weeks after Randomization</outcome_measure>
      <outcome_measure>Assess Pharmacokinetics (PK) of adalimumab following subcutaneous injection; a PK blood draw at protocol defined time points. Serum concentrations of adalimumab will be determined using a validated Ligand binding assay (LBA) method.</outcome_measure>
      <outcome_measure>Safety will be assessed through clinical laboratory tests, vital signs, physical exams and adverse event assessments.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01235689</url>
  </study>
  <study rank="62">
    <title>A Trial of Multi-convergent Therapy for Functional Symptoms and Stress in Patients With Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Multi-Convergent Therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cardiff and Vale University Health Board</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>August 27, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Quality of Life in Inflammatory Bowel Disease Questionnaire</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome Symptom Severity Score</outcome_measure>
      <outcome_measure>Change in Levenstein Perceived Stress Score</outcome_measure>
      <outcome_measure>Change in Hospital Anxiety and Depression Score</outcome_measure>
      <outcome_measure>Abdominal Symptoms Global Improvement Score</outcome_measure>
      <outcome_measure>Relapse rate in inflammatory bowel disease</outcome_measure>
      <outcome_measure>Feasibility of Treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01426568</url>
  </study>
  <study rank="63">
    <title>A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VSL#3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 25, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>August 10, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>to evaluate the effect of a probiotic formulation, VSL#3, versus placebo, on metabolic profile, intestinal permeability, microbiota, cytokines and chemokines expression and other inflammatory markers in pediatric patients with Crohn's Disease</outcome_measure>
      <outcome_measure>To determine the effect on Pediatric Crohn Disease Activity Index (PCDAI);</outcome_measure>
      <outcome_measure>to determine the time till flare of CD pediatric patients on VSL#3 compared to placebo.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01632462</url>
  </study>
  <study rank="64">
    <title>Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Meniere's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Betahistine 24 mg bid (Betaserc)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Solvay Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>January 2003</start_date>
    <last_updated>December 21, 2006</last_updated>
    <last_verified>December 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Patients who have undergone vestibular neurotomy for the treatment of disabling Menière’s disease and who have confirmed vestibular areflexia</outcome_measure>
      <outcome_measure>Other peripheral vestibular disease than Menière’s disease;Central vestibular disease; Neurological disease; Contraindication to betahistine; Pregnant or lactating women</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00160238</url>
  </study>
  <study rank="65">
    <title>Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Measurement of serum infliximab and anti-infliximab antibodies</intervention>
      <intervention type="Procedure">Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Copenhagen University Hospital at Herlev</lead_sponsor>
      <collaborator>Aase and Ejnar Danielsens Foundation</collaborator>
      <collaborator>Beckett Foundation</collaborator>
      <collaborator>the Danish Biotechnology Program</collaborator>
      <collaborator>Colitis-Crohn Foreningen</collaborator>
      <collaborator>Danish Medical Association</collaborator>
      <collaborator>Frode V. Nyegaard and wife’s Foundation</collaborator>
      <collaborator>Health Science Research Foundation of Region of Copenhagen</collaborator>
      <collaborator>Herlev Hospital Research Council</collaborator>
      <collaborator>Lundbeck Foundation</collaborator>
      <collaborator>P. Carl Petersens Fund</collaborator>
      <collaborator>Biomonitor A/S</collaborator>
      <collaborator>Prometheus Inc.</collaborator>
      <collaborator>The Danish Institute for Health Services Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 24, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 24, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with response at week 12, i.e. CDAI decrease of 70 or more for patients with luminal disease, or reduction of 50 percent or more from base line in the number of draining fistulas for patients with fistulising disease.</outcome_measure>
      <outcome_measure>Total expenses related to Crohn's disease during the study (inclusion to week 12).</outcome_measure>
      <outcome_measure>Mean change compared to baseline in WPAI score at week 12.</outcome_measure>
      <outcome_measure>Mean change compared to baseline in IBDQ score at week 12.</outcome_measure>
      <outcome_measure>Mean change compared to baseline in CDAI score at week 4,8, 12,20.</outcome_measure>
      <outcome_measure>Mean change compared to baseline in PDAI score at week 4, 8, 12, and 20.</outcome_measure>
      <outcome_measure>Clinical response at week 4, 8, 20</outcome_measure>
      <outcome_measure>Laboratory parameters</outcome_measure>
      <outcome_measure>Days with subjective feeling of disability due to Crohn's disease</outcome_measure>
      <outcome_measure>Serious adverse drug reactions</outcome_measure>
      <outcome_measure>Expenses related to Crohn's diseae at week 20</outcome_measure>
      <outcome_measure>Expenses related to Crohn's disease compared to change in CDAI-score (luminal disease) or PDAI-score (fistulizing disease), and IBD-score at week 12 and 20</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00851565</url>
  </study>
  <study rank="66">
    <title>African American Community Health Project on Cardiovascular Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Cardiovascular Risk Factor</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">lecture</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>April 4, 2011</first_received>
    <start_date>October 2010</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>April 12, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Weight</outcome_measure>
      <outcome_measure>Body mass index</outcome_measure>
      <outcome_measure>Waist Circumference</outcome_measure>
      <outcome_measure>Multiple choice test on cardiovascular disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01335022</url>
  </study>
  <study rank="67">
    <title>An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>398</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 10, 2006</first_received>
    <start_date>April 2001</start_date>
    <completion_date>February 2004</completion_date>
    <last_updated>May 16, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to the end of the study in the Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) and the Clinician's Interview-Based Impression of Change plus - Japan (CIBIC plus-J)</outcome_measure>
      <outcome_measure>Change from baseline to the end of the study in CIBIC plus-J subscales (Disability Assessment for Dementia [DAD], Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD], the Mental Function Impairment Scale [MENFIS ]).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00301574</url>
  </study>
  <study rank="68">
    <title>A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Drug: NIC5-15</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanetics Corporation</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
      <collaborator>James J. Peters Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 17, 2012</first_received>
    <start_date>April 2007</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>October 14, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score</outcome_measure>
      <outcome_measure>Change in Mini-Mental State Examination (MMSE) Score</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score</outcome_measure>
      <outcome_measure>Change in Neuropsychiatric Inventory (NPI) Score</outcome_measure>
      <outcome_measure>Changes in AD Biomarkers</outcome_measure>
      <outcome_measure>APO-E genotyping</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01928420</url>
  </study>
  <study rank="69">
    <title>Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Given® Diagnostic System including PillCamTM SB Capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rabin Medical Center</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
      <collaborator>Rambam Health Care Campus</collaborator>
      <collaborator>Assaf-Harofeh Medical Center</collaborator>
      <collaborator>Hillel Yaffe Medical Center</collaborator>
      <collaborator>University of Athens</collaborator>
      <collaborator>University of Magdeburg</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 8, 2008</first_received>
    <start_date>January 2007</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>April 28, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>This prospective study is aimed to evaluate the correlation of capsule endoscopy CECDAI with the CDAI (accepted clinical index) and IBDQ (quality of life questionnaire) in patients suffering from small-bowel Crohn's disease</outcome_measure>
      <outcome_measure>Capsule endoscopy investigation and crohn's disease outcome</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00596700</url>
  </study>
  <study rank="70">
    <title>A Study of the Novel Drug Dimebon in Patients With Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">Dimebon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medivation, Inc.</lead_sponsor>
      <collaborator>Huntington Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>29 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>91</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 3, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>May 16, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the safety and tolerability of Dimebon during 3 months of treatment in subjects with Huntington's Disease.</outcome_measure>
      <outcome_measure>To assess the impact of Dimebon during 3 months of treatment on cognitive, motor, and overall function in subjects with Huntington's Disease.</outcome_measure>
      <outcome_measure>To assess the pharmacokinetics of Dimebon.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00497159</url>
  </study>
  <study rank="71">
    <title>The Effects of Naltrexone on Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Inflammation</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone-HCl</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Penn State University</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>The Broad Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 18, 2008</first_received>
    <start_date>September 2006</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>May 16, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>November 30, 2012</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects Achieving a 70-point Decline in CDAI Scores (Crohn's Disease Activity Index) Scores;</outcome_measure>
      <outcome_measure>Percentage Change From Baseline of Quality of Life IBDQ (Inflammatory Bowel Disease Quality of Life Survey)</outcome_measure>
      <outcome_measure>Percentage of Patients With a 5 Point Drop in CDEIS Score by Endoscopy</outcome_measure>
      <outcome_measure>Histology Inflammatory Score by Colon Biopsies</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00663117</url>
  </study>
  <study rank="72">
    <title>Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">adult human mesenchymal stem cells</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mesoblast International Sàrl</lead_sponsor>
      <collaborator>Mesoblast, Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 30, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>October 27, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Disease remission (CDAI at or below 150)</outcome_measure>
      <outcome_measure>Disease improvement (Reduction by at least 100 points in CDAI)</outcome_measure>
      <outcome_measure>Improvement in quality of life (IBDQ)</outcome_measure>
      <outcome_measure>Reduction in number of draining fistulas</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00482092</url>
  </study>
  <study rank="73">
    <title>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Heart Disease, Ischemic</condition>
      <condition>Atherosclerosis, Coronary</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gadolinium</intervention>
      <intervention type="Drug">Adenosine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
      <collaborator>Astellas Pharma US, Inc.</collaborator>
      <collaborator>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 5, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>September 2, 2014</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Magnetic Resonance Image Quality Rating</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01234870</url>
  </study>
  <study rank="74">
    <title>Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Pain Perception in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Repetitive Transcranial Magnetic Stimulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Toulouse</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>December 10, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>June 18, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change of subjective pain threshold determined using thermal stimulation (Thermotest) with the method of levels after rTMS session</outcome_measure>
      <outcome_measure>Analgesic effect of Repetitive Transcranial Magnetic Stimulation using Visual Analogue Scale</outcome_measure>
      <outcome_measure>- Clinical evaluation of the severity of the motor handicap of patients using Unified's Parkinson's Disease Rating Scale (UPDRSIII)</outcome_measure>
      <outcome_measure>Mood assessment using Visual Analogue Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01275573</url>
  </study>
  <study rank="75">
    <title>Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>IDIOPATHIC PARKINSON'S DISEASE</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
      <intervention type="Drug">Placebo Patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>249</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 18, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>July 14, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>May 20, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts II+III, a UPDRS Subtotal) From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Response to Therapy, Defined as ≥20 % Decrease in the Sum of Scores From Activities of Daily Living (ADL) &amp; Motor Examination in Unified Parkinson's Disease Rating Scale (UPDRS Parts II+III, a UPDRS Subtotal) From Baseline to End of Maintenance Period</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale [UPDRS Part II (ADL)] From Baseline to the End of the Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale [UPDRS Part III (Motor Examination)] From Baseline to the End of the Double-blind Maintenance Period</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01646268</url>
  </study>
  <study rank="76">
    <title>Pioglitazone in Early Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 3, 2010</first_received>
    <start_date>March 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in Ambulatory Capacity From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in Schwab and England Scale From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in the Mattis Dementia Rating Scale (DRS-2)From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in the 15-item Geriatric Depression Scale (GDS-15)From Baseline to 44 Weeks</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01280123</url>
  </study>
  <study rank="77">
    <title>Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I] 5-IA</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>November 7, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Radiotracer uptake in cortical regions in PD relative to Healthy Control subjects</outcome_measure>
      <outcome_measure>Nicotinic receptor as a reliable measure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00397696</url>
  </study>
  <study rank="78">
    <title>Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Von Willebrand Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biostate®</intervention>
      <intervention type="Biological">Biostate®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>CSL Behring</lead_sponsor>
      <collaborator>Parexel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 15, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>April 4, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Haemostatic efficacy at time of non-surgical bleeding (NSB) event</outcome_measure>
      <outcome_measure>Haemostatic efficacy overall</outcome_measure>
      <outcome_measure>Number of treatments with blood product transfusions required to resolve any bleeding event</outcome_measure>
      <outcome_measure>vWF/FVIII concentrate usage (number of infusions, IU/kg per dose, per event, per month and per year)</outcome_measure>
      <outcome_measure>Assessment of blood loss during any surgical procedure</outcome_measure>
      <outcome_measure>Number of spontaneous or traumatic NSB events</outcome_measure>
      <outcome_measure>Pharmacokinetic parameters for vWF and FVIII (PK arm only)</outcome_measure>
      <outcome_measure>Development of FVIII inhibitors</outcome_measure>
      <outcome_measure>Development of vWF inhibitors</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00941616</url>
  </study>
  <study rank="79">
    <title>A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPM 962</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>143</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 25, 2012</first_received>
    <start_date>January 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>February 3, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters</outcome_measure>
      <outcome_measure>Skin Irritation Score of the Application Site</outcome_measure>
      <outcome_measure>Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01628965</url>
  </study>
  <study rank="80">
    <title>Safety Study of Erythropoietin (EPO) in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Erythropoietin human recombinant (EPOrh)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>International Center for Neurological Restoration, Cuba</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>November 8, 2009</first_received>
    <start_date>August 2008</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>November 9, 2009</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>safety assessment measured by the absence of adverse events</outcome_measure>
      <outcome_measure>Post-treatment change in the motor score of the Unified Assessment Scale for Parkinson Disease´s (UPDRS) in the &quot;OFF&quot; condition as compared with the baseline.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01010802</url>
  </study>
  <study rank="81">
    <title>Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">certolizumab pegol</intervention>
      <intervention type="Drug">certolizumab pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 25, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>August 1, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subjects reporting at least one Treatment-emergent Adverse Event (TEAE) during study treatment (up to 416 weeks)</outcome_measure>
      <outcome_measure>Number of subjects discontinuing treatment due to a Treatment-emergent Adverse Event (TEAE)</outcome_measure>
      <outcome_measure>Number of subjects who develop anti-nuclear antibodies during the study</outcome_measure>
      <outcome_measure>Number of subjects who develop double-stranded deoxyribonucleic acid (dsDNA) antibodies during the study</outcome_measure>
      <outcome_measure>Percentage of subjects in clinical remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01190410</url>
  </study>
  <study rank="82">
    <title>Searching for Persistence of Infection in Lyme Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lyme Disease</condition>
      <condition>Borrelia Burgdorferi</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Skin Biopsy</intervention>
      <intervention type="Device">Xenodiagnosis</intervention>
      <intervention type="Procedure">Blood Drawing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>June 11, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>August 31, 2016</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine whether xenodiagnosis can detect the continued presence of B. burgdorferi in patients with Lyme disease after antibiotic therapy.</outcome_measure>
      <outcome_measure>Assess the safety of the planned xenodiagnostic procedure in humans.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01143558</url>
  </study>
  <study rank="83">
    <title>Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">nicotine</intervention>
      <intervention type="Other">placebo comparator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Neuraltus Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>83 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 11, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>September 26, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>frequency and severity of adverse events, active vs placebo</outcome_measure>
      <outcome_measure>measure of impulse control (rMIDI), active vs placebo</outcome_measure>
      <outcome_measure>measure of frequency and severity of dyskinesia (USDysRS), active vs placebo</outcome_measure>
      <outcome_measure>Parkinson's disease severity (UPDRS part II,III,IV), active vs placebo</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00957918</url>
  </study>
  <study rank="84">
    <title>Combined Deep Brain Stimulation for Parkinson's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">DBS Surgery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>22 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 31, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change in the amount of time needed to complete a standardized timed up and go (TUG) study at 6 months post-surgery on stimulation</outcome_measure>
      <outcome_measure>TUG study at 1, 3 and 12 months post-surgery.</outcome_measure>
      <outcome_measure>UPDRS III score and UPDRS III points 27-30 at 1, 3, 6 and 12 months</outcome_measure>
      <outcome_measure>PDQ 31 questionnaire at 6 months</outcome_measure>
      <outcome_measure>Swallowing function at 6 moths</outcome_measure>
      <outcome_measure>Static and dynamic posturography parameters at 1, 3, 6 and 12 months on stimulation.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01485276</url>
  </study>
  <study rank="85">
    <title>Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Autologous hematopoietic stem cell transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2008</first_received>
    <start_date>January 1998</start_date>
    <last_updated>November 21, 2008</last_updated>
    <last_verified>November 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Disease-free survival</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Immune Reconstitution</outcome_measure>
      <outcome_measure>Organ-specific response parameters</outcome_measure>
      <outcome_measure>Serological Response (Autoantibodies)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00742300</url>
  </study>
  <study rank="86">
    <title>Mobile Health in Structural Heart Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rheumatic Heart Disease</condition>
      <condition>Heart Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Device">mHealth</intervention>
      <intervention type="Other">Standard-Care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sri Sathya Sai Institute of Higher Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Year</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>253</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>August 18, 2016</first_received>
    <start_date>August 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>August 23, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to definitive treatment with Valvuloplasty or Valve Replacement</outcome_measure>
      <outcome_measure>Cardiovascular Hospitalization and/or Death</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02881398</url>
  </study>
  <study rank="87">
    <title>Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">atomoxetine hydrochloride</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>124</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>October 2003</start_date>
    <completion_date>January 2006</completion_date>
    <last_updated>November 5, 2007</last_updated>
    <last_verified>November 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To see if Alzheimer's patients receiving a stable dose of an Alzheimer's drug randomly assigned to atomoxetine for approximately 6 months will have cognitive performance improved as measured by the Alzheimer's Disease Assessment Scale - Cognitive</outcome_measure>
      <outcome_measure>To see if patients taking an Alzheimer's medication plus atomoxetine for approximately 6 months will be superior to an Alzheimer's medication alone as assessed by the Clinician's Interview-Based Impression of Change (CIBIC+) score.</outcome_measure>
      <outcome_measure>To see if patients taking an Alzheimer's medication plus atomoxetine will display less comorbid psychological symptoms, such as depression, as assessed by the Neuropsychiatric Inventory (NPI). Patients will receive the NPI once before randomization</outcome_measure>
      <outcome_measure>To see if current Alzheimer's medications plus atomoxetine compared to Alzheimer's medications plus placebo is better at preserving or slowing cognitive decline as measured by the Alzheimer's Disease Cooperative Study Inventory - Activities of</outcome_measure>
      <outcome_measure>To show that current Alzheimer's drugs can be taken with atomoxetine without significant side effects.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00191009</url>
  </study>
  <study rank="88">
    <title>Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin-EIR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alfa Wassermann S.p.A.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>410</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 10, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>February 19, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical remission (Crohn's Disease Activity Index &lt; 150 points)</outcome_measure>
      <outcome_measure>Clinical response (reduction of baseline CDAI score by 100 points or more)</outcome_measure>
      <outcome_measure>Clinical response (reduction of baseline CDAI by 70 points or more)</outcome_measure>
      <outcome_measure>Time to obtain clinical response and remission</outcome_measure>
      <outcome_measure>Maintenance of clinical remission</outcome_measure>
      <outcome_measure>Number of treatment failures</outcome_measure>
      <outcome_measure>Definition of therapeutic dose to be used in subsequent phase III trials.</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00528073</url>
  </study>
  <study rank="89">
    <title>Impact of Gum Infection on Heart Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Disease</condition>
      <condition>Periodontal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Periodontal therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boston University</lead_sponsor>
      <collaborator>National Institute of Dental and Craniofacial Research (NIDCR)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 5, 2004</first_received>
    <start_date>September 2004</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>March 29, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Periodontal disease contributes to cardiovascular disease risk in human subjects and may lead to new approaches to therapy.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00093236</url>
  </study>
  <study rank="90">
    <title>Internet Chronic Disease Self-Management Program for Australia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Internet Chronic Disease Self-Management Program (ICDSMP)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>November 6, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>April 9, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Health Status</outcome_measure>
      <outcome_measure>Health behaviors</outcome_measure>
      <outcome_measure>Health care utilization</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00787956</url>
  </study>
  <study rank="91">
    <title>Standardized Fecal Microbiota Transplantation for Crohn&amp;Apos;s Diseases</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Diseases</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">FMT</intervention>
      <intervention type="Drug">5-ASA, Prednisone, Azathioprine or Remicade</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Second Hospital of Nanjing Medical University</lead_sponsor>
      <collaborator>Fourth Military Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>14 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 13, 2013</first_received>
    <start_date>November 2012</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical remission</outcome_measure>
      <outcome_measure>Hospitalization days</outcome_measure>
      <outcome_measure>Adverse events: fever and worsen abdominal pain.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01793831</url>
  </study>
  <study rank="92">
    <title>Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">UC-MSCs by peripheral intravenous infusion</intervention>
      <intervention type="Drug">received hormone maintenance therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fuzhou General Hospital</lead_sponsor>
      <collaborator>Shaanxi Provincial People's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 13, 2015</first_received>
    <start_date>June 2012</start_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's disease activity index</outcome_measure>
      <outcome_measure>Harvey-Bradshaw index</outcome_measure>
      <outcome_measure>Corticosteroid dosage</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02445547</url>
  </study>
  <study rank="93">
    <title>A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease &amp; Chronic Constipation</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RM-131</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Motus Therapeutics, Inc.</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 25, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>September 21, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Investigate the effects of treatment with RM-131 for 14 days on the frequency of spontaneous bowel movements (SBMs) when administered to patients with Parkinson's Disease (PD) and Chronic Constipation (CC)</outcome_measure>
      <outcome_measure>Evaluate the safety and tolerability of multiple doses of RM-131 when administered to patients with PD and CC</outcome_measure>
      <outcome_measure>Effect of RM-131 on stool frequency as measured by complete spontaneous bowel movements, stool consistency, straining, completeness of evacuation, abdominal pain, and global patient reported outcomes of severity of constipation and overall relief.</outcome_measure>
      <outcome_measure>Assess symptoms of Parkinson's disease using the Unified Parkinson Disease Rating Scale (UPDRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01955616</url>
  </study>
  <study rank="94">
    <title>Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">coenzyme q10</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National University Hospital, Singapore</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2013</first_received>
    <start_date>June 2012</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 8, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Biomarkers of oxidative damage</outcome_measure>
      <outcome_measure>Total Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01892176</url>
  </study>
  <study rank="95">
    <title>A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dimebon</intervention>
      <intervention type="Drug">Dimebon</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medivation, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>598</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 7, 2008</first_received>
    <start_date>May 2008</start_date>
    <last_updated>September 24, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog).</outcome_measure>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on the primary measure of global function, the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus).</outcome_measure>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on a measure of self care and daily function, the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL).</outcome_measure>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on a measure of behavior, the Neuropsychiatric Inventory (NPI).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00675623</url>
  </study>
  <study rank="96">
    <title>Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Video Telemonitoring Device with Clinical Care Modules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Minneapolis Veterans Affairs Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 28, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>August 1, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>composite clinical outcome (reduce risk of death, hospitalization, emergency room visits, admission to skilled nursing facility)</outcome_measure>
      <outcome_measure>reduction of cost</outcome_measure>
      <outcome_measure>incidence of end stage kidney disease</outcome_measure>
      <outcome_measure>hospital re-admission</outcome_measure>
      <outcome_measure>Intervention group achieving National Kidney guideline values for blood pressure, glycemia, lipids, and hemoglobin</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01446029</url>
  </study>
  <study rank="97">
    <title>Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PF-04360365 0.1 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 0.5 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 1 mg/kg</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">PF-04360365 3 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 8.5 mg/kg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>198</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 23, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>April 8, 2016</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/tolerability of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 18 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)</outcome_measure>
      <outcome_measure>Pharmacokinetics of PF-04360365 following administration of multiple doses in subjects with mild to moderate Alzheimer's disease. (plasma and cerebrospinal fluid (as available) PF-04360365 concentrations)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma/CSF Abeta; CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; Immunogenicity (anti-drug antibodies)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00722046</url>
  </study>
  <study rank="98">
    <title>Tolerance and Efficacy of Rituximab in Sjogren's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sjogren's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rituximab (mabthera) Injection</intervention>
      <intervention type="Drug">Placebo: NaCl 0.9% or Glucose 5%</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Brest</lead_sponsor>
      <collaborator>Ministry of Health, France</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 22, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>30% improvement between in the values on 2 of the 4 VAS measuring global scores of the disease (activity of the disease), joint pain, fatigue, and dryness.</outcome_measure>
      <outcome_measure>Variations from baseline to week 24 of clinical, biological and histological data</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00740948</url>
  </study>
  <study rank="99">
    <title>Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Pre-hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">carvedilol phosphate</intervention>
      <intervention type="Drug">lisinopril</intervention>
      <intervention type="Drug">carvedilol phosphate and lisinopril</intervention>
      <intervention type="Drug">placebo and placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Minnesota - Clinical and Translational Science Institute</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 5, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>December 9, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 16, 2013</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Overall Rasmussen Disease Score (RDS) Change From Baseline to 9 Months Will be the Primary End-point.</outcome_measure>
      <outcome_measure>Change in Disease Score (DS) Among the Treatment Groups</outcome_measure>
      <outcome_measure>Quantitative Change in Each of the RDS Components From Baseline to 9 Months Will Serve as a Secondary End-point. The 3-month Data Will Provide Early Evidence for Drug Efficacy and Will be Analyzed Similarly as a Secondary End-point.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00553969</url>
  </study>
  <study rank="100">
    <title>A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PF-04360365 10 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 7.5 mg/kg</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 22, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>April 8, 2016</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/tolerability/PK of multiple doses of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 1 year (adverse events, physical/neurological exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)</outcome_measure>
      <outcome_measure>Brain amyloid burden</outcome_measure>
      <outcome_measure>CSF abeta</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma abeta, CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; immunogenicity (anti-drug antibodies)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00945672</url>
  </study>
  <study rank="101">
    <title>AMG 827 in Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AMG 827 350 MG</intervention>
      <intervention type="Drug">AMG 827 210 MG</intervention>
      <intervention type="Drug">AMG 827 700 MG</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amgen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 24, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>December 14, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy of AMG 827 compared with placebo as measured by the proportion of subjects achieving Crohn's Disease Activity Index (CDAI) remission (≤ 150) at week 6.</outcome_measure>
      <outcome_measure>To evaluate the efficacy of AMG 827 as measured by the proportion of subjects with a CDAI response (reduction from baseline of ≥ 100) at week 6</outcome_measure>
      <outcome_measure>To evaluate improvement from baseline in CDAI at week 6</outcome_measure>
      <outcome_measure>To evaluate the short term safety profile of AMG 827 in subjects with Crohn's disease</outcome_measure>
      <outcome_measure>To characterize the pharmacokinetics (PK) of AMG 827 in subjects with Crohn's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01150890</url>
  </study>
  <study rank="102">
    <title>Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">QBECO</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Qu Biologics Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 8, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>August 19, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Clinical improvement</outcome_measure>
      <outcome_measure>Clinical remission</outcome_measure>
      <outcome_measure>Clinical response</outcome_measure>
      <outcome_measure>Intestinal inflammation</outcome_measure>
      <outcome_measure>Systemic inflammation</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01809275</url>
  </study>
  <study rank="103">
    <title>Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn’s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CCX282-B</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ChemoCentryx</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 4, 2005</first_received>
    <start_date>August 2004</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>March 12, 2006</last_updated>
    <last_verified>March 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Crohn’s Disease Activity Index score</outcome_measure>
      <outcome_measure>Safety (Adverse Events, tolerability)</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>Endoscopic appearance and biopsy of colon and terminal ileum</outcome_measure>
      <outcome_measure>Markers of leukocyte subsets and activation status</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00102921</url>
  </study>
  <study rank="104">
    <title>Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nader Pouratian</lead_sponsor>
      <collaborator>Medtronic</collaborator>
      <collaborator>University of California, Los Angeles</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 28, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>September 2017</completion_date>
    <last_updated>February 24, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Change in Hoehn and Yahr Scale</outcome_measure>
      <outcome_measure>Change in Parkinson's Disease Questionnaire (PDQ-39)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02438033</url>
  </study>
  <study rank="105">
    <title>Efficacy of Isradipine in Early Parkinson Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Isradipine</intervention>
      <intervention type="Drug">Placebo (for Isradipine)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
      <collaborator>The Parkinson Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>336</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 18, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>March 2019</completion_date>
    <last_updated>October 14, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Motor function</outcome_measure>
      <outcome_measure>Cognitive function</outcome_measure>
      <outcome_measure>Global measures</outcome_measure>
      <outcome_measure>Functional status and quality of life</outcome_measure>
      <outcome_measure>Functional Status and Quality of Life</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02168842</url>
  </study>
  <study rank="106">
    <title>Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera Cardinale G. Panico</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 26, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>January 22, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Responders to treatment (*) in motor (part III) and Activities of daily living (ADL) (part II) components of Unified Parkinson's Disease Rating Scale (UPDRS) at visit 4 and 6</outcome_measure>
      <outcome_measure>Percentage of Responders to treatment in sleep quality in relation to Parkinson's Disease Sleep Scale-2 (PDSS) at visit 4 and 6</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02103465</url>
  </study>
  <study rank="107">
    <title>Retinoids for Minimal Change Disease and Focal Segmental Glomerulosclerosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Collapsing Glomerulopathy</condition>
      <condition>Glomerulosclerosis, Focal Segmental</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Kidney needle biopsy</intervention>
      <intervention type="Procedure">DEXA Scan</intervention>
      <intervention type="Procedure">X-rays</intervention>
      <intervention type="Drug">Retinoids for Podocyte Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 1, 2004</first_received>
    <start_date>November 2004</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>September 15, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction in proteinuria</outcome_measure>
      <outcome_measure>Fraction of patients who are in CR or PR at 6 months or at the end of 1 year. Fraction of patients who are in CR or PR1 year after stopping therapy.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00098020</url>
  </study>
  <study rank="108">
    <title>Safety Study of Nicotinamide to Treat Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nicotinamide</intervention>
      <intervention type="Drug">Enduramide placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, Irvine</lead_sponsor>
      <collaborator>Alzheimer's Association</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 24, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>December 11, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00580931</url>
  </study>
  <study rank="109">
    <title>Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PPI-1019 (APAN)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>PRAECIS Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 29, 2004</first_received>
    <start_date>December 2004</start_date>
    <completion_date>August 2005</completion_date>
    <last_updated>September 18, 2006</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety will be assessed through the occurrence of clinical adverse events and the occurrence of clinically significant changes from baseline.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00100334</url>
  </study>
  <study rank="110">
    <title>Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases</condition>
      <condition>Crohn's Disease</condition>
      <condition>Gastrointestinal Diseases</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Intestinal Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalazine, Tripterygium glycosides</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Zhu Weiming</lead_sponsor>
      <collaborator>Jinling Hospital, China</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 19, 2014</first_received>
    <start_date>January 2014</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>January 22, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Therapeutic effect measured by Crohn's Disease Activity Index (CDAI)</outcome_measure>
      <outcome_measure>The Side effects of Tripterygium wilfordii (TW)</outcome_measure>
      <outcome_measure>The change of Crohn's Disease Activity Index (CDAI )</outcome_measure>
      <outcome_measure>The change of Simple Endoscopic Score for Crohn's Disease(SES-CD)</outcome_measure>
      <outcome_measure>The change of the Inflammatory Bowel Disease Questionnaire (IBDQ)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02044952</url>
  </study>
  <study rank="111">
    <title>Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dimebon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medivation, Inc.</lead_sponsor>
      <collaborator>Huntington Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 10, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>January 3, 2008</last_updated>
    <last_verified>September 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Dose-limiting toxicities</outcome_measure>
      <outcome_measure>Unified Huntington's Disease Rating Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00387270</url>
  </study>
  <study rank="112">
    <title>AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hodgkin's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">G-CSF Plus Plerixafor</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 2, 2006</first_received>
    <start_date>November 2004</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>February 10, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>February 10, 2009</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF</outcome_measure>
      <outcome_measure>Overall Participant Counts of Adverse Events During the Treatment Period</outcome_measure>
      <outcome_measure>Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF</outcome_measure>
      <outcome_measure>Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL</outcome_measure>
      <outcome_measure>Participant Counts Grouped by Number of Apheresis Days Required to Collect ≥ 5*10^6 CD34+ Cells/kg</outcome_measure>
      <outcome_measure>Number of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment</outcome_measure>
      <outcome_measure>Number of Days Post Transplantation to Platelet (PLT) Engraftment</outcome_measure>
      <outcome_measure>Number of Participants With a Durable Graft at 12 Months</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor</outcome_measure>
      <outcome_measure>Half-life (T1/2) Following a Single Dose of Plerixafor</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor</outcome_measure>
      <outcome_measure>Apparent Clearance (CL/F) of Single-dose Plerixafor</outcome_measure>
      <outcome_measure>Apparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00396201</url>
  </study>
  <study rank="113">
    <title>Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">adult human mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mesoblast International Sàrl</lead_sponsor>
      <collaborator>Mesoblast, Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 2, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>October 27, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Disease remission</outcome_measure>
      <outcome_measure>Disease Improvement</outcome_measure>
      <outcome_measure>Improvement in Quality of Life (IBDQ)</outcome_measure>
      <outcome_measure>Number of Adverse events as a measure of safety</outcome_measure>
      <outcome_measure>Infusional toxicity as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01233960</url>
  </study>
  <study rank="114">
    <title>Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">99mTc-ECDG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cell&gt;Point LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>July 10, 2013</first_received>
    <start_date>February 2014</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>March 25, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Characterization of the efficacy of 99mTCc-ECDG in the evaluation of Coronary Artery Disease</outcome_measure>
      <outcome_measure>Safety: The number of participants with Adverse Events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01899833</url>
  </study>
  <study rank="115">
    <title>Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-00547659 SC injection</intervention>
      <intervention type="Drug">PF-00547659 SC injection</intervention>
      <intervention type="Drug">PF-00547659 SC injection</intervention>
      <intervention type="Drug">PF-00547659 SC injection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>265</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 12, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>December 7, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) 70 response rate at week 8 or week 12 (between the investigational product group and the placebo group).</outcome_measure>
      <outcome_measure>Safety and tolerability of PF-00547659 dose levels versus placebo: the frequency of treatment adverse events, withdrawal due to adverse events, and serious adverse events (SAEs) will be reported.</outcome_measure>
      <outcome_measure>Percent of subjects with a CDAI remission (CDAI &lt;150), CDAI 70 and CDAI 100 responses Weeks 2 through 12.</outcome_measure>
      <outcome_measure>Immunogenicity assessments of antidrug antibodies (ADAs).</outcome_measure>
      <outcome_measure>The PK of total PF-00547659 will be characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life will be estimated using data pooled from both typical and additional PK groups.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01276509</url>
  </study>
  <study rank="116">
    <title>Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
      <condition>Crohn'S-like IBD</condition>
      <condition>Inflammatory Bowel Disease (IBD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 11, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>March 18, 2014</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of Study Drug</outcome_measure>
      <outcome_measure>Efficacy of Treatment With Study Drug</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00325078</url>
  </study>
  <study rank="117">
    <title>Dopaminergic Loss and Pain in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ioflupane 123I (DATSCAN®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Toulouse</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>July 16, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>March 29, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Single photon emission computerized tomography (SPECT) will be used to evaluate binding of 123I FP-CIT to dopamine transporters. This exam will allow calculation of the ratio of specific to non specific binding of 123I FP-CIT to dopamine transporters.</outcome_measure>
      <outcome_measure>Pain perception will be evaluated by the determination of subjective pain thresholds (thermal pain thresholds, thermotest). A thermode will be used to determine the heat and cold pain thresholds.</outcome_measure>
      <outcome_measure>Severity of Parkinson's disease will be evaluated with the Unified Parkinson's disease Rating Scale (UPDRS) and the Hoehn and Yahr scale</outcome_measure>
      <outcome_measure>Short French version of McGill pain questionnaire (MPQ).</outcome_measure>
      <outcome_measure>Pain intensity will be assessed using a 10 cm visual analogue scale (VAS) (0 = no pain; 10 = worst possible pain).</outcome_measure>
      <outcome_measure>DN4 scale</outcome_measure>
      <outcome_measure>Brief Inventory Pain</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression (HAD) scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00940914</url>
  </study>
  <study rank="118">
    <title>Trial of Growth Hormone Therapy in Pediatric Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">growth hormone</intervention>
      <intervention type="Drug">cortecosteroid</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Hospital Medical Center, Cincinnati</lead_sponsor>
      <collaborator>Genentech, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 28, 2005</first_received>
    <start_date>April 2005</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>October 10, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>June 24, 2011</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's Disease Histologic Index of Severity (CDHIS)</outcome_measure>
      <outcome_measure>Serum IGF-1 (Insulin-like Growth Factor 1)z Score</outcome_measure>
      <outcome_measure>IMPACT III Score</outcome_measure>
      <outcome_measure>Pediatric Crohn's Disease Activity Index (PCDAI)</outcome_measure>
      <outcome_measure>Total Corticosteroid Use</outcome_measure>
      <outcome_measure>Crohn's Disease Endoscopic Index of Severity (CDEIS)</outcome_measure>
      <outcome_measure>Height Velocity</outcome_measure>
      <outcome_measure>Fecal Calprotectin</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00109473</url>
  </study>
  <study rank="119">
    <title>Cytokine Profile in Children With Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bifidobacterium breve</intervention>
      <intervention type="Drug">Placebo (for Bifidobacterium breve)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Clinical Centre, Maribor</lead_sponsor>
      <collaborator>Slovenian Research Agency</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Year</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 16, 2014</first_received>
    <start_date>October 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 17, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum TNF-alpha decrease after Bifidobacterium breve daily consumption in children with celiac disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02244047</url>
  </study>
  <study rank="120">
    <title>Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biological: mesenchymal stem cell</intervention>
      <intervention type="Drug">Cyclosporine and Glucocorticoid</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chinese Academy of Medical Sciences</lead_sponsor>
      <collaborator>Zhejiang University</collaborator>
      <collaborator>Chinese PLA General Hospital</collaborator>
      <collaborator>307 Hospital of PLA</collaborator>
      <collaborator>Peking Union Medical College</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 1, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>August 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The total Response rate defined as patients with complete and partial response</outcome_measure>
      <outcome_measure>one-year survival rate</outcome_measure>
      <outcome_measure>disease relapse</outcome_measure>
      <outcome_measure>quality of life</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01526850</url>
  </study>
  <study rank="121">
    <title>Trial of Kuvan in Lesch-Nyhan Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Behavioral Manifestations of Lesch-Nyhan Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sapropterin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Diego</lead_sponsor>
      <collaborator>BioMarin Pharmaceutical</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>4 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>July 8, 2009</start_date>
    <last_updated>March 15, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Clinical responses to be monitored will include frequency and severity of self mutilation episodes, frequency and severity of aggressive acts towards others, and any effect on involuntary movements.</outcome_measure>
      <outcome_measure>Effect of Kuvan on standard chemistries, plasma amino acids, and plasma and urinary catecholamines</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00935753</url>
  </study>
  <study rank="122">
    <title>Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">deferiprone</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 20, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>August 31, 2012</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Decrease the iron overload (as measured by the T2* MRI sequence) in the substantia nigra in patients with Parkinson's disease (PD) after 6 months of deferiprone treatment, relative to the placebo group.</outcome_measure>
      <outcome_measure>Other radiological criteria: Modification of T2* in MRI of the caudal nucleus head, putamen and pallidum</outcome_measure>
      <outcome_measure>Parkinsonian syndrome: UPDRS III</outcome_measure>
      <outcome_measure>Cognitive and behavioral functions: function, attention (simple and choice reaction times), drowsiness and sleep (Epworth scale, Parkinson Disease Sleep Scale), depression (MADRS).</outcome_measure>
      <outcome_measure>The Clinical Global Impression scored by the examiner and the patient</outcome_measure>
      <outcome_measure>Specific biochemistry screen: heavy metal profile, oxidative stress and dopamine metabolism</outcome_measure>
      <outcome_measure>Complete blood count (CBC) with weekly leukocyte counts, standard blood biochemistry profile, blood iron profile, ECG, blood pressure, bodyweight, adverse event reporting.</outcome_measure>
      <outcome_measure>Ancillary study involving analysis of the cerebrospinal fluid (CSF).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00943748</url>
  </study>
  <study rank="123">
    <title>Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">AADvac1</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Axon Neuroscience SE</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 7, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease</outcome_measure>
      <outcome_measure>Immunogenicity of AADvac1</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01850238</url>
  </study>
  <study rank="124">
    <title>A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rofecoxib</intervention>
      <intervention type="Drug">Naproxen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute on Aging (NIA)</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 28, 2000</start_date>
    <completion_date>December 2001</completion_date>
    <last_updated>December 10, 2009</last_updated>
    <last_verified>June 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2001</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00004845</url>
  </study>
  <study rank="125">
    <title>An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Replagal agalsidase alfa</intervention>
      <intervention type="Drug">Replagal</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>39 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 26, 2006</first_received>
    <start_date>October 2003</start_date>
    <last_updated>August 16, 2011</last_updated>
    <last_verified>December 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Kidney function</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00357786</url>
  </study>
  <study rank="126">
    <title>Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Certolizumab Pegol</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Japan Co. Ltd.</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 10, 2006</first_received>
    <start_date>March 2006</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>March 5, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) response (clinical response or remission) at Week 6</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) score at Week 2</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) score at Week 4</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) score at Week 6</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve CDAI response at Week 2</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve CDAI response at Week 4</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 2</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 4</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 6</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve remission (CDAI &lt;= 150) at Week 2</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve remission (CDAI &lt;= 150) at Week 4</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve remission (CDAI &lt;= 150) at Week 6</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 2</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 4</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 6</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 2</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 4</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 6</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 2</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 4</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 6</outcome_measure>
      <outcome_measure>C-reactive protein (CRP) value at Week 2</outcome_measure>
      <outcome_measure>C-reactive protein (CRP) value at Week 4</outcome_measure>
      <outcome_measure>C-reactive protein (CRP) value at Week 6</outcome_measure>
      <outcome_measure>C-reactive protein (CRP) Ratio to Baseline at Week 2</outcome_measure>
      <outcome_measure>C-reactive protein (CRP) Ratio to Baseline at Week 4</outcome_measure>
      <outcome_measure>C-reactive protein (CRP) Ratio to Baseline at Week 6</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00291668</url>
  </study>
  <study rank="127">
    <title>Effect of Aspergillus Niger Prolyl Endoprotease (AN-PEP) Enzyme on the Effects of Gluten Ingestion in Patients With Coeliac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Aspergillus niger prolyl endoprotease</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VU University Medical Center</lead_sponsor>
      <collaborator>DSM Food Specialties</collaborator>
      <collaborator>Leiden University Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 17, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>January 18, 2011</last_updated>
    <last_verified>May 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Histopathological changes according to the Modified Marsh criteria</outcome_measure>
      <outcome_measure>The presence of coeliac disease specific antibodies (EMA, tTGA, gliadin)</outcome_measure>
      <outcome_measure>Presence and activity of gluten reactive Tcells isolated from biopsies and serum</outcome_measure>
      <outcome_measure>Immunophenotype of lymphocytes isolated from biopsies</outcome_measure>
      <outcome_measure>Clinical symptoms after gluten intake with and without AN-PEP</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00810654</url>
  </study>
  <study rank="128">
    <title>A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer´s Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg</intervention>
      <intervention type="Biological">Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg</intervention>
      <intervention type="Biological">Placebo solution: Human Albumin 0.25% - 4 mL/kg</intervention>
      <intervention type="Biological">Placebo solution: Human Albumin 0.25% - 2 mL/kg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baxalta US Inc.</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>390</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 7, 2009</first_received>
    <start_date>December 2008</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>June 26, 2015</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>June 27, 2014</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</outcome_measure>
      <outcome_measure>Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B</outcome_measure>
      <outcome_measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class</outcome_measure>
      <outcome_measure>Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)</outcome_measure>
      <outcome_measure>Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (&gt;1.5 g/dL) Between Consecutive Visits</outcome_measure>
      <outcome_measure>Number of Participants Experiencing a Clinically Significant Rash</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00818662</url>
  </study>
  <study rank="129">
    <title>Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">ABSORB implantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Istituto Clinico Sant'Ambrogio</lead_sponsor>
      <collaborator>Abbott Vascular</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 27, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>November 18, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the cumulative hierarchical incidence of major adverse cardiac events (MACE) defined as: cardiac death, non-fatal target vessel myocardial infarction (MI), or clinically driven target lesion revascularization (TLR).</outcome_measure>
      <outcome_measure>All causes mortality, clinically driven TLR, clinically driven target vessel revascularization (TVR), any revascularisation (non TLR, non TVR) and ARC-defined stent thrombosis, at any time point, any type of angina.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02004730</url>
  </study>
  <study rank="130">
    <title>Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Nervous System Malformations</condition>
      <condition>Arthropathy, Neurogenic</condition>
      <condition>Urticaria</condition>
      <condition>Papilledema</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">anakinra</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 22, 2003</first_received>
    <start_date>September 2003</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>October 7, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>May 6, 2016</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Diary Symptom Sum Score (DSSS) (Fever, Rash, Joint Pain, Vomiting, and Headaches)</outcome_measure>
      <outcome_measure>Patient / Parent Global Score of Overall Disease Activity</outcome_measure>
      <outcome_measure>Parent /Patient Pain Rating</outcome_measure>
      <outcome_measure>Childhood Health Assessment Questionnaire (CHAQ)</outcome_measure>
      <outcome_measure>Serum Amyloid A (SAA) Measurement</outcome_measure>
      <outcome_measure>C-reactive Protein (CRP) Measurement</outcome_measure>
      <outcome_measure>Erythrocyte Sedimentation Rate (ESR) Measurement</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00069329</url>
  </study>
  <study rank="131">
    <title>Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I]B-CIT SPECT imaging</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>22 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>142</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>August 23, 2005</first_received>
    <start_date>April 2000</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>July 15, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>October 7, 2010</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake to the Nondisplaceable Striatal [123I]B-CIT Uptake Between the Two Images</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00134784</url>
  </study>
  <study rank="132">
    <title>Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease With End of Dose &quot;Wearing Off&quot;</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbidopa/levodopa/entacapone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>359</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>February 16, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>December 7, 2010</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change in Parkinson's Disease Quality of Life Score From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change in Parkinson's Disease Quality of Life Score From Baseline to Week 8</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 8</outcome_measure>
      <outcome_measure>Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 8</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment</outcome_measure>
      <outcome_measure>Change in Parkinson's Disease Quality of Life Score From Baseline to End of Treatment</outcome_measure>
      <outcome_measure>Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to End of Treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00219284</url>
  </study>
  <study rank="133">
    <title>A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACR16 10 mg</intervention>
      <intervention type="Drug">ACR16 22.5 mg</intervention>
      <intervention type="Drug">ACR16 45 mg</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Pharmaceutical Industries</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>227</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 24, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>July 20, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sum score of items 4-10 and 13-15 of the UHDRS motor assessment</outcome_measure>
      <outcome_measure>Clinical Global Impressions (CGI)</outcome_measure>
      <outcome_measure>Adverse event profile</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00724048</url>
  </study>
  <study rank="134">
    <title>A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">infliximab or placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centocor, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>580</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>July 2000</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>April 26, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Reductions in the signs and symptoms of Crohn's disease</outcome_measure>
      <outcome_measure>Clinical remission;reduction in the use corticosteroids; mucosal healing</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00207662</url>
  </study>
  <study rank="135">
    <title>Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>Given Imaging Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>December 21, 2007</first_received>
    <start_date>January 2004</start_date>
    <completion_date>August 2004</completion_date>
    <last_updated>January 7, 2008</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sensitivity, positive predictive value, and accuracy of capsule endoscopy, CT enterography, colonoscopy with ileoscopy, and small bowel follow through using a consensus clinical diagnosis of small bowel Crohn's disease as the reference standard.</outcome_measure>
      <outcome_measure>Describe spectrum of right colon lesions visualized by capsule endoscopy in patients with Crohn's disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00588653</url>
  </study>
  <study rank="136">
    <title>A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Infliximab</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Biotech, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>297</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 12, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>January 5, 2016</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>October 16, 2014</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Clinical Recurrence (CR) of Crohn's Disease (CD) Prior to or at Week 76</outcome_measure>
      <outcome_measure>Percentage of Participants With Endoscopic Recurrence of CD Prior to or at Week 76</outcome_measure>
      <outcome_measure>Percentage of Participants With Clinical Recurrence (CR) of Crohn's Disease (CD) Prior to or at Week 104</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01190839</url>
  </study>
  <study rank="137">
    <title>Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I]AV94</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 16, 2008</first_received>
    <start_date>August 2007</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>October 5, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects</outcome_measure>
      <outcome_measure>To perform blood metabolite characterization of 123-I AV94 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I AV94 as a single photon computed tomography (SPECT) brain imaging agent</outcome_measure>
      <outcome_measure>Evaluate the test/retest reproducibility of 123-I AV94 and SPECT in AD subjects and healthy controls</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00605059</url>
  </study>
  <study rank="138">
    <title>18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AADvac1</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Axon Neuroscience SE</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>86 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 7, 2014</first_received>
    <start_date>January 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>July 15, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease</outcome_measure>
      <outcome_measure>Immunogenicity of AADvac1</outcome_measure>
      <outcome_measure>Patient cognition</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02031198</url>
  </study>
  <study rank="139">
    <title>A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">adalimumab</intervention>
      <intervention type="Biological">adalimumab</intervention>
      <intervention type="Biological">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
      <collaborator>Abbott Japan Co.,Ltd</collaborator>
      <collaborator>Eisai Co., Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>15 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 7, 2007</first_received>
    <start_date>February 2007</start_date>
    <last_updated>June 20, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>December 23, 2008</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] &lt; 150) at Week 4</outcome_measure>
      <outcome_measure>Clinical Remission (CDAI &lt; 150) at Week 2</outcome_measure>
      <outcome_measure>Clinical Response (CR-70 and CR-100) in Period A</outcome_measure>
      <outcome_measure>Clinical Response (CR-70 and CR-100) in Period B</outcome_measure>
      <outcome_measure>Clinical Remission (CDAI &lt;150) at Week 6 and Week 8</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00445939</url>
  </study>
  <study rank="140">
    <title>ASTIC Autologous Stem Cell Transplantation for Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Autologous haematopoietic stem cell transplant</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>European Group for Blood and Marrow Transplantation</lead_sponsor>
      <collaborator>The Broad Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 27, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>August 29, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion patients in sustained disease remission</outcome_measure>
      <outcome_measure>patients who have not responded to immunosuppressant medication</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00297193</url>
  </study>
  <study rank="141">
    <title>Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lyme Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Permethrin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Minnesota - Clinical and Translational Science Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>14 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 12, 2009</first_received>
    <start_date>June 2008</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>July 9, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of Lyme disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00958139</url>
  </study>
  <study rank="142">
    <title>Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity</condition>
      <condition>Cardiovascular Disease</condition>
      <condition>Metabolic Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low glycemic load diet</intervention>
      <intervention type="Other">Canada Food Guide Diet</intervention>
      <intervention type="Other">Low glycemic index diet</intervention>
      <intervention type="Other">Low carbohydrate diet</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Queen's University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Caregiver)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>September 2004</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>January 27, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare the effectiveness of a low glycemic load diet with a Canada Food Guide Diet on weight loss in overweight subjects with cardiovascular disease.</outcome_measure>
      <outcome_measure>To compare the effectiveness of a low glycemic load diet with both a low glycemic index diet and a low carbohydrate diet on weight loss in overweight subjects with cardiovascular disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00229229</url>
  </study>
  <study rank="143">
    <title>Dietary Treatment of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Time and attention + fructo-oligosaccharide placebo</intervention>
      <intervention type="Dietary Supplement">dietary therapy + fructo-oligosaccharide placebo</intervention>
      <intervention type="Drug">Time and attention + active fructooligosaccharide supplementation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rush University Medical Center</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>73</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 21, 2006</first_received>
    <start_date>September 2006</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>January 24, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of dietary treatment in maintaining remission of Crohn's disease</outcome_measure>
      <outcome_measure>Quality of life in patients taking dietary treatments</outcome_measure>
      <outcome_measure>Safety of dietary treatments</outcome_measure>
      <outcome_measure>Utility of dietary treatments for patients</outcome_measure>
      <outcome_measure>Changes in ileocolonic flora</outcome_measure>
      <outcome_measure>Changes in colonic oxidative stress</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00343642</url>
  </study>
  <study rank="144">
    <title>Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Argentinean Tango classes</intervention>
      <intervention type="Other">Simple pamphlet about the exercise in PD</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>McGill University Health Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 5, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>December 21, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>April 15, 2015</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Severity of PD (Unified Parkinson Disease Rating Scale - UPDRS, 2008 Version)</outcome_measure>
      <outcome_measure>MiniBESTest</outcome_measure>
      <outcome_measure>Number of Participants With a Fall in the Past 3 Months Using the Falls Questionnaire From the Canadian Longitudinal Study of Aging</outcome_measure>
      <outcome_measure>Freezing of Gait Questionnare (FOG_Q)</outcome_measure>
      <outcome_measure>The Purdue Pegboard</outcome_measure>
      <outcome_measure>The Montreal Cognitive Assessment</outcome_measure>
      <outcome_measure>The Beck Depression Inventory (BDI)</outcome_measure>
      <outcome_measure>Apathy Evaluation Scale (AES)</outcome_measure>
      <outcome_measure>The Krupp Fatigue Severity Scale</outcome_measure>
      <outcome_measure>The Parkinson's Disease Questionnaire is a Quality of Life(PDQ-39)</outcome_measure>
      <outcome_measure>Adherence to Treatment</outcome_measure>
      <outcome_measure>Clinical Global Impression of Change</outcome_measure>
      <outcome_measure>Exit Questionnaire</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01573260</url>
  </study>
  <study rank="145">
    <title>Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Chagas Disease, Indeterminate</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">E1224</intervention>
      <intervention type="Drug">Benznidazole</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Drugs for Neglected Diseases</lead_sponsor>
      <collaborator>Eisai Co., Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 24, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 19, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment</outcome_measure>
      <outcome_measure>Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication</outcome_measure>
      <outcome_measure>Qualitative PCR as a measure of parasite eradication</outcome_measure>
      <outcome_measure>Quantitative PCR as a measure of change in parasite load over time</outcome_measure>
      <outcome_measure>Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies</outcome_measure>
      <outcome_measure>Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay</outcome_measure>
      <outcome_measure>Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole</outcome_measure>
      <outcome_measure>Incidence and severity of adverse events (clinical and laboratory)</outcome_measure>
      <outcome_measure>Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation</outcome_measure>
      <outcome_measure>Early and late predictors of sustainable response to treatments</outcome_measure>
      <outcome_measure>Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01489228</url>
  </study>
  <study rank="146">
    <title>Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB BIOSCIENCES GmbH</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 30, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>July 13, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>December 15, 2014</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Total Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living) + III (Motor Symptoms)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Caregiver (Where Available)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Sum Score of the 8-item Parkinson's Disease Questionnaire (PDQ-8)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Sum Score of the Mood / Cognition Domain of the Nonmotor Symptom Assessment Scale (NMSS)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Sum Score of the Snaith Hamilton Pleasure Scale (SHAPS)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Sum Score of the Beck Depression Inventory Second Edition (BDI-II)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Sum Score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale) in &quot;on&quot; State</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Maintenance Period in the Score of the Clinical Global Impression Scale (CGI) Item I (Severity of Illness)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01782222</url>
  </study>
  <study rank="147">
    <title>Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PF-04360365 8.5 mg/kg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 17, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>August 11, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease dosed for 6 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, immunogenicity and cognitive assessments)</outcome_measure>
      <outcome_measure>Pharmacokinetics of PF-04360365 following administration of multiple doses in Japanese subjects with mild to moderate Alzheimer's disease. (plasma PF-04360365 concentrations)</outcome_measure>
      <outcome_measure>Plasma concentration of Aβ species following administration of multiple doses of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01125631</url>
  </study>
  <study rank="148">
    <title>A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>15 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 4, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>March 11, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>March 11, 2016</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Clinical Remission (CDAI &lt; 150) Every 4 Weeks up to Week 52</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) Every 4 Weeks up to Week 52</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Clinical Response 70 (CR70; Crohn's Disease Activity Index [CDAI] Decrease ≥ 70 From Week 0) Every 4 Weeks up to Week 52</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Clinical Response 100 (CR100; Crohn's Disease Activity Index [CDAI] Decrease of 100 From Week 0) Every 4 Weeks up to Week 52</outcome_measure>
      <outcome_measure>C-reactive Protein (CRP): Mean Change From Baseline (Week 0) to Week 52</outcome_measure>
      <outcome_measure>Number of Participants With Potentially Significant Hematology Parameters</outcome_measure>
      <outcome_measure>Number of Participants With Potentially Significant Clinical Chemistry Parameters</outcome_measure>
      <outcome_measure>Systolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit</outcome_measure>
      <outcome_measure>Diastolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit</outcome_measure>
      <outcome_measure>Heart Rate: Mean Change From Baseline (Week 0) to Each Visit</outcome_measure>
      <outcome_measure>Body Temperature: Mean Change From Baseline (Week 0) to Each Visit</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01958827</url>
  </study>
  <study rank="149">
    <title>Safety of Celecoxib in Patients With Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Celebrex</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>Shadyside Hospital Foundation</collaborator>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>December 2003</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>July 28, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>June 15, 2016</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Crohn's Disease Activity Index (CDAI) Scores in Response to Treatment</outcome_measure>
      <outcome_measure>Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Scores in Response to Treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00177866</url>
  </study>
  <study rank="150">
    <title>Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Huperzine A</intervention>
      <intervention type="Drug">huperzine A</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Shandong Luye Pharmaceutical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>390</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 24, 2011</first_received>
    <start_date>May 2010</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>January 24, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale</outcome_measure>
      <outcome_measure>Clinician's Interview Based Impression of Change, plus caregiver input</outcome_measure>
      <outcome_measure>Activities of Daily Living</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01282619</url>
  </study>
  <study rank="151">
    <title>Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">NO-CO inhalation and expiration</intervention>
      <intervention type="Other">NO-CO inhalation and expiration</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>November 16, 2007</first_received>
    <start_date>February 2008</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>August 2, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Study of lung capillary blood volume and alveolar membrane diffusing capacity using NO-CO method</outcome_measure>
      <outcome_measure>Respiratory physiopathology's study in sickle cell disease</outcome_measure>
      <outcome_measure>Valid alveolar membrane diffusing capacity using NO-CO in children with or without sickle cell disease</outcome_measure>
      <outcome_measure>Purpose respiratory function follow up in sickle cell disease child</outcome_measure>
      <outcome_measure>Find relationship between these vascular abnormalities and NO metabolism</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00560261</url>
  </study>
  <study rank="152">
    <title>Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Levodopa/carbidopa/entacapone</intervention>
      <intervention type="Drug">Levodopa/carbidopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>95</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 24, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>February 16, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>January 4, 2011</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3</outcome_measure>
      <outcome_measure>Change in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3</outcome_measure>
      <outcome_measure>Change in the UPDRS Part III (Motor Function) Score From Baseline to Month 3</outcome_measure>
      <outcome_measure>Change in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3</outcome_measure>
      <outcome_measure>Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 3</outcome_measure>
      <outcome_measure>Patient and Investigator Global Evaluation of the Patient</outcome_measure>
      <outcome_measure>Change on the QUICK Questionnaire (QQ) Score From Baseline to Month 3</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00391898</url>
  </study>
  <study rank="153">
    <title>Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
      <condition>Chronic Kidney Disease, Stage IV (Severe)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Fabrazyme (agalsidase beta)</intervention>
      <intervention type="Biological">Fabrazyme (agalsidase beta)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>CRL/Medinet</collaborator>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 23, 2008</first_received>
    <start_date>December 2002</start_date>
    <completion_date>August 2003</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>December 5, 2008</firstreceived_results_date>
    <primary_completion_date>August 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to Clinically Significant Progression of Cardiac Disease, Cerebrovascular Disease, and/or Death Among Fabry Patients With Severe Kidney Disease</outcome_measure>
      <outcome_measure>Plasma Globotriaosylceramide (GL-3)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00837824</url>
  </study>
  <study rank="154">
    <title>Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sirolimus</intervention>
      <intervention type="Drug">conventional therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mario Negri Institute for Pharmacological Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 12, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>February 22, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Glomerular Filtration Rate (GFR)</outcome_measure>
      <outcome_measure>Liver volume parameters.</outcome_measure>
      <outcome_measure>Renal volume parameters.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01223755</url>
  </study>
  <study rank="155">
    <title>Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anemia of Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cholecalciferol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Year</min_age>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 8, 2012</first_received>
    <start_date>May 2012</start_date>
    <last_updated>September 19, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in serum hepcidin with vitamin D intervention for children with chronic kidney disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01532349</url>
  </study>
  <study rank="156">
    <title>Non-contact Boxing Training and Traditional Therapeutic Exercise for Persons With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Traditional Therapeutic Exercise</intervention>
      <intervention type="Behavioral">Non-Contact Boxing Training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Indianapolis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 13, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>November 20, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mobility: Measured with the Timed Up and Go Test; Four-Square Step Test; Six-Minute Walk Test; Berg Balance Scale; Functional Reach Test</outcome_measure>
      <outcome_measure>Participation: measured with the Activities Specific Balance Confidence Scale and the Parkinson's disease Quality of Life Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01014663</url>
  </study>
  <study rank="157">
    <title>Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ischemic Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ad-HGF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The First Affiliated Hospital with Nanjing Medical University</lead_sponsor>
      <collaborator>Academy Military Medical Science, China</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 15, 2013</first_received>
    <start_date>November 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>August 19, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with death,new myocardial infarction or stroke</outcome_measure>
      <outcome_measure>left ventricular ejection fraction (LVEF)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01925352</url>
  </study>
  <study rank="158">
    <title>A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">IPX066</intervention>
      <intervention type="Drug">IPX066</intervention>
      <intervention type="Drug">IPX066</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IMPAX Laboratories, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>381</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 3, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>January 25, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>December 7, 2015</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire-39 (PDQ-39)</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00880620</url>
  </study>
  <study rank="159">
    <title>African American Study of Kidney Disease and Hypertension ABPM Pilot Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertensive Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">USUAL - take your BP Meds as you usually do</intervention>
      <intervention type="Behavioral">HS DOSING</intervention>
      <intervention type="Drug">ADD On Dosing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 20, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>April 12, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Night Time Blood Pressure</outcome_measure>
      <outcome_measure>Blood pressure in the clinic Daytime blood pressure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00582777</url>
  </study>
  <study rank="160">
    <title>A Study of TRK-170 for the Treatment of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TRK-170</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Toray Industries, Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>123</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 28, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>June 11, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Crohn's Disease Activity Index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01345799</url>
  </study>
  <study rank="161">
    <title>Safety and Efficacy of Motor Cortex Stimulation in the Treatment of Advanced Parkinson Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Motor cortex stimulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Educational/Counseling/Training</study_design>
    </study_designs>
    <first_received>September 7, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>March 5, 2007</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety of the treatment and Unified Parkinson Disease Rating Scale (UPDRS) III 1 month following constant stimulation with and without motor cortex stimulation when the patient has no anti-parkinsonian drug for 12 hours</outcome_measure>
      <outcome_measure>Quality of life: Parkinson's Disease Questionnaire 39 (PDQ39) scores</outcome_measure>
      <outcome_measure>Anti-parkinsonian drug doses (equivalent L-dopa)</outcome_measure>
      <outcome_measure>Results of motor activation study in positron emission tomography (PET) scan</outcome_measure>
      <outcome_measure>Results of the different neuropsychological tests</outcome_measure>
      <outcome_measure>Video movement analysis</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00159172</url>
  </study>
  <study rank="162">
    <title>Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Gaucher Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GA-GCB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Shire</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 20, 2006</first_received>
    <start_date>February 2005</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>May 13, 2016</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>March 4, 2014</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of Long Term Safety</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Hemoglobin Concentration</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Platelet Counts</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Liver Volume</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Spleen Size</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00391625</url>
  </study>
  <study rank="163">
    <title>Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pompe Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clenbuterol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dwight Koeberl, M.D., Ph.D.</lead_sponsor>
      <collaborator>Duke University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 11, 2013</first_received>
    <start_date>September 2013</start_date>
    <last_updated>October 20, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in creatine kinase (CK) reflecting worsening of muscle involvement</outcome_measure>
      <outcome_measure>Change in aspartate aminotransferase (AST), alanine transaminase (ALT), and bilirubin representing liver toxicity</outcome_measure>
      <outcome_measure>Change 6 minute walk test</outcome_measure>
      <outcome_measure>Change in forced vital capacity in pulmonary function testing</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01942590</url>
  </study>
  <study rank="164">
    <title>Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">GSK933776</intervention>
      <intervention type="Biological">GSK933776</intervention>
      <intervention type="Biological">GSK933776</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>August 4, 2011</first_received>
    <start_date>May 2010</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>September 5, 2013</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment</outcome_measure>
      <outcome_measure>The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment</outcome_measure>
      <outcome_measure>The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment</outcome_measure>
      <outcome_measure>Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals.</outcome_measure>
      <outcome_measure>To assess the safety and tolerability after single dose of GSK933776 administration.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01424436</url>
  </study>
  <study rank="165">
    <title>An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SEN0014196 (Low Dose)</intervention>
      <intervention type="Drug">SEN0014196 (High Dose)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Siena Biotech S.p.A.</lead_sponsor>
      <collaborator>Seventh Framework Programme</collaborator>
      <collaborator>European Huntington's Disease Network</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 29, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the change from baseline of a series of pharmacodynamic markers in peripheral blood mononuclear cells</outcome_measure>
      <outcome_measure>To determine the safety and tolerability following repeated doses of SEN0014196 over two weeks at two dose levels in patients with Huntington's disease</outcome_measure>
      <outcome_measure>To determine the pharmacokinetics of repeated doses of SEN0014196 at two dose levels when administered over two weeks in patients with Huntington's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01485952</url>
  </study>
  <study rank="166">
    <title>Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MT-1303</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 27, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>October 12, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve a 100-point decrease from Baseline in CDAI(Crohn's Disease Activity Index) score (i.e., CDAI 100) at Visit 6 (Week 12)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02378688</url>
  </study>
  <study rank="167">
    <title>Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AIN457</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 21, 2007</first_received>
    <start_date>August 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>March 24, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>January 28, 2015</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Change From Baseline in Crohns Disease Activity Index (CDAI) Score</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Remission and/or Response</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Remission</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Response</outcome_measure>
      <outcome_measure>Mean Change From Baseline in CDAI Score</outcome_measure>
      <outcome_measure>Area Under CDAI Curve</outcome_measure>
      <outcome_measure>Percentage of Participants Maintaining Remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00584740</url>
  </study>
  <study rank="168">
    <title>Effect of Addition of Short Course of Prednisolone to Gluten Free Diet in Naive Celiac Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prednisolone and Gluten free diet</intervention>
      <intervention type="Behavioral">Gluten free diet</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>All India Institute of Medical Sciences, New Delhi</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 8, 2010</first_received>
    <start_date>April 2009</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>January 18, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients having improvement in symptoms at 4 weeks</outcome_measure>
      <outcome_measure>Proportion of patients having improvement in histological improvement by at least one grade at 4 weeks</outcome_measure>
      <outcome_measure>Proportion of patients showing normalization of histological abnormalities at 6 months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01045837</url>
  </study>
  <study rank="169">
    <title>Effects of Coenzyme Q10 (CoQ) in Parkinson Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Coenzyme Q10 with vitamin E</intervention>
      <intervention type="Drug">placebo with vitamin E</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>University of Rochester</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 22, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>December 24, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>July 24, 2012</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))</outcome_measure>
      <outcome_measure>Change in Modified Schwab &amp; England Independence Scale From Baseline to 16 Months</outcome_measure>
      <outcome_measure>Change in Modified Rankin Scale From Baseline to 16 Months</outcome_measure>
      <outcome_measure>Change in PD Quality of Life Scale From Baseline to 16 Months</outcome_measure>
      <outcome_measure>Change in Symbol Digit Modalities Test From Baseline to 16 Months</outcome_measure>
      <outcome_measure>Change in Hoehn &amp; Yahr Score From Baseline to 16 Months</outcome_measure>
      <outcome_measure>CoQ10 Levels in Plasma</outcome_measure>
      <outcome_measure>Adverse Experiences: Back Pain</outcome_measure>
      <outcome_measure>Adverse Experiences: Constipation</outcome_measure>
      <outcome_measure>Adverse Experiences: Insomnia</outcome_measure>
      <outcome_measure>Adverse Experiences: Anxiety</outcome_measure>
      <outcome_measure>Adverse Experiences: Tremor</outcome_measure>
      <outcome_measure>Adverse Experiences: Nasopharyngitis</outcome_measure>
      <outcome_measure>Adverse Experiences: Diarrhoea</outcome_measure>
      <outcome_measure>Adverse Experiences: Headache</outcome_measure>
      <outcome_measure>Adverse Experiences: Urinary Tract Infection</outcome_measure>
      <outcome_measure>Adverse Experiences: Nausea</outcome_measure>
      <outcome_measure>Adverse Experiences: Hypertension</outcome_measure>
      <outcome_measure>Adverse Experiences: Depression</outcome_measure>
      <outcome_measure>Adverse Experiences: Constipation: Moderate/Severe</outcome_measure>
      <outcome_measure>Adverse Experiences: Anxiety: Moderate/Severe</outcome_measure>
      <outcome_measure>Adverse Experiences: Back Pain: Moderate/Severe</outcome_measure>
      <outcome_measure>Adverse Experiences: Insomnia: Moderate/Severe</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00740714</url>
  </study>
  <study rank="170">
    <title>Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin</intervention>
      <intervention type="Drug">Clopidogrel</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Texas Southwestern Medical Center</lead_sponsor>
      <collaborator>American Heart Association</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 10, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>January 11, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Whole Blood Platelet Aggregation to 0.5 millimoles arachidonic acid</outcome_measure>
      <outcome_measure>von Willebrand factor (vWF) activity</outcome_measure>
      <outcome_measure>Whole Blood Platelet Aggregation to 2 µg/mL collagen</outcome_measure>
      <outcome_measure>Whole Blood Platelet Aggregation to 20 µg/mL Adenosine Diphosphate</outcome_measure>
      <outcome_measure>beta-thromboglobulin</outcome_measure>
      <outcome_measure>Platelet factor 4</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01768637</url>
  </study>
  <study rank="171">
    <title>Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">3APS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bellus Health Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>950</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 30, 2004</first_received>
    <start_date>June 2004</start_date>
    <last_updated>February 27, 2007</last_updated>
    <last_verified>February 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.</outcome_measure>
      <outcome_measure>The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00088673</url>
  </study>
  <study rank="172">
    <title>Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dimebon</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medivation, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>183</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 15, 2006</first_received>
    <start_date>September 2005</start_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - cognitive subscale</outcome_measure>
      <outcome_measure>Clinical Global Impression of Change</outcome_measure>
      <outcome_measure>Safety Assessed By Number of Participants With Adverse Events</outcome_measure>
      <outcome_measure>Pharmacokinetic (PK) parameter of Dimebon: Cmax</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00377715</url>
  </study>
  <study rank="173">
    <title>Healthier Living Canada</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Asthma</condition>
      <condition>Chronic Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Chronic Disease Self-Management Online Workshop</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
      <collaborator>AHS Cancer Control Alberta</collaborator>
      <collaborator>National Council on Aging (NCOA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>297</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>January 11, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 15, 2014</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>health behaviors</outcome_measure>
      <outcome_measure>health utilization</outcome_measure>
      <outcome_measure>health status</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01047514</url>
  </study>
  <study rank="174">
    <title>Does Bipolar Disease Program (BDP) Intervention Improve Long Term Manic and Depressive Symptoms.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bipolar Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Bipolar Disorder Program</intervention>
      <intervention type="Behavioral">Usual (psychiatric) Care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>382</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <first_received>December 29, 2000</first_received>
    <start_date>July 1997</start_date>
    <last_updated>September 22, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2003</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00007761</url>
  </study>
  <study rank="175">
    <title>Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pramipexole / Rasagiline Mesylate once daily</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pharma Two B Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 15, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>April 30, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Total UPDRS I, II, III scores</outcome_measure>
      <outcome_measure>UPDRS ADL (part II)</outcome_measure>
      <outcome_measure>CGI-S</outcome_measure>
      <outcome_measure>UPDRS Motor (part III)</outcome_measure>
      <outcome_measure>PDQ39</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01968460</url>
  </study>
  <study rank="176">
    <title>Chinese Exercise Modalities in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Chinese exercise modalities</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Center for Complementary and Integrative Health (NCCIH)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 23, 2002</start_date>
    <last_updated>August 17, 2006</last_updated>
    <last_verified>July 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00029809</url>
  </study>
  <study rank="177">
    <title>50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">50 HZ Repetitive TMS</intervention>
      <intervention type="Procedure">Sham rTMS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>November 22, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>August 31, 2012</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Gait Speed</outcome_measure>
      <outcome_measure>Bradykinesia</outcome_measure>
      <outcome_measure>Total UPDRS Score</outcome_measure>
      <outcome_measure>Motor UPDRS</outcome_measure>
      <outcome_measure>Activities of Daily Living UPDRS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00977184</url>
  </study>
  <study rank="178">
    <title>PillCam® Platform With the PillCam Crohn's Disease Capsule</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Pillcam colon capsule and PillCam™ Prep Procedure</intervention>
      <intervention type="Device">Ileocolonoscopy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Given Imaging Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>June 28, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>March 11, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>December 4, 2014</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Per-subject Diagnostic Yield of the PillCam Platform With the CD Capsule Within the Terminal Ileum and Colon as Compared to the Ileocolonoscopy Diagnostic Yield Within the Terminal Ileum and Colon</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01631435</url>
  </study>
  <study rank="179">
    <title>Pilot Study of Minocycline in Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Huntington Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">minocycline</intervention>
      <intervention type="Drug">Matching placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merit Cudkowicz</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
      <collaborator>Huntington Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 12, 2006</first_received>
    <start_date>April 2006</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>April 17, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>March 7, 2013</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]</outcome_measure>
      <outcome_measure>Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00277355</url>
  </study>
  <study rank="180">
    <title>Relaxation Guided Imagery for Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Relaxation guided imagery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rambam Health Care Campus</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 18, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>May 7, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline of Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Change from baseline to week 2 in Clinical Global Impression Scale (CGI)</outcome_measure>
      <outcome_measure>Change from baseline to week 2 in PDQ39</outcome_measure>
      <outcome_measure>Change from baseline to minutes 30 of Unified Parkinson's Disease Rating Scale (UPDRS) after relaxing music</outcome_measure>
      <outcome_measure>Change from baseline to week 2 in the number of OFF hours</outcome_measure>
      <outcome_measure>Change from baseline to month 3 in PDQ39</outcome_measure>
      <outcome_measure>Change from baseline to month 3 in Clinical Global Impression Scale (CGI)</outcome_measure>
      <outcome_measure>Change from baseline to week 1 in the number of OFF hours</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01151111</url>
  </study>
  <study rank="181">
    <title>NET-PD LS-1 Creatine in Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">creatine</intervention>
      <intervention type="Other">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1741</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 20, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>March 23, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>February 19, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Global Outcome Combined Information on Change From Baseline in Schwab England Activities of Daily Living, 39-Item Parkinson's Disease Questionnaire, Ambulatory Capacity, Symbol Digit Modalities, and Modified Rankin at 5 Years.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00449865</url>
  </study>
  <study rank="182">
    <title>Vitamin D Treatment for Crohn´s Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohns Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 18, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>April 12, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Relapse rate within 1 year treatment; CDAI&gt;220</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00132184</url>
  </study>
  <study rank="183">
    <title>ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">DBS-f on</intervention>
      <intervention type="Device">DBS-f off</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Functional Neuromodulation Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 21, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>September 2018</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The study will assess the acute and long-term safety of the system. A detailed assessment of all device and/or therapy related adverse events will be conducted.</outcome_measure>
      <outcome_measure>Efficacy outcomes include: improvement in ADAS-cog 13 at twelve months, improvement in the CDR and changes in glucose metabolism measured by FDG-PET at twelve months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01608061</url>
  </study>
  <study rank="184">
    <title>Mucosal Healing Study in Crohn's Disease (CD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Certolizumab pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 27, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>August 30, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>December 10, 2009</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Mucosal Healing at Week 10 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Mucosal Healing at Week 10 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Mucosal Healing at Week 54 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Mucosal Healing at Week 54 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Response (Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline of More Than 5 Points) at Week 10 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Response (Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline of More Than 5 Points) at Week 10 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Response (Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline of More Than 5 Points) at Week 54 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Response (Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline of More Than 5 Points) at Week 54 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 6) at Week 10 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 6) at Week 10 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 6) at Week 54 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 6) at Week 54 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Complete Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 3) at Week 10 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Complete Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 3) at Week 10 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Complete Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 3) at Week 54 Using Local Non-blinded Assessments</outcome_measure>
      <outcome_measure>Percentage of Patients With Endoscopic Complete Remission (Crohn's Disease Endoscopic Index of Severity (CDEIS) Score Below 3) at Week 54 Using Central Blinded Assessments</outcome_measure>
      <outcome_measure>Change From Baseline in Histological Crohn's Disease Score at Week 10 Using Central Blinded Assessment</outcome_measure>
      <outcome_measure>Change From Baseline in Histological Crohn's Disease Score at Week 54 Using Central Blinded Assessment</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Crohn's Disease Activity Index (CDAI) Response (Defined as a Decrease of at Least 100 Points in CDAI Score From Baseline) at Week 10</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Crohn's Disease Activity Index (CDAI) Response (Defined as a Decrease of at Least 100 Points in CDAI Score From Baseline) at Week 54</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Crohn's Disease Activity Index (CDAI) Remission (Defined as a CDAI Score Less Than or Equal to 150) at Week 10</outcome_measure>
      <outcome_measure>Percentage of Patients Achieving Crohn's Disease Activity Index (CDAI) Remission (Defined as a CDAI Score Less Than or Equal to 150) at Week 54</outcome_measure>
      <outcome_measure>Geometric Mean C-Reactive Protein (CRP) Level (mg/L) at Week 10</outcome_measure>
      <outcome_measure>Ratio to Baseline of C-Reactive Protein (CRP) Level (mg/L) at Week 10</outcome_measure>
      <outcome_measure>Geometric Mean C-Reactive Protein (CRP) Level (mg/L) at Week 52</outcome_measure>
      <outcome_measure>Ratio to Baseline of C-Reactive Protein (CRP) Level (mg/L) at Week 52</outcome_measure>
      <outcome_measure>Correlation Between Mean C-Reactive Protein (CRP) Plasma Level and Crohn's Disease Activity Index (CDAI) Score at Week 10</outcome_measure>
      <outcome_measure>Correlation Between Mean C-Reactive Protein (CRP) Plasma Level and Crohn's Disease Endoscopic Index of Severity (CDEIS) Score at Week 10 Using Local Non-blinded Assessment</outcome_measure>
      <outcome_measure>Correlation Between Mean C-Reactive Protein (CRP) Plasma Level and Crohn's Disease Endoscopic Index of Severity (CDEIS) Score at Week 10 Using Central Blinded Assessment</outcome_measure>
      <outcome_measure>Correlation Between Mean C-Reactive Protein (CRP) Plasma Level and Histological Crohn's Disease Score at Week 10 Using Central Blinded Assessment</outcome_measure>
      <outcome_measure>Change From Baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS) Score at Week 54 Using Local Non-blinded Assessment</outcome_measure>
      <outcome_measure>Change From Baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS) Score at Week 54 Using Central Blinded Assessment</outcome_measure>
      <outcome_measure>Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 10</outcome_measure>
      <outcome_measure>Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 54</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00297648</url>
  </study>
  <study rank="185">
    <title>Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inherited Metabolic Storage Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CAMPATH-1H</intervention>
      <intervention type="Drug">Anti-CD45</intervention>
      <intervention type="Drug">FK506</intervention>
      <intervention type="Drug">Fludarabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>Texas Children's Hospital</collaborator>
      <collaborator>The Methodist Hospital System</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 26, 2003</first_received>
    <start_date>June 2002</start_date>
    <completion_date>June 2003</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2003</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00056979</url>
  </study>
  <study rank="186">
    <title>The Effect of L-Citrulline Malate on Ankle Brachial Index Among Patients With Coronary Heart Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">L-Citrulline malate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Masih Daneshvari Hospital</lead_sponsor>
      <collaborator>Shahid Beheshti University of Medical Sciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 3, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>August 3, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Brachial Index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01917123</url>
  </study>
  <study rank="187">
    <title>Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ropinirole PR/XR</intervention>
      <intervention type="Drug">ropinirole IR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>302</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 15, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>October 13, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>September 1, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part II (at &quot;On&quot;) Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part II (at &quot;Off&quot;) Total Score at Week 24 in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part II (at &quot;On&quot;) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part II (at &quot;Off&quot;) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part III Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part IV Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase</outcome_measure>
      <outcome_measure>Percentage of Responders on the Clinical Global Impression-Improvement (CGI-I) at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Percentage of Responders in Change From Week 0 in Awake Time Spent &quot;Off&quot; at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Percentage of Responders in Percent Change From Week 0 in Awake Time Spent &quot;Off&quot; at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Awake Time Spent &quot;Off&quot; at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Percentage of Awake Time Spent &quot;Off&quot; at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Percent Change From Week 0 in Percentage of Awake Time Spent &quot;Off&quot; at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Awake Time Spent &quot;On&quot; at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Percentage of Awake Time Spent &quot;On&quot; at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Awake Time Spent &quot;On&quot; With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Percentage of Awake Time Spent &quot;On&quot; With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Number of Participants at Each Stage of the Modified Hoehn &amp; Yahr Severity of Illness (at &quot;On&quot;) at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Number of Participants at Each Stage of the Modified Hoehn &amp; Yahr Severity of Illness (at &quot;Off&quot;) at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase</outcome_measure>
      <outcome_measure>Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole IR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 24 (Period Baseline) in the Japanese UPDRS Part I Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 24 in the Japanese UPDRS Part II (at &quot;On&quot;) Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 24 in the Japanese UPDRS Part II (at &quot;Off&quot;) Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 24 in the Japanese UPDRS Part III Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 24 in the Japanese UPDRS Part IV Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part I Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part II (at &quot;On&quot;) Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part II (at &quot;Off&quot;) Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part III Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Japanese UPDRS Part IV Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 24 in Awake Time Spent &quot;Off&quot; at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 24 in Percentage of Awake Time Spent &quot;Off&quot; at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 24 in Awake Time Spent &quot;On&quot; With Troublesome Dyskinesias at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Number of Participants at Each Stage of the Modified Hoehn &amp; Yahr Severity of Illness (at &quot;On&quot;) at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Number of Participants at Each Stage of the Modified Hoehn &amp; Yahr Severity of Illness (at &quot;Off&quot;) at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase</outcome_measure>
      <outcome_measure>Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole IR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Percentage of Responders on the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part II (at &quot;On&quot;) Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part II (at &quot;Off&quot;) Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Japanese UPDRS Part I Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Japanese UPDRS Part II (at &quot;On&quot;) Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Japanese UPDRS Part II (at &quot;Off&quot;) Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Japanese UPDRS Part III Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Japanese UPDRS Part IV Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Percentage of Responders on the CGI-I at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Percentage of Responders in Change From Week 0 in Awake Time Spent &quot;Off&quot; at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Percentage of Responders in Percent Change From Week 0 in Awake Time Spent &quot;Off&quot; at Week 54 in the Long-term Phase</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Awake Time Spent &quot;Off&quot; at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Percentage of Awake Time Spent &quot;Off&quot; at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Mean Change From Week 0 in Awake Time Spent &quot;On&quot; With Troublesome Dyskinesias at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Number of Participants at Each Stage of the Modified Hoehn &amp; Yahr Severity of Illness (at &quot;On&quot;) at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Number of Participants at Each Stage of the Modified Hoehn &amp; Yahr Severity of Illness (at &quot;Off&quot;) at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
      <outcome_measure>Percentage of Participants Remaining in the Study on the Indicated Days During the Long-term Phase in the Ropinirole PR-Ropinirole PR Group</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00823836</url>
  </study>
  <study rank="188">
    <title>Remission in Subjects With Crohn's Disease, Open Label Extension</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Adalimumab 40 mg eow or ew</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>177</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 16, 2010</first_received>
    <start_date>August 2002</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>April 7, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>March 11, 2010</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] &lt;150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).</outcome_measure>
      <outcome_measure>Number of Participants Achieving Clinical Remission (CDAI &lt; 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303).</outcome_measure>
      <outcome_measure>Number of Participants Achieving Clinical Remission (CDAI &lt; 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303).</outcome_measure>
      <outcome_measure>Number of Participants Achieving Clinical Remission (CDAI &lt; 150 Points) at Week 260 (4 Years of Participation in NCT01070303).</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores</outcome_measure>
      <outcome_measure>Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01070303</url>
  </study>
  <study rank="189">
    <title>Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rasagiline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Branded Pharmaceutical Products, R&amp;D Inc.</lead_sponsor>
      <collaborator>Teva Pharmaceutical Industries</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 5, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>February 29, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>January 26, 2016</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Change From Baseline to Week 24 in the Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-COG) Summary Score</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in the Montreal Cognitive Assessment (MoCA) Score</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in the Penn Daily Activities Questionnaire (PDAQ) Score</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study's Clinical Global Impression of Change Modified for Mild Cognitive Impairment (ADCS MCI-CGIC) Score at Week 24</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in the Unified Parkinson's Disease Rating Scale (UPDRS), Motor Subscale (Part 3), Version 3, Score</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in UPDRS, Activities of Daily Living (ADL) Subscale (Part 2), Version 3, Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01723228</url>
  </study>
  <study rank="190">
    <title>SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric</condition>
      <condition>Colon Capsule Endoscopy</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Second generation of colon capsule endoscopy (GIVEN IMAGING)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Policlinico Umberto I</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>July 2, 2014</first_received>
    <start_date>September 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 23, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate and compare the accuracy of Second generation of Colon Capsule Endoscopy with magnetic resonance enterography, small intestine contrast ultrasonography and endoscopy in the evaluation of pediatric Crohn's disease.</outcome_measure>
      <outcome_measure>To evaluate the safety of second generation of colon capsule endoscopy in pediatric Crohn's disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02199626</url>
  </study>
  <study rank="191">
    <title>Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">levodopa-carbidopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Osmotica Pharmaceutical US LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 12, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>January 13, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evidence of a novel levodopa/carbidopa formulation providing a better clinical profile than reference levodopa/carbidopa formulation using Unified Parkinson's Disease Rating Scale (UPDRS III) and patient's diary cards</outcome_measure>
      <outcome_measure>Other measurements to be used for demonstrating clinical profile is UPDRS II and IV, Clinical Global Impression Scale (CGI)/Patient's Global Improvement Scale (PGI), and the Abnormal Involuntary Movement Scale (AIMS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00558337</url>
  </study>
  <study rank="192">
    <title>A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rasagiline Mesylate</intervention>
      <intervention type="Drug">Rasagiline Mesylate</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Pharmaceutical Industries</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1174</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 16, 2005</first_received>
    <start_date>November 2005</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>January 10, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>March 8, 2010</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00256204</url>
  </study>
  <study rank="193">
    <title>Chondroitin Sulfate for Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chondroitin sulfate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospitals Cleveland Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 19, 2010</first_received>
    <start_date>January 2011</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>August 29, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Biologic effect on inflammation</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01245088</url>
  </study>
  <study rank="194">
    <title>Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY450139</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1111</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 26, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>January 28, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>November 6, 2013</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 16 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 16 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in the Resource Utilization in Dementia-Lite (RUD-Lite) up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in the EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) at 76 Weeks</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks</outcome_measure>
      <outcome_measure>LY450139 Population Pharmacokinetics: Clearance of LY450139</outcome_measure>
      <outcome_measure>LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139</outcome_measure>
      <outcome_measure>Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Phosphorylated-Tau (P-tau) Concentration in Spinal Fluid up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 16 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 16 Weeks After Cessation of Study Drug</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00762411</url>
  </study>
  <study rank="195">
    <title>Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albuterol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>July 8, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>December 2, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Presence of obstructive or restrictive lung disease</outcome_measure>
      <outcome_measure>Presence of pulmonary hypertension</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01895998</url>
  </study>
  <study rank="196">
    <title>Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine transdermal patch</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Ono Pharmaceutical Co. Ltd</collaborator>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>859</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 11, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>January 14, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>April 27, 2011</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)</outcome_measure>
      <outcome_measure>Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)</outcome_measure>
      <outcome_measure>Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</outcome_measure>
      <outcome_measure>Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)</outcome_measure>
      <outcome_measure>Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)</outcome_measure>
      <outcome_measure>Change From Baseline in Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</outcome_measure>
      <outcome_measure>Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00423085</url>
  </study>
  <study rank="197">
    <title>Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Liatermin (r-metHuGDNF)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amgen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 22, 2005</first_received>
    <start_date>March 2003</start_date>
    <last_updated>January 10, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>United Parkinson's Disease Rating Scale</outcome_measure>
      <outcome_measure>Timed Motor Tests</outcome_measure>
      <outcome_measure>Dyskinesia ratings</outcome_measure>
      <outcome_measure>Diary ratings</outcome_measure>
      <outcome_measure>Patient reported outcomes measures</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00115427</url>
  </study>
  <study rank="198">
    <title>Effects of SAMe in Patients With Alcoholic Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Liver Disease, Alcoholic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">S-adenosylmethionine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, Davis</lead_sponsor>
      <collaborator>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</collaborator>
      <collaborator>Abbott</collaborator>
      <collaborator>Joint Clinical Research Center</collaborator>
      <collaborator>University of Colorado, Denver</collaborator>
      <collaborator>University of California, Los Angeles</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 12, 2007</first_received>
    <start_date>September 2005</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>June 7, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>February 6, 2013</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in Serum AST Levels</outcome_measure>
      <outcome_measure>Changes in Serum SAM</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00573313</url>
  </study>
  <study rank="199">
    <title>Far Infrared Treatment for Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">Far Infrared Radiation (5μm to 20μm wavelength)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GAAD Medical Research Institute Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 11, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>August 14, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Management and Cure of Alzheimer's Disease</outcome_measure>
      <outcome_measure>Management and Cure of Dementia</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00599469</url>
  </study>
  <study rank="200">
    <title>Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inherited Mitochondrial Disease, Including Leigh Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cysteamine Bitartrate Delayed-release Capsules (RP103)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Raptor Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 17, 2013</first_received>
    <start_date>June 2014</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>January 28, 2016</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Score</outcome_measure>
      <outcome_measure>Change over time in Pharmacodynamic Biomarkers</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02023866</url>
  </study>
  <study rank="201">
    <title>The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Donepezil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Korea Inc.</lead_sponsor>
      <collaborator>Eisai Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>199</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 25, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>August 23, 2012</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>August 3, 2010</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)</outcome_measure>
      <outcome_measure>CERAD-K</outcome_measure>
      <outcome_measure>Neuropsychiatry Inventory (NPI)</outcome_measure>
      <outcome_measure>GDS-K (Geriatric Depression Scale-Korean) Score After Treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00381381</url>
  </study>
  <study rank="202">
    <title>PD4PD:Partnered Dance for Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Tango dancing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>Parkinson's Disease Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 29, 2011</first_received>
    <start_date>July 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>December 7, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Motor Symptom Severity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01388556</url>
  </study>
  <study rank="203">
    <title>Does Pulmonary Rehabilitation Improve Balance in People With Respiratory Disease?</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Lung Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Pulmonary rehabilitation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Manitoba</lead_sponsor>
      <collaborator>The University of Queensland</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 17, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>August 26, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>September 30, 2013</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Standing Balance - Sway Path</outcome_measure>
      <outcome_measure>Dynamic Balance</outcome_measure>
      <outcome_measure>Standing Balance - Critical Point in Time</outcome_measure>
      <outcome_measure>Standing Balance - Critical Point in Distance</outcome_measure>
      <outcome_measure>Balance Confidence</outcome_measure>
      <outcome_measure>Fear of Falling</outcome_measure>
      <outcome_measure>Confidence in Disease Management</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00864084</url>
  </study>
  <study rank="204">
    <title>Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
      <condition>Stem Cell Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">voriconazole</intervention>
      <intervention type="Drug">voriconazole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Phillip Brian Smith</lead_sponsor>
      <collaborator>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</collaborator>
      <collaborator>Duke University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 13, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>November 9, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduced bioavailability of oral voriconazole in pediatric patients status post stem cell transplantation with gastrointestinal graft versus host disease</outcome_measure>
      <outcome_measure>Pharmacokinetics(including clearance, maximum concentration, area under the time concentration curve, and half life) of voriconazole in pediatric patients status post hematopoietic stem cell transplantation.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00792246</url>
  </study>
  <study rank="205">
    <title>A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pridopidine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Branded Pharmaceutical Products, R&amp;D Inc.</lead_sponsor>
      <collaborator>European Huntington's Disease Network</collaborator>
      <collaborator>Huntington Study Group</collaborator>
      <collaborator>Teva Pharmaceutical Industries</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>408</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 5, 2013</first_received>
    <start_date>February 2014</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>September 9, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at week 26</outcome_measure>
      <outcome_measure>Change from Baseline in modified Physical Performance Test (mPPT)</outcome_measure>
      <outcome_measure>Summary of participants with Adverse Events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02006472</url>
  </study>
  <study rank="206">
    <title>Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Mild Cognitive Impairment</condition>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flutemetamol (18F) Injection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GE Healthcare</lead_sponsor>
      <collaborator>Medpace, Inc.</collaborator>
      <collaborator>i3 Statprobe</collaborator>
      <collaborator>i3 Research</collaborator>
      <collaborator>Quintiles, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>365</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>December 7, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>September 3, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>July 30, 2014</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.</outcome_measure>
      <outcome_measure>The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01028053</url>
  </study>
  <study rank="207">
    <title>Mantle Irradiation for Hodgkin's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hodgkin's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Mantle irradiation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dana-Farber Cancer Institute</lead_sponsor>
      <collaborator>Brigham and Women's Hospital</collaborator>
      <collaborator>Massachusetts General Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>May 1992</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>October 30, 2009</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2000</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the risks and benefits of mantle field irradiation alone in treating Hodgkin disease patients.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00165269</url>
  </study>
  <study rank="208">
    <title>Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Vascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Liprostin [liposomal Prostaglandin E1]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Endovasc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 4, 2003</first_received>
    <start_date>February 2003</start_date>
    <completion_date>August 2003</completion_date>
    <last_updated>March 6, 2007</last_updated>
    <last_verified>March 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00053716</url>
  </study>
  <study rank="209">
    <title>A Study to Examine APL-130277 in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">APL-130277</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cynapsus Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>July 20, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the efficacy based on time to ON, percent change in UPDRS. Safety as assessed by adverse events, vital signs and ECGs</outcome_measure>
      <outcome_measure>Evaluate the efficacy, safety and tolerability of treatment with APL-130277 in 16 patients with Parkinson's Disease (PD).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02228590</url>
  </study>
  <study rank="210">
    <title>Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pridopidine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Branded Pharmaceutical Products, R&amp;D Inc.</lead_sponsor>
      <collaborator>Teva Pharmaceutical Industries</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>235</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 28, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>May 2021</completion_date>
    <last_updated>December 1, 2016</last_updated>
    <last_verified>December 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subjects with at least one adverse event</outcome_measure>
      <outcome_measure>Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01306929</url>
  </study>
  <study rank="211">
    <title>Prevention of Pre-Term Birth by Treatment of Periodontal Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Periodontal Diseases</condition>
      <condition>Premature Birth</condition>
      <condition>Pre-Eclampsia</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Treatment of periodontal disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>King Edward Memorial Hospital</lead_sponsor>
      <collaborator>The University of Western Australia</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1094</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 23, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>April 4, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Rate of pre-term birth</outcome_measure>
      <outcome_measure>Rate of fetal growth restriction</outcome_measure>
      <outcome_measure>Rate of pre-eclampsia</outcome_measure>
      <outcome_measure>Rate of complications of pre-term birth</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00133926</url>
  </study>
  <study rank="212">
    <title>Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Semapimod</intervention>
      <intervention type="Drug">Semapimod</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ferring Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 20, 2008</first_received>
    <start_date>October 2002</start_date>
    <completion_date>August 2004</completion_date>
    <last_updated>August 22, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) score</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ)</outcome_measure>
      <outcome_measure>Crohn's disease endoscopic index of severity (CDEIS)</outcome_measure>
      <outcome_measure>Change in level of C-reactive protein (CRP)</outcome_measure>
      <outcome_measure>Safety (Adverse events)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00739986</url>
  </study>
  <study rank="213">
    <title>Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Certolizumab pegol</intervention>
      <intervention type="Biological">Certolizumab pegol</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>539</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 28, 2006</first_received>
    <start_date>April 2006</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>August 30, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>July 7, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase</outcome_measure>
      <outcome_measure>Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase</outcome_measure>
      <outcome_measure>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Induction Phase</outcome_measure>
      <outcome_measure>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 2 of the Induction Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 4 of the Induction Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 6 of the Induction Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 8 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 10 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 12 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 14 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 16 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 18 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 20 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 22 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 24 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CDAI Score at Week 26 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 2 of the Induction Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 4 of the Induction Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 6 of the Induction Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</outcome_measure>
      <outcome_measure>C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 2 of the Induction Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 4 of the Induction Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 6 of the Induction Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 8 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 10 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 12 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 14 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 16 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 18 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 20 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 22 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 24 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Week 26 in the Randomized Maintenance Phase</outcome_measure>
      <outcome_measure>CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00308581</url>
  </study>
  <study rank="214">
    <title>Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Octohydroaminoacridine Succinate Tablets</intervention>
      <intervention type="Drug">Octohydroaminoacridine Succinate Tablets</intervention>
      <intervention type="Drug">Octohydroaminoacridine succinate Tablets</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Changchun Huayang High-tech Co., Ltd</lead_sponsor>
      <collaborator>Beijing Bionovo Medicine Development Co., Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>288</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 30, 2012</first_received>
    <start_date>June 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>April 6, 2012</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale</outcome_measure>
      <outcome_measure>Clinician's Interview Based Impression of Change, plus caregiver input</outcome_measure>
      <outcome_measure>Activities of Daily Living:Activities of Daily Living Scale（ADL)</outcome_measure>
      <outcome_measure>Mental behavior: neuropsychiatric questionnaire (NPI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01569516</url>
  </study>
  <study rank="215">
    <title>Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Parkinsonian Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I]β-CIT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>22 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>225</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 14, 2006</first_received>
    <start_date>January 2006</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>April 21, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess the sensitivity and specificity of olfaction, upper limb kinematic behavior, cognition, voice, metabolomic, proteomic and gene expression profiling in categorizing Parkinson Syndrome (PS) vs non-PS</outcome_measure>
      <outcome_measure>Assess sensitivity and specificity of olfaction, upper limb kinematic behavior, cognition, voice, metabolomic, proteomic and gene expression profiling in categorizing PS vs non-PS</outcome_measure>
      <outcome_measure>Correlate progression of biomarker outcomes for olfaction, upper limb kinematic behavior, cognition, voice, metabolomic and gene expression profiling with progression of PS defined by % change from baseline in putamen [123I]ß-CIT SPECT uptake.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00315250</url>
  </study>
  <study rank="216">
    <title>Study of Vitamin D in Children With Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin D3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gary M Brittenham, MD</lead_sponsor>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Years</min_age>
    <max_age>20 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 12, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>February 27, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum 25-hydroxyvitamin D concentration</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01276587</url>
  </study>
  <study rank="217">
    <title>Repetitive Transcranial Stimulation (r-TMS) Treatment for Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">repetitive transcranial stimulation (r-TMS)</intervention>
      <intervention type="Device">Repetitive transcranial stimulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sheba Medical Center</lead_sponsor>
      <collaborator>Weizmann Institute of Science</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 13, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>October 19, 2009</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson Disease Rating Scale (UPDRS)(Motor Part)</outcome_measure>
      <outcome_measure>Clinical Global Impression of Severity (CGIS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00625300</url>
  </study>
  <study rank="218">
    <title>Resveratrol for Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Resveratrol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alzheimer's Disease Cooperative Study (ADCS)</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 23, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>May 6, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>January 28, 2016</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Adverse Events</outcome_measure>
      <outcome_measure>Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01504854</url>
  </study>
  <study rank="219">
    <title>Pedunculopontine Nucleus Stimulation for Gait Disorders in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Low frequency DBS of the pedunculopontine nucleus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hôpital de la Salpétrière</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 16, 2014</first_received>
    <start_date>May 2009</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>February 3, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change of Rating scale for gait evaluation between 'Off stim off drug&quot; and &quot;On stim off drug&quot; conditions</outcome_measure>
      <outcome_measure>Adverse events records</outcome_measure>
      <outcome_measure>Change of UPDRS part 3 score between &quot;Off Stim Off drug&quot; and &quot;ON stim Off drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of Rating scale for gait evaluation between 'Off stim on drug&quot; and &quot;On stim on drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of UPDRS part 3 score between &quot;Off Stim On drug&quot; and &quot;ON stim On drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of UPDRS part 3 score between &quot;Off Stim Off drug&quot; and &quot;No stim Off drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of UPDRS part 3 score between &quot;Off Stim On drug&quot; and &quot;No stim On drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of Rating scale for gait evaluation between 'Off stim Off drug&quot; and &quot;No stim off drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of Rating scale for gait evaluation between 'Off stim On drug&quot; and &quot;No stim on drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of Rating scale for gait evaluation between 'On stim Off drug&quot; and &quot;No stim off drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of Rating scale for gait evaluation between 'On stim On drug&quot; and &quot;No stim On drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of gait physiological parameters between &quot;Off Stim Off drug&quot; and &quot;ON stim Off drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of gait physiological parameters between &quot;Off Stim On drug&quot; and &quot;ON stim On drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of gait physiological parameters between &quot;No Stim On drug&quot; and &quot;Off stim On drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of gait physiological parameters between &quot;No Stim Off drug&quot; and &quot;On stim off drug&quot; conditions</outcome_measure>
      <outcome_measure>Change of gait physiological parameters between &quot;No Stim Off drug&quot; and &quot;Off stim off drug&quot; conditions</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02055261</url>
  </study>
  <study rank="220">
    <title>A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>301</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 30, 2006</first_received>
    <start_date>January 2002</start_date>
    <completion_date>November 2003</completion_date>
    <last_updated>November 22, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to the need for symptomatic treatment with dopaminergic agents&quot;, defined as the number of days from the first dose of TCH346 study treatment to the date when it symptomatic treatment is required as determined by the investigator</outcome_measure>
      <outcome_measure>Safety assessments as based on the frequency of adverse events and the number of laboratory values that fall outside of the ranges.</outcome_measure>
      <outcome_measure>Annual change rates for Unified Parkinsons Disease Rating Scalescore</outcome_measure>
      <outcome_measure>Changes in UPDRS score after 4 weeks and after withdrawal of study treatment</outcome_measure>
      <outcome_measure>Percentage of patients needing symptomatic treatment within 12 months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00407212</url>
  </study>
  <study rank="221">
    <title>Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">D9421-C, 9mg</intervention>
      <intervention type="Drug">D9421-C, 15mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 13, 2007</first_received>
    <start_date>October 2006</start_date>
    <completion_date>March 2008</completion_date>
    <last_updated>July 2, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>March 18, 2009</firstreceived_results_date>
    <primary_completion_date>March 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Had Remission of Crohn's Disease After 8-week Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Had Remission of Crohn's Disease After 2-week Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Had Remission of Crohn's Disease After 4-week Treatment</outcome_measure>
      <outcome_measure>Cumulative Percentage of Participants Who Achieved Remission up to 8 Weeks by Kaplan-Meier Method</outcome_measure>
      <outcome_measure>Change in CDAI Score From Baseline to 8 Weeks</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00573469</url>
  </study>
  <study rank="222">
    <title>Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AMG 139</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amgen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 9, 2010</first_received>
    <start_date>February 2011</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>May 13, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety &amp; tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139</outcome_measure>
      <outcome_measure>Characterization of the pharmacokinetic (PK) parameters (AUCtau, Cmax, tmax) for AMG 139 after multiple IV and SC dose administrations in healthy subjects and subjects with mild to severe CD</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01258205</url>
  </study>
  <study rank="223">
    <title>Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
      <condition>Chorea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AFQ056</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 19, 2009</first_received>
    <start_date>November 2009</start_date>
    <last_updated>September 22, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of AFQ056 on the severity of chorea in Huntington's disease measured by Unified Huntington's Disease Rating Scale (UHDRS) Maximal Chorea score.</outcome_measure>
      <outcome_measure>Potential effect of AFQ056 on the motor, cognitive, behavioral and functional assessments using UHDRS.</outcome_measure>
      <outcome_measure>Potential effect of AFQ056 on functional and quality of life scales, neuropsychiatric assessments and cognitive assessments in Huntington's Disease patients</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01019473</url>
  </study>
  <study rank="224">
    <title>Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Parkinson Disease</condition>
      <condition>Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F]-FEPPA</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>August 31, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>February 7, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00970333</url>
  </study>
  <study rank="225">
    <title>Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Delayed Release 6MP or Calcitriol vs. Purinethol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva GTC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 2, 2006</first_received>
    <start_date>July 2006</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>July 3, 2008</last_updated>
    <last_verified>July 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Remission-defined as a CDAI (Crohn's Disease Activity Index) of &lt;150</outcome_measure>
      <outcome_measure>Response- defined as a fall in the CDAI by 100 points or more from baseline</outcome_measure>
      <outcome_measure>Improvement in ESR (Erythrocyte Sedimentation Rate), CRP (C-Reactive Protein) levels, and IBDQ (Inflammatory Bowel Disease Questionnaire) &gt;=180 indicative of remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00287170</url>
  </study>
  <study rank="226">
    <title>A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastroesophageal Reflux Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Laparoscopic Nissen Fundoplication</intervention>
      <intervention type="Procedure">Laparoscopic anterior partial fundoplication</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 29, 2007</first_received>
    <start_date>November 2006</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>May 29, 2007</last_updated>
    <last_verified>May 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Recurrence of gastroesophageal reflux disease that required medication therapy</outcome_measure>
      <outcome_measure>1. Dysphagia – measured by the 4-point Likert scale (0 - no dysphagia,1 - mild dysphagia, 2 - moderate dysphagia, 3 - severe dysphagia)</outcome_measure>
      <outcome_measure>2. Ability to bloat / belch</outcome_measure>
      <outcome_measure>3. Overall Satisfaction – (0 – Very satisfactory, 1 – Good, 2 – no comment, 3 – Unsatisfactory)</outcome_measure>
      <outcome_measure>4. Quality of life score – measure by SF36 before operation, 6 months and 12 months after operation</outcome_measure>
      <outcome_measure>5. GERD related QoL assessment</outcome_measure>
      <outcome_measure>6. Perioperative outcomes – hospital stay, operative time, morbidity, mortality</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00480285</url>
  </study>
  <study rank="227">
    <title>Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Standard intervention protocol</intervention>
      <intervention type="Behavioral">Standard intervention protocol + Cognitive training therapy</intervention>
      <intervention type="Behavioral">Standard intervention protocol + Reminiscence therapy</intervention>
      <intervention type="Behavioral">Standard intervention protocol + &quot;Made-to-measure&quot; program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
      <collaborator>Caisse Nationale de Solidarité pour l'Autonomie</collaborator>
      <collaborator>Caisse Nationale d'Assurance Maladie des Travailleurs Non Salariés</collaborator>
      <collaborator>Direction Générale de la Santé, France</collaborator>
      <collaborator>Institut National de la Santé Et de la Recherche Médicale, France</collaborator>
      <collaborator>Université Victor Segalen Bordeaux 2</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>640</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 25, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 31, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of progression to the severe stage of Alzheimer's disease (MMSE score of 15 or lower)</outcome_measure>
      <outcome_measure>Cognitive abilities (ADAS-cog)</outcome_measure>
      <outcome_measure>Functional abilities in activities of daily living (DAD scale)</outcome_measure>
      <outcome_measure>Behavioural disturbance (NPI)</outcome_measure>
      <outcome_measure>Apathy (Apathy Inventory)</outcome_measure>
      <outcome_measure>Quality of life (Quol-AD)</outcome_measure>
      <outcome_measure>Depression (MADRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00646269</url>
  </study>
  <study rank="228">
    <title>Combined THC and CBD Drops for Treatment of Crohn's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">THC 5 mg/ml and CBD 50 mg/ml.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Meir Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 28, 2013</first_received>
    <start_date>March 2013</start_date>
    <last_updated>February 23, 2015</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment sucsess will be defind as a decrease of at least 100 points in CDAI after 8 weeks of treatment.</outcome_measure>
      <outcome_measure>Remission of disease</outcome_measure>
      <outcome_measure>endoscopic improvment</outcome_measure>
      <outcome_measure>Improvment of CRP and calprotectine</outcome_measure>
      <outcome_measure>Improvment of blood cytokine levls</outcome_measure>
      <outcome_measure>Improvment of at least 30 points in quality of life as measured by the SF 36.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01826188</url>
  </study>
  <study rank="229">
    <title>Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">certolizumab pegol 400 mg</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>174</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>August 26, 2014</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>July 1, 2010</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects Who Have Been Withdrawn From Prednisone or Prednisolone Therapy According to the Corticosteroid Tapering Schedule and Have Remained Off Corticosteroids and in Disease Remission at Week 38</outcome_measure>
      <outcome_measure>Percentage of Subjects With Continuous Remission Off Steroids at Week 38</outcome_measure>
      <outcome_measure>Cumulative Percentage of Subjects With Relapse/Treatment Failure at Week 38</outcome_measure>
      <outcome_measure>Time to Relapse/Treatment Failure During the 38-week Double-blind Treatment Period</outcome_measure>
      <outcome_measure>Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period</outcome_measure>
      <outcome_measure>Per-subject Cumulative Dose of Corticosteroids Over the 48-week Study Period</outcome_measure>
      <outcome_measure>Change From the 6-week run-in Period in Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) Score at Week 38</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score at Week 38</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38</outcome_measure>
      <outcome_measure>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00349752</url>
  </study>
  <study rank="230">
    <title>The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">VSL#3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Samsung Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>13 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>February 17, 2012</first_received>
    <start_date>January 2010</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>March 7, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction in Frequency of Infliximab Administration from q 8 Weeks to q 12 Weeks in Children with Crohn's Disease Receiving Probiotic VSL#3 Supplementation</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01548014</url>
  </study>
  <study rank="231">
    <title>Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ischemic Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">coronary artery bypass grafting with administration of autologous bone marrow stem cells</intervention>
      <intervention type="Procedure">coronary artery bypass grafting with administration of 0.9 % NaCl (sodium chloride) 0.2 ml</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St. Petersburg State Pavlov Medical University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 1, 2014</first_received>
    <start_date>February 2013</start_date>
    <completion_date>February 2018</completion_date>
    <last_updated>April 13, 2016</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>All-cause mortality associated with the progression of basic disease</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02059512</url>
  </study>
  <study rank="232">
    <title>A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline (KW-6002)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Hakko Kirin Company, Limited</lead_sponsor>
      <collaborator>Kyowa Hakko Kirin Co., Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 4, 2005</first_received>
    <start_date>November 2005</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>August 28, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To establish the efficacy of 40mg/d doses of istradefylline for the change in UPDRS part-III (Motor examination) score in patients with Parkinson's disease (PD).</outcome_measure>
      <outcome_measure>To evaluate the efficacy of 40mg/d dose of istradefylline for the change in UPDRS part-I (Mentation, behavior and mood), part-II (Activities of daily living) score and UPDRS total (parts I-III) score.</outcome_measure>
      <outcome_measure>To evaluate change in the Clinical Global Impression - Improvement scale (CGI-I).</outcome_measure>
      <outcome_measure>To evaluate change in the Clinical Global Impression - Severity of Illness scale (CGI-S).</outcome_measure>
      <outcome_measure>To evaluate the safety of 40mg/d doses of istradefylline.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00250393</url>
  </study>
  <study rank="233">
    <title>Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Blood Stem Cell Transplantation</condition>
      <condition>Anemia, Sickle Cell</condition>
      <condition>Graft-Versus-Host Disease</condition>
      <condition>Sirolimus (Rapamune )</condition>
      <condition>Alemtuzumab (Campath )</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">PBMC Transplant</intervention>
      <intervention type="Drug">Alemtuzumab (Campath )</intervention>
      <intervention type="Drug">Sirolimus (Rapamune )</intervention>
      <intervention type="Drug">Cyclophosphamide (Cytoxan )</intervention>
      <intervention type="Procedure">Low Dose Irradiation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Heart, Lung, and Blood Institute (NHLBI)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 15, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>August 2017</completion_date>
    <last_updated>November 15, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>1 year post-transplant w/ sustained donor type hemoglobin for pts w/sickle cell dx or are transfusion-independent for pts w/thalassemia and not have severe graft-versus-host disease.</outcome_measure>
      <outcome_measure>1) The level of chimerism required to maintain both graft survival as well as hematologic normalcy; 2) Incidence of acute and chronic GVHD; 3) Disease-free survival and overall survival; 4) Relapse rate and graft rejection rate.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00977691</url>
  </study>
  <study rank="234">
    <title>Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Indeterminate Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Home Monitoring</intervention>
      <intervention type="Behavioral">Home Monitoring</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Maryland</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
      <collaborator>Vanderbilt University</collaborator>
      <collaborator>Agency for Healthcare Research and Quality (AHRQ)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>349</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>September 13, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>August 24, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Disease Activity</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
      <outcome_measure>Health Care Utilization</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01692743</url>
  </study>
  <study rank="235">
    <title>Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">retroviral SF71-gp91phox transduced CD34+ cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
      <collaborator>Goethe University</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>1 Year</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 22, 2009</first_received>
    <start_date>June 2004</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>September 26, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>eradication of pre-existing therapy refractory bacterial and/or fungal infections</outcome_measure>
      <outcome_measure>Reconstitution of ROS production by peripheral blood cells</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00927134</url>
  </study>
  <study rank="236">
    <title>Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F] MNI-558</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 1, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>July 22, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy safety of MNI-558 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer disease (AD) compared to healthy volunteers (HV)</outcome_measure>
      <outcome_measure>To assess the dynamic uptake of MNI-558, a potential imaging biomarker for B-amyloid burden in brain, using positron emission tomography (PET) in similarly aged Alzheimer (AD) subjects and healthy volunteers (HV</outcome_measure>
      <outcome_measure>To determine pharmacokinetics pattern of MNI-558 in venous plasma of healthy and AD subjects.</outcome_measure>
      <outcome_measure>To determine metabolite pattern of MNI-558 in venous plasma of healthy and AD subjects.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01217021</url>
  </study>
  <study rank="237">
    <title>Physical Exercise Program in Chronic Chagas Heart Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chagas Disease</condition>
      <condition>Chagas Cardiomyopathy</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Exercise, nutritional and pharmaceutical counceling</intervention>
      <intervention type="Behavioral">Nutritional and pharmaceutical counceling</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Evandro Chagas National Institute of Infectious Disease</lead_sponsor>
      <collaborator>National Institute of Cardiology, Laranjeiras, Brazil</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 5, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>August 2, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Functional capacity measured by peak exercise oxygen consumption</outcome_measure>
      <outcome_measure>Muscle respiratory strength</outcome_measure>
      <outcome_measure>Body composition (body fat percentage)</outcome_measure>
      <outcome_measure>Cardiac function (maily ejection fraction)</outcome_measure>
      <outcome_measure>Laboratorial biomarkers composite</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>24 hours Holter</outcome_measure>
      <outcome_measure>Nutritional assessment</outcome_measure>
      <outcome_measure>Pharmaceutical assessment</outcome_measure>
      <outcome_measure>Microvascular reactivity</outcome_measure>
      <outcome_measure>Body mass index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02517632</url>
  </study>
  <study rank="238">
    <title>16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>221</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 19, 2013</first_received>
    <start_date>August 2014</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>August 21, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score</outcome_measure>
      <outcome_measure>Change From Baseline in Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Score</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Caregiver Burden Inventory (CBI) Score</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued From the Stduy Due to Any Adverse Event (AE)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01948791</url>
  </study>
  <study rank="239">
    <title>Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alphatocopherol</intervention>
      <intervention type="Drug">Selenium</intervention>
      <intervention type="Drug">Placebo replacement for vitamin E</intervention>
      <intervention type="Drug">Placebo replacement for Selenium</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Kentucky</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>60 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>June 25, 2002</first_received>
    <start_date>May 2002</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>February 21, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effect on the incidence of dementia (including Alzheimer's disease) over time</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00040378</url>
  </study>
  <study rank="240">
    <title>Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pompe Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">rAAV1-CMV-GAA (study agent) Administration</intervention>
      <intervention type="Other">RMST</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 13, 2009</first_received>
    <start_date>September 2010</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety assessments of the rAAV1-CMV-GAA (study agent), changes post study agent administration.</outcome_measure>
      <outcome_measure>Change in pulmonary function testing from baseline pulmonary function testing</outcome_measure>
      <outcome_measure>Evaluation of Ventilatory performance benefit of rAAV1-CMV-GAA gene transfer and Respiratory Muscle Strength Training (RMST) compared to RMST alone.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00976352</url>
  </study>
  <study rank="241">
    <title>A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CCX282-B</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ChemoCentryx</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>436</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 21, 2006</first_received>
    <start_date>March 2006</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>February 8, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving a clinical response (defined as a decrease from baseline in Crohn's Disease Activity Index [CDAI] score of at least 70) on Day 57</outcome_measure>
      <outcome_measure>Percentage of subjects achieving clinical remission (defined as a Crohn's Disease Activity Index [CDAI] score less than or equal to 150) on Day 57</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00306215</url>
  </study>
  <study rank="242">
    <title>Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Varenicline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 29, 2008</first_received>
    <start_date>July 2009</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>October 12, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>October 12, 2011</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6</outcome_measure>
      <outcome_measure>Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI) Total Score at Week 3</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI) Total Score at Week 6</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3</outcome_measure>
      <outcome_measure>Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00744978</url>
  </study>
  <study rank="243">
    <title>Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prochymal™ adult human mesenchymal stem cells</intervention>
      <intervention type="Drug">adult human mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mesoblast International Sàrl</lead_sponsor>
      <collaborator>Mesoblast, Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 17, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>December 2, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's disease activity index</outcome_measure>
      <outcome_measure>Inflammatory bowel disease quality-of-life questionnaire</outcome_measure>
      <outcome_measure>Crohn's disease endoscopic index of severity</outcome_measure>
      <outcome_measure>Crohn's remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00294112</url>
  </study>
  <study rank="244">
    <title>Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPECT scan</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <first_received>January 16, 2008</first_received>
    <start_date>August 2007</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>October 5, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00605046</url>
  </study>
  <study rank="245">
    <title>Imuran Dosing in Crohn's Disease Study</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IMURAN (azathioprine)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Prometheus Laboratories</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>226</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 8, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>January 12, 2010</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects achieving clinical remission at week #16.</outcome_measure>
      <outcome_measure>Proportion of subjects maintaining clinical remission at week #28 and #52</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00113503</url>
  </study>
  <study rank="246">
    <title>Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pompe Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albuterol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 21, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>October 19, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with Adverse Events.</outcome_measure>
      <outcome_measure>Change in forced vital capacity from pulmonary function tests at 30 weeks and 52 weeks.</outcome_measure>
      <outcome_measure>Change in 6 minute walk test</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01885936</url>
  </study>
  <study rank="247">
    <title>Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MNI-513-01</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 22, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>October 5, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01000870</url>
  </study>
  <study rank="248">
    <title>Open-label Trial of Leukine in Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sargramostim (Leukine)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>378</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>February 2003</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>December 2, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To establish a safety profile for long-term, repeated cycles of sargramostim administered to subjects with Crohn's disease.</outcome_measure>
      <outcome_measure>Crohn's disease activity</outcome_measure>
      <outcome_measure>Duration of clinical remission and time to disease flare</outcome_measure>
      <outcome_measure>Patient compliance</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00206700</url>
  </study>
  <study rank="249">
    <title>Use of FDG PET/CT to Evaluate Crohn Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">FDG PET/CT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Université de Sherbrooke</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 2, 2006</first_received>
    <start_date>September 2006</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>April 5, 2007</last_updated>
    <last_verified>October 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Diagnosis of Crohn Disease de novo and Crohn Disease recurrences with FDG PET/CT.</outcome_measure>
      <outcome_measure>Detection of inflammatory areas not suspected with usual tests</outcome_measure>
      <outcome_measure>Detection of an inflammatory activity for remission patients</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00383344</url>
  </study>
  <study rank="250">
    <title>Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">NTCELL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Living Cell Technologies</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 18, 2012</first_received>
    <start_date>July 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>February 9, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the safety of xenotransplantation of NTCELL</outcome_measure>
      <outcome_measure>Brain metabolism as demonstrated on PET with [18F]-fluorodopa measured at 26 weeks post-implant 1 compared with baseline</outcome_measure>
      <outcome_measure>Brain metabolism as demonstrated on PET with [11C]-tetrabenazine measured at 26 weeks post-implant 1 compared with baseline</outcome_measure>
      <outcome_measure>Scores measured by the Unified Parkinson's Disease Rating Scale (UPDRS Parts I, II, III, IV - Parts II and III will be performed in the 'off' and 'on' state) over 26 weeks post-implant 1 compared with the baseline scores</outcome_measure>
      <outcome_measure>Modified Hoehn and Yahr stages over 26 weeks post-implant 1 compared with the baseline stages</outcome_measure>
      <outcome_measure>Scores measured by the Unified Dyskinesia Rating Scale (UDysRS Parts I, II, III, IV - Parts III and IV will be performed in the 'off' and 'on' state) over 26 weeks post-implant 1 compared with the baseline scores</outcome_measure>
      <outcome_measure>Times for hand-arm movement between 2 points (tapping test) in accordance with the CAPSIT-PD protocol (Defer et al. 1999) over 26 weeks post-implant 1 compared with the baseline times</outcome_measure>
      <outcome_measure>Scores measured by the modified walking test in accordance with the CAPSIT-PD protocol (Defer et al. 1999) (walking 4.5m back and forth instead of 7m back and forth) over 26 weeks post-implant 1 compared with the baseline scores</outcome_measure>
      <outcome_measure>Scores measured by the Parkinson's Disease Questionnaire (PDQ-39) over 26 weeks post-implant 1 compared with the baseline scores</outcome_measure>
      <outcome_measure>Scores measured by neuropsychological tests at 26 weeks post-implant 1 compared with the baseline scores</outcome_measure>
      <outcome_measure>Psychiatric assessment at 26 weeks post-implant 1 compared with the baseline psychiatric assessment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01734733</url>
  </study>
  <study rank="251">
    <title>Fecal Transplantation for Inflammatory Bowel Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Fecal microbial l transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Meir Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 5, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>June 13, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement of disease activity index.</outcome_measure>
      <outcome_measure>improvement of endoscopic score</outcome_measure>
      <outcome_measure>Maintenance of remission/ improvement during follow up</outcome_measure>
      <outcome_measure>Patients perspective of the treatment (do patients regard the treatment as acceptable)</outcome_measure>
      <outcome_measure>Cost estimation of the treatment</outcome_measure>
      <outcome_measure>side effects (presence of fever,or rise of 50% or more in the number of bowel movements)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02391012</url>
  </study>
  <study rank="252">
    <title>Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Central Nervous System Diseases</condition>
      <condition>Cognition</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">EVP-6124</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FORUM Pharmaceuticals Inc</lead_sponsor>
      <collaborator>INC Research Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>409</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 19, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>March 28, 2014</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive subscale-13 (ADAS-cog-13)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive subscale-11</outcome_measure>
      <outcome_measure>Controlled Oral Word Association Test</outcome_measure>
      <outcome_measure>Category Fluency Test</outcome_measure>
      <outcome_measure>Clinical Dementia Rating Scale Sum of Boxes</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study-Activities of Daily Living</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory</outcome_measure>
      <outcome_measure>Mini-Mental State Exam</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01073228</url>
  </study>
  <study rank="253">
    <title>Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Graft-versus-host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bortezomib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baylor Research Institute</lead_sponsor>
      <collaborator>Millennium Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 6, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>January 15, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the effectiveness and safety of the proteasome inhibitor Bortezomib (Velcade) in the treatment of steroid refractory chronic Graft-vs-Host Disease (cGVHD)</outcome_measure>
      <outcome_measure>To examine blood cells from patients who develop steroid resistant cGVHD following allogeneic HSCT for disease related gene signatures using DNA microarray analysis techniques</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01158105</url>
  </study>
  <study rank="254">
    <title>Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Charcot Marie Tooth Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Coenzyme Q10</intervention>
      <intervention type="Dietary Supplement">Coenzyme Q10</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Medical Center</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>October 9, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>July 11, 2013</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in weakness, fatigue and pain in persons with Charcot-Marie-Tooth disease after supplementation with 600 mgs a day of Coenzyme Q10.</outcome_measure>
      <outcome_measure>Improvements in quality of life in subjects with CMT before and after CoQ10 supplementation.</outcome_measure>
      <outcome_measure>Measure blood serum levels of the oxidized and reduced forms of CoQ10.</outcome_measure>
      <outcome_measure>Measure liver function tests</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00541164</url>
  </study>
  <study rank="255">
    <title>Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hodgkin's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">R-mabHD</intervention>
      <intervention type="Drug">ABVD</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>American Scitech International</lead_sponsor>
      <collaborator>ImClone LLC</collaborator>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 24, 2008</first_received>
    <start_date>July 2011</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>July 19, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>There will be a reduction in the size of the tumor after initiating treatment.</outcome_measure>
      <outcome_measure>There will be an improvement in the general condition of the patient and it will be possible to estimate the event free survival rate.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00797472</url>
  </study>
  <study rank="256">
    <title>Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hematologic Malignancies</condition>
      <condition>Graft vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">reduced intensity, related donor stem cell transplant</intervention>
      <intervention type="Drug">tacrolimus (standard GVHD prophylaxis)</intervention>
      <intervention type="Drug">mycophenolate (standard GVHD prophylaxis)</intervention>
      <intervention type="Drug">vorinostat</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pavan Reddy, MD</lead_sponsor>
      <collaborator>University of Michigan Cancer Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 17, 2008</first_received>
    <start_date>January 2009</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>March 5, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>November 27, 2013</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD)</outcome_measure>
      <outcome_measure>Number of Serious Adverse Events</outcome_measure>
      <outcome_measure>Percent Cumulative Incidence of Relapse at 2 Years.</outcome_measure>
      <outcome_measure>Percent Survival at 2-years</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00810602</url>
  </study>
  <study rank="257">
    <title>An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dehydroepiandrosterone [DHEA]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Inflabloc Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 22, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>October 17, 2007</last_updated>
    <last_verified>October 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Achieving CDAI (Crohn's Disease Activity Index) of 150 or less after 8 weeks of treatment</outcome_measure>
      <outcome_measure>Achieving a CDAI score of 150 or less at 4 weeks</outcome_measure>
      <outcome_measure>Change in CDAI from baseline of at least 100 points at 4 and 8 weeks</outcome_measure>
      <outcome_measure>Change in CRP (C-Reactive Protein) from baseline at 4 and 8 weeks</outcome_measure>
      <outcome_measure>Change in health-related quality of life from baseline at 8 weeks as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ)</outcome_measure>
      <outcome_measure>Change from baseline in diarrhea and abdominal pain sub-scores from CDAI</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00106314</url>
  </study>
  <study rank="258">
    <title>Mild Cognitive Impairment in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Mild Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Exelon Patch (rivastigmine transdermal system)</intervention>
      <intervention type="Drug">Placebo Patches</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 10, 2012</first_received>
    <start_date>December 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>February 24, 2015</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC)</outcome_measure>
      <outcome_measure>Treatment Emergent Symptom Scale (TESS)</outcome_measure>
      <outcome_measure>Montreal Cognitive Assessment (MoCA)</outcome_measure>
      <outcome_measure>Mind Streams Global Assessment Battery (GAB)</outcome_measure>
      <outcome_measure>Clinical Dementia Rating (CDR)</outcome_measure>
      <outcome_measure>Functional Activities Questionnaire (FAQ)</outcome_measure>
      <outcome_measure>Assessment of Daily Function Questionnaire</outcome_measure>
      <outcome_measure>Parkinson Disease Questionnaire (PDQ-8)</outcome_measure>
      <outcome_measure>Gordon Diagnostic System (GDS)</outcome_measure>
      <outcome_measure>Dementia Rating Scale (DRS-2)</outcome_measure>
      <outcome_measure>Psychiatric Measures</outcome_measure>
      <outcome_measure>Measures of Parkinson's Disease Severity</outcome_measure>
      <outcome_measure>Everyday Cognition Battery (ECB) and Memory Acquisition-Transfer Task</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01519271</url>
  </study>
  <study rank="259">
    <title>Phase IIb Study to Study the Efficacy of AT1001 to Treat Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AT-1001</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alba Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>72 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>184</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 25, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>January 18, 2010</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy of multiple dose levels of AT-1001 in preventing intestinal permeability changes induced by a 6- week gluten challenge.</outcome_measure>
      <outcome_measure>To prospectively validate a composite, weighed index of celiac disease activity</outcome_measure>
      <outcome_measure>Monitoring of adverse events (AEs) including signs and symptoms of gluten toxicity, Vital signs, Physical exam findings, EKG, Pregnancy Screening, Clinical laboratory testing of chemistry, hematology, and urinalysis specimens</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00492960</url>
  </study>
  <study rank="260">
    <title>Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Allogeneic Stem Cell Therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 27, 2011</first_received>
    <start_date>January 2010</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>July 11, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>CDAI</outcome_measure>
      <outcome_measure>CSS</outcome_measure>
      <outcome_measure>IBDQ</outcome_measure>
      <outcome_measure>CPAQ</outcome_measure>
      <outcome_measure>SF-36</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01288053</url>
  </study>
  <study rank="261">
    <title>A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dimebon 20 mg po TID</intervention>
      <intervention type="Drug">Placebo po TID</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
      <collaborator>Medivation, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 1, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>August 30, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>July 30, 2012</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Severe Impairment Battery (SIB) Score at Week 26</outcome_measure>
      <outcome_measure>Change From Baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (Severe) (ADCS-ADLsev) Score at Week 26</outcome_measure>
      <outcome_measure>Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score at Week 26</outcome_measure>
      <outcome_measure>Sum of the Delusions and Hallucinations Sub-domain Scores of the NPI</outcome_measure>
      <outcome_measure>Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 26</outcome_measure>
      <outcome_measure>Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Scores</outcome_measure>
      <outcome_measure>Resource Utilization in Dementia-Lite Version (RUD-Lite)</outcome_measure>
      <outcome_measure>Euro Quality of Life - 5 Domain (EQ-5D) Assessment</outcome_measure>
      <outcome_measure>Population Pharmacokinetic (PK) Analysis</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00912288</url>
  </study>
  <study rank="262">
    <title>Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">α1 Proteinase Inhibitor</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Human Genetics and Biochemistry</lead_sponsor>
      <collaborator>AIDS Community Research Initiative of America</collaborator>
      <collaborator>Grifols Biologicals Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>November 19, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>December 18, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>CD4 counts</outcome_measure>
      <outcome_measure>cholesterol levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01731691</url>
  </study>
  <study rank="263">
    <title>Cannabis for Inflammatory Bowel Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">smoking of cannabis</intervention>
      <intervention type="Drug">smoking cigarettes with placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Meir Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 29, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>December 15, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>reduction of CDAI by 70 points</outcome_measure>
      <outcome_measure>adverse events due to cannabis smoking</outcome_measure>
      <outcome_measure>change in quality of life before and at the end of study</outcome_measure>
      <outcome_measure>change in IL-10. IL-2. TGF beta</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01040910</url>
  </study>
  <study rank="264">
    <title>Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Systemic Lupus Erythematosus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Group B SLE one blood donation</intervention>
      <intervention type="Other">Blood drawing only Group C</intervention>
      <intervention type="Drug">Group A SLE prospective study</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oklahoma Medical Research Foundation</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>14 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>158</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 30, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>October 17, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>August 28, 2013</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00987831</url>
  </study>
  <study rank="265">
    <title>Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TA-650</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 9, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>December 5, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>September 2, 2012</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Median Crohn's Disease Activity Index (CDAI) Change From Week 0 to Week 8 in the Increased Dose Period</outcome_measure>
      <outcome_measure>CDAI at Each Evaluation Time Point in the Increased Dose Period</outcome_measure>
      <outcome_measure>CDAI Remission Rates at Each Evaluation Time Point in the Increased Dose Period</outcome_measure>
      <outcome_measure>CDAI Change at Each Evaluation Time Point in the Increased Dose Period</outcome_measure>
      <outcome_measure>Serum Concentration of TA-650 at Each Time Point</outcome_measure>
      <outcome_measure>Antibody to TA-650 Determination</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00805766</url>
  </study>
  <study rank="266">
    <title>A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ticagrelor</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>30 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>June 17, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of days with pain due to Sickle Cell Disease</outcome_measure>
      <outcome_measure>Intensity of pain due to Sickle Cell Disease</outcome_measure>
      <outcome_measure>Days of analgesic use</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02482298</url>
  </study>
  <study rank="267">
    <title>Creatine Therapy for Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Creatine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Center for Complementary and Integrative Health (NCCIH)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 15, 2001</first_received>
    <start_date>October 2001</start_date>
    <completion_date>June 2006</completion_date>
    <last_updated>August 17, 2006</last_updated>
    <last_verified>July 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00026988</url>
  </study>
  <study rank="268">
    <title>Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ISCHEMIC CARDIOMYOPATHY</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>November 12, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>November 14, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>COMPARISON OF MYOCARDIAL INFARCTION SIZE MEASUREMENTS USING INVESTIGATIONAL MANGANESE-ENHANCED MRI OR DELAYED GADOLINIUM ENHANCED MRI, AND CORRELATION WITH LONG-TERM OUTCOMES</outcome_measure>
      <outcome_measure>Evidence of clinically definite ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by non-investigational CT or MRI</outcome_measure>
      <outcome_measure>SAFETY AND TOLERABILITY OF MANGANESE CONTRAST REAGENT</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01989195</url>
  </study>
  <study rank="269">
    <title>A Trial of MitoQ for the Treatment of People With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MitoQ</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Antipodean Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>July 19, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) score at the final study visit compared to baseline</outcome_measure>
      <outcome_measure>The following assessments performed at the final study visit compared to baseline</outcome_measure>
      <outcome_measure>UPDRS sub scores</outcome_measure>
      <outcome_measure>Mini Mental State Examination</outcome_measure>
      <outcome_measure>Schwab and England Scale</outcome_measure>
      <outcome_measure>Modified Hoehn and Yahr Scale</outcome_measure>
      <outcome_measure>Timed tapping score</outcome_measure>
      <outcome_measure>The following safety outcomes will be measured over the course of the trial</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>ECG changes</outcome_measure>
      <outcome_measure>Laboratory sample results</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00329056</url>
  </study>
  <study rank="270">
    <title>Vercise Implantable Stimulator for Treating Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Deep Brain Stimulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boston Scientific Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>53</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 8, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>December 7, 2016</last_updated>
    <last_verified>December 2016</last_verified>
    <firstreceived_results_date>July 27, 2015</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Change in UPDRS III Score From Baseline in the Meds Off Condition (no Medications) to 26 Weeks Post First Lead Implantation in the Stim on/Meds Off Condition (Stimulation on and no Medications).</outcome_measure>
      <outcome_measure>Mean Change in UPDRS III Score From Baseline Meds Off to 12 and 52 Weeks Post First Lead Implantation Stim on/Meds Off.</outcome_measure>
      <outcome_measure>Mean Change in UPDRS II Score From Baseline Meds Off to 12, 26 and 52 Weeks Post First Lead Implantation Stim on/Meds Off.</outcome_measure>
      <outcome_measure>Mean Change in Antiparkinsonian Medication Use in Mgs (Levodopa or Equivalents) From Baseline to 12, 26 and 52 Weeks Post First Lead Implantation</outcome_measure>
      <outcome_measure>Mean Change in the Number of Waking Hours Per Day With Good Symptom Control and no Troublesome Dyskinesia From Baseline to 12, 26 and 52 Weeks Post First Lead Implantation.</outcome_measure>
      <outcome_measure>Mean Percent Change in Quality of Life Scale Scores: Parkinson's Disease Questionnaire (PDQ-39) From Baseline Meds on to 12, 26 and 52 Weeks Post First Lead Implantation Stim on/Meds on.</outcome_measure>
      <outcome_measure>Mean Percent Change in Quality of Life Scale Scores: Modified Schwab and England (SE) Scores From Baseline Meds on to 12, 26 and 52 Weeks Post First Lead Implantation Stim on/Meds on</outcome_measure>
      <outcome_measure>Percentage of Participants With Improved, No Change or Worsened Global Impression of Change (GIC) as Compared to Baseline, Evaluated by the Neurologist.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01221948</url>
  </study>
  <study rank="271">
    <title>Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Umbilical Cord Derived MSC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Affiliated Hospital to Academy of Military Medical Sciences</lead_sponsor>
      <collaborator>Peking University Third Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 5, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>February 18, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse event</outcome_measure>
      <outcome_measure>Changes from the baseline in Alzheimer' s Disease Assessment Scale-cognitive subscale(ADAS-Cog) at 10 weeks post-dose</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01547689</url>
  </study>
  <study rank="272">
    <title>Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Certolizumab pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 24, 2006</first_received>
    <start_date>April 2007</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>August 30, 2011</last_updated>
    <last_verified>December 2009</last_verified>
    <firstreceived_results_date>September 8, 2009</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Patients With at Least a 100-point Decrease From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 6</outcome_measure>
      <outcome_measure>Number of Patients With at Least a 100-point Decrease From Baseline in Crohn's Disease Activity Index (CDAI) Score at Weeks 1, and 14 or Withdrawal</outcome_measure>
      <outcome_measure>Number of Patients With at Least a 70-point Decrease From Baseline in Crohn's Disease Activity Index (CDAI) Score at Weeks 1, 6 and 14</outcome_measure>
      <outcome_measure>Number of Patients With a Crohn's Disease Activity Index (CDAI) Score ≤150 (Remission) at Weeks 1, 6 and 14 or Withdrawal</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) Score at Each of Weeks 1, 2, 4, 6, 8, 12 and 14</outcome_measure>
      <outcome_measure>Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Each of Weeks 1, 2, 4, 6, 8, 12 and 14</outcome_measure>
      <outcome_measure>C-reactive Protein Level at Each of Weeks 1, 2, 4, 6, 8, 12 and 14</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Baseline, and Weeks 6 and 14</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptoms Domain Score at Baseline, and Weeks 6 and 14</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Symptoms Domain Score at Baseline, and Weeks 6 and 14</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Function Domain Score at Baseline, and Weeks 6 and 14</outcome_measure>
      <outcome_measure>Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score at Baseline, and Weeks 6 and 14</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00307931</url>
  </study>
  <study rank="273">
    <title>Parkinsonics: A Controlled Study of Group Singing in Parkinson Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Group singing</intervention>
      <intervention type="Behavioral">Facilitated Discussion Group</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 25, 2016</first_received>
    <start_date>December 2015</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>August 30, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Parkinson Disease Quality of Life Questionnaire (PDQ)-39 scores</outcome_measure>
      <outcome_measure>Voice-Related Quality of Life</outcome_measure>
      <outcome_measure>Movement Disorder Society-Unified Parkinson Disease Rating Scale Motor scores</outcome_measure>
      <outcome_measure>Montreal Cognitive Assessment</outcome_measure>
      <outcome_measure>Geriatric Depression Scale-15</outcome_measure>
      <outcome_measure>Lorig Self-efficacy scale</outcome_measure>
      <outcome_measure>Short Form-36</outcome_measure>
      <outcome_measure>Sound pressure level (decibels)</outcome_measure>
      <outcome_measure>Voice jitter</outcome_measure>
      <outcome_measure>Voice shimmer</outcome_measure>
      <outcome_measure>Harmonic to noise ratio</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02753621</url>
  </study>
  <study rank="274">
    <title>A Risk Based Approach to Improving Chronic Kidney Disease Management</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Electronic Decision Support</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
      <collaborator>Harvard Vanguard Medical Associates</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>September 15, 2010</first_received>
    <start_date>May 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>February 14, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Annual Nephrology Evaluation</outcome_measure>
      <outcome_measure>Appropriate ACE/ARB Use</outcome_measure>
      <outcome_measure>Annual lab monitoring for CKD</outcome_measure>
      <outcome_measure>Outcomes According to Primary Care Use</outcome_measure>
      <outcome_measure>Outcomes According to Physician Attitudes</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01203813</url>
  </study>
  <study rank="275">
    <title>European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">HF0220</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hunter-Fleming Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 26, 2006</first_received>
    <start_date>July 2006</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>August 20, 2008</last_updated>
    <last_verified>August 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/tolerability of HF 0220 in mild to moderate Alzheimer's patients</outcome_measure>
      <outcome_measure>Validate biochemical markers relevant to Alzheimer's disease</outcome_measure>
      <outcome_measure>Assess the suitability of chosen HF0220 dose levels for future studies</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00357357</url>
  </study>
  <study rank="276">
    <title>Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Amnestic Mild Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AH110690 (18F) Injection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GE Healthcare</lead_sponsor>
      <collaborator>i3 Statprobe</collaborator>
      <collaborator>Medpace, Inc.</collaborator>
      <collaborator>Hvidovre Hospital Center Demark Danish Research Centre for Magnetic Resonance</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>25 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>November 4, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>December 4, 2009</last_updated>
    <last_verified>December 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.</outcome_measure>
      <outcome_measure>Examine the efficacy and parameters of brain [18F] uptake for separating 25 subjects with probable AD from 25 HV, assigning 20 amnestic MCI cases to an AD or HV category by measuring ranges of regional cerebral to cerebellum tracer uptake ratios.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00785759</url>
  </study>
  <study rank="277">
    <title>A Study of AA4500 in Men With Peyronie's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Peyronie's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">AA4500</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Endo Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>348</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 17, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 7, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>February 4, 2015</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage Change From Baseline in Penile Curvature</outcome_measure>
      <outcome_measure>Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</outcome_measure>
      <outcome_measure>Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ</outcome_measure>
      <outcome_measure>Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4</outcome_measure>
      <outcome_measure>A Responder Analysis Based on Subject Overall Global Assessment</outcome_measure>
      <outcome_measure>Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Plaque Consistency</outcome_measure>
      <outcome_measure>A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Length</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01243411</url>
  </study>
  <study rank="278">
    <title>Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TRx0237 150 mg/day</intervention>
      <intervention type="Drug">TRx0237 250 mg/day</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TauRx Therapeutics Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>891</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 14, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>April 7, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)</outcome_measure>
      <outcome_measure>Change from Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)</outcome_measure>
      <outcome_measure>Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes</outcome_measure>
      <outcome_measure>Change from Baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</outcome_measure>
      <outcome_measure>Change from Baseline on Mini-Mental Status Examination (MMSE)</outcome_measure>
      <outcome_measure>Change in expected decline of whole brain volume as measured by brain MRI</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01689246</url>
  </study>
  <study rank="279">
    <title>Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease</title>
    <recruitment open="N">Suspended</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Type I Gaucher Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ambroxol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Exsar Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 27, 2011</first_received>
    <start_date>December 2012</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>February 12, 2013</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety assessment based on potential changes in physical exam, vital signs, ECG, adverse event query, and clinical lab results, when compared to baseline values.</outcome_measure>
      <outcome_measure>efficacy based on biomarker (glucocerebrosidase activities), lab results, as well as hepatic and splenic volumes from imaging scans.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01463215</url>
  </study>
  <study rank="280">
    <title>The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STA-5326</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 5, 2005</first_received>
    <start_date>November 2005</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>February 24, 2007</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00250198</url>
  </study>
  <study rank="281">
    <title>Masked Faces in Parkinson Disease: Mechanism and Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Respiratory muscle strength training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 5, 2006</first_received>
    <start_date>December 2004</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>April 4, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>February 6, 2012</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Facial Entropy Score From Baseline [Off Dopamine Medication]</outcome_measure>
      <outcome_measure>Change in Facial Entropy Score From Baseline [On Dopamine Medication]</outcome_measure>
      <outcome_measure>Change in Parkinson Disease Quality of Life-39 Scale (PDQ-39)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00350402</url>
  </study>
  <study rank="282">
    <title>Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Certolizumab Pegol (CDP870)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>392</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <first_received>September 7, 2005</first_received>
    <start_date>February 2004</start_date>
    <completion_date>May 2005</completion_date>
    <last_updated>September 6, 2013</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical response at Week 26, in the strata defined by CRP ≥ 10 mg/L.</outcome_measure>
      <outcome_measure>In population with CRP ≥ 10 mg/L at baseline; Time to disease progression up to and including Week 26; Proportion of patients with clinical remission at Week 26; Proportion of patients with IBDQ response at Week 26; F-36 sub-scores and change from basel</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00152425</url>
  </study>
  <study rank="283">
    <title>A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lucerastat</intervention>
      <intervention type="Drug">Enzyme replacement therapy (ERT)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Actelion</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 10, 2016</first_received>
    <start_date>February 2015</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>October 13, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in blood pressure</outcome_measure>
      <outcome_measure>Change from baseline in heart rate</outcome_measure>
      <outcome_measure>Change from baseline in electrocardiogram (ECG) variables</outcome_measure>
      <outcome_measure>Change from baseline in body weight</outcome_measure>
      <outcome_measure>Number of subjects with treatment-emergent adverse events and serious adverse events</outcome_measure>
      <outcome_measure>Number of subjects with adverse events leading to premature discontinuation of lucerastat or ERT</outcome_measure>
      <outcome_measure>Number of subjects with treatment-emergent abnormalities in laboratory variables</outcome_measure>
      <outcome_measure>Change from baseline in plasma biomarkers of Fabry Disease</outcome_measure>
      <outcome_measure>Change from baseline in urine biomarker of Fabry Disease</outcome_measure>
      <outcome_measure>Change from baseline in left ventricular ejection fraction (LVEF)</outcome_measure>
      <outcome_measure>Change from baseline in left ventricular mass index (LVMi)</outcome_measure>
      <outcome_measure>Change from baseline in estimated glomerular filtration rate (eGFR)</outcome_measure>
      <outcome_measure>Change from baseline in urine albumin-to-creatinine ratio (UACR)</outcome_measure>
      <outcome_measure>Maximum plasma concentration (Cmax) of lucerastat</outcome_measure>
      <outcome_measure>Time to reach Cmax (tmax) of lucerastat</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve [AUC(tau)] of lucerastat</outcome_measure>
      <outcome_measure>Terminal half-life [t(1/2)]of lucerastat</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02930655</url>
  </study>
  <study rank="284">
    <title>A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Pulmonary Disease, Chronic Obstructive</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Biological">Benralizumab 100 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MedImmune LLC</lead_sponsor>
      <collaborator>AstraZeneca</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>421</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 21, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>August 11, 2016</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>August 11, 2016</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)</outcome_measure>
      <outcome_measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</outcome_measure>
      <outcome_measure>Number of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)</outcome_measure>
      <outcome_measure>Percentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)</outcome_measure>
      <outcome_measure>Annual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)</outcome_measure>
      <outcome_measure>Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393</outcome_measure>
      <outcome_measure>Percentage of Participants With Improvement in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total Score</outcome_measure>
      <outcome_measure>Change From Baseline in Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS) Domain Scores at Day 393</outcome_measure>
      <outcome_measure>Percentage of Participants With a 0.5-Point Improvement in Chronic Respiratory Questionnaire Self-administered Standardized Format (CRQ-SAS) Domain Scores at Day 393</outcome_measure>
      <outcome_measure>Change From Baseline in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Scores at Day 393</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01227278</url>
  </study>
  <study rank="285">
    <title>An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AIN457</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 5, 2009</first_received>
    <start_date>October 2009</start_date>
    <last_updated>May 31, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the long-term safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who participated in the core CAIN457A2202 phase II proof-of-concept study.</outcome_measure>
      <outcome_measure>To assess the long term immunogenicity of AIN457</outcome_measure>
      <outcome_measure>To assess the long term concentration of IL-17 in blood</outcome_measure>
      <outcome_measure>To assess markers of disease activity CRP, calprotectin and lactoferrin in the long term</outcome_measure>
      <outcome_measure>To assess the pharmacokinetics of AIN457 at steady-state</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01009281</url>
  </study>
  <study rank="286">
    <title>Safety and Tolerability Study of AT1001 in Celiac Disease Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AT1001</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alba Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>79</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 8, 2006</first_received>
    <start_date>August 2006</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>November 12, 2007</last_updated>
    <last_verified>February 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To demonstrate the safety and tolerability of multiple, oral doses of AT-1001 in celiac disease subjects that maintain a gluten-free diet.</outcome_measure>
      <outcome_measure>To evaluate the efficacy of multiple dose levels of AT-1001 in preventing intestinal permeability changes induced by gluten challenge</outcome_measure>
      <outcome_measure>to evaluate the effects of multiple dose levels of AT-1001 in preventing the induction of celiac disease signs and symptoms resulting from gluten challenge.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00362856</url>
  </study>
  <study rank="287">
    <title>A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Larazotide Acetate 0.5 mg</intervention>
      <intervention type="Drug">Larazotide Acetate 1 mg</intervention>
      <intervention type="Drug">Larazotide Acetate 2 mg</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alba Therapeutics</lead_sponsor>
      <collaborator>Teva Pharmaceuticals USA</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>342</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 14, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>July 16, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Celiac disease domains of the gastrointestinal symptoms rating scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01396213</url>
  </study>
  <study rank="288">
    <title>Monoclonal Antibody Treatment of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">J695</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 9, 2000</first_received>
    <start_date>December 2000</start_date>
    <completion_date>November 2002</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>November 2002</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00007163</url>
  </study>
  <study rank="289">
    <title>Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Visilizumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Facet Biotech</lead_sponsor>
      <collaborator>PDL BioPharma, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 19, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>March 6, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical response, defined as external closure of at least 50% of perianal fistulas, without an accompanying increase in dose of concomitant medications, the addition of new medications, or Crohn's Disease-related surgery.</outcome_measure>
      <outcome_measure>Frequency of complete clinical response, confirm internal healing by MRI, duration of disease improvement.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00267709</url>
  </study>
  <study rank="290">
    <title>Whole Body Vibration in Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Whole Body Vibration</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Universidade Federal de Pernambuco</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>74 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 29, 2014</first_received>
    <start_date>April 2015</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>November 13, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>muscle strength, as measured by isokinetic dynamometer (Kgf)</outcome_measure>
      <outcome_measure>postural equilibrium, as measured by biodex balance (score)</outcome_measure>
      <outcome_measure>functional capacity, as measured by 6MWT</outcome_measure>
      <outcome_measure>quality of life, as measured by questionnaire</outcome_measure>
      <outcome_measure>Thickness of Quadriceps Muscle, as measured by ultrasound</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02413073</url>
  </study>
  <study rank="291">
    <title>Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fibrosis</condition>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pirfenidone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Guadalajara</lead_sponsor>
      <collaborator>Cell Therapy And Technology, S.a. De C.v.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 31, 2015</first_received>
    <start_date>September 2009</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>April 2, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the results of the use of Pirfenidone in the progression of renal damage in patients with Chronic Kidney Disease.</outcome_measure>
      <outcome_measure>Effect of the use of Pirfenidone in renal function</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02408744</url>
  </study>
  <study rank="292">
    <title>Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ST101</intervention>
      <intervention type="Drug">ST101</intervention>
      <intervention type="Drug">ST101</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sonexa Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 10, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>June 5, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00842673</url>
  </study>
  <study rank="293">
    <title>Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">UVADEX and UVAR XTS Photopheresis System</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 10, 2003</first_received>
    <start_date>March 2003</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>November 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00056355</url>
  </study>
  <study rank="294">
    <title>Memory and Insulin in Early Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Insulin Aspart</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Jeff Burns, MD</lead_sponsor>
      <collaborator>University of Kansas Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>December 19, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>July 10, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>January 9, 2014</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>fMRI Measure of Hippocampal Activation</outcome_measure>
      <outcome_measure>Global Cognition</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00581867</url>
  </study>
  <study rank="295">
    <title>Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABX-CBL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abgenix</lead_sponsor>
      <collaborator>Sangstat Medical Corporation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Year</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>95</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 6, 2002</first_received>
    <start_date>October 1999</start_date>
    <completion_date>June 2003</completion_date>
    <last_updated>June 23, 2005</last_updated>
    <last_verified>July 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00035880</url>
  </study>
  <study rank="296">
    <title>A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Peyronie's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">AA4500</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Endo Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>189</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 7, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>February 4, 2015</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage Change From Baseline in Penile Curvature</outcome_measure>
      <outcome_measure>Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</outcome_measure>
      <outcome_measure>Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ</outcome_measure>
      <outcome_measure>Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4</outcome_measure>
      <outcome_measure>A Responder Analysis Based on Subject Overall Global Assessment</outcome_measure>
      <outcome_measure>Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Plaque Consistency</outcome_measure>
      <outcome_measure>A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Length</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01685437</url>
  </study>
  <study rank="297">
    <title>Behavioral Treatments for Anxiety and Depression in Veterans With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
      <condition>Anxiety</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive Behavioral Therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Michael Debakey Veterans Affairs Medical Center</lead_sponsor>
      <collaborator>South Central VA Mental Illness Research, Education &amp; Clinical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 25, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>April 30, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hospital Anxiety and Depression Scale and Hamilton Anxiety Scale</outcome_measure>
      <outcome_measure>Hamilton Depression Scale and Geriatric Depression Scale - 15</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire -8</outcome_measure>
      <outcome_measure>Client Satisfaction Questionnaire</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01323699</url>
  </study>
  <study rank="298">
    <title>Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Samsung Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>13 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>August 7, 2012</first_received>
    <start_date>October 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>August 7, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease with anti TNF-α Therapy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01661257</url>
  </study>
  <study rank="299">
    <title>Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Meniere's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Drug">Gentamicin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
      <collaborator>Imperial College Healthcare NHS Trust</collaborator>
      <collaborator>Medical Research Council</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 4, 2008</first_received>
    <start_date>April 2009</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>August 31, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>May 9, 2016</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Vertigo Attacks</outcome_measure>
      <outcome_measure>Change in Hearing</outcome_measure>
      <outcome_measure>Change in Speech Discrimination</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00802529</url>
  </study>
  <study rank="300">
    <title>Breast-Sparing Proton Therapy for Hodgkin's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hodgkins Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">Proton</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>10 Years</min_age>
    <max_age>30 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 19, 2012</first_received>
    <start_date>September 2011</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>February 3, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparative DVH data for delivered proton plan and accompanying photon plan for target volume and normal tissues.</outcome_measure>
      <outcome_measure>Treatment toxicity and disease control of proton therapy for the treatment of pediatric Hodgkin's Lymphoma.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02070393</url>
  </study>
  <study rank="301">
    <title>Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Propranolol</intervention>
      <intervention type="Drug">Losartan</intervention>
      <intervention type="Drug">Eprosartan</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>March 15, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>May 28, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01087749</url>
  </study>
  <study rank="302">
    <title>A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline</intervention>
      <intervention type="Drug">Istradefylline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Hakko Kirin Company, Limited</lead_sponsor>
      <collaborator>Kyowa Hakko Kirin Co., Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>363</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 2, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>August 28, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with Parkinson's disease (PD) treated with levodopa/dopa-decarboxylase inhibitor.</outcome_measure>
      <outcome_measure>To evaluate the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean percentage of awake time per day spent in the OFF state.</outcome_measure>
      <outcome_measure>To evaluate mean change in the total hours and the percentage of awake time per day spent in the ON state (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia).</outcome_measure>
      <outcome_measure>To evaluate the change in Unified Parkinson's Disease Rating Scale (UPDRS).</outcome_measure>
      <outcome_measure>To evaluate change in the Clinical Global Impression - Improvement scale (CGI-I).</outcome_measure>
      <outcome_measure>To evaluate the safety of 20 mg/day and 40mg/day doses of istradefylline</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00455507</url>
  </study>
  <study rank="303">
    <title>Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">azathioprine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>14 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <first_received>December 3, 2004</first_received>
    <start_date>April 2005</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>February 19, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To identify an optimal weight-based dose of azathioprine for the treatment of active Crohn's disease and for maintaining remission in those subjects.</outcome_measure>
      <outcome_measure>To characterize prospectively the predictive value of erythrocyte thioguanine nucleotide levels for response to azathioprine in who are wild type for the (thiopurine methyltransferase) TPMT gene</outcome_measure>
      <outcome_measure>To explore the relationship of 6-thioguanine (TGN) levels to TPMT enzyme activity</outcome_measure>
      <outcome_measure>To determine the effect of azathioprine dose upon time to relapse among subjects in remission induced by a course of prednisone</outcome_measure>
      <outcome_measure>To prospectively determine the rate of adverse events associated with a range of doses of azathioprine</outcome_measure>
      <outcome_measure>To preliminarily identify genetic polymorphisms associated with therapeutic response or toxicity to azathioprine.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00098111</url>
  </study>
  <study rank="304">
    <title>Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neurodegenerative Disease</condition>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">dextromethorphan</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 1999</first_received>
    <start_date>July 1993</start_date>
    <completion_date>June 2001</completion_date>
    <last_updated>July 12, 2006</last_updated>
    <last_verified>July 2000</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001365</url>
  </study>
  <study rank="305">
    <title>Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ST101</intervention>
      <intervention type="Drug">ST101</intervention>
      <intervention type="Drug">ST101</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sonexa Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 10, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>June 5, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-cog)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00842816</url>
  </study>
  <study rank="306">
    <title>Study of Sargramostim in Moderately to Severely Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sargramostim (Leukine)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 23, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>December 2, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>CDAI [Crohn's Disease Active Index] improvements</outcome_measure>
      <outcome_measure>PRO [Patient-reported outcome] variables (QOL [Quality of life]</outcome_measure>
      <outcome_measure>PGI-C [Patient global impression of change])</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00329537</url>
  </study>
  <study rank="307">
    <title>Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Polypill: Red Heart Pill</intervention>
      <intervention type="Drug">Usual medication</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
      <collaborator>Imperial College Healthcare NHS Trust</collaborator>
      <collaborator>Royal College of Surgeons, Ireland</collaborator>
      <collaborator>UMC Utrecht</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>665</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 29, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>May 28, 2015</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>change in intima-media (artery wall) thickness in the common carotid artery</outcome_measure>
      <outcome_measure>change in intima-media (artery wall) thickness and extent of atherosclerotic plaques in the carotid artery bifurcation</outcome_measure>
      <outcome_measure>change in central aortic blood pressure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01326676</url>
  </study>
  <study rank="308">
    <title>Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamin B12 Supplementation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>57</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>September 2006</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>December 16, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Vitamin B12 concentration</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00208611</url>
  </study>
  <study rank="309">
    <title>BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.</title>
    <recruitment open="N">Suspended</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 425809 dose 1</intervention>
      <intervention type="Drug">BI 425809 dose 2</intervention>
      <intervention type="Drug">BI 425809 dose 3</intervention>
      <intervention type="Drug">BI 425809 dose 4</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>585</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 27, 2016</first_received>
    <start_date>August 2016</start_date>
    <completion_date>April 2019</completion_date>
    <last_updated>December 2, 2016</last_updated>
    <last_verified>December 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The change from baseline in ADAS-Cog13 (Alzheimer's Disease Assessment Scale - cognitive 13 item subscale) total score</outcome_measure>
      <outcome_measure>Change from baseline in the ADCS-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living) score</outcome_measure>
      <outcome_measure>Change from baseline CDR-SB (Clinical Dementia Rating / Sum of Boxes)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02788513</url>
  </study>
  <study rank="310">
    <title>Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">deep brain stimulation (ACTIVA PC, Medtronic)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
      <collaborator>Medtronic</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 13, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>August 7, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>'Axial score'</outcome_measure>
      <outcome_measure>CAPSIT-PD</outcome_measure>
      <outcome_measure>Freezing of gait assessment course</outcome_measure>
      <outcome_measure>Freezing of gait questionnaire</outcome_measure>
      <outcome_measure>Berg Balance Scale</outcome_measure>
      <outcome_measure>Non-motor symptoms scale</outcome_measure>
      <outcome_measure>Non-motor symptoms quest</outcome_measure>
      <outcome_measure>Beck's depression scale index</outcome_measure>
      <outcome_measure>Minnesota Impulsive Disorders Interview</outcome_measure>
      <outcome_measure>Barratt Impulsiveness Scale</outcome_measure>
      <outcome_measure>UPDRS I-IV</outcome_measure>
      <outcome_measure>PDQ-39</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01355835</url>
  </study>
  <study rank="311">
    <title>Famvir for Treatment of Hearing in Unilateral Meniere's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Meniere's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Famciclovir</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>House Research Institute</lead_sponsor>
      <collaborator>House Clinic, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 31, 2012</first_received>
    <start_date>December 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>August 27, 2015</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pure-tone threshold change</outcome_measure>
      <outcome_measure>Tinnitus and/or dizziness handicap change</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01526408</url>
  </study>
  <study rank="312">
    <title>Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">saracatinib</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stephen M. Strittmatter</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 8, 2013</first_received>
    <start_date>July 2013</start_date>
    <last_updated>June 12, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Adverse Events on AZD0530</outcome_measure>
      <outcome_measure>CNS availability of AZD0530 after oral dosing</outcome_measure>
      <outcome_measure>Effects of AZD0530 on cognitive function in patients with Alzheimer's disease</outcome_measure>
      <outcome_measure>Effect of AZD0530 on brain glucose metabolism in patients with Alzheimer's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01864655</url>
  </study>
  <study rank="313">
    <title>Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I]-IBVM</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>May 30, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Does 123-I IBVM SPECT provide a quantitative measure of acetylcholinergic transporters in Healthy controls and AD patients?</outcome_measure>
      <outcome_measure>Does 123-I IBVM SPECT demonstrate reduced acetylcholinergic transporter binding in AD compared to healthy controls?</outcome_measure>
      <outcome_measure>Does 123-I IBVM SPECT provide a reliable measure of acetylcholinergic transporters in healthy controls and AD patients?</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00480701</url>
  </study>
  <study rank="314">
    <title>Depression in Alzheimer's Disease-2</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sertraline (Zoloft)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 25, 2004</first_received>
    <start_date>July 2004</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>September 17, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Depression remission (measured by the Cornell Scale for Depression in Dementia) and a global response measure (mADCS-CGI measuring mood, activity enjoyment, neurovegetative function and depressive cognitions.)</outcome_measure>
      <outcome_measure>Caregiver Burden and Quality of Life</outcome_measure>
      <outcome_measure>Patient Cognitive Functioning, Quality of Life</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00086138</url>
  </study>
  <study rank="315">
    <title>Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">13-valent conjugate pneumococcal vaccine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Michigan State University</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 28, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>September 27, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>September 27, 2016</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Antibody Concentrations After 13-valent Conjugate Pneumococcal Vaccination in in Patients 50 Years or Older With End Stage Renal Disease on Dialysis</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01974817</url>
  </study>
  <study rank="316">
    <title>Transcranial Magnetic Stimulation to Treat Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Real iTBS</intervention>
      <intervention type="Device">Sham iTBS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mark Hallett</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>October 14, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>August 31, 2012</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Gait Speed</outcome_measure>
      <outcome_measure>Bradykinesia</outcome_measure>
      <outcome_measure>Total UPDRS Score</outcome_measure>
      <outcome_measure>Motor UPDRS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00753519</url>
  </study>
  <study rank="317">
    <title>Riluzole to Treat Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IV Levodopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 24, 2001</first_received>
    <start_date>March 2001</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>March 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00013624</url>
  </study>
  <study rank="318">
    <title>Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GMI-1070</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 27, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>August 17, 2016</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>September 11, 2012</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety as Measured by the Number of Participants With Adverse Events</outcome_measure>
      <outcome_measure>Total Plasma Clearance</outcome_measure>
      <outcome_measure>Volume of the Central Compartment</outcome_measure>
      <outcome_measure>Intercompartmental Clearance</outcome_measure>
      <outcome_measure>Volume of the Peripheral Compartment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00911495</url>
  </study>
  <study rank="319">
    <title>Psychodynamic Therapy for Treating Panic Disorder</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Panic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Other">PFPP</intervention>
      <intervention type="Other">ART</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 5, 2005</first_received>
    <start_date>February 2000</start_date>
    <completion_date>July 2005</completion_date>
    <last_updated>June 26, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>PDSS (panic disorder severity scale)</outcome_measure>
      <outcome_measure>SDS (Sheehan disability scale)</outcome_measure>
      <outcome_measure>HARS (Hamilton anxiety rating scale)</outcome_measure>
      <outcome_measure>HDRS (Hamilton depression rating scale)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00128388</url>
  </study>
  <study rank="320">
    <title>Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">bone marrow derived mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Guangzhou General Hospital of Guangzhou Military Command</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 4, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>October 4, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Effect assessment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01446614</url>
  </study>
  <study rank="321">
    <title>Probiotics in GastroIntestinal Disorders</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ulcerative Colitis</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Bifidobacterium infantis 35624</intervention>
      <intervention type="Biological">Lactobacillus salivarius UCC118</intervention>
      <intervention type="Biological">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University College Cork</lead_sponsor>
      <collaborator>European Commission</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 2, 2007</first_received>
    <start_date>January 2002</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>June 13, 2011</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To determine whether ingestion of probiotic preparations (containing Lactobacillus salivarius subsp. salivarius UCC118 or Bifidobacterium infantis 35624) can help in the maintenance of remission of patients with Crohn's disease and ulcerative colitis</outcome_measure>
      <outcome_measure>Evaluation of the immunological and biochemical parameters of the immuno-inflammatory response and an assessment of the faecal flora in patients consuming the probiotic and control products</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00510978</url>
  </study>
  <study rank="322">
    <title>Open Label Study of TRx0014 in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TRx0014</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TauRx Therapeutics Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2008</first_received>
    <start_date>July 2007</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cognitive ability measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and by the Mini-Mental State Examination (MMSE).</outcome_measure>
      <outcome_measure>Dementia severity assessed by the Clinical Dementia Rating - sum of the boxes (CDR-sb).</outcome_measure>
      <outcome_measure>Daily living activities assessed by the Alzheimer's Disease functional Assessment and Change Scale (ADFACS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00684944</url>
  </study>
  <study rank="323">
    <title>Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Raloxifene</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Wisconsin, Madison</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 31, 2003</first_received>
    <start_date>September 2001</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2005</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00065767</url>
  </study>
  <study rank="324">
    <title>A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline (KW-6002)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Kirin Pharmaceutical Development, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>June 2004</start_date>
    <completion_date>January 2006</completion_date>
    <last_updated>July 12, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To establish the efficacy of a 20 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.</outcome_measure>
      <outcome_measure>To evaluate the efficacy of a 20 mg/d dose of istradefylline for reducing the total hours of OFF time.</outcome_measure>
      <outcome_measure>To evaluate the change in percentage of ON time (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia).</outcome_measure>
      <outcome_measure>To evaluate the change in Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination score (part III) and/or in Activities of Daily Living (ADL) score (part II).</outcome_measure>
      <outcome_measure>To evaluate the change in Parkinson's Disease Questionnaire (PDQ-39) and Medical Outcomes Study 36-item Short Form (SF-36).</outcome_measure>
      <outcome_measure>To evaluate the change in the Patient Global Impression - Improvement scale (PGI-I).</outcome_measure>
      <outcome_measure>To evaluate change in the Clinical Global Impression - Severity of Illness scale (CGI-S).</outcome_measure>
      <outcome_measure>To evaluate the safety of a 20 mg/d dose of istradefylline.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00199407</url>
  </study>
  <study rank="325">
    <title>Intra-Arterial Catheter Directed Therapy for Severe Graft vs. Host Disease (GVHD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">intra-arterial treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hadassah Medical Organization</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>September 4, 2005</first_received>
    <start_date>December 2000</start_date>
    <completion_date>August 2005</completion_date>
    <last_updated>November 6, 2006</last_updated>
    <last_verified>March 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To assess the efficacy of intra-arterial Methylprednisolone treatment in decreasing the severity of acute GVHD.</outcome_measure>
      <outcome_measure>1. Time to GVHD response. 2. Overall survival. 3. Disease free survival. 4. Acute toxicity.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00146978</url>
  </study>
  <study rank="326">
    <title>Effects Of tDCS With Physical Therapy On Rehabilitation In Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">tDCS</intervention>
      <intervention type="Behavioral">Physiotherapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Universidade Federal de Pernambuco</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 11, 2013</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>May 14, 2015</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>February 26, 2015</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Unified Parkinson´s Disease Rating Scale - UPDRS</outcome_measure>
      <outcome_measure>Change From Cortical Excitability Via Single Transcranial Magnetic Stimulation</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01877148</url>
  </study>
  <study rank="327">
    <title>A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MABT5102A</intervention>
      <intervention type="Drug">MABT5102A</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genentech, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>448</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 27, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>August 10, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score</outcome_measure>
      <outcome_measure>Change in Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01343966</url>
  </study>
  <study rank="328">
    <title>Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">duloxetine</intervention>
      <intervention type="Drug">placebo of duloxetine</intervention>
      <intervention type="Drug">injection of apomorphine</intervention>
      <intervention type="Drug">injection of placebo of apomorphine</intervention>
      <intervention type="Drug">L-Dopa</intervention>
      <intervention type="Drug">injection of placebo of L-Dopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Toulouse</lead_sponsor>
      <collaborator>French Parkinson Association</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>December 30, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 10, 2015</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Subjective pain threshold determined using thermal stimulations (thermotest) with the method of levels</outcome_measure>
      <outcome_measure>Objective pain threshold determined recording the nociceptive reflex of flexion</outcome_measure>
      <outcome_measure>Clinical evaluation of the severity of the motor handicap of patients using the Unified Parkinson's Disease Rating Scale (UPDRS III)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01504178</url>
  </study>
  <study rank="329">
    <title>Glutathione (GSH) In The Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Glutathione</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of South Florida</lead_sponsor>
      <collaborator>Wellness Health &amp; Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 5, 2010</first_received>
    <start_date>September 2003</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>August 6, 2010</last_updated>
    <last_verified>January 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Timed walking test</outcome_measure>
      <outcome_measure>Tapping test</outcome_measure>
      <outcome_measure>CGI-clinical global assessment by both the physician and the patient</outcome_measure>
      <outcome_measure>Patient diaries</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire, a quality of life measurement</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01177319</url>
  </study>
  <study rank="330">
    <title>Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine transdermal patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Ono Pharmaceutical Co. Ltd</collaborator>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 6, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J cog)</outcome_measure>
      <outcome_measure>Adverse Events, Serious Adverse Events, Adverse event leading to discontinuation of study drug</outcome_measure>
      <outcome_measure>Change From Baseline in Disability Assessment for Dementia (DAD)</outcome_measure>
      <outcome_measure>Change From Baseline in Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change From Baseline in Japanese version of the Clinical global impression of change (J-CGIC)</outcome_measure>
      <outcome_measure>Change From Baseline in Modified Crichton Scale</outcome_measure>
      <outcome_measure>Formulation usability questionnaire</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01529619</url>
  </study>
  <study rank="331">
    <title>Bone Response to Enzyme Replacement in Gaucher's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gaucher's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CEREDASE™</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 1999</first_received>
    <start_date>December 1993</start_date>
    <completion_date>November 2000</completion_date>
    <last_updated>September 21, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001416</url>
  </study>
  <study rank="332">
    <title>Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I] IMPY &amp; SPECT Imaging</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>Alzheimer's Association</collaborator>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>February 2, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>March 2008</completion_date>
    <last_updated>March 6, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Does 123-I IMPY demonstrate qualitatively increased radiotracer uptake in cortical regions consistent with β-amyloid deposition in AD patients relative to controls</outcome_measure>
      <outcome_measure>Can 123-I IMPY and SPECT provide a quantitative and reproducible measure of amyloid deposition</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00287248</url>
  </study>
  <study rank="333">
    <title>Desensitising Celiac Disease Patients With the Human Hookworm</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Necator americanus</intervention>
      <intervention type="Biological">Necator americanus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Prince Charles Hospital</lead_sponsor>
      <collaborator>National Health and Medical Research Council, Australia</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 6, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>October 10, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>September 21, 2014</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Duodenal Villus Height:Crypt Depth</outcome_measure>
      <outcome_measure>Intraepithelial Lymphocyte Count</outcome_measure>
      <outcome_measure>Number of Participants With 2 Points Increase in Marsh Score Post GC-1g</outcome_measure>
      <outcome_measure>Serum Anti-tissue Transglutaminase Antibodies Measured as International Units/mL (IU/mL)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01661933</url>
  </study>
  <study rank="334">
    <title>Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Levetiracetam</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>September 8, 2005</first_received>
    <start_date>July 2003</start_date>
    <completion_date>November 2004</completion_date>
    <last_updated>December 5, 2013</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with Idiopathic Parkinson's Disease by assessing the reduction in mean duration of dyskinesias during &quot;on&quot; period at 10-week</outcome_measure>
      <outcome_measure>Reduction in mean duration of dyskinesias per day at 9 month;Safety</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00160576</url>
  </study>
  <study rank="335">
    <title>Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rasagiline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Neuroscience, Inc.</lead_sponsor>
      <collaborator>H. Lundbeck A/S</collaborator>
      <collaborator>Teva Pharmaceutical Industries</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>328</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 13, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>April 20, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>October 9, 2014</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to Week 18 in the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Parts I, II and III</outcome_measure>
      <outcome_measure>Change From Baseline to Week 18 in the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Part II - Activities of Daily Living</outcome_measure>
      <outcome_measure>Change From Baseline to Week 18 in the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Part III - Motor Function</outcome_measure>
      <outcome_measure>Clinical Global Improvement (CGI) Score at Week 18 As Assessed by the Site Rater</outcome_measure>
      <outcome_measure>Clinical Global Improvement (CGI) Score at Week 18 As Assessed by the Participant</outcome_measure>
      <outcome_measure>Illness Severity Score at Day 0 and Week 18 As Assessed by the Site Rater</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01049984</url>
  </study>
  <study rank="336">
    <title>A Pilot Study of Oxaloacetate in Subjects With Treated PD</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Oxaloacetate (OAA)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Kansas Medical Center</lead_sponsor>
      <collaborator>Terra Biological LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 1, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>February 18, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>January 18, 2016</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) Total Score</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) ADL + Motor Score</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire - 39 (PDQ-39)</outcome_measure>
      <outcome_measure>Montreal Cognitive Assessment (MoCA)</outcome_measure>
      <outcome_measure>Geriatric Depression Scale (GDS)</outcome_measure>
      <outcome_measure>NonMotor Symptom Questionnaire (NMSQuest)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01741701</url>
  </study>
  <study rank="337">
    <title>Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine transdermal patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>380</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 5, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>March 28, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients who can reach the target rivastigmine patch size of 10 cm2 and stay on it for at least 8 weeks.</outcome_measure>
      <outcome_measure>Mini-Mental State Examination (MMSE), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Global Deterioration Scale (GDS), caregiver burden (Zarit Burden Interview).</outcome_measure>
      <outcome_measure>Patient compliance (drug accounting)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00731224</url>
  </study>
  <study rank="338">
    <title>Randomized Trial of a Nutritional Supplement in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Resveratrol with Glucose, and Malate</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
      <collaborator>Alzheimer's Association</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 7, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>November 13, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer Disease Assessment Scale (ADAScog)</outcome_measure>
      <outcome_measure>CGIC</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00678431</url>
  </study>
  <study rank="339">
    <title>Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Central Nervous System Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">EVP-6124 (0.1 mg/day)</intervention>
      <intervention type="Drug">EVP-6124 (0.3 mg/day)</intervention>
      <intervention type="Drug">EVP-6124 (1.0 mg/day)</intervention>
      <intervention type="Drug">Comparator: Placebo</intervention>
      <intervention type="Drug">Donepezil</intervention>
      <intervention type="Drug">Rivastigmine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FORUM Pharmaceuticals Inc</lead_sponsor>
      <collaborator>INC Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 1, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>April 18, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>June 16, 2011</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease</outcome_measure>
      <outcome_measure>EVP-6124 PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</outcome_measure>
      <outcome_measure>EVP-6124 PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</outcome_measure>
      <outcome_measure>EVP-6124 PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</outcome_measure>
      <outcome_measure>Donepezil PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</outcome_measure>
      <outcome_measure>Donepezil PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</outcome_measure>
      <outcome_measure>Donepezil PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</outcome_measure>
      <outcome_measure>Rivastigmine PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)</outcome_measure>
      <outcome_measure>Rivastigmine PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)</outcome_measure>
      <outcome_measure>Rivastigmine PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00766363</url>
  </study>
  <study rank="340">
    <title>A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline (KW-6002)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Hakko Kirin Company, Limited</lead_sponsor>
      <collaborator>Kyowa Hakko Kirin Co., Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>April 2005</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>May 21, 2014</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To establish the efficacy of 20 mg/d and 40mg/d doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/DCI.</outcome_measure>
      <outcome_measure>To evaluate the efficacy of 20 mg/d and 40mg/d dose of istradefylline for reducing the total hours of OFF time.</outcome_measure>
      <outcome_measure>To evaluate the change in percentage of ON time (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia).</outcome_measure>
      <outcome_measure>To evaluate the change in Unified Parkinson's Disease Rating Scale (UPDRS).</outcome_measure>
      <outcome_measure>To evaluate change in the Clinical Global Impression - Improvement scale (CGI-I).</outcome_measure>
      <outcome_measure>To evaluate change in the Clinical Global Impression - Severity of Illness scale (CGI-S).</outcome_measure>
      <outcome_measure>To evaluate the safety of 20 mg/d and 40mg/d doses of istradefylline.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00199355</url>
  </study>
  <study rank="341">
    <title>Compare the Efficacy of Aloe Vera Mouthwash With Non- Alcoholic Chlorhexidine Mouthwash on Periodontal Diseases</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Periodontal Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Active Comparator:Aloe Vera mouthwash</intervention>
      <intervention type="Drug">Active Comparator:Chlorhexidine mouthwash</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Islamic Azad University, Tehran</lead_sponsor>
    </sponsors>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 24, 2015</first_received>
    <start_date>March 2014</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 3, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction of pocket depth</outcome_measure>
      <outcome_measure>Reduction of bleeding on probing</outcome_measure>
      <outcome_measure>Reduction of plaque index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02560870</url>
  </study>
  <study rank="342">
    <title>Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft-Versus-Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Mesenchymal stromal cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>Stockholm County Council, Sweden</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 24, 2012</first_received>
    <start_date>August 2011</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>May 30, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in disease activity according to National Institute of Health criteria</outcome_measure>
      <outcome_measure>Change in disease activity as measured by histological examination</outcome_measure>
      <outcome_measure>Change in self-assessed disease activity and quality of life</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Freedom from steroids at 1 year after MSC treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01522716</url>
  </study>
  <study rank="343">
    <title>Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Coenzyme Q10 Nanodispersion (Nanoquinone)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Technische Universität Dresden</lead_sponsor>
      <collaborator>Deutsche Parkinson-Vereinigung e.V.</collaborator>
      <collaborator>MSE Pharmazeutika GmbH, Bad Homburg</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>132</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>September 2003</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>January 16, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) Part II and III</outcome_measure>
      <outcome_measure>Total UPDRS</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>PDQ-39</outcome_measure>
      <outcome_measure>SF36</outcome_measure>
      <outcome_measure>CGI</outcome_measure>
      <outcome_measure>Schwab&amp;England</outcome_measure>
      <outcome_measure>Montgomery-Asperg</outcome_measure>
      <outcome_measure>Pain</outcome_measure>
      <outcome_measure>Incontinence</outcome_measure>
      <outcome_measure>Sexual behavior</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00180037</url>
  </study>
  <study rank="344">
    <title>Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Delayed Release 6 mercaptopurine</intervention>
      <intervention type="Drug">6 Mercaptopurine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva GTC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 25, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 6, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with clinical response at study end</outcome_measure>
      <outcome_measure>Time to clinical response</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01094613</url>
  </study>
  <study rank="345">
    <title>PBMC (Peripheral Blood Mononuclear Cells) /Lymphocyte SPECT (Single Photon Emission Computerized Tomography) Imaging in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Labeling Ceretec</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>December 3, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>February 2011</completion_date>
    <last_updated>May 29, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Quantification of scintigraphic activity score for small bowel disease (for both PBMC and lymphocyte imaging methodologies)</outcome_measure>
      <outcome_measure>Tolerability endpoints including AEs</outcome_measure>
      <outcome_measure>Variability and reproducibility of the PBMC and lymphocyte imaging methodologies at visits 1 and 2.</outcome_measure>
      <outcome_measure>Rate of label accumulation in small bowel</outcome_measure>
      <outcome_measure>Circulating PBMC and lymphocyte subpopulation cell counts and correlation with scintigraphic activity scores.</outcome_measure>
      <outcome_measure>Correlation between CDAI, CRP, calprotectin, ASCA antibodies and SAS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01051622</url>
  </study>
  <study rank="346">
    <title>Parkinson's Disease Treatment With Coenzyme Q10</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Coenzyme Q10</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 25, 2000</first_received>
    <start_date>September 1998</start_date>
    <completion_date>October 2003</completion_date>
    <last_updated>June 23, 2005</last_updated>
    <last_verified>December 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00004731</url>
  </study>
  <study rank="347">
    <title>Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BIIB014</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biogen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>83</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 20, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 10, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number and proportion of subjects with adverse events</outcome_measure>
      <outcome_measure>Assessment of clinical laboratory parameters</outcome_measure>
      <outcome_measure>Assessment of vital signs</outcome_measure>
      <outcome_measure>Assessment of ECG parameters.</outcome_measure>
      <outcome_measure>Assess PK by measuring concentrations of BIIB014 and its N-acetyl metabolite in blood plasma.</outcome_measure>
      <outcome_measure>Explore activity of BIIB014 by evaluating standard Parkinson's disease assessments</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00438607</url>
  </study>
  <study rank="348">
    <title>A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
      <condition>Sickle Cell Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">N-Acetylcysteine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bloodworks (Puget Sound Blood Center)</lead_sponsor>
      <collaborator>University of Washington</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 21, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>August 2018</completion_date>
    <last_updated>April 8, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Laboratory measures of VWF activity</outcome_measure>
      <outcome_measure>Laboratory measures of red blood cell hemolysis and oxidation</outcome_measure>
      <outcome_measure>Adverse events during and following NAC administration</outcome_measure>
      <outcome_measure>Pain during VOC</outcome_measure>
      <outcome_measure>Use of pain medications in morphine equivalents</outcome_measure>
      <outcome_measure>Hospital length of stay (LOS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01800526</url>
  </study>
  <study rank="349">
    <title>Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">I123MNI388/I123MNI390</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 22, 2009</first_received>
    <start_date>March 2009</start_date>
    <last_updated>September 20, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the reliability of MNI 388/390 as a potential imaging biomarker for amyloid imaging in the brain</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00886951</url>
  </study>
  <study rank="350">
    <title>Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Nexell Isolex with T-cell Depletion</intervention>
      <intervention type="Device">Baxter isolex 300i</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 1999</first_received>
    <start_date>April 1998</start_date>
    <completion_date>February 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>February 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001765</url>
  </study>
  <study rank="351">
    <title>A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Olokizumab (OKZ)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB BIOSCIENCES GmbH</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 3, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 29, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with clinical response or remission as measured by the Crohn's Disease Activity Index (CDAI) at Week 8</outcome_measure>
      <outcome_measure>Percentage of subjects with clinical response as measured by the Crohn's Disease Activity Index (CDAI) at Week 16</outcome_measure>
      <outcome_measure>Percentage of subjects with clinical remission as measured by the Crohn's Disease Activity Index (CDAI) at Week 16</outcome_measure>
      <outcome_measure>Change from Baseline in the Crohn's Disease Activity Index (CDAI) to Week 16</outcome_measure>
      <outcome_measure>Change from Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 16</outcome_measure>
      <outcome_measure>Percentage of subjects with Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 16</outcome_measure>
      <outcome_measure>Percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 16</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01635621</url>
  </study>
  <study rank="352">
    <title>Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">T-Cell Depleted &amp; CD34+Select/w/StemCell Enriched Product</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 29, 2001</first_received>
    <start_date>August 2001</start_date>
    <completion_date>June 2004</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>June 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00023192</url>
  </study>
  <study rank="353">
    <title>Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>Hypomagnesemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mablet 360 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Zealand University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 12, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>April 27, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Intracellular magnesium</outcome_measure>
      <outcome_measure>Total serum magnesium</outcome_measure>
      <outcome_measure>Ionized serum magnesium</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02216877</url>
  </study>
  <study rank="354">
    <title>Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NS2330</intervention>
      <intervention type="Drug">Levodopa and Domperidone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 4, 2000</first_received>
    <start_date>August 2000</start_date>
    <completion_date>July 2003</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>July 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00006077</url>
  </study>
  <study rank="355">
    <title>A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Muckle Wells Syndrome</condition>
      <condition>Autoinflammatory</condition>
      <condition>Behcet's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">XOMA 052</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 29, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>September 26, 2015</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in clinical and biochemical indicators of inflammation</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Duration of response to single dose</outcome_measure>
      <outcome_measure>Long term clinical and biochemical responses</outcome_measure>
      <outcome_measure>Number of flares during randomized withdrawal</outcome_measure>
      <outcome_measure>If applicable, assessment of the lack of complete response in relation to pharmacologic parameters.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01211977</url>
  </study>
  <study rank="356">
    <title>Study for the Treatment of Crohn's Disease With Adacolumn</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Adacolumn</intervention>
      <intervention type="Device">Sham</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka America Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>235</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>March 5, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>January 15, 2009</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical Remission</outcome_measure>
      <outcome_measure>Frequency and Severity of Adverse Events Through Week 12</outcome_measure>
      <outcome_measure>CDAI Score Change From Baseline</outcome_measure>
      <outcome_measure>Clinical Response</outcome_measure>
      <outcome_measure>Mean Change in Short-Form 36 Questionnaire (SF-36) Physical Component Summary (PCS) Score</outcome_measure>
      <outcome_measure>Mean Change in Short-Form 36 Questionnaire (SF-36) Mental Component Summary (MCS) Score</outcome_measure>
      <outcome_measure>Mean Change in Inflammatory Bowel Diseases Questionnaire (IBDQ)</outcome_measure>
      <outcome_measure>Mean Change in EuroQol Score (Single Index)</outcome_measure>
      <outcome_measure>Mean Change in EuroQol Score (Visual Analog Scale)</outcome_measure>
      <outcome_measure>Mean Change in Work Limitations Questionnaire (Time Management)</outcome_measure>
      <outcome_measure>Mean Change in Work Limitations Questionnaire (Physical Demands)</outcome_measure>
      <outcome_measure>Mean Change in Work Limitations Questionnaire (Mental-Interpersonal Demands)</outcome_measure>
      <outcome_measure>Mean Change in Work Limitations Questionnaire (Output Demands)</outcome_measure>
      <outcome_measure>Mean Change in Work Limitations Questionnaire (WLQ Index)</outcome_measure>
      <outcome_measure>Mean Change in Crohn's Disease Endoscopic Index of Severity</outcome_measure>
      <outcome_measure>Mean Change in Subject Global Rating</outcome_measure>
      <outcome_measure>Mean Change in C-Reactive Protein</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00162942</url>
  </study>
  <study rank="357">
    <title>A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPM 962</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>174</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 24, 2012</first_received>
    <start_date>August 2006</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>February 3, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score</outcome_measure>
      <outcome_measure>UPDRS Part 2 Sum Score (Average Score of on State and Off State)</outcome_measure>
      <outcome_measure>Off Time</outcome_measure>
      <outcome_measure>Effective Rate in UPDRS Part 3 Sum Score</outcome_measure>
      <outcome_measure>UPDRS Part 1 Sum Score</outcome_measure>
      <outcome_measure>Effective Rate in Off Time</outcome_measure>
      <outcome_measure>UPDRS Part 2 Sum Score (on State)</outcome_measure>
      <outcome_measure>UPDRS Part 2 Sum Score (Off State)</outcome_measure>
      <outcome_measure>UPDRS Part 4 Sum Score</outcome_measure>
      <outcome_measure>Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score</outcome_measure>
      <outcome_measure>Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.</outcome_measure>
      <outcome_measure>The Modified Hoehn &amp; Yahr Severity of Illness</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01628848</url>
  </study>
  <study rank="358">
    <title>Deep Brain Stimulation for Parkinson's Disease Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">deep brain stimulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Minnesota - Clinical and Translational Science Institute</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>123</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 4, 2003</first_received>
    <start_date>June 1999</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>April 2, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean change in total UPDRS score (baseline to six-months post DBS surgery)</outcome_measure>
      <outcome_measure>Mean change in UPDRS subscales and individual scores</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00053625</url>
  </study>
  <study rank="359">
    <title>Periodontal Disease and Cardiovascular Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Periodontal Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Triclosan</intervention>
      <intervention type="Drug">Fluoride</intervention>
      <intervention type="Drug">Fluoride</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Colgate Palmolive</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>438</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 26, 2008</first_received>
    <start_date>November 2000</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>September 30, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Periodontal disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00763165</url>
  </study>
  <study rank="360">
    <title>Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Visilizumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Facet Biotech</lead_sponsor>
      <collaborator>PDL BioPharma, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 19, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>March 6, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical response, defined as a 100-point or more decrease in Crohn's Disease Activity Index, without an accompanying increase in dose of concomitant medications, additional medications, or Crohn's Disease-related surgery.</outcome_measure>
      <outcome_measure>Frequency of clinical remission, duration of effect, endoscopic evidence of mucosal healing, change in C-reactive protein levels, pharmacokinetics, and immunogenicity.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00267722</url>
  </study>
  <study rank="361">
    <title>Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TRx0237 200 mg/day</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TauRx Therapeutics Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 14, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>June 15, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)</outcome_measure>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)</outcome_measure>
      <outcome_measure>Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes</outcome_measure>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</outcome_measure>
      <outcome_measure>Change from Baseline in Mini-Mental Status Examination (MMSE)</outcome_measure>
      <outcome_measure>Change from Baseline in Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)</outcome_measure>
      <outcome_measure>Change in expected decline of whole brain volume as measured by brain MRI</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01689233</url>
  </study>
  <study rank="362">
    <title>Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbidopa/levodopa/entacapone</intervention>
      <intervention type="Drug">Immediate release carbidopa/levodopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Orion Corporation, Orion Pharma</collaborator>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>747</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>December 10, 2004</first_received>
    <start_date>September 2004</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>April 19, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>December 15, 2010</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to First Occurrence of Dyskinesia</outcome_measure>
      <outcome_measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score (Parts II and III)</outcome_measure>
      <outcome_measure>Occurrence of Wearing-off</outcome_measure>
      <outcome_measure>Time to First Occurrence of Wearing-off</outcome_measure>
      <outcome_measure>Occurrence of Dyskinesia</outcome_measure>
      <outcome_measure>Change From Baseline in Health-related Quality of Life Assessed Using the 39-item Parkinson's Disease Questionnaire (PDQ-39)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00099268</url>
  </study>
  <study rank="363">
    <title>Study of Biostate® in Children With Von Willebrand Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Von Willebrand Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biostate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>CSL Behring</lead_sponsor>
      <collaborator>Parexel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 1, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>November 12, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Haemostatic efficacy</outcome_measure>
      <outcome_measure>Incremental Recovery of VWF</outcome_measure>
      <outcome_measure>Incremental Recovery of FVIII</outcome_measure>
      <outcome_measure>Half-life of VWF</outcome_measure>
      <outcome_measure>Half-life of FVIII</outcome_measure>
      <outcome_measure>Area under the concentration curve (AUC) of VWF</outcome_measure>
      <outcome_measure>AUC of FVIII</outcome_measure>
      <outcome_measure>Maximum plasma concentration (Cmax) of VWF</outcome_measure>
      <outcome_measure>Maximum plasma concentration (Cmax) of FVIII</outcome_measure>
      <outcome_measure>Minimum plasma concentration (Cmin) of VWF</outcome_measure>
      <outcome_measure>Minimum plasma concentration (Cmin) of FVIII</outcome_measure>
      <outcome_measure>Time to maximum concentration (tmax) of VWF</outcome_measure>
      <outcome_measure>Time to maximum concentration (tmax) of FVIII</outcome_measure>
      <outcome_measure>Mean residence time (MRT) of VWF</outcome_measure>
      <outcome_measure>Mean residence time (MRT) of FVIII</outcome_measure>
      <outcome_measure>Clearance (CL) of VWF</outcome_measure>
      <outcome_measure>Clearance (CL) of FVIII</outcome_measure>
      <outcome_measure>Volume of distribution of steady state (Vss) of VWF</outcome_measure>
      <outcome_measure>Volume of distribution of steady state (Vss) of FVIII</outcome_measure>
      <outcome_measure>Frequency of adverse events (AEs) per infusion</outcome_measure>
      <outcome_measure>Severity of AEs per infusion</outcome_measure>
      <outcome_measure>Severity of AEs per subject</outcome_measure>
      <outcome_measure>Relatedness of AEs per infusion</outcome_measure>
      <outcome_measure>Relatedness of AEs per subject</outcome_measure>
      <outcome_measure>Development of VWF inhibitors</outcome_measure>
      <outcome_measure>Development of FVIII inhibitors</outcome_measure>
      <outcome_measure>Frequency of adverse events (AEs) per subject</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01213446</url>
  </study>
  <study rank="364">
    <title>Effects of Music Therapy on Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Music Therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>July 2004</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>August 19, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To examine the feasibility and tolerability of a treatment program of MT for subjects with HD.</outcome_measure>
      <outcome_measure>To determine if MT improves the mood and motor features of HD while improving quality of life.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00178360</url>
  </study>
  <study rank="365">
    <title>Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Solanezumab</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 12, 2013</first_received>
    <start_date>July 2013</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>November 30, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)</outcome_measure>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)</outcome_measure>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)</outcome_measure>
      <outcome_measure>Change from Baseline in Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)</outcome_measure>
      <outcome_measure>Change from Baseline in Functional Activities Questionnaire (FAQ)</outcome_measure>
      <outcome_measure>Change from Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)</outcome_measure>
      <outcome_measure>Change from Baseline in Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Change from Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)</outcome_measure>
      <outcome_measure>Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)</outcome_measure>
      <outcome_measure>Change from Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)</outcome_measure>
      <outcome_measure>Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)</outcome_measure>
      <outcome_measure>Proportion of Cognitive and Functional Responders</outcome_measure>
      <outcome_measure>Change from Baseline in Plasma Amyloid-Beta (Aβ) Species</outcome_measure>
      <outcome_measure>Change from Baseline in volumetric Magnetic Resonance Imaging (vMRI)</outcome_measure>
      <outcome_measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)</outcome_measure>
      <outcome_measure>Change from Baseline in Florbetapir Positron Emission Tomography (PET) Scan</outcome_measure>
      <outcome_measure>Change from Baseline in Cerebrospinal Fluid (CSF) Aβ Levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01900665</url>
  </study>
  <study rank="366">
    <title>Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson`s Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">VIUSID/ALZER</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Catalysis SL</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 28, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>May 2, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment)</outcome_measure>
      <outcome_measure>Hoehn-Yarh will be done at the beginning, every three months until one year (end of the treatment)</outcome_measure>
      <outcome_measure>Dosage levodopa will be done at the beginning, every three months until one year (end of the treatment)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01016470</url>
  </study>
  <study rank="367">
    <title>A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon-gamma</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 1999</first_received>
    <start_date>May 1992</start_date>
    <completion_date>July 2001</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>May 2000</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001317</url>
  </study>
  <study rank="368">
    <title>Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MEDI2070</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">MEDI2070</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
      <collaborator>MedImmune Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>174</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 24, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>December 7, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary endpoint of the study is Crohn's Disease Activity Index (CDAI) response at Week 8, defined by either a CDAI score of &lt; 150 or a CDAI reduction from baseline of at least 100 points</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) remission at Week 8, as defined by a CDAI score of &lt; 150</outcome_measure>
      <outcome_measure>A reduction of at least 100 points from baseline in Crohn's Disease Activity Index (CDAI) at Week 8</outcome_measure>
      <outcome_measure>A reduction of at least 70 points from baseline in Crohn's Disease Activity Index (CDAI) at Week 8</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) response (either remission defined by CDAI &lt; 150 or a CDAI reduction from baseline of at least 100 points from baseline) at Week 12</outcome_measure>
      <outcome_measure>Change from baseline Crohn's Disease Activity Index (CDAI) at Week 8</outcome_measure>
      <outcome_measure>Pharmacokinetic (PK) evaluation of Multiple Doses of MEDI2070</outcome_measure>
      <outcome_measure>Immunogenicity (IM) evaluation of Multiple Doses of MEDI2070</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01714726</url>
  </study>
  <study rank="369">
    <title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-494</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 16, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>October 24, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve endoscopic remission</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve clinical remission</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Crohn's Disease Activity Index (CDAI) less than 150</outcome_measure>
      <outcome_measure>Proportion of subjects with decrease in CDAI greater than or equal to 70 points</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve remission at Week 52</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02365649</url>
  </study>
  <study rank="370">
    <title>SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease (IBD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SC12267 (4SC-101)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>4SC AG</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 9, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of SC12267 (4SC-101) at a dose of 35 mg once daily in patients with Crohn's Disease (CD) or Ulcerative Colitis (UC) after a 12 week therapy as measured by the number of patients with complete or partial response.</outcome_measure>
      <outcome_measure>The secondary objective of this study is to evaluate the safety and tolerability of SC12267 (4SC-101) at a dose of 35 mg once daily in patients with CD or UC and to explore plasma levels (trough values) of SC12267 (4SC-101).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00820365</url>
  </study>
  <study rank="371">
    <title>Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">lecozotan SR (SRA-333)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 12, 2006</first_received>
    <start_date>March 2006</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>February 14, 2013</last_updated>
    <last_verified>July 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>All events and physical and neurological function and score change from baseline to 24 weeks in ratings for cognitive and global function scales</outcome_measure>
      <outcome_measure>Score change from baseline to 24 weeks on functional and behavioral scales</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00277810</url>
  </study>
  <study rank="372">
    <title>Talampanel to Treat Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IV Levodopa</intervention>
      <intervention type="Drug">Talampanel</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 15, 2005</first_received>
    <start_date>April 2005</start_date>
    <completion_date>February 2006</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>February 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00108667</url>
  </study>
  <study rank="373">
    <title>Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute on Aging (NIA)</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 3, 2003</first_received>
    <start_date>December 2002</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>July 24, 2009</last_updated>
    <last_verified>June 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00053599</url>
  </study>
  <study rank="374">
    <title>Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine capsule</intervention>
      <intervention type="Drug">Rivastigmine transdermal patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>583</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 14, 2008</first_received>
    <start_date>January 2008</start_date>
    <last_updated>October 19, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>October 19, 2011</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) Due, or Potentially Due, to Worsening of Parkinson Disease (PD) Motor Symptoms (Tremor, Muscle Rigidity, Bradykinesia, Fall)</outcome_measure>
      <outcome_measure>Percentage of Participants With Study Drug Discontinuations Due to Predefined AEs That Are Due, or Potentially Due, to Worsening of PD Motor Symptoms (Tremor, Muscle Rigidity, Bradykinesia, Fall)</outcome_measure>
      <outcome_measure>Change in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination Scores at Weeks 8, 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline</outcome_measure>
      <outcome_measure>Change in Mattis Dementia Rating Scale (Mattis DRS-2) Scores at Weeks 16, 24, 52 and 76 Compared to Baseline</outcome_measure>
      <outcome_measure>Change in Ten Point Clock Test (TPCT) Scores at Weeks 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline</outcome_measure>
      <outcome_measure>Change in Neuropsychiatric Inventory-10 (NPI-10) Scores at Weeks 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study-Activities Of Daily Living (ADCS-ADL) Scores at Weeks 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline</outcome_measure>
      <outcome_measure>UPDRS Part V Stage (Modified Hoehn and Yahr Staging)at Baseline, Week 8,16,24,52 and 76 (or Early Discontinuation)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00623103</url>
  </study>
  <study rank="375">
    <title>Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">PROCHYMAL adult human mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mesoblast International Sàrl</lead_sponsor>
      <collaborator>Mesoblast, Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 11, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>October 12, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Duration of clinical benefit (Crohn's disease activity index)</outcome_measure>
      <outcome_measure>Re-induction of clinical benefit (Crohn's disease activity index)</outcome_measure>
      <outcome_measure>Improvement in quality of life (Inflammatory Bowel Disease Quality of Life assessment IBDQ instrument)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00543374</url>
  </study>
  <study rank="376">
    <title>State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS)</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Activa PC+S</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Minnesota - Clinical and Translational Science Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>March 1, 2016</first_received>
    <start_date>May 2016</start_date>
    <completion_date>May 2019</completion_date>
    <last_updated>October 25, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cortical and sub-cortical brain signals using Activa PC+S</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02709148</url>
  </study>
  <study rank="377">
    <title>Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Body Dysmorphic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Levetiracetam</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Butler Hospital</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 12, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>November 16, 2010</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>October 18, 2010</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Responders on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS)</outcome_measure>
      <outcome_measure>Body Dysmorphic Disorder Clinical Global Impressions Scale; Hamilton Rating Scale for Depression; Quality of Life Enjoyment and Satisfaction Questionnaire; Social Phobia Inventory; Beck Anxiety Inventory;</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00265109</url>
  </study>
  <study rank="378">
    <title>Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PB127 for Injectable Suspension</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Point Biomedical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>December 20, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>July 1, 2008</last_updated>
    <last_verified>July 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the diagnostic performance of PB127 MPE for the detection and/or exclusion of significant obstructive coronary artery disease as defined by qualitative coronary angiography or qualifying clinical outcome</outcome_measure>
      <outcome_measure>To compare the diagnostic performance of PB127 MPE to SPECT for the detection and/or exclusion of significant obstructive coronary artery disease.</outcome_measure>
      <outcome_measure>To assess the concordance of PB127 MPE with SPECT in the differentiation of defect type (fixed versus reversible) in patients with significant obstructive CAD.</outcome_measure>
      <outcome_measure>To evaluate the diagnostic performance characteristics of PB127 MPE for identifying the location of significant obstructive CAD as defined by quantitative coronary angiography</outcome_measure>
      <outcome_measure>To assess the change in diagnostic certainty when PB127 MPE and relevant clinical information are combined over relevant clinical information alone.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00584896</url>
  </study>
  <study rank="379">
    <title>The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotic</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Baruch Padeh Medical Center, Poriya</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>January 6, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>January 10, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>endothelial stem cells</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01765998</url>
  </study>
  <study rank="380">
    <title>Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ProSavin</intervention>
      <intervention type="Biological">ProSavin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oxford BioMedica</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>48 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 31, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>May 9, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety as measured by the number and severity of Adverse Events</outcome_measure>
      <outcome_measure>Efficacy as measured by the UPDRS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00627588</url>
  </study>
  <study rank="381">
    <title>A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">autologous mesenchymal stromal cell</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
      <collaborator>Atlanta Clinical and Translational Science Institute</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 6, 2012</first_received>
    <start_date>July 2012</start_date>
    <last_updated>October 13, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Crohn's disease activity Index (CDAI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01659762</url>
  </study>
  <study rank="382">
    <title>Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Influenza Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Adjuvanted influenza vaccine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Vaccines</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>361</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 20, 2007</first_received>
    <start_date>November 2006</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>November 30, 2016</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Compare immunogenicity of a single IM inj. of an adj. inactivated subunit flu vaccine vs. inactivated subunit virus flu vaccine, with regards to A/H3N2 antigen, when administered to adults with underlying chronic disease, as measured by HI test at day 22</outcome_measure>
      <outcome_measure>Compare immunogenicity of an IM injection of an adj. inactivated subunit flu vaccine vs. inactivated subunit virus flu vaccine, with regards to B antigen, when administered to adults with underlying chronic disease, as measured by HI test at day 22</outcome_measure>
      <outcome_measure>Evaluate immunog. of a single IM inj. of an adj. inactivated subunit flu vaccine vs. inactivated subunit virus flu vaccine, with regards to A/H1N1 antigen, when administered to adults with underlying chronic disease, as measured by HI test at day 22</outcome_measure>
      <outcome_measure>To evaluate the safety of a single IM injection of the two influenza vaccines, when administered to adult subjects with underlying chronic disease(s).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00519064</url>
  </study>
  <study rank="383">
    <title>Magnesium Sulphate for Severe Hand, Foot and Mouth Disease in Vietnam</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hand, Foot and Mouth Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Magnesium Sulphate</intervention>
      <intervention type="Drug">Sterile water</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oxford University Clinical Research Unit, Vietnam</lead_sponsor>
      <collaborator>Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam</collaborator>
      <collaborator>Children's Hospital Number 1, Ho Chi Minh City, Vietnam</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Months</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 22, 2013</first_received>
    <start_date>April 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>September 29, 2016</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who experience at least one of the clinical events listed below (composite endpoint)</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Blood pressure criteria necessitating addition of milrinone following Vietnam Ministry of Health guidelines for the treatment of hand, foot and mouth disease</outcome_measure>
      <outcome_measure>Need for mechanical ventilation</outcome_measure>
      <outcome_measure>Development of shock</outcome_measure>
      <outcome_measure>Requirement for inotropic agents (eg dobutamine)</outcome_measure>
      <outcome_measure>Presence of neurological sequelae at discharge in survivors</outcome_measure>
      <outcome_measure>Neurodevelopmental status</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Number of adverse events and serious adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01940250</url>
  </study>
  <study rank="384">
    <title>Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CD-LD ER</intervention>
      <intervention type="Drug">CD-LD IR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IMPAX Laboratories, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 13, 2005</first_received>
    <start_date>October 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>March 13, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Parkinsonian disability at Visits 1 and 5</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00239564</url>
  </study>
  <study rank="385">
    <title>A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Deferiprone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 22, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>October 16, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>safety and efficacy</outcome_measure>
      <outcome_measure>Disease modification</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01539837</url>
  </study>
  <study rank="386">
    <title>A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Kawasaki Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sestamibi</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Lantheus Medical Imaging</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>4 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>445</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>October 8, 2013</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>April 30, 2013</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Kawasaki Disease Population at High and Low Risk of Developing Cardiac Events Though Three Years Follow-up.</outcome_measure>
      <outcome_measure>Concordance Will be Determined Between the Presence of Perfusion Abnormalities Detected on Sestamibi Images and the Classification of Ischemic Heart Disease.</outcome_measure>
      <outcome_measure>In Addition, a Determination of the Safety of Sestamibi Will be Evaluated at the End of the Study Through Adverse and Serious Adverse Events Reported and Evaluating Vital Signs, ECGs, Physical Exams and Laboratory Tests for Each Subject.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00162032</url>
  </study>
  <study rank="387">
    <title>Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Stem cell transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 24, 2000</first_received>
    <start_date>October 2000</start_date>
    <completion_date>November 2004</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>November 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00006417</url>
  </study>
  <study rank="388">
    <title>The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 23, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>June 24, 2009</last_updated>
    <last_verified>June 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Timed Up and Go</outcome_measure>
      <outcome_measure>Time to perform a 360 degree turn while standing in place</outcome_measure>
      <outcome_measure>Time to complete a figure-eight walking pattern around cones placed anterior and posterior to the subject</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00762814</url>
  </study>
  <study rank="389">
    <title>Trial of Vitamin D Supplementation in Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Cholecalciferol</intervention>
      <intervention type="Dietary Supplement">Miglyol oil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Barts &amp; The London NHS Trust</lead_sponsor>
      <collaborator>National Health Service, United Kingdom</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 14, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>February 3, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to first upper respiratory tract infection</outcome_measure>
      <outcome_measure>Time to first moderate / severe COPD exacerbation</outcome_measure>
      <outcome_measure>Time to unscheduled health service use for upper respiratory tract infection or moderate / severe exacerbation of chronic obstructive pulmonary disease</outcome_measure>
      <outcome_measure>Proportion of participants experiencing hypercalcaemia</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00977873</url>
  </study>
  <study rank="390">
    <title>A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Perfusion CMR for detection of coronary artery disease</intervention>
      <intervention type="Other">Perfusion cardiac magnetic resonance imaging</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amersham Buchler, GmbH &amp; Co KG</lead_sponsor>
      <collaborator>Beacon Bioscience, Inc.</collaborator>
      <collaborator>Cleveland Clinic Foundation, Cleveland, USA (Corelab for coronary angiography analysis)</collaborator>
      <collaborator>CRL, Medinet Europe, Breda, The Netherlands (Corelab for blood sample analyses)</collaborator>
      <collaborator>Biomedical Systems</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>533</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>September 14, 2009</first_received>
    <start_date>July 2003</start_date>
    <completion_date>June 2004</completion_date>
    <last_updated>September 14, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Non-inferiority of perfusion CMR vs SPECT for sensitivity and specificity (binary reading) for the detection of coronary artery disease</outcome_measure>
      <outcome_measure>Assessment of the diagnostic performance of CMR and SPECT expressed as area under the receiver operator characteristics curve to detect coronary artery disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00977093</url>
  </study>
  <study rank="391">
    <title>Gene Therapy for Chronic Granulomatous Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>3 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 31, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>August 6, 2016</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Can conditioning with busulfan improve gene therapy outcomes</outcome_measure>
      <outcome_measure>1) To evaluate further the safety of gene therapy2) To monitor long-term results of gene therapy with conditioning</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00394316</url>
  </study>
  <study rank="392">
    <title>Extension Study of Biostate in Subjects With Von Willebrand Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Von Willebrand Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biostate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>CSL Behring</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 8, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>April 8, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Haemostatic efficacy</outcome_measure>
      <outcome_measure>Development of FVIII inhibitors</outcome_measure>
      <outcome_measure>Development of VWF inhibitors</outcome_measure>
      <outcome_measure>Frequency of Adverse events (AEs) per subject</outcome_measure>
      <outcome_measure>Severity of AEs per subject</outcome_measure>
      <outcome_measure>Severity of AEs per infusion</outcome_measure>
      <outcome_measure>Causality of AEs per subject</outcome_measure>
      <outcome_measure>Causality of AEs per infusion</outcome_measure>
      <outcome_measure>Frequency of Adverse events (AEs) per infusion</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01224808</url>
  </study>
  <study rank="393">
    <title>MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AChEI - Either donepezil or galantamine or rivastigmine with or without memantine</intervention>
      <intervention type="Drug">RO4602522 1 mg</intervention>
      <intervention type="Drug">RO4602522 5 mg</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>531</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 30, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>November 17, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Alzheimer's Disease Assessment Scale - Cognitive Behaviour Subscale (ADAS-Cog-11) score</outcome_measure>
      <outcome_measure>Change in Alzheimer's disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale score</outcome_measure>
      <outcome_measure>Effect on behavioural symptoms: Change in Behavioural Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (BEHAVE-AD-FW)/Apathy Evaluation Scale (AES) score</outcome_measure>
      <outcome_measure>Effect on global measures: Alzheimer's Disease Cooperative Study Clinician Global Impression of Change (ADCS-CGIC) scale/Global Deterioration Scale (GDS) at 12 months</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01677754</url>
  </study>
  <study rank="394">
    <title>HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Kidney, Polycystic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lisinopril</intervention>
      <intervention type="Drug">Telmisartan</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Boehringer Ingelheim</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Polycystic Kidney Disease Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>15 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>486</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 17, 2013</first_received>
    <start_date>January 2006</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>February 25, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>February 2, 2015</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.</outcome_measure>
      <outcome_measure>Albuminuria</outcome_measure>
      <outcome_measure>Aldosterone</outcome_measure>
      <outcome_measure>Hospitalizations</outcome_measure>
      <outcome_measure>Cardiovascular Hospitalizations</outcome_measure>
      <outcome_measure>Quality of Life Physical Component Summary</outcome_measure>
      <outcome_measure>Quality of Life Mental Component Summary</outcome_measure>
      <outcome_measure>Pain</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01885559</url>
  </study>
  <study rank="395">
    <title>Efficacy Study of Pneumococcal Vaccination in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">23-valent polysaccharide pneumococcal vaccine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyunghee University Medical Center</lead_sponsor>
      <collaborator>Wonju Severance Christian Hospital</collaborator>
      <collaborator>Seoul National University Hospital</collaborator>
      <collaborator>Asan Medical Center</collaborator>
      <collaborator>Soonchunhyang University Hospital</collaborator>
      <collaborator>Ewha Womans University</collaborator>
      <collaborator>Kosin University Gospel Hospital</collaborator>
      <collaborator>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</collaborator>
      <collaborator>Inje University</collaborator>
      <collaborator>The Catholic University of Korea</collaborator>
      <collaborator>Keimyung University Dongsan Medical Center</collaborator>
      <collaborator>Korea University</collaborator>
      <collaborator>Wonkwang University</collaborator>
      <collaborator>Severance Hospital</collaborator>
      <collaborator>Konkuk University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 2, 2012</first_received>
    <start_date>December 2011</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>October 14, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serological response rates</outcome_measure>
      <outcome_measure>Safety assessment of the vaccine</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01505855</url>
  </study>
  <study rank="396">
    <title>Study of Zonisamide in Early Parkinson Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Zonisamide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mazandaran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 8, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>January 9, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to need for dopaminergic therapy</outcome_measure>
      <outcome_measure>change in UPDRS score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01766128</url>
  </study>
  <study rank="397">
    <title>Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Top-down</intervention>
      <intervention type="Drug">Step-up</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Roma La Sapienza</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 12, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>March 5, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical response or clinical remission as determined by PCDAI in top-down vs. step-up group</outcome_measure>
      <outcome_measure>Rate of mucosal healing in top-down vs. step-up group</outcome_measure>
      <outcome_measure>Rate of adverse events in top-down vs. step-up group</outcome_measure>
      <outcome_measure>Hospitalization and surgery</outcome_measure>
      <outcome_measure>Growth</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01752790</url>
  </study>
  <study rank="398">
    <title>A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine Patch</intervention>
      <intervention type="Drug">Rivastigmine Capsules</intervention>
      <intervention type="Drug">Placebo to Rivastigmine patch</intervention>
      <intervention type="Drug">Placebo to Rivastigmine capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>501</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 19, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>July 10, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>May 5, 2014</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline on Cognition, Assessed by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)</outcome_measure>
      <outcome_measure>Change From Baseline in Global Functioning, Assessed by the Alzheimer's Disease Assessment Scale Clinical Impression of Change (ADCS-CGIC)</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score</outcome_measure>
      <outcome_measure>Change From Baseline in Mini-Mental State Examination (MMSE) Total Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01399125</url>
  </study>
  <study rank="399">
    <title>ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ADX48621</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Addex Pharma S.A.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>83</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 4, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>July 13, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with abnormal safety and tolerability assessment parameters</outcome_measure>
      <outcome_measure>Dyskinesia severity score measured by mAIMS</outcome_measure>
      <outcome_measure>Change in Parkinson's disease severity</outcome_measure>
      <outcome_measure>Patient-rated and clinician-rated global impression of change in dyskinesia and Parkinson's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01336088</url>
  </study>
  <study rank="400">
    <title>Transcranial Direct Current Stimulation (tDCS) and Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Cranial Electric Stimulation (CES)</intervention>
      <intervention type="Device">Treadmill</intervention>
      <intervention type="Device">CES and Treadmill</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Maryland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 19, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>June 13, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>December 19, 2011</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Stride Length</outcome_measure>
      <outcome_measure>Gait Velocity</outcome_measure>
      <outcome_measure>Cadence</outcome_measure>
      <outcome_measure>Number of Steps to Regain Balance</outcome_measure>
      <outcome_measure>First Step Length</outcome_measure>
      <outcome_measure>First Step Velocity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01100762</url>
  </study>
  <study rank="401">
    <title>Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ACC-001 (vanutide cridificar)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 20, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>December 11, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the effect of ACC-001 in combination with an adjuvant immunostimulatory agent (QS-21), administered intramuscularly compared to placebo on cerebral amyloid burden in subjects with mild to moderate Alzheimer's disease.</outcome_measure>
      <outcome_measure>To evaluate the safety and tolerability of 2 dosage levels of ACC-001 plus QS-21 vs. placebo in subjects with mild to moderate AD.</outcome_measure>
      <outcome_measure>Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in disease biomarkers.</outcome_measure>
      <outcome_measure>Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in measurements of immunogenicity.</outcome_measure>
      <outcome_measure>Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in cognitive and functional scales.</outcome_measure>
      <outcome_measure>Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in health outcome measures.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01284387</url>
  </study>
  <study rank="402">
    <title>Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cushing Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pasireotide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>August 2004</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>November 15, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Long term efficacy (UFC) in patients with Cushing's disease</outcome_measure>
      <outcome_measure>Long term safety</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Pharmacokinetics</outcome_measure>
      <outcome_measure>Development of biomarker</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00171951</url>
  </study>
  <study rank="403">
    <title>Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
      <condition>Parkinsonian Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I]B-CIT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 4, 2006</first_received>
    <start_date>January 2006</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>April 21, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Dopamine transporter density</outcome_measure>
      <outcome_measure>Correlation of the imaging outcome with both clinical outcomes (olfaction, reaction time, handwriting, etc) and biochemical measures</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00273351</url>
  </study>
  <study rank="404">
    <title>Replagal Enzyme Replacement Therapy for Adults With Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Replagal (Agalsidase Alfa)</intervention>
      <intervention type="Drug">Replagal</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 30, 2004</first_received>
    <start_date>November 2004</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>December 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00097890</url>
  </study>
  <study rank="405">
    <title>Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tamibarotene</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Osaka City University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 30, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 21, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in Alzheimer's Disease Assessment Scale (ADAS-JCog)</outcome_measure>
      <outcome_measure>Changes in Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Changes in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Changes in Clinician Interview-Based Assessment of Change Plus Caregiver Information (CIBIC-Plus)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01120002</url>
  </study>
  <study rank="406">
    <title>A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sNN0031</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Newron Sweden AB</lead_sponsor>
      <collaborator>Medtronic</collaborator>
      <collaborator>Quintiles, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 18, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>January 9, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability through assessment of adverse events, ECGs, vital signs, clinical laboratory variables, MRI of brain and spinal cord, CSF sampling, and device performance as characterized by catheter tip placement and infusion accuracy.</outcome_measure>
      <outcome_measure>Time course of PD disease activity as measured by the UPDRS, MADRS and MMT rating scales.</outcome_measure>
      <outcome_measure>Change in caudate and putamen dopamine turnover using PET scans of 11C-PE2I uptake</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00866502</url>
  </study>
  <study rank="407">
    <title>Crohn's Disease Stem Cell Transplantation</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Autologous Stem Cell Transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 2, 2006</first_received>
    <start_date>April 2005</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>February 10, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>May 8, 2013</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Remission or Clinical Improvement as Assessed by Crohn's Disease Activity Index (CDAI) Scores</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00271947</url>
  </study>
  <study rank="408">
    <title>Study Evaluating ERB-041 in Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ERB-041</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 26, 2005</first_received>
    <start_date>April 2004</start_date>
    <completion_date>April 2005</completion_date>
    <last_updated>September 9, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Inflammatory serum markers</outcome_measure>
      <outcome_measure>Pharmacogenomics</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI) scores.</outcome_measure>
      <outcome_measure>Cell surface markers</outcome_measure>
      <outcome_measure>Fecal markers</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00245947</url>
  </study>
  <study rank="409">
    <title>Study of Enzyme Supplements to Treat Celiac Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
      <condition>Dermatitis Herpetiformis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STAN1</intervention>
      <intervention type="Drug">Placebo enzyme</intervention>
      <intervention type="Drug">STAN1+gluten</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Heim Pal Children's Hospital</lead_sponsor>
      <collaborator>Stanford University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 18, 2009</first_received>
    <start_date>August 2008</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>August 17, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Negative seroconversion or a drop of more than 50% in anti-transglutaminase antibody blood levels by ELISA</outcome_measure>
      <outcome_measure>Negative seroconversion or drop of at least two dilution steps in the EMA test</outcome_measure>
      <outcome_measure>Negative conversion for celiac antibodies in the blood by the rapid test</outcome_measure>
      <outcome_measure>Change in symptoms or rash (if any)</outcome_measure>
      <outcome_measure>Favorable changes in morphometry in small bowel biopsy specimens</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00962182</url>
  </study>
  <study rank="410">
    <title>Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Nonalcoholic Fatty Liver Disease (NAFLD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DR cysteamine bitartrate capsule</intervention>
      <intervention type="Other">DR cysteamine bitartrate placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>8 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>169</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 18, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>October 6, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in NAFLD</outcome_measure>
      <outcome_measure>Reduction in serum aminotransferase and gamma-glutamyl transpeptidase</outcome_measure>
      <outcome_measure>Reduction in MRI-determined hepatic fat fraction</outcome_measure>
      <outcome_measure>Changes to markers of oxidation and anti-oxidant status: malondialdehyde, F2alpha-isoprostane, total antioxidant capacity, oxidized LDL</outcome_measure>
      <outcome_measure>Changes in fasting insulin and glucose</outcome_measure>
      <outcome_measure>Changes in weight, height, BMI, and waist circumference</outcome_measure>
      <outcome_measure>Changes in the Pediatric Quality of Life score</outcome_measure>
      <outcome_measure>Changes to any symptoms the patient may have experienced</outcome_measure>
      <outcome_measure>Proportion with a change from a histological diagnosis of definite NASH or indeterminate for NASH to not NASH at end of treatment</outcome_measure>
      <outcome_measure>Individual histological characteristics at end of treatment compared to baseline such as steatosis, lobular inflammation, portal chronic inflammation, ballooning, fibrosis score and stage 1a vs 1b fibrosis</outcome_measure>
      <outcome_measure>Change in mean NAFLD Activity Score (NAS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01529268</url>
  </study>
  <study rank="411">
    <title>A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nilvadipine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Prof Brian Lawlor</lead_sponsor>
      <collaborator>University of Dublin, Trinity College</collaborator>
      <collaborator>Molecular Medicine Ireland LBG</collaborator>
      <collaborator>Alzheimer Europe</collaborator>
      <collaborator>Archer Pharmaceuticals, Inc.</collaborator>
      <collaborator>E-Search Limited</collaborator>
      <collaborator>University College Dublin</collaborator>
      <collaborator>GABO:mi</collaborator>
      <collaborator>King's College London</collaborator>
      <collaborator>Istituto Di Ricerche Farmacologiche Mario Negri</collaborator>
      <collaborator>University Hospital, Lille</collaborator>
      <collaborator>University of Ulm</collaborator>
      <collaborator>Szeged University</collaborator>
      <collaborator>Goeteborgs Universitet</collaborator>
      <collaborator>University College Cork</collaborator>
      <collaborator>Aristotle University Of Thessaloniki</collaborator>
      <collaborator>Stichting Katholieke Universiteit</collaborator>
      <collaborator>St. James's Hospital, Ireland</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 16, 2013</first_received>
    <start_date>October 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>May 25, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale (ADAS) Cog</outcome_measure>
      <outcome_measure>Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)</outcome_measure>
      <outcome_measure>Disability Assessment for Dementia (DAD)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02017340</url>
  </study>
  <study rank="412">
    <title>Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Semapimod</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ferring Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 21, 2008</first_received>
    <start_date>December 2002</start_date>
    <completion_date>September 2004</completion_date>
    <last_updated>August 22, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's disease activity index (CDAI)</outcome_measure>
      <outcome_measure>Safety measured by adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00740103</url>
  </study>
  <study rank="413">
    <title>Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lithium</intervention>
      <intervention type="Drug">Divalproex</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 2, 2004</first_received>
    <start_date>October 2004</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>March 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00095355</url>
  </study>
  <study rank="414">
    <title>Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ODM-101 65mg Carbidopa</intervention>
      <intervention type="Drug">ODM-101 105mg Carbidopa</intervention>
      <intervention type="Drug">Stalevo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Orion Corporation, Orion Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>November 22, 2012</first_received>
    <start_date>May 2011</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>November 20, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Duration of off time</outcome_measure>
      <outcome_measure>Unified Parkinson's disease rating Scale (UPDRS) I-IV and the sum of UPDRS II and III ('total score')</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01766258</url>
  </study>
  <study rank="415">
    <title>CP-461 for the Treatment of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CP-461</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
      <collaborator>Cell Pathways</collaborator>
      <collaborator>OSI Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 22, 2002</first_received>
    <start_date>July 2002</start_date>
    <completion_date>September 2003</completion_date>
    <last_updated>October 14, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00042055</url>
  </study>
  <study rank="416">
    <title>12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline (KW-6002)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Kirin Pharmaceutical Development, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>325</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 3, 2007</first_received>
    <start_date>March 2002</start_date>
    <completion_date>October 2003</completion_date>
    <last_updated>July 13, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline to Endpoint in percentage of awake time per day in an OFF state based on the subjects' valid ON/OFF Parkinson's disease diary data.</outcome_measure>
      <outcome_measure>Actual values and mean change from Baseline in percentage and total hours of awake time per day in the OFF state and ON state, UPDRS I-IV, II and III Scores during ON and OFF states, Global Clinical Impression-Improvement (CGI-I), safety</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00456794</url>
  </study>
  <study rank="417">
    <title>A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon beta-1a</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck KGaA</lead_sponsor>
      <collaborator>Merck Serono S.P.A., Italy</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 24, 2010</first_received>
    <start_date>November 2004</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>January 20, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>March 7, 2012</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score</outcome_measure>
      <outcome_measure>Mini Mental Status Examination (MMSE) Score</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score</outcome_measure>
      <outcome_measure>Instrumental Activities of Daily Living (IADL) Score</outcome_measure>
      <outcome_measure>Physical Self-Maintenance Scale (PSMS) Score</outcome_measure>
      <outcome_measure>Clinician's Interview Based Impression of Change (CIBIC-PLUS) Score</outcome_measure>
      <outcome_measure>Geriatric Depression Scale (GDS) Score</outcome_measure>
      <outcome_measure>Global Deterioration Scale Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01075763</url>
  </study>
  <study rank="418">
    <title>Caffeine as a Therapy for Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Caffeine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>McGill University Health Center</lead_sponsor>
      <collaborator>Pontifícia Universidade Católica do Paraná</collaborator>
      <collaborator>University of Calgary</collaborator>
      <collaborator>University of Newfoundland and Eastern Health</collaborator>
      <collaborator>University Health Network, Toronto</collaborator>
      <collaborator>UBC Hospital</collaborator>
      <collaborator>Movement Disorder Clinic - Deer Lodge Centre</collaborator>
      <collaborator>The Ottawa Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 28, 2012</first_received>
    <start_date>April 2014</start_date>
    <last_updated>December 7, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2021</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Motor manifestations associated with Parkinson's disease</outcome_measure>
      <outcome_measure>MDS-UPDRS components and subscales - each individual component will be assessed, including:</outcome_measure>
      <outcome_measure>Cognition</outcome_measure>
      <outcome_measure>Sleep</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Medication utilization</outcome_measure>
      <outcome_measure>Tolerability and side effects of caffeine</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01738178</url>
  </study>
  <study rank="419">
    <title>The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Panic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Duloxetine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Eli Lilly and Company</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 20, 2007</first_received>
    <start_date>August 2006</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>March 24, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>July 19, 2013</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Panic Disorder Severity Scale (PDSS)</outcome_measure>
      <outcome_measure>Clinical Global Impression of Severity Scale (CGI-S)</outcome_measure>
      <outcome_measure>Panic Attack Scale (PAS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00438971</url>
  </study>
  <study rank="420">
    <title>Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease</title>
    <recruitment open="N">Suspended</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Donepezil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Newcastle-upon-Tyne Hospitals NHS Trust</lead_sponsor>
      <collaborator>University of Newcastle Upon-Tyne</collaborator>
      <collaborator>University of Cambridge</collaborator>
      <collaborator>University of Manchester</collaborator>
      <collaborator>University of Birmingham</collaborator>
      <collaborator>Bangor University</collaborator>
      <collaborator>London School of Economics and Political Science</collaborator>
      <collaborator>University College, London</collaborator>
      <collaborator>Lancashire Care NHS Foundation Trust</collaborator>
      <collaborator>Newcastle University</collaborator>
      <collaborator>King's College London</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 16, 2009</first_received>
    <start_date>January 2013</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To demonstrate the superiority of donepezil over placebo in improving cognitive function, neuropsychiatric burden and functional ability in people with Parkinson's disease and mild dementia after 24 months of treatment.</outcome_measure>
      <outcome_measure>To demonstrate the superiority of donepezil over placebo in improving patient and carer quality of life and to establish the cost-effectiveness of donepezil.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01014858</url>
  </study>
  <study rank="421">
    <title>Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-288</intervention>
      <intervention type="Drug">donepezil</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>242</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 20, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>February 2011</completion_date>
    <last_updated>January 22, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ADAS-cog: Alzheimer's Disease Assessment Scale - Cognition portion</outcome_measure>
      <outcome_measure>MMSE: Mini Mental Status Exam</outcome_measure>
      <outcome_measure>NPI: Neuropsychiatric Inventory</outcome_measure>
      <outcome_measure>ADCS-ADL: Alzheimer's Disease Cooperative Study</outcome_measure>
      <outcome_measure>CIBIC-Plus: Clinician Interview-Baed Impression of Change - plus</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01018875</url>
  </study>
  <study rank="422">
    <title>Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sodium bicarbonate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Albert Einstein College of Medicine of Yeshiva University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 23, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>February 12, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>serum bicarbonate levels</outcome_measure>
      <outcome_measure>muscle strength as measured by sit-to stand test</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00888290</url>
  </study>
  <study rank="423">
    <title>Codeine in Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Codeine (30 mg)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>PriCara, Unit of Ortho-McNeil, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>June 29, 2011</last_updated>
    <last_verified>July 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Plasma morphine and codeine concentrations</outcome_measure>
      <outcome_measure>CYP2D6 genotype</outcome_measure>
      <outcome_measure>Disease severity</outcome_measure>
      <outcome_measure>Hospitalizations and admissions</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00174538</url>
  </study>
  <study rank="424">
    <title>Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 21, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>October 17, 2014</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>March 17, 2010</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance)</outcome_measure>
      <outcome_measure>Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)</outcome_measure>
      <outcome_measure>Change From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance)</outcome_measure>
      <outcome_measure>Change From Baseline in Number of Nocturias at Week 13 (End of Maintenance)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00519532</url>
  </study>
  <study rank="425">
    <title>A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Disease</condition>
      <condition>Diabetes Mellitus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">torcetrapib/atorvastatin</intervention>
      <intervention type="Drug">atorvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>15067</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 22, 2005</first_received>
    <start_date>July 2004</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>January 30, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The time to first occurrence of a major cardiovascular disease event</outcome_measure>
      <outcome_measure>Various composites of major cardiovascular disease events and other lipid parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00134264</url>
  </study>
  <study rank="426">
    <title>Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Arterial Occlusive Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">intraarterial stem cell therapy</intervention>
      <intervention type="Other">Stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johann Wolfgang Goethe University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 25, 2006</first_received>
    <start_date>October 2005</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>August 23, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Ankle brachial index</outcome_measure>
      <outcome_measure>Ulcer size</outcome_measure>
      <outcome_measure>Pain</outcome_measure>
      <outcome_measure>Walking distance</outcome_measure>
      <outcome_measure>TCO2</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00282646</url>
  </study>
  <study rank="427">
    <title>An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Replagal</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 2003</first_received>
    <start_date>October 2003</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>June 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00071877</url>
  </study>
  <study rank="428">
    <title>Alternative Dosing and Regimen of Replagal to Treat Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Replagal</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 6, 2004</first_received>
    <start_date>January 2004</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>November 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00075244</url>
  </study>
  <study rank="429">
    <title>Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kawasaki Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab</intervention>
      <intervention type="Drug">IVIG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fudan University</lead_sponsor>
      <collaborator>Shanghai Children's Medical Center</collaborator>
      <collaborator>Shanghai 10th People's Hospital</collaborator>
      <collaborator>Shanghai 8th People's Hospital</collaborator>
      <collaborator>Shanghai Xuhui Distrct Center Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Months</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 23, 2014</first_received>
    <start_date>January 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>February 2, 2016</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>change in concentrations of cytokines</outcome_measure>
      <outcome_measure>incidence of coronary artery lesions(CAL)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02298062</url>
  </study>
  <study rank="430">
    <title>EMD 128130 for the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">EMD 128130</intervention>
      <intervention type="Drug">IV Levodopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 23, 2001</first_received>
    <start_date>January 2001</start_date>
    <completion_date>December 2003</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>December 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00009048</url>
  </study>
  <study rank="431">
    <title>Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">TNFa Kinoid</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Neovacs</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 12, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>June 7, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence and severity of adverse events</outcome_measure>
      <outcome_measure>Antibody response</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00808262</url>
  </study>
  <study rank="432">
    <title>Long-term Pleiotropic Effect of Statins in Patients With Peripheral Arterial Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atorvastatin</intervention>
      <intervention type="Drug">Standard Medical Treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Universitario Getafe</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>December 31, 2009</first_received>
    <start_date>January 2008</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>January 4, 2010</last_updated>
    <last_verified>December 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>High-sensitivity C-Reactive Protein (hsCRP) and nitrites plasma levels at baseline and after one month and one year of inclusion.</outcome_measure>
      <outcome_measure>Lipid profile</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01041729</url>
  </study>
  <study rank="433">
    <title>Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Certolizumab pegol (CZP)</intervention>
      <intervention type="Biological">Certolizumab pegol (CZP)</intervention>
      <intervention type="Biological">Certolizumab pegol (CZP)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Japan Co. Ltd.</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>February 27, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>April 7, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 26</outcome_measure>
      <outcome_measure>Change From Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 8</outcome_measure>
      <outcome_measure>Change From Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 12</outcome_measure>
      <outcome_measure>Change From Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 16</outcome_measure>
      <outcome_measure>Change From Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 20</outcome_measure>
      <outcome_measure>Change From Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 24</outcome_measure>
      <outcome_measure>Change From Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 26</outcome_measure>
      <outcome_measure>Change From Week 0 in Crohn's Disease Activity Index (CDAI) Score at Last Visit [Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals]</outcome_measure>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 8</outcome_measure>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 12</outcome_measure>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 16</outcome_measure>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 20</outcome_measure>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 24</outcome_measure>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Last Visit [Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals]</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Remission at Week 8</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Remission at Week 12</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Remission at Week 16</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Remission at Week 20</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Remission at Week 24</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Remission at Week 26</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Remission at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals)</outcome_measure>
      <outcome_measure>Time to Disease Progression</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score</outcome_measure>
      <outcome_measure>Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Week 0</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Week 8</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Week 12</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Week 16</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Week 20</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Week 24</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Week 26</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Level at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals)</outcome_measure>
      <outcome_measure>Ratio of C-Reactive Protein (CRP) Level at Week 8 to Week 0</outcome_measure>
      <outcome_measure>Ratio of C-Reactive Protein (CRP) Level at Week 12 to Week 0</outcome_measure>
      <outcome_measure>Ratio of C-Reactive Protein (CRP) Level at Week 16 to Week 0</outcome_measure>
      <outcome_measure>Ratio of C-Reactive Protein (CRP) Level at Week 20 to Week 0</outcome_measure>
      <outcome_measure>Ratio of C-Reactive Protein (CRP) Level at Week 24 to Week 0</outcome_measure>
      <outcome_measure>Ratio of C-Reactive Protein (CRP) Level at Week 26 to Week 0</outcome_measure>
      <outcome_measure>Ratio of C-Reactive Protein (CRP) Level at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) to Week 0</outcome_measure>
      <outcome_measure>Percentage of Subjects at Week 8 Achieving a Reduction in Crohn's Disease Activity Index (CDAI) Score of ≥70 Points From Week 0</outcome_measure>
      <outcome_measure>Percentage of Subjects at Week 12 Achieving a Reduction in Crohn's Disease Activity Index (CDAI) Score of ≥70 Points From Week 0</outcome_measure>
      <outcome_measure>Percentage of Subjects at Week 16 Achieving a Reduction in Crohn's Disease Activity Index (CDAI) Score of ≥70 Points From Week 0</outcome_measure>
      <outcome_measure>Percentage of Subjects at Week 20 Achieving a Reduction in Crohn's Disease Activity Index (CDAI) Score of ≥70 Points From Week 0</outcome_measure>
      <outcome_measure>Percentage of Subjects at Week 24 Achieving a Reduction in Crohn's Disease Activity Index (CDAI) Score of ≥70 Points From Week 0</outcome_measure>
      <outcome_measure>Percentage of Subjects at Week 26 Achieving a Reduction in Crohn's Disease Activity Index (CDAI) Score of ≥70 Points From Week 0</outcome_measure>
      <outcome_measure>Percentage of Subjects at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) Achieving a Reduction in Crohn's Disease Activity Index (CDAI) Score of ≥70 Points From Week 0</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00329550</url>
  </study>
  <study rank="434">
    <title>Caffeine for Excessive Daytime Somnolence in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Excessive Daytime Somnolence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Caffeine 100-200 mg BID</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ron Postuma</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
      <collaborator>University of Toronto</collaborator>
      <collaborator>McGill University Health Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 11, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>April 15, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Epworth Sleepiness Scale</outcome_measure>
      <outcome_measure>Unified Parkinson Disease Rating Scale</outcome_measure>
      <outcome_measure>Clinical Global Impression of Change</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index</outcome_measure>
      <outcome_measure>Fatigue Severity Scale</outcome_measure>
      <outcome_measure>Stanford Sleep Scale</outcome_measure>
      <outcome_measure>PDQ-39</outcome_measure>
      <outcome_measure>SF-36</outcome_measure>
      <outcome_measure>Tolerability of Caffeine</outcome_measure>
      <outcome_measure>Beck Depression Inventory</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00459420</url>
  </study>
  <study rank="435">
    <title>Fecal Microbiota Transplantation in Pediatric Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases (IBD)</condition>
      <condition>Crohn's Disease (CD)</condition>
      <condition>Ulcerative Colitis (UC)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Fecal Microbiota Transplantation (FMT)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>Children's Hospital of Pittsburgh</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>22 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 21, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>April 1, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary Objective: Study the safety of Fecal Microbiome Transplantation in patients with Inflammatory Bowel Diseases by assessing change in fecal microbiome.</outcome_measure>
      <outcome_measure>Examine the efficacy of Fecal Microbiome Transplant in the treatment of children with IBD using the Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn Disease Activity Index (PCDAI) analysis, and assessing the change.</outcome_measure>
      <outcome_measure>Correlate the patient outcomes with the fecal microbiome prior to, and after Fecal Microbiome Transplantation.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02108821</url>
  </study>
  <study rank="436">
    <title>A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Type 2 Diabetes</condition>
      <condition>Major Depressive Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Diabetes and depression intervention</intervention>
      <intervention type="Behavioral">Diabetes intervention</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 13, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>September 21, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Glycosylated Hemoglobin</outcome_measure>
      <outcome_measure>Quick Inventory of Depressive Symptoms - Self Report</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00939250</url>
  </study>
  <study rank="437">
    <title>Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Fresh Frozen Plasma</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Caregiver)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 4, 2015</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>January 20, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Accuracy of Plasma Transfusion Dosing Algorithm to accurately predict necessary plasma dose required to reach INR commonly targeted compared clinician chosen dose</outcome_measure>
      <outcome_measure>Time (minutes) from initiation of first dose of plasma to initiation of planned procedure (in patient undergoing transfusion before a procedure) for clinician dosing compared to algorithm dosing strategies.</outcome_measure>
      <outcome_measure>Dose difference (average # units) between clinician dosing and algorithm dosing (units of FFP) per patient.</outcome_measure>
      <outcome_measure>Hospital length of stay</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02366845</url>
  </study>
  <study rank="438">
    <title>JP-1730 to Treat Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">JP 1730</intervention>
      <intervention type="Drug">IV Levodopa</intervention>
      <intervention type="Drug">IV Apomorphine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 21, 2002</first_received>
    <start_date>June 2002</start_date>
    <completion_date>July 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>July 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00040209</url>
  </study>
  <study rank="439">
    <title>Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mild Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sodium Oxybate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Clayton Sleep Insititute</lead_sponsor>
      <collaborator>St. Louis University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 24, 2008</start_date>
    <last_updated>July 6, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To evaluate and monitor the safety and tolerability of 6 to 9 g/day sodium oxybate in patients with mild Alzheimer's disease (AD) between the ages of 50 and 65 years.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00706186</url>
  </study>
  <study rank="440">
    <title>VI-1121 for the Treatment Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VI-1121</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VIVUS, Inc.</lead_sponsor>
      <collaborator>Medpace, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 31, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>November 15, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy variable is the change in Alzheimer's Disease Assessment-Cognitive Subscale (ADAS-Cog) score from baseline to Week 12 of each treatment period.</outcome_measure>
      <outcome_measure>The secondary efficacy endpoint is the mean change in Mini-Mental State Examination (MMSE) score from baseline to Week 12 of each treatment period.</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve 3-point improvement in ADAS-Cog score from baseline to Week 12 of each treatment period.</outcome_measure>
      <outcome_measure>Change in Clinician's Interview Based Impression of Change Plus Caregiver's Input (CIBIC-plus) score from baseline to Week 12 of each treatment period</outcome_measure>
      <outcome_measure>Mean change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) score from baseline to Weeks 4, 8, and 12 of each treatment period</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01428362</url>
  </study>
  <study rank="441">
    <title>Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Graft vs. Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ustekinumab</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Tacrolimus (TAC)</intervention>
      <intervention type="Drug">Sirolimus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>H. Lee Moffitt Cancer Center and Research Institute</lead_sponsor>
      <collaborator>Gateway for Cancer Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 22, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>June 2017</completion_date>
    <last_updated>October 25, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>July 15, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>T Regulatory Cell (Treg)/Total Cluster of Differentiation 4 (CD4)+ Ratio</outcome_measure>
      <outcome_measure>Incidence of Acute Graft vs. Host Disease (AGVHD)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01713400</url>
  </study>
  <study rank="442">
    <title>Study of AA4500 in the Treatment of Peyronie's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Peyronie's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">AA4500</intervention>
      <intervention type="Biological">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Endo Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>418</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 8, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>September 7, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>February 4, 2015</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage Change From Baseline in Penile Curvature</outcome_measure>
      <outcome_measure>Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</outcome_measure>
      <outcome_measure>A Responder Analysis Based on Subject Overall Global Assessment of Peyronie's Disease</outcome_measure>
      <outcome_measure>Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms</outcome_measure>
      <outcome_measure>Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Plaque Consistency</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Length</outcome_measure>
      <outcome_measure>Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4</outcome_measure>
      <outcome_measure>Composite Responder Based on Change in Curvature Deformity and Change in Peyronie's Disease Bother Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01221597</url>
  </study>
  <study rank="443">
    <title>Omega 3 Supplementation and Ocular Surface Disease in Glaucoma</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ocular Surface Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Fishoil supplement</intervention>
      <intervention type="Dietary Supplement">Olive Oil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Illinois at Chicago</lead_sponsor>
      <collaborator>American Glaucoma Society</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 31, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>August 7, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Ocular Surface Disease Index Score</outcome_measure>
      <outcome_measure>Schirmer test score</outcome_measure>
      <outcome_measure>Lissamine Green Staining Score</outcome_measure>
      <outcome_measure>Fluorescein tear break-up time</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01630551</url>
  </study>
  <study rank="444">
    <title>Role of Mosapride in Patients With Gastroesophageal Reflux Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastroesophageal Reflux Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">mosapride for the first month and placebo for the 2nd month</intervention>
      <intervention type="Drug">placebo for the first and mosapride for the second month</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Lotung Poh-Ai Hospital</lead_sponsor>
      <collaborator>Tomorrow Medical Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 31, 2008</first_received>
    <start_date>June 2008</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>May 12, 2009</last_updated>
    <last_verified>May 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Symptom improvement evaluated by frequent scale for the symptoms of gastroesophageal reflux disease (FSSG)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00729339</url>
  </study>
  <study rank="445">
    <title>A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease With Cognitive Impairments</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">safinamide</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Newron</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 28, 2010</first_received>
    <start_date>September 2010</start_date>
    <last_updated>March 28, 2013</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Parkinson's Disease Cognitive Rating Scale (PD-CRS)</outcome_measure>
      <outcome_measure>PD-CRS subscale scores</outcome_measure>
      <outcome_measure>PD-CRS total score</outcome_measure>
      <outcome_measure>Dementia Rating Scale - 2 (DRS-2) total score</outcome_measure>
      <outcome_measure>DRS-2 total score</outcome_measure>
      <outcome_measure>DRS-2 subscale scores</outcome_measure>
      <outcome_measure>Clinical Global Impression (CGI) Change in Cognitive Dysfunction (CGI-C Cognition)</outcome_measure>
      <outcome_measure>CGI-C Cognition</outcome_measure>
      <outcome_measure>CGI-Severity in Cognitive Dysfunction (CGI-S Cognition)</outcome_measure>
      <outcome_measure>CGI-S Cognition</outcome_measure>
      <outcome_measure>Patient's Clinical Global Impression of Change in Cognitive (PCGI-C Cognition)</outcome_measure>
      <outcome_measure>PCGI-C Cognition</outcome_measure>
      <outcome_measure>Grid-Hamilton Depression Rating Scale (Grid-HAMD)</outcome_measure>
      <outcome_measure>Grid-HAMD</outcome_measure>
      <outcome_measure>Parkinson's Disease Sleep Scale (PDSS)</outcome_measure>
      <outcome_measure>PDSS</outcome_measure>
      <outcome_measure>Apathy Scale (AS)</outcome_measure>
      <outcome_measure>AS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01211587</url>
  </study>
  <study rank="446">
    <title>Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End-stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Calcium carbonate ( Intensive phosphate control)</intervention>
      <intervention type="Drug">Calcium carbonate (Liberalized phosphate control)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St. Michael's Hospital, Toronto</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 20, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>June 22, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum phosphate concentration</outcome_measure>
      <outcome_measure>Number of patients who successfully achieved target serum P at week 26 based on the arm to which they were randomized</outcome_measure>
      <outcome_measure>Treatment compliance as defined by taking the study medication at least 80% of the time</outcome_measure>
      <outcome_measure>Number of serious adverse events</outcome_measure>
      <outcome_measure>Number of hospitalizations for vascular reasons that are unrelated to dialysis access</outcome_measure>
      <outcome_measure>Proportion of patients with a vascular death or non-fatal vascular event</outcome_measure>
      <outcome_measure>Proportion of patients developing serum calcium &gt; 2.60 mmol/L</outcome_measure>
      <outcome_measure>Number of fractures</outcome_measure>
      <outcome_measure>Number of patients developing calcific uremic arteriolopathy (ie, calciphylaxis)</outcome_measure>
      <outcome_measure>Change in quality-of-life</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01994733</url>
  </study>
  <study rank="447">
    <title>A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-04447943</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>198</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 29, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>April 9, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline on Alzheimer's Disease Assessment Scale (Cognitive Subscale)</outcome_measure>
      <outcome_measure>Change from baseline on Neuropsychiatric Inventory</outcome_measure>
      <outcome_measure>Clinical Global Impression - Improvement</outcome_measure>
      <outcome_measure>Safety Assessments (including adverse events, vital signs, electrocardiograms, laboratory tests)</outcome_measure>
      <outcome_measure>Plasma Concentrations of PF-04447943</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00930059</url>
  </study>
  <study rank="448">
    <title>Phase IIb Study of Intranasal Glutathione in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Reduced Glutathione 100mg</intervention>
      <intervention type="Drug">Reduced Glutathione 200mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bastyr University</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 15, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>June 23, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score</outcome_measure>
      <outcome_measure>Red blood cell (RBC) GSH levels will be measured at baseline, week 4, week 12, and 16.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02424708</url>
  </study>
  <study rank="449">
    <title>A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IPX066</intervention>
      <intervention type="Drug">IR CD-LD</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IMPAX Laboratories, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>471</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 10, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>January 21, 2016</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>December 8, 2015</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of &quot;Off&quot; Time During Waking Hours at End of Study</outcome_measure>
      <outcome_measure>&quot;Off&quot; Time Hours</outcome_measure>
      <outcome_measure>&quot;On&quot; Time Without Troublesome Dyskinesia</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00974974</url>
  </study>
  <study rank="450">
    <title>NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Mild Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAOI-B</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 14, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>June 3, 2013</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24</outcome_measure>
      <outcome_measure>Change from baseline in Mini Mental Status Examination at week 8, 16 and 24</outcome_measure>
      <outcome_measure>Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24</outcome_measure>
      <outcome_measure>Change from baseline in Verbal learning and memory at week 24</outcome_measure>
      <outcome_measure>Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01600469</url>
  </study>
  <study rank="451">
    <title>CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">CERE-110: Adeno-Associated Virus Delivery of NGF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ceregene</lead_sponsor>
      <collaborator>Sangamo Biosciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 13, 2004</first_received>
    <start_date>June 2004</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>October 27, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability of three different doses of CERE-110 in subjects with mild to moderate Alzheimer's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00087789</url>
  </study>
  <study rank="452">
    <title>Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ALV003</intervention>
      <intervention type="Biological">ALV003 placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alvine Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 3, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>July 30, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Intestinal mucosal morphology</outcome_measure>
      <outcome_measure>Safety: Tolerability of ALV003</outcome_measure>
      <outcome_measure>Efficacy: Change in intestinal intraepithelial lymphocyte numbers/phenotype</outcome_measure>
      <outcome_measure>Efficacy: Change in serological markers of celiac disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01255696</url>
  </study>
  <study rank="453">
    <title>The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylphenidate</intervention>
      <intervention type="Drug">Methylphenidate</intervention>
      <intervention type="Drug">Placebo 10</intervention>
      <intervention type="Drug">Placebo 20</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Laval University</lead_sponsor>
      <collaborator>Fonds de la Recherche en Santé du Québec</collaborator>
      <collaborator>Quebec Memory and Motor Skills Disorders Research Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 18, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>October 19, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Conners' Continuous Performance Test-II score</outcome_measure>
      <outcome_measure>Orthostatic drop - blood pressure in mmHg</outcome_measure>
      <outcome_measure>Average speed of center of pressure oscillations</outcome_measure>
      <outcome_measure>Total area of center of pressure oscillations</outcome_measure>
      <outcome_measure>Visual analog fatigue scale scores</outcome_measure>
      <outcome_measure>Blood pressure (mmHg)</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Number of errors recorded for 'Backward Digit Span' task</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01244269</url>
  </study>
  <study rank="454">
    <title>Effect of Lithium and Divalproex in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Divalproex</intervention>
      <intervention type="Drug">Lithium</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 23, 2004</first_received>
    <start_date>July 2004</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>March 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00088387</url>
  </study>
  <study rank="455">
    <title>Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">BiPAP Pro 2, Phillips Respironics</intervention>
      <intervention type="Device">CPAP sham</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Respiratory Diseases, Mexico</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>October 20, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>May 22, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>acute exacerbations of Chronic Obstructive Pulmonary Disease frequency</outcome_measure>
      <outcome_measure>acute exacerbation of chronic obstructive pulmonary disease severity</outcome_measure>
      <outcome_measure>lymphocyte subpopulations Th-1 and Th-17</outcome_measure>
      <outcome_measure>six-minute walking test</outcome_measure>
      <outcome_measure>Forced expiratory volume in first second (FEV1) and forced expiratory capacity</outcome_measure>
      <outcome_measure>Maximal inspiratory pressure and maximal expiratory pressure</outcome_measure>
      <outcome_measure>gas exchange response (carbon and oxygen dioxide arterial pressure)</outcome_measure>
      <outcome_measure>Health related quality of life</outcome_measure>
      <outcome_measure>anxiety and depression measures (HAD and Beck Questionnaires)</outcome_measure>
      <outcome_measure>echocardiographic parameters</outcome_measure>
      <outcome_measure>survival</outcome_measure>
      <outcome_measure>IL-1 and IL-6 cytokines</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01481727</url>
  </study>
  <study rank="456">
    <title>Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-384</intervention>
      <intervention type="Drug">donepezil</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>267</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 7, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>January 24, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to final observation in the Alzheimer's Disease Assessment Scale-Cognition portion (ADAS-cog) total score</outcome_measure>
      <outcome_measure>Mini Mental Status Examination (MMSE) score at Baseline, Weeks 4, 8, and 12</outcome_measure>
      <outcome_measure>Clinician's Interview Based Impression of Change-plus (CIBIC-plus) score at Baseline, Weeks 4, 8, and 12</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI) score at Baseline, Weeks 4, 8, and 12</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score at Baseline, Weeks 4, 8, and 12</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01137526</url>
  </study>
  <study rank="457">
    <title>A Long-Term Extension Study of RP103-MITO-001 to Assess RP103 in Children With Inherited Mitochondrial Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mitochondrial Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cysteamine Bitartrate Delayed-release Capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Raptor Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 10, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>May 2018</completion_date>
    <last_updated>January 28, 2016</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Score</outcome_measure>
      <outcome_measure>Change in pre-eminent symptom scales (choice of 6-minute walk; Jama dynamometer; Barry-Albright Dystonia Scale; Friedreich Ataxia Rating Scale;Gross Motor Function Measure; Modified Lansky Play Performance Scale; Vision/Eye Examination)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02473445</url>
  </study>
  <study rank="458">
    <title>SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Alternative donor bone marrow and cord blood</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 22, 2005</first_received>
    <start_date>January 2006</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 16, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the frequency of donor engraftment after alternate donor transplantation in children with severe sickle cell disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00257543</url>
  </study>
  <study rank="459">
    <title>Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon beta-1a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>EMD Serono</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>192</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 14, 2006</first_received>
    <start_date>November 2001</start_date>
    <completion_date>September 2003</completion_date>
    <last_updated>August 4, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy endpoint was the proportion of patients who maintained remission (relapse-free) and did not receive any additional treatment for the management of Crohn's disease by week 26.</outcome_measure>
      <outcome_measure>The secondary efficacy endpoints assessed the effect of treatment with IFN beta 1a on the following measures:</outcome_measure>
      <outcome_measure>The proportion of patients who maintained remission (relapse-free) and did not receive any additional treatment for the management of Crohn's disease by week 52</outcome_measure>
      <outcome_measure>Time to relapse</outcome_measure>
      <outcome_measure>Change from baseline to end of treatment in Quality of Life (IBDQ) score, CDAI score, biological markers of inflammation (CRP and ESR), number of fistulas (including new fistulas and closure of existing ones), and antibodies to interferon beta-1a.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00304252</url>
  </study>
  <study rank="460">
    <title>Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diverticular Disease of the Colon</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalazine plus Lactobacillus casei</intervention>
      <intervention type="Drug">Mesalazine placebo plus Lactobacillus casei placebo</intervention>
      <intervention type="Drug">Mesalazine 800 mg</intervention>
      <intervention type="Drug">Lactobacillus casei</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Cristo Re</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 4, 2012</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 14, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients maintaining remission of symptomatic uncomplicated diverticular disease of the colon</outcome_measure>
      <outcome_measure>Safety of the treatments</outcome_measure>
      <outcome_measure>Influence of severity of diverticulosis on number of patients maintaining remission of symptomatic diverticular disease of the colon</outcome_measure>
      <outcome_measure>Concomitant diseases</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01534754</url>
  </study>
  <study rank="461">
    <title>A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ropinirole monotherapy</intervention>
      <intervention type="Drug">placebo monotherapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>186</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 1, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>March 9, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>December 18, 2014</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline (BL) in Unified Parkinson Disease (PD) Rating Scale (UPDRS) Motor Score</outcome_measure>
      <outcome_measure>Number of Participants With a &gt;=5 Points Reduction From Baseline in UPDRS Motor Score</outcome_measure>
      <outcome_measure>Number of Participants With a &gt;=10 Points Reduction From Baseline in UPDRS Motor Score</outcome_measure>
      <outcome_measure>Number of Participants With a &gt;=10 Points Reduction From Baseline in UPDRS Parts II and III Combined</outcome_measure>
      <outcome_measure>Responder Rate Defined as Participants With a &gt;=30% Reduction in Baseline UPDRS Motor Score</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS Parts II and III Combined</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS Activities of Daily Living</outcome_measure>
      <outcome_measure>Change From Baseline in the Total UPDRS Score (Parts I-III)</outcome_measure>
      <outcome_measure>Change From Baseline in the UPDRS Part I (Mentation)</outcome_measure>
      <outcome_measure>Responder Rate According to the Clinical Global Impression - Global Improvement (CGI-I) Scale</outcome_measure>
      <outcome_measure>Percentage of Participants Withdrawn From the Study Due to Lack of Efficacy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01485172</url>
  </study>
  <study rank="462">
    <title>Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Botulinum Toxin Type A</intervention>
      <intervention type="Biological">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Cincinnati</lead_sponsor>
      <collaborator>Allergan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>February 13, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the change in the &quot;on&quot; time with LID 1 month and 3 months after injected compared to baseline scores. A reduction of 40% in the mean &quot;on&quot; time with LID in the Botox® group compared to the placebo group will be considered significant.</outcome_measure>
      <outcome_measure>changes in: the duration, severity, and pain of LID using the UPDRS Part IV, physician and patient Clinical Global Impression [CGI] of change, Schwab &amp; England score, Abnormal Involuntary Movement Scale, 4-point modified dyskinesia rating scale (Goetz)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00477802</url>
  </study>
  <study rank="463">
    <title>Alpha-Galactosidase A Replacement Therapy for Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DRX005B</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 8, 2002</first_received>
    <start_date>November 2002</start_date>
    <completion_date>November 2003</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>November 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00048906</url>
  </study>
  <study rank="464">
    <title>Study of AA4500 in the Treatment of Peyronie's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Peyronie's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">AA4500</intervention>
      <intervention type="Biological">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Endo Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>418</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 8, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>September 7, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>February 4, 2015</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage Change From Baseline in Penile Curvature</outcome_measure>
      <outcome_measure>Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</outcome_measure>
      <outcome_measure>A Responder Analysis Based on Subject Overall Global Assessment</outcome_measure>
      <outcome_measure>Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ</outcome_measure>
      <outcome_measure>Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Plaque Consistency</outcome_measure>
      <outcome_measure>Change From Baseline in Penile Length</outcome_measure>
      <outcome_measure>Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4</outcome_measure>
      <outcome_measure>A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01221623</url>
  </study>
  <study rank="465">
    <title>Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ROZEREM</intervention>
      <intervention type="Drug">Ramelteon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Southern California Institute for Research and Education</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 16, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>November 10, 2010</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neuropsychiatric Inventory with Caregiver Distress (NPI-D) Sleep Behavior Subscale</outcome_measure>
      <outcome_measure>The Epworth Sleepiness Scale</outcome_measure>
      <outcome_measure>Sleep Disorders Questionnaire (short form)</outcome_measure>
      <outcome_measure>Memory - Hopkins Verbal Learning Test (HVLT)</outcome_measure>
      <outcome_measure>Movement - Abnormal Involuntary Movement Scale (AIMS)</outcome_measure>
      <outcome_measure>Movement - Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Movement - Continuous motor activity (actigraphy/motion logger)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00462254</url>
  </study>
  <study rank="466">
    <title>Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>Obesity</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Diet and exercise</intervention>
      <intervention type="Procedure">Bariatric Surgery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Cleveland Clinic</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>19 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 10, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>October 26, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in renal function using iothalamate studies and urinary protein excretion using 24 hour urinary studies</outcome_measure>
      <outcome_measure>Changes in markers of insulin resistance and inflammation, adipokines, and body composition.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01180101</url>
  </study>
  <study rank="467">
    <title>Gene Therapy for Chronic Granulomatous Disease in Korea</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VM106</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ViroMed Co., Ltd. dba VM BioPharma</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 21, 2008</first_received>
    <start_date>January 2007</start_date>
    <completion_date>October 2022</completion_date>
    <last_updated>February 10, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The incidence of adverse events through 1 year</outcome_measure>
      <outcome_measure>RCR, insertional mutagenesis, immune response against normal gp91 protein</outcome_measure>
      <outcome_measure>Safety and efficacy of fludarabine/busulfan conditioning</outcome_measure>
      <outcome_measure>Functional reconstitution of respiratory burst</outcome_measure>
      <outcome_measure>Presence of vector-positive cells</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00778882</url>
  </study>
  <study rank="468">
    <title>Phase 3 IGIV, 10% in Alzheimer´s Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer´s Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Immune Globulin Intravenous (Human), 10% Solution</intervention>
      <intervention type="Biological">Human albumin 0.25%</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baxalta US Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>508</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 20, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>June 26, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>February 3, 2015</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)</outcome_measure>
      <outcome_measure>Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory</outcome_measure>
      <outcome_measure>ADCS-Clinical Global Impression of Change (CGIC) at 18 Months</outcome_measure>
      <outcome_measure>Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement</outcome_measure>
      <outcome_measure>Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)</outcome_measure>
      <outcome_measure>Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Any AEs and/or SAEs</outcome_measure>
      <outcome_measure>Number of Infusions Temporally Associated With AEs and/or SAEs</outcome_measure>
      <outcome_measure>Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion</outcome_measure>
      <outcome_measure>Number of Infusions Causally Associated With AEs and/or SAEs</outcome_measure>
      <outcome_measure>Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01524887</url>
  </study>
  <study rank="469">
    <title>Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Individualized management of AD including caregiver training</intervention>
      <intervention type="Drug">Memantine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>New York University School of Medicine</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
      <collaborator>Fisher Center for Alzheimer's Research Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
    </study_designs>
    <first_received>July 12, 2005</first_received>
    <start_date>August 2006</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>September 15, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>April 28, 2016</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)</outcome_measure>
      <outcome_measure>Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)</outcome_measure>
      <outcome_measure>Change From Baseline of the Severe Impairment Battery (SIB)</outcome_measure>
      <outcome_measure>Change From Baseline of the Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)</outcome_measure>
      <outcome_measure>Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)</outcome_measure>
      <outcome_measure>Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency</outcome_measure>
      <outcome_measure>Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00120874</url>
  </study>
  <study rank="470">
    <title>Creatine Safety &amp; Tolerability in Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Huntington's Disease (HD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Creatine monohydrate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 5, 2011</first_received>
    <start_date>April 2005</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>July 9, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>November 28, 2012</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Clinical Measures</outcome_measure>
      <outcome_measure>Biological Markers of Disease Progression</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01412151</url>
  </study>
  <study rank="471">
    <title>Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sodium oligo-mannurarate 600mg</intervention>
      <intervention type="Drug">Sodium oligo-mannurarate 900mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Shanghai Greenvalley Pharmaceutical Co., Ltd.</lead_sponsor>
      <collaborator>Shanghai Mental Health Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>255</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 30, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>January 25, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>November 13, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule</outcome_measure>
      <outcome_measure>Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule</outcome_measure>
      <outcome_measure>Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule</outcome_measure>
      <outcome_measure>Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01453569</url>
  </study>
  <study rank="472">
    <title>Couple-Based Treatment for Alcohol Use Disorders and Post-Traumatic Stress Disorder</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alcohol-related Disorders</condition>
      <condition>Post-traumatic Stress Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Couple-Based Treatment for Alcohol Use Disorders and PTSD</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 23, 2009</first_received>
    <start_date>August 2010</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>January 12, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>December 8, 2015</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinician-administered PTSD Scale (CAPS)</outcome_measure>
      <outcome_measure>Percentage Days of Heavy Drinking</outcome_measure>
      <outcome_measure>Patient-reported PTSD Checklist</outcome_measure>
      <outcome_measure>Partner-reported PTSD Checklist</outcome_measure>
      <outcome_measure>Patient-reported Beck Depression Inventory - II (BDI-II)</outcome_measure>
      <outcome_measure>Patient-reported Dyadic Adjustment Scale</outcome_measure>
      <outcome_measure>Partner-reported Beck Depression Inventory - II</outcome_measure>
      <outcome_measure>Partner-reported Dyadic Adjustment Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00946322</url>
  </study>
  <study rank="473">
    <title>Safety and Efficacy of ALV003 for the Treatment of Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ALV003</intervention>
      <intervention type="Biological">ALV003 placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alvine Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 13, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>July 30, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Intestinal mucosal morphology</outcome_measure>
      <outcome_measure>Safety: Tolerability of ALV003</outcome_measure>
      <outcome_measure>Efficacy: Change in intestinal intraepithelial lymphocyte numbers/phenotype</outcome_measure>
      <outcome_measure>Efficacy: Change in serological markers of celiac disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00959114</url>
  </study>
  <study rank="474">
    <title>Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">PET-CT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Wisconsin, Madison</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>October 2004</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Does this technique provide an accurate assessment of disease inflammation compared to standard clinical markers?</outcome_measure>
      <outcome_measure>Does this technique provide additional information for practitioners on extent of disease?</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00205062</url>
  </study>
  <study rank="475">
    <title>OTO-104 for the Treatment of Meniere's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Meniere's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">OTO-104</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otonomy, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>154</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 31, 2011</first_received>
    <start_date>November 2013</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>August 18, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction in vertigo frequency as measure of efficacy of OTO-104 in subjects with Meniere's disease</outcome_measure>
      <outcome_measure>Evaluation of adverse events, otoscopic exams, audiometry, Word Recognition Score and tympanometry as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Evaluation of tinnitus patient reported questionnaire and daily diary as a measure of impact of tinnitus on activities of daily living</outcome_measure>
      <outcome_measure>Evaluation of patient reported questionnaires as a measure of impact on patient daily activities</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01412177</url>
  </study>
  <study rank="476">
    <title>Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atomoxetine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical University of South Carolina</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 28, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>March 14, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neuropsychological Testing Battery</outcome_measure>
      <outcome_measure>Safety measures</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01738191</url>
  </study>
  <study rank="477">
    <title>Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Memory Decline</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Panax Ginseng</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>40 Years</min_age>
    <max_age>83 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 22, 2006</first_received>
    <start_date>April 2004</start_date>
    <completion_date>October 2005</completion_date>
    <last_updated>October 22, 2006</last_updated>
    <last_verified>October 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Cognitive performances monitored by MMSE and Alzheimer’s disease assessment scales.</outcome_measure>
      <outcome_measure>Biomarkers including hematopoietic progenitor cell count.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00391833</url>
  </study>
  <study rank="478">
    <title>Donepezil to Treat Dementia in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Donepezil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 15, 2002</first_received>
    <start_date>February 2002</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>March 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00030979</url>
  </study>
  <study rank="479">
    <title>Lenalidomide in Kaposi Disease Associated With HIV Infection</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infection Associated Kaposi Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lenalidomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Celgene Corporation</collaborator>
      <collaborator>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>19 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 21, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>July 31, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the efficacy of treatment with Lenalidomide in progressive Kaposi disease in Human immunodeficiency virus (HIV)-infected patients receiving Combined Antiretroviral Therapy (cART).</outcome_measure>
      <outcome_measure>To estimate the safety of lenalidomide</outcome_measure>
      <outcome_measure>To estimate the time to the response and the duration of the response</outcome_measure>
      <outcome_measure>To evaluate the efficacy of treatment at 48 weeks</outcome_measure>
      <outcome_measure>To evaluate the efficacy using ACTG criteria</outcome_measure>
      <outcome_measure>To evaluate the survival and the survival with no progression</outcome_measure>
      <outcome_measure>To describe the evolution of virologic and immunological parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01282047</url>
  </study>
  <study rank="480">
    <title>Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STA-5326 mesylate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Synta Pharmaceuticals Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>282</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2005</first_received>
    <start_date>August 2005</start_date>
    <last_updated>December 3, 2008</last_updated>
    <last_verified>December 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving clinical remission and clinical response at Day 29</outcome_measure>
      <outcome_measure>Proportion of patients achieving: a clinical remission at Days 29 and 43</outcome_measure>
      <outcome_measure>a clinical response from Baseline to Day 29 and from Baseline to Day 43</outcome_measure>
      <outcome_measure>a reduction in endoscopic scores from Baseline to Day 29</outcome_measure>
      <outcome_measure>an increase in the Inflammatory Bowel Disease Questionnaire (IBDQ) score from Baseline to Days 29 and 43</outcome_measure>
      <outcome_measure>a clinical remission or clinical response at Days 29 and 43 in the subset of patients with elevated C-reactive protein</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00138840</url>
  </study>
  <study rank="481">
    <title>Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease (PAD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">clopidogrel (SR25990)</intervention>
      <intervention type="Drug">ticlopidine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sanofi</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>431</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>March 9, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>July 16, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety events of interest including clinical significant bleeding, blood disorders, hepatic dysfunction and other serious adverse drug reactions (death, hospitalization...)</outcome_measure>
      <outcome_measure>Bleeding adverse events, Serious adverse events, Overall safety</outcome_measure>
      <outcome_measure>Vascular events</outcome_measure>
      <outcome_measure>Safety events of interest (see above)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00862420</url>
  </study>
  <study rank="482">
    <title>Glucocorticoid Treatment in Addison's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Addison's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Solu-Cortef (hydrocortisone)</intervention>
      <intervention type="Drug">Cortef (hydrocortisone)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Haukeland University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 26, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 19, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Morning (08-09) plasma ACTH</outcome_measure>
      <outcome_measure>Health-Related Quality of Life; evaluated by SF-36 vitality scores and AddiQoL scores</outcome_measure>
      <outcome_measure>Sleep; evaluated by Pittsburgh Sleep Quality Index (PSQI), and 7-days' Actigraph registration combined with self-reported sleep diary</outcome_measure>
      <outcome_measure>24h cortisol profiles in serum and saliva</outcome_measure>
      <outcome_measure>S-glucose, 24 h profile</outcome_measure>
      <outcome_measure>Insulin sensitivity assessed by euglycemic clamp</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01063569</url>
  </study>
  <study rank="483">
    <title>Sleep Apnea Intervention for Cardiovascular Disease Reduction</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obstructive Sleep Apnea</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Conservative Medical Therapy</intervention>
      <intervention type="Behavioral">Active PAP with Behavioral Modification</intervention>
      <intervention type="Device">Sham PAP</intervention>
      <intervention type="Device">Active PAP with RT Support</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
      <collaborator>Beth Israel Deaconess Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 15, 2010</first_received>
    <start_date>March 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>March 4, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effectiveness of continuous positive airway pressure therapy on cardiovascular disease, using mean 24 hour systolic blood pressure as the trial's primary endpoint.</outcome_measure>
      <outcome_measure>Recruitment and retention rates of patients with moderate to severe obstructive sleep apnea and cardiovascular disease risk factors or established CVD participating in a controlled trial.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01261390</url>
  </study>
  <study rank="484">
    <title>Chronic Kidney Disease Prevention of An-Lo District, Keelung</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>End Stage Renal Disease</condition>
      <condition>Death</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">multidisciplinary predialysis education</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>March 20, 2008</first_received>
    <start_date>July 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>September 5, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>reduction of estimated glomerular filtration rate by 50 %</outcome_measure>
      <outcome_measure>death</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00644046</url>
  </study>
  <study rank="485">
    <title>The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
      <condition>Unstable Angina</condition>
      <condition>Blood Stasis Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Xuesaitong soft capsule</intervention>
      <intervention type="Drug">Xuesaitong soft capsule Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 28, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>January 12, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01615003</url>
  </study>
  <study rank="486">
    <title>VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VSL#3</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Orphan Australia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 14, 2005</first_received>
    <start_date>June 2005</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>September 17, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective of the study is to compare the efficacy of the probiotic VSL#3 versus placebo, in addition to standard maintenance drugs, in maintaining remission in Crohn's disease (CD)</outcome_measure>
      <outcome_measure>Time till flare of CD</outcome_measure>
      <outcome_measure>To assess whether concurrent therapy with VSL#3 leads to an improvement in the quality of life</outcome_measure>
      <outcome_measure>To assess whether concurrent therapy with VSL#3 reduces the severity of a flare if it occurs</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00114465</url>
  </study>
  <study rank="487">
    <title>Sitaxsentan in Proteinuric Chronic Kidney Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>Proteinuria</condition>
      <condition>Blood Pressure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sitaxsentan</intervention>
      <intervention type="Drug">Nifedipine</intervention>
      <intervention type="Drug">Placebo tablet</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Edinburgh</lead_sponsor>
      <collaborator>Encysive Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 5, 2009</first_received>
    <start_date>May 2007</start_date>
    <last_updated>January 5, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The principal objective of this study is to evaluate whether sitaxsentan reduces proteinuria in people with chronic kidney disease.</outcome_measure>
      <outcome_measure>Secondary objective of this study is to evaluate whether sitaxsentan reduces systemic blood pressure in people with chronic kidney disease.</outcome_measure>
      <outcome_measure>Secondary objective is to determine whether sitaxsentan improves indices of arterial stiffness in people with chronic kidney disease</outcome_measure>
      <outcome_measure>Secondary objectives is to determine the safety of sitaxsentan in chronic kidney disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00817037</url>
  </study>
  <study rank="488">
    <title>Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
      <condition>Hematologic Malignancies</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Palifermin</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Other">Conditioning Regimen</intervention>
      <intervention type="Procedure">Allogeneic stem cell transplant</intervention>
      <intervention type="Drug">Methotrexate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Swedish Orphan Biovitrum</lead_sponsor>
      <collaborator>Amgen</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 15, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>September 12, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>November 25, 2009</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD)</outcome_measure>
      <outcome_measure>Number of Participants With Grade 2 to 4 Acute Graft Versus Host Disease (GVHD)</outcome_measure>
      <outcome_measure>Number of Participants With Day 11 Methotrexate Graft Versus Host Disease Prophylaxis Administration</outcome_measure>
      <outcome_measure>Number of Participants With Severe (Grade 3 or 4) Oral Mucositis</outcome_measure>
      <outcome_measure>Duration of Severe Oral Mucositis (WHO Grade 3 and 4)</outcome_measure>
      <outcome_measure>Number of Participants With Parenteral or Transdermal Opioid Analgesic Use</outcome_measure>
      <outcome_measure>Duration of Hospitalization</outcome_measure>
      <outcome_measure>Area Under the Curve (AUC) of Mouth and Throat Soreness Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00189488</url>
  </study>
  <study rank="489">
    <title>A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric</condition>
      <condition>Hodgkin's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">COPP/ABV</intervention>
      <intervention type="Drug">COPP/ABV</intervention>
      <intervention type="Drug">intensive chemo with concurrent growth factor</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
      <collaborator>Children's Cancer Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 26, 2007</first_received>
    <start_date>March 1996</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>December 21, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 1999</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine the role of adjuvant low dose involved field radiotherapy in pediatric patients with Hodgkin's disease who attain a complete response following initial chemotherapy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00592111</url>
  </study>
  <study rank="490">
    <title>Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ateronon</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
      <collaborator>CamNutra Ltd.</collaborator>
      <collaborator>Cambridge Theranostics Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>213</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 13, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>August 15, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Carotid intima-media thickness</outcome_measure>
      <outcome_measure>Biomarkers for coronary heart disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00939237</url>
  </study>
  <study rank="491">
    <title>A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Certolizumab pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 28, 2006</first_received>
    <start_date>November 2007</start_date>
    <last_updated>May 25, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>For ethical reasons, provide the opportunity for patients &gt; 18 years suffering from Crohn's disease who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizum</outcome_measure>
      <outcome_measure>Incidence of adverse events reported by the patients during the long-term treatment period of the study.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00358683</url>
  </study>
  <study rank="492">
    <title>Study to Evaluate the Safety of AT2220 in Pompe Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pompe Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AT2220</intervention>
      <intervention type="Drug">AT2220</intervention>
      <intervention type="Drug">AT2220</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amicus Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>74 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 30, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>May 16, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment-emergent Adverse Events</outcome_measure>
      <outcome_measure>Change in functional parameters from Baseline to End of Study</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00688597</url>
  </study>
  <study rank="493">
    <title>Effect of Indomethacin on the Progression of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">indomethacin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>American Health Assistance Foundation</collaborator>
      <collaborator>Netherlands Brain Foundation</collaborator>
      <collaborator>Netherlands Alzheimer Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 5, 2007</first_received>
    <start_date>May 2000</start_date>
    <completion_date>August 2005</completion_date>
    <last_updated>February 5, 2007</last_updated>
    <last_verified>February 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Score on the Cognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months.</outcome_measure>
      <outcome_measure>Score on the Noncognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months</outcome_measure>
      <outcome_measure>Score on the Clinician Interview-Based Impression of Change with caregiver input at 12 months</outcome_measure>
      <outcome_measure>Score on the Mini-Mental State Examination at 12 months</outcome_measure>
      <outcome_measure>Score on the Neuropsychiatric Inventory at 12 months</outcome_measure>
      <outcome_measure>Score on the The Interview for Deterioration in Daily living activities in Dementia at 12 months</outcome_measure>
      <outcome_measure>The occurrence of adverse events during 12 months of treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00432081</url>
  </study>
  <study rank="494">
    <title>A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">250mg rilapladib</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>124</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 1, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>April 27, 2015</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in CSF Abeta42, Abeta40, Abeta42/ Abeta40 ratio</outcome_measure>
      <outcome_measure>Change from baseline in CSF tau and P-tau</outcome_measure>
      <outcome_measure>Change from baseline in working memory/executive function composite score</outcome_measure>
      <outcome_measure>Change from baseline in CSF albumin quotient</outcome_measure>
      <outcome_measure>Change from baseline in plasma Abeta levels (Abeta42, Abeta40 and Abeta42/Abeta40 ratio)</outcome_measure>
      <outcome_measure>Change from baseline in CSF and plasma Lp-PLA2 activity</outcome_measure>
      <outcome_measure>Change from baseline in other aspects of cognition, including attention, episodic memory and an overall composite score</outcome_measure>
      <outcome_measure>Assessment of safety and tolerability of rilapladib in subjects with Alzheimer's disease over a 24 week treatment period, including AEs, vital signs, clinical labs</outcome_measure>
      <outcome_measure>Assessment of plasma concentrations of rilapladib and its active metabolite in plasma and CSF</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01428453</url>
  </study>
  <study rank="495">
    <title>Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">18F-DTBZ AV-133</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 6, 2012</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>January 27, 2016</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the changes in 18F-DTBZ uptake in a cohort of Parkinson's disease patients from baseline to month 18, and 36.</outcome_measure>
      <outcome_measure>Determine whether the rate of reduction in 18F-DTBZ uptake in sequential PET imaging during a 36 month interval will correlate with changes in the clinical measures of severity of disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01556100</url>
  </study>
  <study rank="496">
    <title>Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Repetitive transcranial magnetic stimulation (rTMS)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
      <collaborator>University of California, Los Angeles</collaborator>
      <collaborator>University of Florida</collaborator>
      <collaborator>University Health Network, Toronto</collaborator>
      <collaborator>The Cleveland Clinic</collaborator>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>85</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 3, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>February 13, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Motor subscale of the Unified Parkinson's Disease Rating Scale (UPDRS Part III)</outcome_measure>
      <outcome_measure>Hamilton Depression Scale (HAM-D)</outcome_measure>
      <outcome_measure>Clinical Anxiety Scale (CAS)</outcome_measure>
      <outcome_measure>Apathy Evaluation Scale (AES)</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire 39 (PDQ-39)</outcome_measure>
      <outcome_measure>Montreal Cognitive Assessment (MoCA)</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) Parts I, II, and IV</outcome_measure>
      <outcome_measure>Beck Depression Inventory (BDI-II)</outcome_measure>
      <outcome_measure>Global Impression Scales</outcome_measure>
      <outcome_measure>The number and severity of akk types of adverse events (i.e., serious, treatment-emergent, adverse events of interest, total adverse events)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01080794</url>
  </study>
  <study rank="497">
    <title>Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dimebon</intervention>
      <intervention type="Drug">Dimebon</intervention>
      <intervention type="Drug">Placebo comparator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medivation, Inc.</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1003</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 23, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>September 24, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale</outcome_measure>
      <outcome_measure>Clinician's Interview Based Impression of Change, plus caregiver input (CIBIC-plus)</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Resource Utilization in Dementia Lite (RUD lite)</outcome_measure>
      <outcome_measure>Euro Quality of Life 5 (EQ-5D)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00829374</url>
  </study>
  <study rank="498">
    <title>ELND005 in Patients With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo Control</intervention>
      <intervention type="Drug">ELND005</intervention>
      <intervention type="Drug">ELND005</intervention>
      <intervention type="Drug">ELND005</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Transition Therapeutics Ireland Limited</lead_sponsor>
      <collaborator>Transition Therapeutics</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>353</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 4, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>April 11, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>September 27, 2011</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Full Analysis Set; FAS)</outcome_measure>
      <outcome_measure>Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Per Protocol Set; PPS)</outcome_measure>
      <outcome_measure>Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Full Analysis Set; FAS)</outcome_measure>
      <outcome_measure>Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Per Protocol Set; PPS)</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score From Baseline to Week 78 (Full Analysis Set; FAS)</outcome_measure>
      <outcome_measure>Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score From Baseline to Week 78 (Full Analysis Set; FAS)</outcome_measure>
      <outcome_measure>Change in Neuropsychiatric Inventory (NPI) Score From Baseline to Week 78 (Full Analysis Set; FAS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00568776</url>
  </study>
  <study rank="499">
    <title>Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hodgkin's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methotrexate</intervention>
      <intervention type="Drug">Leucovorin calcium</intervention>
      <intervention type="Drug">6-Thioguanine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 26, 2007</first_received>
    <start_date>March 1994</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>June 10, 2009</last_updated>
    <last_verified>June 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the incidence of complete and partial response and the duration of response in patients with recurrent or resistant Hodgkin's Disease (HD) treated with sequential administration of oral 6-Thioguanine (6-TG) after IV Methotrexate (MTX).</outcome_measure>
      <outcome_measure>Define Toxicity of this sequential drug combination.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00587873</url>
  </study>
  <study rank="500">
    <title>The Fish and Fruit Study: Trial of Fish and Fruit to Improve Survival of Aboriginal People With End Stage Renal Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">diet of fish and fruit</intervention>
      <intervention type="Behavioral">fruit and fish</intervention>
      <intervention type="Behavioral">diet only</intervention>
      <intervention type="Behavioral">regular diet</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Menzies School of Health Research</lead_sponsor>
      <collaborator>The George Institute</collaborator>
      <collaborator>Northern Territory Government of Australia</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 11, 2005</first_received>
    <start_date>May 2004</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>August 3, 2011</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Deaths due to cardiovascular disease</outcome_measure>
      <outcome_measure>Non-invasive cardiovascular markers: carotid intimal medial thickness</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00192543</url>
  </study>
  <study rank="501">
    <title>A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotic - VSL#3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Alberta</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>December 2003</start_date>
    <last_updated>May 12, 2008</last_updated>
    <last_verified>May 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Prevention of severe endoscopic recurrence of Crohn's disease.</outcome_measure>
      <outcome_measure>Endoscopic recurrence at 90 days and 360 days</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI)</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Safety and tolerance of VSL#3</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00175292</url>
  </study>
  <study rank="502">
    <title>Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PYM50028</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Phytopharm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>425</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 1, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 1, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's Disease Rating Scale parts II &amp; III combined score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01060878</url>
  </study>
  <study rank="503">
    <title>Safety Study in Subjects With Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AMG 827</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amgen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>December 14, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy of AMG 827 as measured by the Harvey-Bradshaw Index (HBI) and Crohn's Disease Activity Index (CDAI). To evaluate the maintenance of effect as measured by the HBI and CDAI</outcome_measure>
      <outcome_measure>To evaluate the safety of long-term exposure with AMG 827 in subjects with Crohn's disease.</outcome_measure>
      <outcome_measure>To determine if subjects develop anti-AMG 827 antibodies; to evaluate the change of EQ-5D from baseline at all timepoints, the effect of treatment on inflammatory markers (C-reactive protein [CRP]) at post-base, and the pharmacokinetics of AMG 827.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01199302</url>
  </study>
  <study rank="504">
    <title>Safety Study of Galantamine in Tic Disorders</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tourette's Syndrome</condition>
      <condition>Motor Tic Disorder</condition>
      <condition>Vocal Tic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Parkinson's Disease and Movement Disorders Center</lead_sponsor>
      <collaborator>Ortho-McNeil Neurologics, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 23, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>August 21, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Treatment related adverse experience</outcome_measure>
      <outcome_measure>Severity Score of the Yale Global Tic Severity Scale</outcome_measure>
      <outcome_measure>Yale-Brown Obsessive-Compulsive Survey</outcome_measure>
      <outcome_measure>Connors Adult Attention Deficit Hyperactivity Rating Scale</outcome_measure>
      <outcome_measure>Hamilton Rating Scale for Depression</outcome_measure>
      <outcome_measure>Hamilton Rating Scale for Anxiety</outcome_measure>
      <outcome_measure>Short Form 36</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00226824</url>
  </study>
  <study rank="505">
    <title>CNI-1493 for Treatment of Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">semapimod</intervention>
      <intervention type="Drug">semapimod</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ferring Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 5, 2002</first_received>
    <start_date>June 2002</start_date>
    <completion_date>June 2003</completion_date>
    <last_updated>August 22, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in CDAI</outcome_measure>
      <outcome_measure>Change in IBDQ</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00038766</url>
  </study>
  <study rank="506">
    <title>Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pramipexole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>535</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 3, 2006</first_received>
    <start_date>May 2006</start_date>
    <last_updated>May 7, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>December 18, 2009</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3</outcome_measure>
      <outcome_measure>Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3</outcome_measure>
      <outcome_measure>Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3</outcome_measure>
      <outcome_measure>Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3</outcome_measure>
      <outcome_measure>Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6</outcome_measure>
      <outcome_measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3</outcome_measure>
      <outcome_measure>Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6</outcome_measure>
      <outcome_measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3</outcome_measure>
      <outcome_measure>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9</outcome_measure>
      <outcome_measure>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15</outcome_measure>
      <outcome_measure>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12</outcome_measure>
      <outcome_measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15</outcome_measure>
      <outcome_measure>Percentage Change From Baseline in the Striatum Uptake at Month 15</outcome_measure>
      <outcome_measure>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Haematology and Electrolytes</outcome_measure>
      <outcome_measure>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Enzymes</outcome_measure>
      <outcome_measure>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Substrates</outcome_measure>
      <outcome_measure>Clinically Significant Abnormalities in Vital Signs</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00321854</url>
  </study>
  <study rank="507">
    <title>Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Moderate to Severe Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ADALIMUMAB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
      <collaborator>Laboratorio Echevarne</collaborator>
      <collaborator>Pivotal S.L.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 23, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 2, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with clinical response</outcome_measure>
      <outcome_measure>Proportion of patients with clinical remission</outcome_measure>
      <outcome_measure>Change in EuroQOL five dimensions (EQ-5D) questionnaire</outcome_measure>
      <outcome_measure>Change in Fatigue</outcome_measure>
      <outcome_measure>Change in analytic markers of inflammation</outcome_measure>
      <outcome_measure>Correlation between Clinical response and remission</outcome_measure>
      <outcome_measure>Change in Inflammatory Bowel Disease Questionnaire-36 (IBDQ36) questionnaire</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02148718</url>
  </study>
  <study rank="508">
    <title>UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">polypill</intervention>
      <intervention type="Drug">Usual cardiovascular medications</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
      <collaborator>European Commission</collaborator>
      <collaborator>Imperial College Healthcare NHS Trust</collaborator>
      <collaborator>Royal College of Surgeons, Ireland</collaborator>
      <collaborator>UMC Utrecht</collaborator>
      <collaborator>The George Institute</collaborator>
      <collaborator>Public Health Foundation of India</collaborator>
      <collaborator>Dr. Reddy's Laboratories Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2004</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 26, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>November 26, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adherence to medication; self-reported current use of antiplatelet, statin and combination (≥ 2) blood pressure lowering therapy</outcome_measure>
      <outcome_measure>Change in blood pressure</outcome_measure>
      <outcome_measure>Change in LDL cholesterol</outcome_measure>
      <outcome_measure>Self reported current use of antiplatelet, statin and combination (&gt;2) blood pressure lowering therapy</outcome_measure>
      <outcome_measure>Reasons for stopping cardiovascular medications</outcome_measure>
      <outcome_measure>Serious adverse events</outcome_measure>
      <outcome_measure>New onset cardiovascular events</outcome_measure>
      <outcome_measure>Participant 'Quality of Life' assessment</outcome_measure>
      <outcome_measure>Changes in total cholesterol and other lipid fractions (HDL-cholesterol, triglycerides)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01057537</url>
  </study>
  <study rank="509">
    <title>A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TVP-1012 1mg</intervention>
      <intervention type="Drug">TVP-1012 0.5mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Takeda</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>404</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 9, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 29, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the mean daily off-time</outcome_measure>
      <outcome_measure>Mean daily off-time</outcome_measure>
      <outcome_measure>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II total score</outcome_measure>
      <outcome_measure>MDS-UPDRS Part III total score</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index score and scores for individual domains</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02337738</url>
  </study>
  <study rank="510">
    <title>Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine 5 cm^2</intervention>
      <intervention type="Drug">Rivastigmine 10 cm^2</intervention>
      <intervention type="Drug">Rivastigmine 15 cm^2</intervention>
      <intervention type="Drug">Placebo to 15 cm^2 patch</intervention>
      <intervention type="Drug">Placebo to 10 cm^2 patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1584</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 20, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>September 17, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>May 1, 2012</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period</outcome_measure>
      <outcome_measure>Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period</outcome_measure>
      <outcome_measure>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period</outcome_measure>
      <outcome_measure>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period</outcome_measure>
      <outcome_measure>Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00506415</url>
  </study>
  <study rank="511">
    <title>A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK933776</intervention>
      <intervention type="Drug">Placebo to match GSK933776</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 11, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>December 15, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events. Changes suggesting potential adverse events detected in the physical &amp; neurological examination, brain MRI, cognitive status, laboratory parameters, ECG &amp; vital signs.</outcome_measure>
      <outcome_measure>Plasma pharmacokinetic parameters of GSK933776. Pharmacodynamic effects of GSK 933776. CSF detectable levels of GSK933776. Effects of GSK933776 on plasma and CSF biomarkers. Titre &amp; neutralising activity of anti-GSK933776 antibodies. Exploratory PET scan</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00459550</url>
  </study>
  <study rank="512">
    <title>Study Evaluating rhIL-11 in Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Recombinant Human Interleukin-11 (rhIL-11)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 27, 2002</first_received>
    <start_date>April 2002</start_date>
    <completion_date>October 2003</completion_date>
    <last_updated>February 7, 2013</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2003</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00040521</url>
  </study>
  <study rank="513">
    <title>A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">epoetin alfa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
      <collaborator>Centocor Ortho Biotech Services, L.L.C.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 17, 2008</first_received>
    <start_date>January 2006</start_date>
    <completion_date>November 2006</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>The primary objective of the study is to describe the pharmacokinetic (PK) profiles of 4 different dosing regimens of PROCRIT in patients with anemia secondary to chronic kidney disease (CKD) not on dialysis.</outcome_measure>
      <outcome_measure>The secondary objective is to describe the pharmacodynamic (PD) response to the four PROCRIT study dosing regimens using the following outcomes: absolute and % reticulocyte count, hemoglobin (Hb), hematocrit (Hct), and red blood cell (RBC) count.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00641589</url>
  </study>
  <study rank="514">
    <title>Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Muscimol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 13, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 2, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Determine potential effectiveness of PD symptom reversal by muscimol infusion. Effectiveness will be determined by improvements in (off) and (on) scale UPDRS scores (motor subsection), pegboard testing of bradykinesia and TGUG gait assessment.</outcome_measure>
      <outcome_measure>Determine feasibilty of distributing muscimol by CED in the STN of PD patients. This endpoint will be the MR-imaging confirmation of distribution.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00921128</url>
  </study>
  <study rank="515">
    <title>Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Levodopa infusion</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Helsinki University</lead_sponsor>
      <collaborator>Solvay Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 1, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>February 23, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Orthostatic blood pressure change</outcome_measure>
      <outcome_measure>Sweating measured by evaporimeter</outcome_measure>
      <outcome_measure>Autonomic nervous system symptoms questionnaire (NMSS)</outcome_measure>
      <outcome_measure>Quality of life questionnaire (PDQ-39)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00914134</url>
  </study>
  <study rank="516">
    <title>Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rituximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dana-Farber Cancer Institute</lead_sponsor>
      <collaborator>Brigham and Women's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2005</first_received>
    <start_date>January 2004</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>June 10, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the safety and efficacy of up to three four week courses of rituximab in steroid-refractory chronic GVHD</outcome_measure>
      <outcome_measure>To determine the effects of rituximab therapy on quality of life of patients with steroid-refractory GVHD</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00136396</url>
  </study>
  <study rank="517">
    <title>Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 16, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>August 2021</completion_date>
    <last_updated>February 17, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective of the study is to determine the response rate (complete and partial) at day 56 after administration of Tocilizumab for treatment of steroid refractory GVHD</outcome_measure>
      <outcome_measure>Proportion of patients with partial, mixed or no GVHD responses</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01475162</url>
  </study>
  <study rank="518">
    <title>Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Roflumilast 500</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Spanish Research Center for Respiratory Diseases</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 9, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>May 9, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Endotelial function</outcome_measure>
      <outcome_measure>Arterial siffness</outcome_measure>
      <outcome_measure>Serum and plasma inflammation markers: (CRP, fibrinogen, leucocytes, interleukin (IL)-8, IL-6, IL-10, tumor necrosis factor alpha (TNFα), sICAM-1, MCP-1, PARC/CCL-18)</outcome_measure>
      <outcome_measure>Serum oxidatrive stress markers: MPO, TRX</outcome_measure>
      <outcome_measure>Serum endothelial dysfunction markers:TWEAKs, FasL, ADMA</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01595750</url>
  </study>
  <study rank="519">
    <title>A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Gait Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dalfampridine</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Miami</lead_sponsor>
      <collaborator>Acorda Therapeutics</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 8, 2011</first_received>
    <start_date>July 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>January 11, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>gait velocity and stride length.</outcome_measure>
      <outcome_measure>United Parkinson's Disease Rating Scale score(UPDRS) ,</outcome_measure>
      <outcome_measure>Freezing of Gait Questionnaire (FOGQ)</outcome_measure>
      <outcome_measure>Timed Up and Go (TUG) score</outcome_measure>
      <outcome_measure>Timed 25-foot Walk test (T25FW)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01491022</url>
  </study>
  <study rank="520">
    <title>A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glycogen Storage Disease Type II</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Myozyme</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>26 Weeks</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 22, 2003</first_received>
    <start_date>April 2003</start_date>
    <completion_date>September 2005</completion_date>
    <last_updated>February 4, 2014</last_updated>
    <last_verified>July 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the safety profile of MZ</outcome_measure>
      <outcome_measure>To estimate the proportion of patients treated w/ MZ who were alive and free of ventilator support at 12 months of age; compared to historical cohort</outcome_measure>
      <outcome_measure>Determine PK/PD profile of MZ</outcome_measure>
      <outcome_measure>Determine effect of different doses of MZ on safety and efficacy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00059280</url>
  </study>
  <study rank="521">
    <title>Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">adalimumab</intervention>
      <intervention type="Biological">placebo</intervention>
      <intervention type="Biological">adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>135</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2006</first_received>
    <start_date>August 2006</start_date>
    <last_updated>April 7, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>September 15, 2009</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Without Mucosal Ulceration at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Clinical Remission Crohn's Disease Activity Index (CDAI) &lt; 150 at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects Without Mucosal Ulceration at Week 52</outcome_measure>
      <outcome_measure>Number of Subjects With Clinical Remission (CDAI &lt; 150) at Week 52</outcome_measure>
      <outcome_measure>Number of Subjects Without Mucosal Ulceration at Both Week 12 and Week 52</outcome_measure>
      <outcome_measure>Number of Subjects With Clinical Remission (CDAI &lt; 150) at Both Week 12 and Week 52</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00348283</url>
  </study>
  <study rank="522">
    <title>Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">donepezil</intervention>
      <intervention type="Drug">ABT-126</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>438</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 3, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>November 6, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - cognitive subscale</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Mini Mental Status Exam (MMSE)</outcome_measure>
      <outcome_measure>DEMentia Quality of Life (DEMQOL)</outcome_measure>
      <outcome_measure>Clinician Interview-Based Impression of Change - plus (CIBIC-plus)</outcome_measure>
      <outcome_measure>Neuropsychiatry Inventory (NPI)</outcome_measure>
      <outcome_measure>Partner-Patient Questionnaire for Shared Activities (PPQSA)</outcome_measure>
      <outcome_measure>Resource Use in Dementia (RUD-Lite)</outcome_measure>
      <outcome_measure>EuroQol-5D Questionnaires</outcome_measure>
      <outcome_measure>Wechsler Memory Scale-III (WMS-III) Working Memory Index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01527916</url>
  </study>
  <study rank="523">
    <title>Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Temporomandibular Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Biofeedback-Based Cognitive Behavioral Treatment</intervention>
      <intervention type="Device">Dental treatment with occlusal splint (OS)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Philipps University Marburg Medical Center</lead_sponsor>
      <collaborator>Psychotherapie-Ambulanz Marburg e.V.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 8, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>December 4, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>May 24, 2013</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pain Intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD))</outcome_measure>
      <outcome_measure>Pain Disability (Pain Disability Index)</outcome_measure>
      <outcome_measure>Jaw Use Limitations (JDL)</outcome_measure>
      <outcome_measure>Somatoform Symptoms (Screening for Somatoform Disorders, SOMS)</outcome_measure>
      <outcome_measure>Depressive Symptoms (Centers for Epidemiologic Studies Depression Scale)</outcome_measure>
      <outcome_measure>General Anxiety Symptoms (GAD-7)</outcome_measure>
      <outcome_measure>Pain Coping (FESV)</outcome_measure>
      <outcome_measure>TMD Related Symptoms</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00769561</url>
  </study>
  <study rank="524">
    <title>Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cabergoline</intervention>
      <intervention type="Drug">Levodopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Technische Universität Dresden</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 7, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>December 17, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference of dopamine turnover rate measured by Fluoro-Dopa-PET in the putamen between patients with Parkinson's disease treated with cabergoline and levodopa for 3 months.</outcome_measure>
      <outcome_measure>Changes of clinical outcome measured with parkinsonian rating scales (UPDRS, PDQ-39, ESS, olfactory function)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00153972</url>
  </study>
  <study rank="525">
    <title>A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Early Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPM 962</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 27, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>February 3, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3</outcome_measure>
      <outcome_measure>Efficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3</outcome_measure>
      <outcome_measure>Mean Change in UPDRS Part 2 Sum Score</outcome_measure>
      <outcome_measure>Efficacy Rate in UPDRS Part 2 Sum Score</outcome_measure>
      <outcome_measure>UPDRS Part 3 Sum Score</outcome_measure>
      <outcome_measure>Efficacy Rate in UPDRS Part 3 Sum Score</outcome_measure>
      <outcome_measure>UPDRS Part 1 Sum Score</outcome_measure>
      <outcome_measure>UPDRS Part 4 Sum Score</outcome_measure>
      <outcome_measure>Total of Each Sum Score of UPDRS Part 1, 2, 3, and 4</outcome_measure>
      <outcome_measure>The Modified Hoehn and Yahr Stage</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00537485</url>
  </study>
  <study rank="526">
    <title>A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SK-PC-B70M</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SK Chemicals Co.,Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 5, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>December 8, 2009</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ADAS-cog(Alzheimer's Disease Assessment Scale-Cognitive subscale)</outcome_measure>
      <outcome_measure>MMSE(Mini Mental State Examination)</outcome_measure>
      <outcome_measure>CDR-SB(Clinical Dementia Rating Sum of Box)</outcome_measure>
      <outcome_measure>QOL-AD(Quality of Life in Alzheimer's Disease)</outcome_measure>
      <outcome_measure>Delayed Word-Recall Task</outcome_measure>
      <outcome_measure>Symbol Digit Modalities Test</outcome_measure>
      <outcome_measure>Digit Backward</outcome_measure>
      <outcome_measure>Maze Task</outcome_measure>
      <outcome_measure>Digit Cancellation Task</outcome_measure>
      <outcome_measure>Verbal Fluency-Categories</outcome_measure>
      <outcome_measure>Concentration / Distractibility</outcome_measure>
      <outcome_measure>GDS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00443417</url>
  </study>
  <study rank="527">
    <title>Intra-monocyte Imiglucerase Kinetics in Gaucher Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gaucher Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Imiglucérase (drug) pharmacokinetics</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Clermont-Ferrand</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 2, 2013</first_received>
    <start_date>November 2012</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>September 24, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Enzyme intra-monocyte activity (sum of endogenous enzyme activities and therapeutic enzyme)in patients treated with imiglucerase</outcome_measure>
      <outcome_measure>Residual rate</outcome_measure>
      <outcome_measure>Endogeneous intra-monocyte glucocérébrosidase activity from untreated patients</outcome_measure>
      <outcome_measure>Biomarker dosages will provide serum concentration values</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01951989</url>
  </study>
  <study rank="528">
    <title>The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cat-scratch Disease</condition>
      <condition>Bartonella Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">prednison and azithromycin</intervention>
      <intervention type="Drug">prednison, azithromycin</intervention>
      <intervention type="Drug">prednison, Azenil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tel-Aviv Sourasky Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>14 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2011</first_received>
    <start_date>December 2011</start_date>
    <last_updated>November 10, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Severity score of lymphadenitis using a lymphadenitis Score (LS).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01469702</url>
  </study>
  <study rank="529">
    <title>Anti-Oxidant Treatment of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin E, Vitamin C, and Alpha-lipoic Acid</intervention>
      <intervention type="Drug">Coenzyme Q</intervention>
      <intervention type="Drug">Placebo capsules</intervention>
      <intervention type="Drug">Placebo wafers</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute on Aging (NIA)</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2005</first_received>
    <start_date>January 2006</start_date>
    <completion_date>September 2007</completion_date>
    <last_updated>April 1, 2009</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>effect on cerebrospinal fluid (CSF) biomarkers related to oxidative damage</outcome_measure>
      <outcome_measure>change in plasma and CSF concentrations of a-beta42 and a-beta40</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00117403</url>
  </study>
  <study rank="530">
    <title>Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">trospium chloride inhalation powder (TrIP)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Endo Pharmaceuticals</lead_sponsor>
      <collaborator>Alkermes, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 24, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>December 3, 2013</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and efficacy (measured by spirometry) of TrIP will be assessed in patients with chronic obstructive pulmonary disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00465959</url>
  </study>
  <study rank="531">
    <title>Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Degenerative Disc Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YH14618</intervention>
      <intervention type="Drug">YH14618</intervention>
      <intervention type="Drug">YH14618</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Yuhan Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 31, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>May 27, 2015</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaulate the safety and tolerability after single intradiscal administation</outcome_measure>
      <outcome_measure>Change from baseline in disc height index at 12 week</outcome_measure>
      <outcome_measure>Change from baseline in magnetic resonance imaging(MRI) index</outcome_measure>
      <outcome_measure>Change from oswestry diability index(ODI) at week 12</outcome_measure>
      <outcome_measure>Change from baseline in visual analogue scale(VAS) at week 12</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01526330</url>
  </study>
  <study rank="532">
    <title>Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Gaucher's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">N-acetylcysteine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Minnesota - Clinical and Translational Science Institute</lead_sponsor>
      <collaborator>Rare Diseases Clinical Research Network</collaborator>
      <collaborator>National Center for Advancing Translational Science (NCATS)</collaborator>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 30, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>August 2, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>May 22, 2013</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Brain GSH</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01427517</url>
  </study>
  <study rank="533">
    <title>A Study of Abatacept in Patients With Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">abatacept</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">abatacept</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>451</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 1, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>September 10, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>July 30, 2010</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85</outcome_measure>
      <outcome_measure>Maintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI &lt;150) at Day MP-365 (12 Months)</outcome_measure>
      <outcome_measure>Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs</outcome_measure>
      <outcome_measure>OL; Number of Participants With Adverse Events (AEs) of Special Interest</outcome_measure>
      <outcome_measure>IP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome)</outcome_measure>
      <outcome_measure>IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship</outcome_measure>
      <outcome_measure>IP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ)</outcome_measure>
      <outcome_measure>IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs</outcome_measure>
      <outcome_measure>IP; Number of Participants With Adverse Events (AEs) of Special Interest</outcome_measure>
      <outcome_measure>IP; Number of Participants With Positive Antibody Response to Abatacept (ABA)</outcome_measure>
      <outcome_measure>IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)</outcome_measure>
      <outcome_measure>IP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF</outcome_measure>
      <outcome_measure>IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship</outcome_measure>
      <outcome_measure>MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due To AEs</outcome_measure>
      <outcome_measure>MP; Number of Participants With Adverse Events (AEs) of Special Interest:</outcome_measure>
      <outcome_measure>MP; Number of Participants With Positive Antibody Response to Abatacept</outcome_measure>
      <outcome_measure>MP; Number of Participants With CDAI-defined Clinical Response at Day MP-365.</outcome_measure>
      <outcome_measure>MP; Number of Participants in CDAI-defined Clinical Remission at Both Day MP-169 and Day MP-365</outcome_measure>
      <outcome_measure>MP; Change From Baseline to Day MP-365 in Short Form-36 (SF-36)</outcome_measure>
      <outcome_measure>MP; Change From Baseline to Day MP-365 in Inflammatory Bowel Disease Questionnaire (IBDQ)</outcome_measure>
      <outcome_measure>MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among All Participants Who Received Baseline Corticosteroid Therapy</outcome_measure>
      <outcome_measure>MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among Participants Who Received Baseline Corticosteroid Therapy and Who Achieved CDAI-Defined Clinical Remission</outcome_measure>
      <outcome_measure>MP; Number of Participants With CDAI-Defined Clinical Response Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)</outcome_measure>
      <outcome_measure>MP; Number of Participants in CDAI-Defined Clinical Remission Among Participants With Inadequate Response and/or Intolerance to Anti-TNF</outcome_measure>
      <outcome_measure>OL; Number of Participants Who Were Not On Background Corticosteroid Therapy Among All Participants Who Received Baseline Corticosteroid Therapy</outcome_measure>
      <outcome_measure>OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-169</outcome_measure>
      <outcome_measure>OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-365</outcome_measure>
      <outcome_measure>OL; Number of Participants With Positive Antibody Response to Abatacept</outcome_measure>
      <outcome_measure>OL; Number of Participants With Pharmacogenomic Marker Activity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00406653</url>
  </study>
  <study rank="534">
    <title>Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>All India Institute of Medical Sciences, New Delhi</lead_sponsor>
      <collaborator>University of Zurich</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 6, 2011</first_received>
    <start_date>April 2010</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>December 12, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum serum concentration (Cmax ) of simvastatin (20 mg, orally dosed after fasting) in subjects with celiac sprue</outcome_measure>
      <outcome_measure>Duodenal level of cytochrome CYP3A4</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01338324</url>
  </study>
  <study rank="535">
    <title>Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">tDCS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Georgetown University</lead_sponsor>
      <collaborator>Ferrell Family Charitable Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 2, 2014</first_received>
    <start_date>October 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>August 19, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement of Motor and Speech Symptoms of Parkinson's Disease or Related Disorders</outcome_measure>
      <outcome_measure>Improvement of Neuropsychiatric Symptoms of Parkinson's Disease or Related Disorders</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02104401</url>
  </study>
  <study rank="536">
    <title>Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Hematopoietic Stem Cell Transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
      <collaborator>Blood and Marrow Transplant Clinical Trials Network</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>National Marrow Donor Program</collaborator>
      <collaborator>Sickle Cell Disease Clinical Research Network</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Years</min_age>
    <max_age>19 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 29, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>May 17, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Event-free survival</outcome_measure>
      <outcome_measure>Survival; neutrophil and platelet recovery; acute graft-versus-host disease (aGVHD); chronic GVHD (cGVHD); hepatic veno-occlusive disease; idiopathic pneumonia syndrome; and central nervous system toxicity</outcome_measure>
      <outcome_measure>Neurocognitive dysfunction; cytomegalovirus, adenovirus, and fungal infections; Epstein Barr virus infection; chimerism; immune reconstitution; and quality of life</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00745420</url>
  </study>
  <study rank="537">
    <title>Safety Study of MT-4666 in Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MT-4666</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 23, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of 2 fixed doses of EVP-6124 in subjects with Alzheimer's disease. Criteria for evaluation include: adverse events, clinical laboratory tests, vital signs, body weight, 12-lead ECG, Columbia Suicide Severity Rating Scale (C-SSRS)</outcome_measure>
      <outcome_measure>Change in Mini Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change in Neuropsychiatric Inventory (NPI) total score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02327182</url>
  </study>
  <study rank="538">
    <title>Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Intervertebral Disc Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Instrumented posterolateral arthrodesis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Red de Terapia Celular</lead_sponsor>
      <collaborator>Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán</collaborator>
      <collaborator>Spanish National Health System</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 16, 2012</first_received>
    <start_date>January 2010</start_date>
    <last_updated>October 19, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT01513694</url>
  </study>
  <study rank="539">
    <title>Effect of LY2062430 on the Progression of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY2062430</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1040</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 18, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>December 11, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 14-Item Scale (ADAS-Cog14)</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Neuropsychiatric Inventory (NPI) Score</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in volumetric Magnetic Resonance Imaging (vMRI)</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Mini-Mental State Examination (MMSE) Score</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Resource Utilization in Dementia - Lite (RUD-Lite) Score</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy) Score</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Quality of Life in Alzheimer's Disease (QoL-AD) Score</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Plasma Amyloid Beta Levels</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item and 12-Item Scale (ADAS-Cog11 and ADAS-Cog12)</outcome_measure>
      <outcome_measure>Change from Baseline to Week 80 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00904683</url>
  </study>
  <study rank="540">
    <title>Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastroesophageal Reflux Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexlansoprazole 30 mg</intervention>
      <intervention type="Drug">Dexlansoprazole 60 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Takeda</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>295</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 27, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>July 21, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of 24-hour heartburn and acid regurgitation-free days in non-erosive reflux disease (NERD) participants</outcome_measure>
      <outcome_measure>Percentage of 24-hour heartburn and acid regurgitation-free days in erosive esophagitis (EE) participants</outcome_measure>
      <outcome_measure>The percentage of 24 hour heartburn-free days in non-erosive reflux disease (NERD) participants</outcome_measure>
      <outcome_measure>The percentage of 24-hour acid regurgitation-free days in non-erosive reflux disease (NERD) participants</outcome_measure>
      <outcome_measure>The percentage of 24 hour heartburn-free days in erosive esophagitis (EE) participants</outcome_measure>
      <outcome_measure>The percentage of 24-hour acid regurgitation-free days over 8 weeks in erosive esophagitis (EE) participants</outcome_measure>
      <outcome_measure>Percentage of nights (participant sleep time) without nighttime heartburn and acid regurgitation in non-erosive reflux disease (NERD) group</outcome_measure>
      <outcome_measure>The percentage of nights (patient sleep time) without nighttime heartburn in non-erosive reflux disease (NERD) group</outcome_measure>
      <outcome_measure>The percentage of nights (Patient sleep time) without nighttime acid regurgitation in non-erosive reflux disease (NERD) group</outcome_measure>
      <outcome_measure>The percentage of nights (patient sleep time) without nighttime heartburn and acid regurgitation in erosive esophagitis (EE) group</outcome_measure>
      <outcome_measure>The percentage of nights (patient sleep time) without nighttime heartburn in erosive esophagitis (EE) group</outcome_measure>
      <outcome_measure>The percentage of nights (patient sleep time) without nighttime acid regurgitation in erosive esophagitis (EE) group</outcome_measure>
      <outcome_measure>Severity of gastroesophageal reflux disease (GERD) symptoms based on investigator assessment in non-erosive reflux disease (NERD) participants</outcome_measure>
      <outcome_measure>Severity of gastroesophageal reflux disease (GERD) symptoms based on investigator assessment in erosive esophagitis (EE) participants</outcome_measure>
      <outcome_measure>Percentage of study participants in the erosive esophagitis (EE) group who have endoscopically evaluated macroscopic healing of their esophagus</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02351960</url>
  </study>
  <study rank="541">
    <title>EPANOVA in Crohn's Disease, Study 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Epanova</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tillotts Pharma AG</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>384</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 15, 2008</first_received>
    <start_date>January 2003</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>April 3, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>time to clinical relapse</outcome_measure>
      <outcome_measure>CDAI Investigator and subject global rating Quality of life C-reactive protein</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00613197</url>
  </study>
  <study rank="542">
    <title>Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">G-CSF</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Buddhist Tzu Chi General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 22, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>March 3, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>July 17, 2014</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Motor Performance of Unified Parkinson's Disease Rating Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01227681</url>
  </study>
  <study rank="543">
    <title>A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo and ginkgo extract</intervention>
      <intervention type="Drug">Curcumin and ginkgo extract</intervention>
      <intervention type="Drug">Curcumin and ginkgo extract</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
      <collaborator>BUPA Foundation</collaborator>
      <collaborator>Kwong Wah Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>October 2004</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>April 25, 2008</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in isoprostane level in plasma</outcome_measure>
      <outcome_measure>Change in A-beta level in serum</outcome_measure>
      <outcome_measure>Change in cognitive function (MMSE score)</outcome_measure>
      <outcome_measure>Change in cholesterol and triglycerides in serum</outcome_measure>
      <outcome_measure>Change in metals in serum</outcome_measure>
      <outcome_measure>Level of curcumin in plasma vs. dose</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00164749</url>
  </study>
  <study rank="544">
    <title>Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-126</intervention>
      <intervention type="Drug">ABT-126</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>434</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 7, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>October 24, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - cognitive subscale</outcome_measure>
      <outcome_measure>Mini Mental Status Exam</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>DEMentia Quality of Life (DEMQOL)</outcome_measure>
      <outcome_measure>Clinician Interview-Based Impression of Change - plus (CIBIC-plus)</outcome_measure>
      <outcome_measure>Neuropsychiatry Inventory (NPI)</outcome_measure>
      <outcome_measure>Partner-Patient Questionnaire for Shared Activities (PPQSA)</outcome_measure>
      <outcome_measure>Resource Use in Dementia (RUD-Lite)</outcome_measure>
      <outcome_measure>EuroQol-5D Questionnaires</outcome_measure>
      <outcome_measure>Wechsler Memory Scale-III (WMS-III) Working Memory Index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01549834</url>
  </study>
  <study rank="545">
    <title>A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACR16</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Pharmaceutical Industries</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>437</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 22, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>July 19, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.</outcome_measure>
      <outcome_measure>Safety and tolerability assessed from adverse event profile.</outcome_measure>
      <outcome_measure>The effects of ACR16 on CGI, cognitive function, behaviour and symptoms of depression and anxiety.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00665223</url>
  </study>
  <study rank="546">
    <title>Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ciprofloxacin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>Crohn's and Colitis Foundation</collaborator>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 24, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>March 21, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>November 12, 2012</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability of Ciprofloxacin</outcome_measure>
      <outcome_measure>Endoscopic Recurrence Under Postoperative Treatment With Study Medication at 6 Months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00609973</url>
  </study>
  <study rank="547">
    <title>Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AC-3933</intervention>
      <intervention type="Drug">AC-3933</intervention>
      <intervention type="Other">Sugar Pill</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sunovion</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>171</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 1, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>May 28, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>April 11, 2011</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Total Score of Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)From Best Total Score (0) to Worst Total Score (70)</outcome_measure>
      <outcome_measure>Clinicians Interview Based Impression of Change (CIBIC)-Plus</outcome_measure>
      <outcome_measure>Disability Assessment for Dementia (DAD)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00359944</url>
  </study>
  <study rank="548">
    <title>Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Liatermin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amgen</lead_sponsor>
      <collaborator>Medtronic</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 27, 2005</first_received>
    <start_date>December 2003</start_date>
    <completion_date>February 2006</completion_date>
    <last_updated>February 25, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent change in UPDRS</outcome_measure>
      <outcome_measure>Incidence of treatment emergent and device related adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00111982</url>
  </study>
  <study rank="549">
    <title>Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">10% Metronidazole Ointment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>S.L.A. Pharma AG</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 30, 2007</first_received>
    <start_date>May 2005</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>December 12, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the effect of 10% metronidazole ointment, applied topically three times a day, in and around the anus, on the change in perianal Crohn's disease activity.</outcome_measure>
      <outcome_measure>To evaluate and compare the relief of perianal pain and discomfort associated with Crohn's disease, against placebo.</outcome_measure>
      <outcome_measure>To evaluate and compare Patient Global Impression of Improvement</outcome_measure>
      <outcome_measure>To compare visual improvement (using photographic documentation assessed by a blinded independent observer)</outcome_measure>
      <outcome_measure>To compare Quality of Life assessments</outcome_measure>
      <outcome_measure>To evaluate and compare the number of analgesics required prior to treatment and to that required by the treatment and placebo group</outcome_measure>
      <outcome_measure>To evaluate and compare fistula healing</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00509639</url>
  </study>
  <study rank="550">
    <title>Treatment of Parkinson's Disease With Eliprodil</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Movement Disorders</condition>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eliprodil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 1999</first_received>
    <start_date>March 1999</start_date>
    <completion_date>January 2001</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>January 2000</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001929</url>
  </study>
  <study rank="551">
    <title>Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Epigallocatechin-Gallate</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 3, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>January 20, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ADAS-COG (Score 0-70) (Baseline to treatment)</outcome_measure>
      <outcome_measure>Safety and tolerability of the verum</outcome_measure>
      <outcome_measure>MMSE (Score 0-30) after 18 months compared to baseline</outcome_measure>
      <outcome_measure>Time to hospitalisation and Time to death related to AD</outcome_measure>
      <outcome_measure>Brain atrophy assessed by brain MRI</outcome_measure>
      <outcome_measure>Baseline-ADAS-COG and Baseline-MMSE as covariates</outcome_measure>
      <outcome_measure>CIBIC+ and WHO-QOL-Bref</outcome_measure>
      <outcome_measure>Trail Making Test and MVGT</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00951834</url>
  </study>
  <study rank="552">
    <title>Study of LY300164 for the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dyskinesias</condition>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY300164</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 17, 2000</first_received>
    <start_date>February 2000</start_date>
    <completion_date>August 2000</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>February 2000</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00004576</url>
  </study>
  <study rank="553">
    <title>Pivotal Study in Advanced Parkinsons Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pramipexol Extended Release</intervention>
      <intervention type="Drug">Pramipexol Immediate Release</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>32 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>517</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 25, 2007</first_received>
    <start_date>April 2007</start_date>
    <last_updated>June 24, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>November 17, 2009</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage Off-time at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage On-time Without Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Clinical Global Impression - Global Improvement (CGI-I) Responder</outcome_measure>
      <outcome_measure>Response in Patient Global Impression (PGI-I)</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS I Score After 18 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS III Score After 18 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS IV Score After 18 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18</outcome_measure>
      <outcome_measure>Clinically Significant Abnormalities: Clinical Laboratory Evaluations (Biochemistry and Haematology)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00466167</url>
  </study>
  <study rank="554">
    <title>Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Lymphoproliferative Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GRN163L</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Geron Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 25, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>December 22, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or recommended phase II dose of GRN163L in patients with relapsed or refractory chronic lymphoproliferative disease</outcome_measure>
      <outcome_measure>PK and PD</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00124189</url>
  </study>
  <study rank="555">
    <title>Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Positron-Emission Tomography</condition>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">F-18 FEDAA1106 (BAY85-8101)</intervention>
      <intervention type="Drug">F-18 FEDAA1106 (BAY85-8101)</intervention>
      <intervention type="Drug">F-18 FEDAA1106 (BAY85-8101)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bayer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>December 17, 2009</first_received>
    <start_date>June 2007</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>January 7, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Visual analysis/description of the uptake and description of brain PET scans</outcome_measure>
      <outcome_measure>Standardized uptake value (SUV) in various cerebral regions/volumes of interest (ROI/VOI) assumed and found to be involved in the pathophysiology of Alzheimer's disease.</outcome_measure>
      <outcome_measure>Standard quantification variables derived from 3D PET imaging and brain modeling</outcome_measure>
      <outcome_measure>Standard Safety Measurement:adverse event collection</outcome_measure>
      <outcome_measure>Standard Safety Measurement:electrocardiogram</outcome_measure>
      <outcome_measure>Standard Safety Measurement:safety laboratory</outcome_measure>
      <outcome_measure>Standard Safety Measurement: vital signs</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01035164</url>
  </study>
  <study rank="556">
    <title>Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Relapsing Remitting Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fingolimod</intervention>
      <intervention type="Drug">Disease Modifying therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>881</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 18, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>March 28, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Retention on treatment</outcome_measure>
      <outcome_measure>Reasons for Discontinuation</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Cognitive impairment</outcome_measure>
      <outcome_measure>Percent change in brain volume</outcome_measure>
      <outcome_measure>Treatment satisfaction</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01623596</url>
  </study>
  <study rank="557">
    <title>Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Visilizumab</intervention>
      <intervention type="Drug">Tacrolimus</intervention>
      <intervention type="Drug">Methotrexate</intervention>
      <intervention type="Drug">Antithymocyte globulin (ATG)</intervention>
      <intervention type="Drug">Tacrolimus</intervention>
      <intervention type="Drug">Methotrexate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>H. Lee Moffitt Cancer Center and Research Institute</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>July 21, 2008</first_received>
    <start_date>December 2007</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 10, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>May 1, 2014</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Grade II-IV Acute Graft-versus-Host Disease (GVHD) Score at 100 Days</outcome_measure>
      <outcome_measure>Incidence of Epstein-Barr Virus (EBV) Reactivation</outcome_measure>
      <outcome_measure>Incidence of Rituximab Response to Reactivated EBV Without PTLD</outcome_measure>
      <outcome_measure>Overall Survival (OS)</outcome_measure>
      <outcome_measure>Pharmacodynamics of Visilizumab - Test 1</outcome_measure>
      <outcome_measure>Pharmacodynamics of Visilizumab - Test 2</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00720629</url>
  </study>
  <study rank="558">
    <title>Alzheimer`s Disease Acitretin Medication</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Acitretin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johannes Gutenberg University Mainz</lead_sponsor>
      <collaborator>Alzheimer Forschungsinitiative e.V. (AFI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>76</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 1, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>September 14, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference in CSF APPSα concentration at Visit 3 compared to Baseline</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01078168</url>
  </study>
  <study rank="559">
    <title>Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chagas Disease</condition>
      <condition>Heart Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Implantable Cardiac Monitor</intervention>
      <intervention type="Procedure">Standard of Care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medtronic Cardiac Rhythm and Heart Failure</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 9, 2012</first_received>
    <start_date>July 2013</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>October 10, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare the time to the physician's decision to treat for electrical disorders (brady/tachyarrhythmias) between the two randomized groups.</outcome_measure>
      <outcome_measure>Summarize the recorded arrhythmic events stored within the ICM (bradyarrhythmia and tachyarrhythmia.</outcome_measure>
      <outcome_measure>Compute the time duration spent in arrhythmias for ICM patients.</outcome_measure>
      <outcome_measure>Compute the incidence of symptomatic arrhythmias in patients with an ICM</outcome_measure>
      <outcome_measure>Compare the time to the physician's decision to treat with components of the composite primary endpoint between randomization arms.</outcome_measure>
      <outcome_measure>Compare the mortality rate between randomization arms.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01539161</url>
  </study>
  <study rank="560">
    <title>Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">treatment with Nintendo wii.</intervention>
      <intervention type="Other">Physical therapy conventional.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of Bahia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 10, 2010</first_received>
    <start_date>May 2011</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>December 6, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Motor performance</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01120392</url>
  </study>
  <study rank="561">
    <title>A Novel Intervention Promoting Eating Disorder Treatment Among College Students</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Eating Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Promoting Eating Disorder Treatment among College Students</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>1149</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>November 3, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>May 27, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Help-seeking behavior (Use of services (e.g., counseling/therapy) for eating and body image issues)</outcome_measure>
      <outcome_measure>Predictors of help-seeking behavior (e.g., perceived need/urgency, knowledge, attitudes, intentions to seek help)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02284685</url>
  </study>
  <study rank="562">
    <title>SAM-e for the Treatment of Depression in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SAM-e</intervention>
      <intervention type="Drug">oral escitalopram</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>New York University School of Medicine</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
      <collaborator>Office of Dietary Supplements (ODS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 9, 2003</first_received>
    <start_date>July 2003</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>June 2, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>May 3, 2013</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Hamilton Depression Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00070941</url>
  </study>
  <study rank="563">
    <title>Expiratory Muscle Training in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">EMST - Active Treatment</intervention>
      <intervention type="Device">sham EMST</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 12, 2009</first_received>
    <start_date>January 2004</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>September 16, 2011</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Expiratory Pressure</outcome_measure>
      <outcome_measure>Penetration-Aspiration Score</outcome_measure>
      <outcome_measure>Peak Expiratory Flow Rate</outcome_measure>
      <outcome_measure>Laryngeal Compression Duration</outcome_measure>
      <outcome_measure>Speech timing</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00843739</url>
  </study>
  <study rank="564">
    <title>Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Teduglutide (ALX-0600)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Shire</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>March 2004</start_date>
    <completion_date>June 2006</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The percentage of subjects who are in remission (CDAI score less than 150) at week 12 of this study.</outcome_measure>
      <outcome_measure>The percentage of subjects (of those who achieved response in CL0600-008) who, at week 12 of this study, maintain the response they previously achieved.</outcome_measure>
      <outcome_measure>The percentage of subjects who did not respond in CL0600-008 who do respond at week 12 in this study</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00308438</url>
  </study>
  <study rank="565">
    <title>Premanifest Huntington's Disease: Creatine Safety &amp; Tolerability Extension Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Creatine Monohydrate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>26 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 4, 2011</first_received>
    <start_date>May 2009</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>January 10, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Clinical measures</outcome_measure>
      <outcome_measure>Biological Markers of Disease Progression</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01411150</url>
  </study>
  <study rank="566">
    <title>A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">CP-690,550</intervention>
      <intervention type="Drug">CP-690,550</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 11, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>June 15, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects in clinical remission at week 8 as defined by a Crohn's disease activity index (CDAI) score of less than 150 points.</outcome_measure>
      <outcome_measure>The proportions of subjects in clinical remission (CDAI&lt;150) at Week 2 and 4.</outcome_measure>
      <outcome_measure>The proportion of subjects achieving clinical response-70 at Week 2, 4, and 8 as defined by a decrease in CDAI score of at least 70 points from baseline.</outcome_measure>
      <outcome_measure>The proportion of subjects achieving clinical response-100 at Week 2, 4, and 8 as defined by a decrease in CDAI score of at least 100 points from baseline.</outcome_measure>
      <outcome_measure>The proportion of subjects achieving either clinical response-100 or clinical remission (CDAI&lt;150) at Week 2, 4, and 8.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01393626</url>
  </study>
  <study rank="567">
    <title>Treatment of Parkinson's Disease With a Transdermal Skin Patch</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">N-0923</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 31, 2007</first_received>
    <start_date>May 1999</start_date>
    <completion_date>January 2001</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>June 2000</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001931</url>
  </study>
  <study rank="568">
    <title>Premanifest Huntington's Disease Extension Study II: Creatine Safety &amp; Tolerability</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Creatine monohydrate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>26 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 4, 2011</first_received>
    <start_date>April 2010</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>January 10, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Clinical measures</outcome_measure>
      <outcome_measure>Biological Markers of Disease Progression</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01411163</url>
  </study>
  <study rank="569">
    <title>Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Symptomatic Gastroesophageal Reflux Disease (sGERD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">rabeprazole sodium</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>305</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 29, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>January 4, 2016</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>June 8, 2015</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in Average Daily Severity Score of Gastroesophageal Reflux Disease (GERD)-Related Symptoms at Week 4</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00911534</url>
  </study>
  <study rank="570">
    <title>Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Placebo matching with BMS-945429</intervention>
      <intervention type="Biological">Placebo matching with BMS-945429</intervention>
      <intervention type="Biological">Placebo matching with BMS-945429</intervention>
      <intervention type="Biological">Placebo matching with BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
      <intervention type="Biological">BMS-945429</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alder Biopharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 1, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 24, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with clinical remission as measured by the Crohn's Disease Activity Index</outcome_measure>
      <outcome_measure>Proportion of subjects with clinical response during Induction Period</outcome_measure>
      <outcome_measure>Change from baseline of Inflammatory Bowel Disease Questionnaire (IBDQ) and Short Form-36 (SF-36)</outcome_measure>
      <outcome_measure>Safety during the Induction Period as measured by adverse events, vital signs, physical examinations and safety lab values</outcome_measure>
      <outcome_measure>Immunogenicity during the Induction Period will be assessed based on levels of anti-BMS-945429 antibodies</outcome_measure>
      <outcome_measure>Steady-state trough concentration (Cmin) of BMS-945429 during the Induction Period</outcome_measure>
      <outcome_measure>Observed maximum concentration (Cmax) of BMS-945429 during the Induction Period</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)] of BMS-945429 during the Induction Period</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01545050</url>
  </study>
  <study rank="571">
    <title>Peyronie's Disease Treatment Protocol</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peyronie's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">H-100</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hybrid Medical</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 9, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>February 24, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety measure</outcome_measure>
      <outcome_measure>Efficacy measure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02072018</url>
  </study>
  <study rank="572">
    <title>Phase II Study of RR110 in Patients With Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RR110 (Tamibarotene)</intervention>
      <intervention type="Drug">RR110 (Tamibarotene)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>R&amp;R Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 28, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>May 25, 2008</last_updated>
    <last_verified>May 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Crohn's disease active index (CDAI) score</outcome_measure>
      <outcome_measure>Rate of clinical response as defined by CDAI decrease &gt; 70 or 100 from baseline</outcome_measure>
      <outcome_measure>Rate of clinical remission as defined by CDAI &lt; 150</outcome_measure>
      <outcome_measure>Change in CRP, SAA, and fibrinogen levels, and IBDQ and CDEIS scores</outcome_measure>
      <outcome_measure>Safety parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00417391</url>
  </study>
  <study rank="573">
    <title>Bacteriotherapy in Pediatric Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>CD</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Bacteriotherapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>David Suskind</lead_sponsor>
      <collaborator>Seattle Children's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 22, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>April 18, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>November 16, 2015</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease Activity Index (PCDAI) Scoring</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01757964</url>
  </study>
  <study rank="574">
    <title>Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bipolar Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Quetiapine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mood Disorders Center of Ottawa</lead_sponsor>
      <collaborator>AstraZeneca</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <max_age>20 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 9, 2005</first_received>
    <start_date>June 2004</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>June 2, 2008</last_updated>
    <last_verified>June 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated study patients maintained on monotherapy for the duration of the trial compared to the proportion requiring systematic adjunctive medication.</outcome_measure>
      <outcome_measure>Time to an episode recurrence (Montgomery-Asberg Depression Rating Scale</outcome_measure>
      <outcome_measure>/Young Mania Rating Scale [MADRS/YMRS] &gt; 15)</outcome_measure>
      <outcome_measure>Time to hospitalization</outcome_measure>
      <outcome_measure>Autobiographical Memory Interview (AMI) mean score over treatment</outcome_measure>
      <outcome_measure>Clinical Global Impression-Bipolar Disorder (CGI-BP) score during treatment and at study completion</outcome_measure>
      <outcome_measure>YMRS total score during treatment and at study completion</outcome_measure>
      <outcome_measure>MADRS total score during treatment and at study completion</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00252226</url>
  </study>
  <study rank="575">
    <title>Evaluation of PET CT in the Management of Patients With Crohn's Disease.</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">FDG PET CT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rabin Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>August 3, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>December 22, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00731809</url>
  </study>
  <study rank="576">
    <title>The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-alcoholic Fatty Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Efamax</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 8, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>July 3, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction of intrahepatic fat content as determined by magnetic resonance spectroscopy</outcome_measure>
      <outcome_measure>Serum liver function tests, lipids, free fatty acids</outcome_measure>
      <outcome_measure>Insulin resistance as assessed by HOMA-IR and Adipose Tissue Insulin Resistance Index</outcome_measure>
      <outcome_measure>Liver saturated, monounsaturated and polyunsaturated fatty acid indexes as assessed by MR spectroscopy</outcome_measure>
      <outcome_measure>Visceral obesity as quantified by MRI, and the adipose derived serum leptin and adiponectin</outcome_measure>
      <outcome_measure>Primary assessment of the fibrotic and inflammatory status of the liver with serum TGF beta, TNF a, IL-6, IL-8, IL-8, IL-10</outcome_measure>
      <outcome_measure>Further informative cytokine analyses: GM-CSF, IFN-G, IL-1B, IL-1RA, IL-2, IL-4, IL-5, MCP1</outcome_measure>
      <outcome_measure>Compliance assessed by serum phospholipid fatty acids</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00819338</url>
  </study>
  <study rank="577">
    <title>Active With Heart Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cardiac habilitation program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oslo University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>June 19, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 20, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Increased level of physical activity</outcome_measure>
      <outcome_measure>Increased physical fitness</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01624818</url>
  </study>
  <study rank="578">
    <title>Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dense Deposit Disease</condition>
      <condition>Membranoproliferative Glomerulonephritis Type II</condition>
      <condition>C3 Glomerulonephritis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CDX-1135</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Celldex Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>4 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 29, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>March 6, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>C3 and AP Normalization</outcome_measure>
      <outcome_measure>Duration of and time to normalize C3 and AP</outcome_measure>
      <outcome_measure>Renal Function</outcome_measure>
      <outcome_measure>Renal biopsy</outcome_measure>
      <outcome_measure>Immunogenicity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01791686</url>
  </study>
  <study rank="579">
    <title>Safety and Maintenance Study of Entocort for Children With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entocort</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Perrigo Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 14, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>September 2, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>February 11, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse Event</outcome_measure>
      <outcome_measure>PCDAI</outcome_measure>
      <outcome_measure>IMPACT 3</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01453946</url>
  </study>
  <study rank="580">
    <title>Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F]MPPF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>September 27, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>June 2, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the dynamic uptake and washout of [18F]MPPF in brain using positron emission tomography(PET) imaging</outcome_measure>
      <outcome_measure>To assess the influence of dopaminergic replacement therapy on 5HT1A activity in PD subjects</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01461083</url>
  </study>
  <study rank="581">
    <title>TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ethyl-EPA (Miraxion™)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amarin Neuroscience Ltd</lead_sponsor>
      <collaborator>Huntington Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 2, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>December 24, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare with placebo the effect of ethyl-EPA on the Total Motor Score-4 component (TMS) of the Unified Huntington's Disease Rating Scale (UHDRS) over a 6-month period of observation.</outcome_measure>
      <outcome_measure>To compare with placebo the effect of ethyl-EPA over a 6-month period of observation on, 1) Chorea (UHDRS Total Motor Score Scale); 2) Total Motor Score component (TMS) of the UHDRS; and, 3) Clinical Global Impression (CGI) score.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00146211</url>
  </study>
  <study rank="582">
    <title>A Unified Treatment for Anxiety Disorders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Emotional Disorders</condition>
      <condition>Anxiety Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Unified treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boston University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 21, 2007</first_received>
    <start_date>September 2005</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>November 29, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Anxiety Disorders Interview Schedule for DSM-IV</outcome_measure>
      <outcome_measure>Structured Interview Guide for the Hamilton Anxiety Rating Scale</outcome_measure>
      <outcome_measure>Structured Interview Guide for the Hamilton Depression Rating Scale</outcome_measure>
      <outcome_measure>Positive and Negative Affect Scale</outcome_measure>
      <outcome_measure>Beck Depression Inventory - II</outcome_measure>
      <outcome_measure>Beck Anxiety Inventory</outcome_measure>
      <outcome_measure>Work and Social Adjustment Scale</outcome_measure>
      <outcome_measure>Obsessive Compulsive Inventory - Revised</outcome_measure>
      <outcome_measure>Panic Disorder Severity Scale - Self Report Version</outcome_measure>
      <outcome_measure>Penn State Worry Questionnaire</outcome_measure>
      <outcome_measure>Social Interaction Anxiety Scale</outcome_measure>
      <outcome_measure>Quality of Life Inventory</outcome_measure>
      <outcome_measure>Yale-Brown Obsessive Compulsive Scale</outcome_measure>
      <outcome_measure>Emotion Regulation Questionnaire - 2</outcome_measure>
      <outcome_measure>BIS/BAS Scales (Carver &amp; White, 1994)</outcome_measure>
      <outcome_measure>Affective Control Scale</outcome_measure>
      <outcome_measure>Anxiety Sensitivity Index</outcome_measure>
      <outcome_measure>The Thought-Action Fusion Scale (Shafran et al., 1996)</outcome_measure>
      <outcome_measure>Intolerance of Uncertainty Scale (IUS)</outcome_measure>
      <outcome_measure>The Trait Meta-Mood Scale (TMMS; Salovey et al., 1995)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00586001</url>
  </study>
  <study rank="583">
    <title>Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic GVHD</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sirolimus + calcineurin inhibitor + prednisone</intervention>
      <intervention type="Drug">Sirolimus + prednisone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>Blood and Marrow Transplant Clinical Trials Network</collaborator>
      <collaborator>National Marrow Donor Program</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>161</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 16, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>March 2019</completion_date>
    <last_updated>August 1, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Phase II: Proportion of subjects with Complete Response or Partial Response; Phase III: Proportion of subjects with Complete Response; resolution of graft versus host disease manifestations</outcome_measure>
      <outcome_measure>Phase II: Avg. daily dose % reduction of prednisone</outcome_measure>
      <outcome_measure>Phase II: Cumulative incidence of treatment failure</outcome_measure>
      <outcome_measure>Phase II: Prevalence of active symptomatic chronic GVHD</outcome_measure>
      <outcome_measure>Phase II: Incidence of discontinuation of all systemic immunosuppressive therapy</outcome_measure>
      <outcome_measure>Phase II: Overall and cancer progression-free survival</outcome_measure>
      <outcome_measure>Phase II: Serum biomarkers of chronic GVHD</outcome_measure>
      <outcome_measure>Phase III: Avg. daily dose % reduction of prednisone</outcome_measure>
      <outcome_measure>Phase III: Cumulative incidence of treatment failure</outcome_measure>
      <outcome_measure>Phase III: Prevalence of active symptomatic chronic GVHD</outcome_measure>
      <outcome_measure>Phase III: Incidence of discontinuation of all systemic immunosuppressive therapy</outcome_measure>
      <outcome_measure>Phases III: Overall and cancer progression-free survival</outcome_measure>
      <outcome_measure>Phase III: Serum biomarkers of chronic GVHD</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01106833</url>
  </study>
  <study rank="584">
    <title>Effectiveness of Laying-on-of-hands for Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
      <condition>Pain Crisis Recurrent</condition>
      <condition>Anemia</condition>
      <condition>Infection</condition>
      <condition>Death</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">laying-on-of-hands</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MOA Health Science Foundation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>January 21, 2012</first_received>
    <start_date>March 2006</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>disease-related episodes and mortality</outcome_measure>
      <outcome_measure>blood data</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01518218</url>
  </study>
  <study rank="585">
    <title>Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY451395</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 17, 2003</first_received>
    <start_date>November 2002</start_date>
    <completion_date>June 2003</completion_date>
    <last_updated>July 18, 2006</last_updated>
    <last_verified>July 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00051909</url>
  </study>
  <study rank="586">
    <title>Effect of LY2062430 on the Progression of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY2062430</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 18, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>September 18, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to endpoint in Alzheimer's Disease Assessment Scale—Cognitive subscore (ADAS-Cog11)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in Alzheimer's Disease Cooperative Study—Activities of Daily Living Inventory (ADCS-ADL)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in Clinical Dementia Rating—Sum of Boxes (CDR-SB)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in volumetric magnetic resonance imaging (vMRI)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in Resource Utilization in Dementia—Lite (RUD-Lite)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in plasma LY2062430 to investigate a relationship between plasma LY2062430 and plasma A Beta levels.</outcome_measure>
      <outcome_measure>Change from baseline to endpoint in plasma A Beta</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00905372</url>
  </study>
  <study rank="587">
    <title>Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cyclosporine</intervention>
      <intervention type="Drug">hydroxychloroquine</intervention>
      <intervention type="Drug">prednisone</intervention>
      <intervention type="Drug">tacrolimus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Oncology Group</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Year</min_age>
    <max_age>29 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>March 8, 2002</first_received>
    <start_date>April 2002</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>February 12, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression Free Survival</outcome_measure>
      <outcome_measure>Compare the efficacy of a two-drug regimen</outcome_measure>
      <outcome_measure>Compare conventional outcomes measures</outcome_measure>
      <outcome_measure>To determine if cytokine levels and T helper cell subtypes (Th1 and Th2) correlate with chronic GVHD activity and response</outcome_measure>
      <outcome_measure>Determine if whole blood hydroxychloroquine levels correlate with response and toxicity.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00031824</url>
  </study>
  <study rank="588">
    <title>Study of Tai Chi Exercise and Balance in Persons With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Tai Chi</intervention>
      <intervention type="Behavioral">Strength training</intervention>
      <intervention type="Behavioral">Low-Impact Exercise Control</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oregon Research Institute</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>195</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 6, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>October 10, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Balance</outcome_measure>
      <outcome_measure>gait, physical performance, Unified Parkinson's Disease Rating Scale, falls, Muscle strength</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00611481</url>
  </study>
  <study rank="589">
    <title>XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Degenerative Disc Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">XL TDR</intervention>
      <intervention type="Other">Lumbar fusion surgery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>NuVasive</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>246</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 22, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 28, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in ODI</outcome_measure>
      <outcome_measure>Disc Height</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00927238</url>
  </study>
  <study rank="590">
    <title>A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centocor, Inc.</lead_sponsor>
      <collaborator>Centocor BV</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>February 2003</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>May 16, 2011</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Clinical response at Week 10, defined as a decrease from baseline in the PCDAI score of at least 15 points with a total score of no more than 30 points at Week 10.</outcome_measure>
      <outcome_measure>Clinical response at Week 54; Clinical remission at Week 54; Change from baseline in corticosteroid use at Week 54; Change from baseline in height status at Week 54</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00207675</url>
  </study>
  <study rank="591">
    <title>Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MT-1303</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 20, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 10, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Plasma concentration of MT-1303</outcome_measure>
      <outcome_measure>Plasma concentration of MT-1303 metabolite</outcome_measure>
      <outcome_measure>Change from baseline in lymphocyte count after MT-1303 administration</outcome_measure>
      <outcome_measure>Type of adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02148185</url>
  </study>
  <study rank="592">
    <title>Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SR57667B</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sanofi</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>183</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 16, 2005</first_received>
    <start_date>January 2004</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>December 22, 2008</last_updated>
    <last_verified>December 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in average (left and right) putamen 18F-Dopa influx constant (Ki) from baseline to two year 18F-Dopa PET</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00220272</url>
  </study>
  <study rank="593">
    <title>Treatment of Alzheimer's Disease With CX516 (Ampalex)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CX516 (Ampalex)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 1999</first_received>
    <start_date>December 1996</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>November 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001662</url>
  </study>
  <study rank="594">
    <title>KW-6002 to Treat Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">KW-6002</intervention>
      <intervention type="Drug">IV Levodopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 4, 2000</first_received>
    <start_date>October 2000</start_date>
    <completion_date>January 2002</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>January 2002</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00006337</url>
  </study>
  <study rank="595">
    <title>Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Leuprolide acetate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Voyager Pharmaceutical Corporation</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 22, 2004</first_received>
    <start_date>December 2003</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>December 10, 2009</last_updated>
    <last_verified>March 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00076440</url>
  </study>
  <study rank="596">
    <title>A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Advanced Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-SLV187</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 11, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>October 26, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the Non-Motor Symptoms Scale (NMSS) Total Score</outcome_measure>
      <outcome_measure>Change in the Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score</outcome_measure>
      <outcome_measure>Change in Clinical Global Impression of Change (CGI-C) Score</outcome_measure>
      <outcome_measure>Change in Patient Global Impression of Change (PGIC) Score</outcome_measure>
      <outcome_measure>Change in Parkinson's Disease Questionnaire (PDQ-8) Score</outcome_measure>
      <outcome_measure>Change in Parkinson's Anxiety Scale (PAS) Score</outcome_measure>
      <outcome_measure>Change in Geriatric Depression Scale (GDS-15) Score</outcome_measure>
      <outcome_measure>Change in King's PD Pain Scale Score</outcome_measure>
      <outcome_measure>Change in Montreal Cognitive Assessment (MoCA) Score</outcome_measure>
      <outcome_measure>Change in Mini-Mental State Examination (MMSE) Score</outcome_measure>
      <outcome_measure>Change in Sleep Attack Questionnaire (SAQ) Score</outcome_measure>
      <outcome_measure>Change in 12-lead electrocardiogram (ECG)</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>Minnesota Impulsive Disorders Interview (MIDI)</outcome_measure>
      <outcome_measure>Columbia-Suicide Severity Rating Scale (C-SSRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02549092</url>
  </study>
  <study rank="597">
    <title>A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline (KW-6002)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Kirin Pharmaceutical Development, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>580</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>July 2004</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>July 12, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To establish the efficacy of 10, 20 and 40 mg/d istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.</outcome_measure>
      <outcome_measure>To evaluate the dose-response of 10, 20 and 40 mg/d istradefylline using the primary efficacy outcome variable.</outcome_measure>
      <outcome_measure>To evaluate the efficacy of 10, 20 and 40 mg/d istradefylline for reducing the total hours of OFF time.</outcome_measure>
      <outcome_measure>To evaluate the change in total hours of ON time (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia).</outcome_measure>
      <outcome_measure>To evaluate the change in Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination score (part III) and/or in Activities of Daily Living (ADL) score (part II).</outcome_measure>
      <outcome_measure>To evaluate the change in Parkinson's Disease Questionnaire (PDQ-39) and Medical Outcomes Study 36-item Short Form (SF-36).</outcome_measure>
      <outcome_measure>To evaluate the Patient Global Impression - Improvement scale (PGI-I).</outcome_measure>
      <outcome_measure>To evaluate change in the Clinical Global Impression - Severity of Illness scale (CGI-S).</outcome_measure>
      <outcome_measure>To evaluate the safety of 10, 20, and 40 mg/d istradefylline by changes in safety parameters as noted in Section 7.2.4.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00199420</url>
  </study>
  <study rank="598">
    <title>Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Opioid (morphine sulphate) in low dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nova Scotia Health Authority</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
      <collaborator>Nova Scotia Health Research Foundation</collaborator>
      <collaborator>Atlantic Health Sciences Corporation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>September 21, 2009</first_received>
    <start_date>March 2010</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>January 22, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To understand the experiences of patients and informal caregivers living with severe COPD, following the addition of opioid therapy to conventional treatment.</outcome_measure>
      <outcome_measure>To explore the effect of opioid therapy on dyspnea and on quality of life, anxiety, depression, caregiver experiences and to determine proportion of patients finding opioids helpful at 4-6 months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00982891</url>
  </study>
  <study rank="599">
    <title>A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SBR759</intervention>
      <intervention type="Drug">SBR759</intervention>
      <intervention type="Drug">SBR759</intervention>
      <intervention type="Drug">SBR759</intervention>
      <intervention type="Drug">SBR759</intervention>
      <intervention type="Drug">SBR759</intervention>
      <intervention type="Drug">SBR759</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2008</first_received>
    <start_date>February 2007</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>October 16, 2013</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>In addition to the standard safety assessments (vital signs, ECGs, clinical chemistry and adverse events), serum phosphorus concentration is frequently measured during the study.</outcome_measure>
      <outcome_measure>Several biomarkers and patient-reported outcomes are assessed at specified time points, before and after treating patients with the study drug.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00750295</url>
  </study>
  <study rank="600">
    <title>Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
      <condition>Chronic and Expanded Graft Versus Host Disease</condition>
      <condition>Immune System Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.</intervention>
      <intervention type="Other">Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</lead_sponsor>
      <collaborator>Iniciativa Andaluza en Terapias Avanzadas</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 14, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>November 17, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment</outcome_measure>
      <outcome_measure>Overall survival and disease-free survival.</outcome_measure>
      <outcome_measure>Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01222039</url>
  </study>
  <study rank="601">
    <title>Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Korea Co., Ltd.</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>380</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 27, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>November 16, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>October 12, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in the Score of Beck Depression Inventory (BDI-II)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living-ADL Subscale)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in the Combined Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (ADL) Plus Part III (Motor Subscale)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in the Score of Apathy Scale (AS)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance Period in the Score of Snaith-Hamilton Pleasure Scale (SHAPS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01523301</url>
  </study>
  <study rank="602">
    <title>Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Neurogenic Orthostatic Hypotension in Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Elastic abdominal binder</intervention>
      <intervention type="Device">Placebo binder</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical University Innsbruck</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 17, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>August 12, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effect of an elastic abdominal binder versus a placebo binder on mean blood pressure (mmHg) after 3 minutes of orthostatic challenge (on passive tilting) with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</outcome_measure>
      <outcome_measure>Effect of an elastic abdominal binder versus a placebo binder on systolic blood pressure (mmHg) after 3 minutes of orthostatic challenge with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</outcome_measure>
      <outcome_measure>Effect of an elastic abdominal binder versus a placebo binder on diastolic blood pressure (mmHg) after 3 minutes of orthostatic challenge with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</outcome_measure>
      <outcome_measure>Effect of an elastic abdominal binder with respect to a placebo binder on orthostatic symptoms after 3 minutes of orthostatic challenge in Parkinson's disease patients suffering from neurogenic orthostatic hypotension</outcome_measure>
      <outcome_measure>Effect of an elastic abdominal binder with respect to a placebo binder on mean supine blood pressure (mmHg) in Parkinson's disease patients suffering from neurogenic orthostatic hypotension</outcome_measure>
      <outcome_measure>Effects of an abdominal binder on orthostatic symptoms in daily living during 4-weeks open label trial</outcome_measure>
      <outcome_measure>Effect of an elastic abdominal binder versus a placebo binder on mean blood pressure (mmHg) after 3 minutes of orthostatic challenge (on active standing) with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01971008</url>
  </study>
  <study rank="603">
    <title>Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vaso-occlusive Crisis</condition>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Saline</intervention>
      <intervention type="Drug">MST-188</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mast Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>4 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>388</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 27, 2012</first_received>
    <start_date>May 2013</start_date>
    <last_updated>October 26, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease.</outcome_measure>
      <outcome_measure>Re-hospitalization rate for VOC</outcome_measure>
      <outcome_measure>Occurence of acute chest syndrome</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01737814</url>
  </study>
  <study rank="604">
    <title>A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">eravacycline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tetraphase Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 5, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess the pharmacokinetic (PK) profile of eravacycline after administration of a single intravenous (IV) dose (1.5 mg/kg) to subjects with end stage renal disease (ESRD) compared with normal healthy subjects</outcome_measure>
      <outcome_measure>Determine the safety and tolerability of eravacycline after administration of a single IV dose (1.5 mg/kg) in subjects with ESRD compared with normal healthy subjects</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02135276</url>
  </study>
  <study rank="605">
    <title>The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
      <intervention type="Other">Placebo, sugar pill</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Penn State University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 14, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>May 29, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>August 4, 2011</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Patients Reporting Side Effects</outcome_measure>
      <outcome_measure>Pediatric Crohn's Disease Activity Index Score (PCDAI)</outcome_measure>
      <outcome_measure>Change in Quality of Life Scores From Baseline to After 8 Weeks of Naltrexone Therapy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00715117</url>
  </study>
  <study rank="606">
    <title>Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">123-I MNI-340</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 25, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>August 27, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I MNI-340.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00968097</url>
  </study>
  <study rank="607">
    <title>The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Tyrosine</intervention>
      <intervention type="Other">Placebo Comparator:Sugar Pill</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>New York Institute of Technology</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 28, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>April 15, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine the effects of tyrosine supplementation on orthostatic hypotension in people with PD</outcome_measure>
      <outcome_measure>To determine the effects of tyrosine supplementation in people with PD with autonomic insufficiency on heart rate, blood pressure, and norepinephrine responses during acute exercise stress.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01676103</url>
  </study>
  <study rank="608">
    <title>A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
      <collaborator>Ortho-McNeil Neurologics, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>63</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2, 2002</start_date>
    <completion_date>May 2003</completion_date>
    <last_updated>June 6, 2011</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To measure the differences between galantamine and donepazil for sleep and attention, explore methods of measuring sleep in patients with Alzheimer's Disease (AD)and their caregivers and attention in AD patients; GI tolerance</outcome_measure>
      <outcome_measure>To assess the tolerability, overall effect, quality of life and safety of galantamine compared with donepezil</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00035204</url>
  </study>
  <study rank="609">
    <title>Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medtronic Endovascular</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 8, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>August 14, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>June 5, 2014</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Successful Revascularization</outcome_measure>
      <outcome_measure>Major Adverse Event Free Rate 30 Days</outcome_measure>
      <outcome_measure>Technical Procedural Success</outcome_measure>
      <outcome_measure>Residual Diameter Stenosis</outcome_measure>
      <outcome_measure>Presence of Debris in Deployed SpiderFx™ Embolic Protection Device</outcome_measure>
      <outcome_measure>Preservation of Run-off Distal to the Filter</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00733135</url>
  </study>
  <study rank="610">
    <title>Extension Study of MT-1303 in Subjects With Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MT-1303</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 10, 2015</first_received>
    <start_date>August 2015</start_date>
    <completion_date>August 2017</completion_date>
    <last_updated>October 12, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects with Adverse Events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02389790</url>
  </study>
  <study rank="611">
    <title>Effectiveness of Cognitive Behavioral Couples Therapy for Post-traumatic Stress Disorder</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Post-traumatic Stress Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ryerson University</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 29, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>November 22, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinician-Administered PTSD Scale</outcome_measure>
      <outcome_measure>Dyadic Adjustment Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00669981</url>
  </study>
  <study rank="612">
    <title>VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AUC monitored withdrawal of MMF or CNI</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Leiden University Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>December 13, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary endpoint: progression of subclinical cardiovascular disease as assessed by intima media thickness (IMT), pulse wave velocity (PWV) and left ventricular hypertrophy (LVH)</outcome_measure>
      <outcome_measure>Secondary endpoint: Cardiovascular risk factors: a) Hypertension, b) Hyperlipidemia, c) Diabetes mellitus/glucose intolerance</outcome_measure>
      <outcome_measure>Graft function</outcome_measure>
      <outcome_measure>Incidence of acute rejection</outcome_measure>
      <outcome_measure>Graft survival (creatinine clearance &lt; 15 ml/min or dialysis)</outcome_measure>
      <outcome_measure>Patient survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00169910</url>
  </study>
  <study rank="613">
    <title>Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Donepezil HCL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Korea Inc.</lead_sponsor>
      <collaborator>Eisai Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>171</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 24, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>May 20, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>March 30, 2016</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall Summary of Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Change From Baseline in the Mini-Mental State Examination (MMSE) Score</outcome_measure>
      <outcome_measure>Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02097056</url>
  </study>
  <study rank="614">
    <title>A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">4 dose levels of ALV003</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alvine Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 13, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>August 17, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>safety and tolerability</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00626184</url>
  </study>
  <study rank="615">
    <title>Clobetasol for Oral Graft-Versus-Host Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Oral Chronic Graft vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clobetasol Oral Rinse</intervention>
      <intervention type="Drug">Placebo oral rinse</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 16, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 23, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To investigate efficacy of topical clobetasol 0.05% oral rinse for oral chronic graft-versus-host-disease (cGVHD) during a four-week treatment period as assessed by Oral Mucositis Rating Scale (OMRS).</outcome_measure>
      <outcome_measure>To assess the effect of topical clobetasol on oral cGVHD related pain, sensitivity, and dryness.</outcome_measure>
      <outcome_measure>To evaluate the basic pharmacodynamics and pharmacokinetics of clobetasol mouth rinse in cGVHD patients.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01557517</url>
  </study>
  <study rank="616">
    <title>Dual Task Practice in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">physical therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Katholieke Universiteit Leuven</lead_sponsor>
      <collaborator>University Medical Center Nijmegen</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
    </study_designs>
    <first_received>June 15, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>October 30, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Gait speed during dual task conditions (untrained Auditory Stroop task, trained Digit Span)</outcome_measure>
      <outcome_measure>Functional Dual task, single task gait measures, cognitive outcomes, Freezing of Gait Questionnaire, Quality of life scores (PDQ39)</outcome_measure>
      <outcome_measure>Fall rate as determined by weekly phonecall</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01375413</url>
  </study>
  <study rank="617">
    <title>Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Vascular Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vasovist (BAY86-5283, MS-325)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bayer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>261</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>February 24, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>April 22, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Diagnostic potential of Vasovist enhanced MRA</outcome_measure>
      <outcome_measure>Comparison of the quantitative assessment and the qualitative assessment of arterial stenosis/disease as compared to X-ray angiography</outcome_measure>
      <outcome_measure>Quantitative assessment of vessel enhancement</outcome_measure>
      <outcome_measure>Qualitative assessment of disease</outcome_measure>
      <outcome_measure>Qualitative assessment of plaque morphology</outcome_measure>
      <outcome_measure>Evaluation of quality of vascular anatomy and delineation of vessel wall, venous enhancement and diagnostic potential of venous enhancement</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00296855</url>
  </study>
  <study rank="618">
    <title>Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Panic Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VENLAFAXINE</intervention>
      <intervention type="Drug">Paroxetine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>April 1, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.</outcome_measure>
      <outcome_measure>Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00195598</url>
  </study>
  <study rank="619">
    <title>A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MK-0249 7.5 mg</intervention>
      <intervention type="Drug">MK-0249 25 mg</intervention>
      <intervention type="Drug">Donepezil 5mg</intervention>
      <intervention type="Drug">Placebo to MK-0249</intervention>
      <intervention type="Drug">Placebo to Donepezil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 2, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>May 26, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>May 26, 2015</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Participants With Alzheimer's Disease</outcome_measure>
      <outcome_measure>Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Healthy Participants</outcome_measure>
      <outcome_measure>Time Weighted Average of the Change From Baseline After Single Dose Administration of MK-0249, Measured by GMLT in Participants With Alzheimer's Disease.</outcome_measure>
      <outcome_measure>Time Weighted Average of the Change From Baseline After Single Dose Administration of MK-0249, Measured by GMLT in Healthy Participants.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00874939</url>
  </study>
  <study rank="620">
    <title>A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bapineuzumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>51 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>896</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 7, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>November 26, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinically important changes in safety assessment results including vital signs, weight, clinical laboratory tests, electrocardiograms (ECGs), brain magnetic resonance imaging (MRI), physical and neurological examinations, and infusion site assessments.</outcome_measure>
      <outcome_measure>To evaluate the efficacy of long term treatment of IV administered bapineuzumab in subjects with AD.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00937352</url>
  </study>
  <study rank="621">
    <title>Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TC-5619</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Targacept Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>December 2, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>September 3, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Pharmacokinetic profiles</outcome_measure>
      <outcome_measure>Markers of inflammation in cerebrospinal fluid</outcome_measure>
      <outcome_measure>Markers of inflammation in plasma</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01254448</url>
  </study>
  <study rank="622">
    <title>Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Von Hippel-Lindau Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vorinostat</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 5, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>December 6, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The presence and quantity of mutant VHL protein in resected hemangioblastoma specimens, including comparison of specimens without vorinostat treatment and those with presurgical vorinostat treatment.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02108002</url>
  </study>
  <study rank="623">
    <title>A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">adalimumab</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
      <collaborator>Eisai Co., Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>15 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 7, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>March 31, 2010</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment</outcome_measure>
      <outcome_measure>Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment</outcome_measure>
      <outcome_measure>Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment</outcome_measure>
      <outcome_measure>Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment</outcome_measure>
      <outcome_measure>Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment</outcome_measure>
      <outcome_measure>Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00445432</url>
  </study>
  <study rank="624">
    <title>MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Safinamide, MAO-B inhibitor</intervention>
      <intervention type="Drug">Safinamide, MAO-B inhibitor</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Newron</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>507</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 7, 2009</first_received>
    <start_date>October 2009</start_date>
    <last_updated>March 27, 2013</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time from baseline to first intervention, i.e., change in the dose of Dopamine (DA) agonist, addition of another DA-agonist, levodopa, or other Parkinson Disease (PD) therapy, or discontinuation due to lack of efficacy</outcome_measure>
      <outcome_measure>Proportion of subjects requiring intervention</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) Section III (motor) score change from baseline to week 78</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) Section II (ADL) score change from baseline to week 78</outcome_measure>
      <outcome_measure>Clinical Global impression (CGI) - Change scale score, change from Day 0 of Trial 27918 to week 78</outcome_measure>
      <outcome_measure>Clinical Global impression (CGI) - Severity scale score change from baseline to week 78</outcome_measure>
      <outcome_measure>EuroQoL 5D (EQ-5D) score change from baseline to week 78</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire (PDQ-39) score change from baseline to week 78</outcome_measure>
      <outcome_measure>Cogtest® PD battery test score change from baseline to week 78</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01028586</url>
  </study>
  <study rank="625">
    <title>Expiratory Muscle Training for Persons With Neurodegenerative Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">EMST</intervention>
      <intervention type="Device">Sham</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
      <collaborator>University of Florida</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 3, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>October 5, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>February 26, 2016</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Expiratory Pressure (MEP)</outcome_measure>
      <outcome_measure>Penetration-Aspiration Scale Score</outcome_measure>
      <outcome_measure>Swallow-related Quality of Life (SWAL-QOL)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00856518</url>
  </study>
  <study rank="626">
    <title>Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sargramostim (Leukine)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>264</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>July 2004</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>December 2, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving clinical response or remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00206713</url>
  </study>
  <study rank="627">
    <title>Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">florbetapir F 18</intervention>
      <intervention type="Drug">[11C]-PIB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Avid Radiopharmaceuticals</lead_sponsor>
      <collaborator>American College of Radiology Imaging Network</collaborator>
      <collaborator>General Electric</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 2, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>June 19, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>May 4, 2012</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Differences in Standard Uptake Value Ratio (SUVR) for Frontal Cortex/Cerebellum and Whole Brain/Cerebellum of the Positron Emission Tomography (PET) Scan With [18F]-AV-45 for Probable Alzheimer's Disease (AD) Versus Cognitively Normal Subjects.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00855868</url>
  </study>
  <study rank="628">
    <title>Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Kinetra and Soletra (neurostimulator, Medtronic)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>German Parkinson Study Group (GPS)</lead_sponsor>
      <collaborator>University of Schleswig-Holstein</collaborator>
      <collaborator>Assistance Publique - Hôpitaux de Paris</collaborator>
      <collaborator>KKS Netzwerk</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>251</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 19, 2006</first_received>
    <start_date>July 2006</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>January 27, 2012</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.</outcome_measure>
      <outcome_measure>Change in the Unified Parkinson's disease Rating Scale (UPDRS) part III, Change in the number of hours per day in the &quot;best&quot;-state,Frequency and severity of &quot;best&quot;state dyskinesias,Sleeping-hours per day,Changes in gait and speech,</outcome_measure>
      <outcome_measure>UPDRS II and VI, SCOPA-PS, BDI, MADRS, BPRS, Mattis Dementia Scale,Ardouin Behaviour Scale, Starkstein-Apathy Scale, professional fitness, SF-36,pain (VAS), clinical global impression (CGI-GI)</outcome_measure>
      <outcome_measure>Frequency, type and severity of therapy related adverse events of medication or DBS, Change in medication (L-DOPA equivalents)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00354133</url>
  </study>
  <study rank="629">
    <title>Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BIIB014</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biogen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 1, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>January 8, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number and proportion of subjects with adverse events</outcome_measure>
      <outcome_measure>Assessment of clinical laboratory parameters.</outcome_measure>
      <outcome_measure>Assessment of vital signs.</outcome_measure>
      <outcome_measure>Assessment of ECG parameters.</outcome_measure>
      <outcome_measure>Assess PK by measuring concentrations of BIIB014 and its N-acetyl metabolite in blood plasma.</outcome_measure>
      <outcome_measure>Explore BIIB014 activity by evaluating standard Parkinson's disease assessments.</outcome_measure>
      <outcome_measure>Explore the PK/pharmacodynamic relationships for BIIB014.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00442780</url>
  </study>
  <study rank="630">
    <title>Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 7, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>October 14, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve endoscopic improvement</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02185014</url>
  </study>
  <study rank="631">
    <title>GTA-Glyceryltriacetate for Canavan Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infantile Canavan Disease</condition>
      <condition>Deficiency Disease, Aspartoacylase</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GTA: Glyceryltriacetate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sheba Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <max_age>15 Months</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 15, 2006</first_received>
    <start_date>January 2006</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>August 11, 2006</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>All primary outcome will be evaluated 4 months following the initiation of treatment:</outcome_measure>
      <outcome_measure>Neurological Status</outcome_measure>
      <outcome_measure>Brain Imaging: MRI &amp; MRS</outcome_measure>
      <outcome_measure>NAA Levels in Urine</outcome_measure>
      <outcome_measure>Ophthalmologic Examination</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00278707</url>
  </study>
  <study rank="632">
    <title>Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">BIBR 796 BS, 5 mg</intervention>
      <intervention type="Drug">BIBR 796 BS, 20 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>284</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 5, 2014</first_received>
    <start_date>October 2001</start_date>
    <last_updated>August 5, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical Remission defined as Crohn's Disease Activity Index (CDAI) &lt; 150</outcome_measure>
      <outcome_measure>Clinical remission (defined as a CDAI score below 150)</outcome_measure>
      <outcome_measure>Stabilised clinical remission at the end of the main treatment phase</outcome_measure>
      <outcome_measure>Time to clinical remission</outcome_measure>
      <outcome_measure>Duration of maintenance of clinical remission</outcome_measure>
      <outcome_measure>Clinical response (defined as a reduction of CDAI score ≥70)</outcome_measure>
      <outcome_measure>Time to clinical response</outcome_measure>
      <outcome_measure>Duration of maintenance of clinical response</outcome_measure>
      <outcome_measure>Changes from baseline in the CDAI score</outcome_measure>
      <outcome_measure>Changes from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) score</outcome_measure>
      <outcome_measure>Number of patients with 50% fistulae reduction</outcome_measure>
      <outcome_measure>Changes from baseline in the number of draining fistulae</outcome_measure>
      <outcome_measure>Changes from baseline in C-reactive protein (CRP) measurements</outcome_measure>
      <outcome_measure>Changes from baseline in the daily corticosteroid dose</outcome_measure>
      <outcome_measure>Number of drop-outs due to treatment failure</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with clinically relevant changes in laboratory parameters</outcome_measure>
      <outcome_measure>Number of patients with relevant findings in electrocardiogram (ECG)</outcome_measure>
      <outcome_measure>Extended clinical response (defined as a reduction of CDAI score ≥ 100)</outcome_measure>
      <outcome_measure>Time to extended clinical response</outcome_measure>
      <outcome_measure>Duration of maintenance of extended clinical response</outcome_measure>
      <outcome_measure>Changes from baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) score</outcome_measure>
      <outcome_measure>Changes from baseline in the histological scoring of biopsy specimens</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02209792</url>
  </study>
  <study rank="633">
    <title>Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methoxsalen +ECP</intervention>
      <intervention type="Procedure">Extracorporeal Photopheresis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mallinckrodt</lead_sponsor>
      <collaborator>ICON plc</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>June 2006</completion_date>
    <last_updated>October 18, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohns Disease Activity Index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00221026</url>
  </study>
  <study rank="634">
    <title>Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ALV003</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alvine Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>April 21, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>February 17, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00669825</url>
  </study>
  <study rank="635">
    <title>The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">18F-FDG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 12, 2013</first_received>
    <start_date>August 2010</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>November 10, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To analyze the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of PD ,PSP,MSA,CBD.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01824056</url>
  </study>
  <study rank="636">
    <title>A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohns Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">glatiramer acetate</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tel-Aviv Sourasky Medical Center</lead_sponsor>
      <collaborator>Teva Pharmaceutical Industries</collaborator>
      <collaborator>Given Imaging Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 6, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>March 1, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary endpoints: The proportion of patients at clinical remission (CDAI&lt;150)</outcome_measure>
      <outcome_measure>Proportion of patients at clinical remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00731172</url>
  </study>
  <study rank="637">
    <title>Study of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Neopulse Magnetic Stimulator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 17, 2002</first_received>
    <start_date>January 2002</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>March 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00029666</url>
  </study>
  <study rank="638">
    <title>Pediatric Trial Investigating the Incidence &amp; Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatic Veno-Occlusive Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Defibrotide</intervention>
      <intervention type="Drug">Defibrotide</intervention>
      <intervention type="Drug">Defibrotide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>European Group for Blood and Marrow Transplantation</lead_sponsor>
      <collaborator>Jazz Pharmaceuticals</collaborator>
      <collaborator>Deutsche Krebshilfe e.V., Bonn (Germany)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 4, 2006</first_received>
    <start_date>December 2005</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>June 8, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD</outcome_measure>
      <outcome_measure>Occurrence of Multi-System Organ Failure and Survival (all causes of mortality)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00272948</url>
  </study>
  <study rank="639">
    <title>Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>CROHN'S DISEASE</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Immune Ablation and Hematopoietic Stem Cell Support</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Richard Burt, MD</lead_sponsor>
      <collaborator>Northwestern University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 15, 2006</first_received>
    <start_date>April 2001</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>February 4, 2014</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>11.1 CDAI - If the index worsens by 50 points for more than 4 weeks, the disease will be considered progressive; if it improves by 70 points for more than four weeks, it will be considered improved; otherwise it will be considered stable.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00278577</url>
  </study>
  <study rank="640">
    <title>Double Blind Study of Trp01 in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tryptophan</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Queen's University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>April 2001</start_date>
    <completion_date>March 2002</completion_date>
    <last_updated>September 13, 2005</last_updated>
    <last_verified>November 2002</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>1. MMSE score</outcome_measure>
      <outcome_measure>2. Alzheimer’s Disease Assessment Scale, cognitive subpart (ADAS-Cog) as an evaluation of cognitive functioning</outcome_measure>
      <outcome_measure>1. Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC)</outcome_measure>
      <outcome_measure>2. Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>3. Disability Assessment for Dementia (DAD)</outcome_measure>
      <outcome_measure>4. Physical Self-Maintenance Scale (PSMS)</outcome_measure>
      <outcome_measure>5. Functional Activities Questionnaire (FAQ)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00202124</url>
  </study>
  <study rank="641">
    <title>Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">migalastat hydrochloride</intervention>
      <intervention type="Biological">agalsidase</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amicus Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>74 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 6, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 25, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>renal function assessed by iohexol Glomerular Filtration Rate (GFR)</outcome_measure>
      <outcome_measure>renal function (assessed by estimated GFR and 24-hour urine protein)</outcome_measure>
      <outcome_measure>composite clinical outcome (assessed by time to occurrence of renal, cardiac, cerebrovascular events or death)</outcome_measure>
      <outcome_measure>cardiac function (assessed by echocardiography)</outcome_measure>
      <outcome_measure>patient reported outcomes (pain and quality of life)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01218659</url>
  </study>
  <study rank="642">
    <title>Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Decidual Stromal Cells thawed in plasma</intervention>
      <intervention type="Biological">Decidual Stromal Cells thawed in human albumin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>Karolinska University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 17, 2014</first_received>
    <start_date>January 2011</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>November 8, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Actuarial survival at six months after first DSC infusion</outcome_measure>
      <outcome_measure>Response at 28 days after onset of graft versus host disease</outcome_measure>
      <outcome_measure>Response at 84 days after onset of graft versus host disease</outcome_measure>
      <outcome_measure>Response at 168 days after onset of graft versus host disease</outcome_measure>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Incidence of severe infections</outcome_measure>
      <outcome_measure>Disease free survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02172937</url>
  </study>
  <study rank="643">
    <title>Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
      <condition>Alzheimer Disease</condition>
      <condition>Healthy Controls</condition>
      <condition>Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I]CLINDE</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 16, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>September 20, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the dynamic uptake and washout of 123-I CLINDE, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00612872</url>
  </study>
  <study rank="644">
    <title>Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tacrolimus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Aberdeen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>November 2, 2010</start_date>
    <last_updated>November 2, 2010</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Assessment of standardised digital photography by three independent assessors following the Physicians' Global Severity Scale before and after treatment</outcome_measure>
      <outcome_measure>Global Self Assessment</outcome_measure>
      <outcome_measure>Perineal Disease Activity Index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01233570</url>
  </study>
  <study rank="645">
    <title>Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">T3D-959</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>T3D Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 28, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>June 6, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The effect of treatment with T3D-959 on changes in 18F-FDG-PET measurements of the cerebral metabolic rate for glucose (CMRgl) in an empirically pre-specified statistical region of interest (sROI) that is preferentially affected by AD.</outcome_measure>
      <outcome_measure>The effect of treatment with T3D-959 on changes in resting state Blood Oxygen Level Dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks.</outcome_measure>
      <outcome_measure>Change from Baseline in the score of the Digit Symbol Substitution Test</outcome_measure>
      <outcome_measure>Comparison of the response to treatment of T3D-959 based on ApoE genotype</outcome_measure>
      <outcome_measure>Change from Baseline in the plasma metabolome profile after 2 week treatment with T3D-959 using mass spectrometry.</outcome_measure>
      <outcome_measure>Change from Baseline in the total score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02560753</url>
  </study>
  <study rank="646">
    <title>Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Safinamide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Newron</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>965</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 10, 2009</first_received>
    <start_date>March 2009</start_date>
    <last_updated>March 28, 2013</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in Physical Exams</outcome_measure>
      <outcome_measure>Change from baseline in Neurologic Exams</outcome_measure>
      <outcome_measure>Change from baseline in Vital Signs</outcome_measure>
      <outcome_measure>Change from baseline in Laboratory Evaluations</outcome_measure>
      <outcome_measure>Change from baseline in Electrocardiograms</outcome_measure>
      <outcome_measure>Summary of Participants who had Adverse Experiences</outcome_measure>
      <outcome_measure>Change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Change from baseline in Dermatologic Exams</outcome_measure>
      <outcome_measure>Change from baseline in Ophthalmologic Exams</outcome_measure>
      <outcome_measure>Change from baseline in Health Resource Utilisation</outcome_measure>
      <outcome_measure>Change from baseline in EuroQol Group EQ-5D™ Quality of Life Scale</outcome_measure>
      <outcome_measure>Change from baseline in Parkinson Disease Questionnaire 39 (PDQ-39)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00865579</url>
  </study>
  <study rank="647">
    <title>Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>High Risk HLA-A2+ Melanoma</condition>
      <condition>Metastatic Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Melanoma vaccine modified to express HLA A2/4-1BB ligand</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hadassah Medical Organization</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 20, 2012</first_received>
    <start_date>June 2013</start_date>
    <last_updated>May 23, 2013</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of adverse effects</outcome_measure>
      <outcome_measure>Overall and disease free survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01861938</url>
  </study>
  <study rank="648">
    <title>Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Amyloid Beta-Protein</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Florbetaben (BAY94-9172)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Piramal Imaging SA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>422</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>September 9, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>July 15, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 16, 2014</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth</outcome_measure>
      <outcome_measure>Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.</outcome_measure>
      <outcome_measure>Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment</outcome_measure>
      <outcome_measure>Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)</outcome_measure>
      <outcome_measure>Standard Uptake Value Ratios for Florbetaben Signal</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00750282</url>
  </study>
  <study rank="649">
    <title>Aspirin Prophylaxis in Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">aspirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>University of Miami</collaborator>
      <collaborator>Bayer</collaborator>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>7 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>November 29, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>August 9, 2011</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Serious Adverse Events</outcome_measure>
      <outcome_measure>Number of Adverse Events</outcome_measure>
      <outcome_measure># of Subjects Recruited Over Time, Screening Failures, Withdrawal Rates;Compliance (Pill Counts &amp; Labs);Changes in Performance on Neurocognitive Tests; Changes in MRI/MRA; Changes in TCD;Incidences of Stroke, Acute Chest Crises, and Pain Crises</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00178464</url>
  </study>
  <study rank="650">
    <title>Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Placebo</intervention>
      <intervention type="Biological">ABT-874</intervention>
      <intervention type="Biological">ABT-874</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>74 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>246</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 21, 2007</first_received>
    <start_date>November 2007</start_date>
    <last_updated>August 18, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects achieving clinical remission, defined as CDAI score of &lt;150 points</outcome_measure>
      <outcome_measure>Patient reported outcomes, clinical response indicators, safety parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00562887</url>
  </study>
  <study rank="651">
    <title>Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">Far Infrared Radiation (5μm to 20μm wavelength)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GAAD Medical Research Institute Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 6, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>January 2, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cure for PD</outcome_measure>
      <outcome_measure>Rehabilitation of PD Patients</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00674895</url>
  </study>
  <study rank="652">
    <title>Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Low Bone Mineral Density</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">risedronate</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Alberta</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <start_date>October 5, 2010</start_date>
    <last_updated>October 5, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT01215890</url>
  </study>
  <study rank="653">
    <title>Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gait Disorders, Neurologic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">droxidopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chelsea Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 13, 2010</first_received>
    <start_date>April 2012</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 27, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the safety of droxidopa as measured by the incidence, relatedness, and severity of adverse events.</outcome_measure>
      <outcome_measure>Evaluate the effect of droxidopa on freezing of gait symptoms using the Freezing of Gait Questionnaire</outcome_measure>
      <outcome_measure>Evaluate the efficacy of droxidopa in the treatment of freezing of gait by using the Observed Freezing of Gait Rating (OFGR) scale</outcome_measure>
      <outcome_measure>Evaluate the effect of droxidopa on signs and symptoms associated with Parkinson's Disease utilizing the composite scores of the Unified Parkinson's Disease Rating Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01331122</url>
  </study>
  <study rank="654">
    <title>Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RPC1063</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Celgene</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 20, 2015</first_received>
    <start_date>September 2015</start_date>
    <last_updated>August 26, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Simple Endoscopic Score for Crohn's Disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02531113</url>
  </study>
  <study rank="655">
    <title>Curcumin in Pediatric Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Curcumin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seattle Children's Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 24, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>June 16, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the tolerability of curcumin in pediatric patients with inflammatory bowel disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00889161</url>
  </study>
  <study rank="656">
    <title>Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Parkinson-Dementia Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">[F18]-FDDNP</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fundacion Clinic per a la Recerca Biomédica</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>August 13, 2014</first_received>
    <start_date>March 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>September 16, 2014</last_updated>
    <last_verified>December 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Relative Volume of Distribution of [F18]-FDDNP in non-demented patients with Parkinson's disease (PDND), demented patients with Parkinson's disease (PDD) and controls.</outcome_measure>
      <outcome_measure>Concentration ( pg/mL) of beta-amyloid, tau and phospho-tau in cerebrospinal fluid (CSF) of non-demented patients with Parkinson's disease (PDND), demented patients with Parkinson's disease (PDD) and controls.</outcome_measure>
      <outcome_measure>Number of patients without dementia at baseline that switch to dementia at 18 months follow-up</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02243982</url>
  </study>
  <study rank="657">
    <title>Therapies for Treatment-Resistant Panic Disorder Symptoms</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Panic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clonazepam</intervention>
      <intervention type="Drug">Sertraline</intervention>
      <intervention type="Behavioral">Cognitive behavioral therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 6, 2005</first_received>
    <start_date>March 1999</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>June 5, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>June 5, 2009</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6)</outcome_measure>
      <outcome_measure>Change in Panic Disorder Symptoms, Phase 2 (Week 6 - Week 12)</outcome_measure>
      <outcome_measure>Change in Panic Disorder Symptoms, Phase 3 (Week 12 - Week 24)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00118417</url>
  </study>
  <study rank="658">
    <title>Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STA-5326 mesylate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Synta Pharmaceuticals Corp.</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <first_received>October 5, 2005</first_received>
    <start_date>November 2005</start_date>
    <last_updated>December 3, 2008</last_updated>
    <last_verified>December 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To measure the changes from predose in peripheral blood and mucosal cytokines in subjects with active CD after administration of STA-5326 mesylate or placebo for 4 weeks</outcome_measure>
      <outcome_measure>To measure changes in other immunologic parameters.</outcome_measure>
      <outcome_measure>To explore the level of cell-surface markers and specific gene expression patterns.</outcome_measure>
      <outcome_measure>To measure changes in laboratory surrogate efficacy markers.</outcome_measure>
      <outcome_measure>To measure the proportion of subjects in clinical remission at Day 29.</outcome_measure>
      <outcome_measure>To measure the proportion of subjects with a clinical response at Day 29.</outcome_measure>
      <outcome_measure>To measure the proportion of subjects with both clinical remission and clinical response at Day 29.</outcome_measure>
      <outcome_measure>To confirm STA-5326 mesylate (and metabolite) levels in blood following oral administration to CD patients.</outcome_measure>
      <outcome_measure>To measure the changes in endoscopic scores from Baseline to Day 29.</outcome_measure>
      <outcome_measure>To measure the changes in the Inflammatory Bowel Disease Questionnaire overall score from Baseline to Day 29.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00234741</url>
  </study>
  <study rank="659">
    <title>Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AT1001</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amicus Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 5, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 19, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Long term safety and outcomes measures assessed at each visit.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00526071</url>
  </study>
  <study rank="660">
    <title>Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GLPG0634</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Galapagos NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>175</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 27, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>February 21, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving clinical remission at Week 10</outcome_measure>
      <outcome_measure>Percentage of subjects achieving clinical remission</outcome_measure>
      <outcome_measure>Percentage of subjects achieving clinical response</outcome_measure>
      <outcome_measure>Percentage of subjects achieving endoscopic remission at Week 10</outcome_measure>
      <outcome_measure>Percentage of subjects achieving endoscopic response at Week 10</outcome_measure>
      <outcome_measure>Percentage of subjects achieving mucosal healing at Week 10</outcome_measure>
      <outcome_measure>Change from Baseline in Crohn's Disease Activity Index score</outcome_measure>
      <outcome_measure>Change from Screening in endoscopic score</outcome_measure>
      <outcome_measure>Change from Screening in histopathology biopsy score</outcome_measure>
      <outcome_measure>Change from Baseline in Subjects' Quality of Life (based on the Inflammatory Bowel Disease Questionnaire (IBDQ) questionnaire score)</outcome_measure>
      <outcome_measure>The number of subjects with adverse events</outcome_measure>
      <outcome_measure>The number of subjects with abnormal lab tests</outcome_measure>
      <outcome_measure>The number of subjects with abnormal vital signs</outcome_measure>
      <outcome_measure>The number of subjects with abnormal ECG</outcome_measure>
      <outcome_measure>The plasma levels of GLPG0634 and its metabolite</outcome_measure>
      <outcome_measure>The change versus Baseline in levels of immune- and inflammation-related parameters in whole blood and serum</outcome_measure>
      <outcome_measure>The change versus Baseline in levels of faecal calprotectin</outcome_measure>
      <outcome_measure>The change versus Baseline in microbial communities in stool samples</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02048618</url>
  </study>
  <study rank="661">
    <title>A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PRX-03140</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Epix Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>420</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 2, 2008</first_received>
    <start_date>April 2008</start_date>
    <last_updated>July 28, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive subscale.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00672945</url>
  </study>
  <study rank="662">
    <title>Bexarotene Amyloid Treatment for Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bexarotene</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Cleveland Clinic</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 29, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>February 10, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>February 10, 2016</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain</outcome_measure>
      <outcome_measure>Primary Outcome by Genotype (ALL SUBJECTS)</outcome_measure>
      <outcome_measure>Primary Outcome by Genotype (NON ApoE4 CARRIERS)</outcome_measure>
      <outcome_measure>Primary Outcome by Genotype (ApoE4 CARRIERS)</outcome_measure>
      <outcome_measure>Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)</outcome_measure>
      <outcome_measure>Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)</outcome_measure>
      <outcome_measure>Change in MMSE Score in ALL Subjects From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change in NPI Scores in ALL Subjects From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4</outcome_measure>
      <outcome_measure>Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)</outcome_measure>
      <outcome_measure>Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)</outcome_measure>
      <outcome_measure>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects</outcome_measure>
      <outcome_measure>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01782742</url>
  </study>
  <study rank="663">
    <title>Open-label Study With Bosentan in Interstitial Lung Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Interstitial Lung Disease</condition>
      <condition>Scleroderma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">bosentan</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Actelion</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>132</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 26, 2006</first_received>
    <start_date>July 2004</start_date>
    <completion_date>February 2006</completion_date>
    <last_updated>April 28, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to all assessed time points in 6-minute walk test distance.</outcome_measure>
      <outcome_measure>Change from baseline to all assessed time points in Borg dyspnea index, FVC and DLco, SpO2 at rest and de-saturation index (6-minute walk distance multiplied by SpO2 mean value).</outcome_measure>
      <outcome_measure>Transition Dyspnea Index at all assessed time points.</outcome_measure>
      <outcome_measure>Change from baseline to all assessed time points in SpO2 mean value, time to de-saturation (decrease in SpO2 ≥ 4%), trough SpO2 and area under the curve during 6-minute walk test.</outcome_measure>
      <outcome_measure>Adverse events; serious adverse events.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00319033</url>
  </study>
  <study rank="664">
    <title>The Effects of Vitamin D and Bone Loss in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamin D3</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Medical Center</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>July 11, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Direct changes in bone formation and resorption will be investigated by measuring serum 25-hydroxyvitamin D [25(OH)D] level,serum parathyroid hormone (PTH) levels, serum osteocalcin, and serum n-telopeptides (N-Tx)</outcome_measure>
      <outcome_measure>Serum clacium will be measured to monitor for hypercalcemia.</outcome_measure>
      <outcome_measure>Using the Unified Parkinson's Disease Rating Scale (UPDRS) to assess the impact of vitamin D supplementation on PD symptoms</outcome_measure>
      <outcome_measure>Using the Parkinson's Quality of Life measure (PD QoL) to examine the effect of vitamin D supplementation on quality of life</outcome_measure>
      <outcome_measure>Conducting a brief falls assessment to track the incidence of falls throughout the duration of the study</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00907972</url>
  </study>
  <study rank="665">
    <title>Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ROTIGOTINE</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Luye Pharma Group Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 31, 2016</first_received>
    <start_date>May 2016</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>December 2, 2016</last_updated>
    <last_verified>December 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>CMax of ROTIGOTINE</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02728947</url>
  </study>
  <study rank="666">
    <title>A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">OPC-6535(Tetomilast)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 21, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>April 28, 2008</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical improvement rate (number of patients showing clinical improvement/number of patients evaluated x 100) after 8 weeks of study drug administration</outcome_measure>
      <outcome_measure>Clinical improvement rate after 2 and 4 weeks of study drug administration</outcome_measure>
      <outcome_measure>Remission rate (number of patients showing remission/number of patients evaluated x 100) after 2, 4, and 8 weeks of study drug administration</outcome_measure>
      <outcome_measure>Improvement rate by change in total CDAI score (number of patients for each change/number of patients evaluated x 100) after 2, 4, and 8 weeks of study drug administration</outcome_measure>
      <outcome_measure>Mean change in total CDAI score after 2, 4, and 8 weeks of study drug administration</outcome_measure>
      <outcome_measure>Mean change from the baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) score after 8 weeks of study drug administration</outcome_measure>
      <outcome_measure>Mean change from the baseline in CDEIS score after 8 weeks of study drug administration</outcome_measure>
      <outcome_measure>Time course of mean CRP level and mean change in CRP level from the baseline after 4 and 8 weeks of study drug administration</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00317369</url>
  </study>
  <study rank="667">
    <title>Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease 11</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prednisone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>53</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>October 22, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 31, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determination of steroid-induced mood changes.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01981889</url>
  </study>
  <study rank="668">
    <title>A Phase II Study of CCX282-B in Patients With Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CCX282-B</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ChemoCentryx</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 5, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>July 21, 2008</last_updated>
    <last_verified>July 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of the effect of CCX282-B compared to placebo on the villous height/crypt depth ratio of small intestinal biopsy specimens taken from subjects with celiac disease, before and after gluten exposure.</outcome_measure>
      <outcome_measure>Evaluation of CCX282-B compared to placebo on small intestinal mucosal inflammation before and after gluten exposure</outcome_measure>
      <outcome_measure>Evaluation of CCX282-B compared to placebo on gluten-induced celiac-type serology before and after gluten exposure</outcome_measure>
      <outcome_measure>Evaluation of CCX282-B compared to placebo on symptom scores before and after gluten exposure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00540657</url>
  </study>
  <study rank="669">
    <title>Open Label Extension Study for the Long-term Efficacy and Safety of FG-4592 in Dialysis and Non-dialysis Chronic Kidney Disease Patients</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>End Stage Renal Disease</condition>
      <condition>Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">FG-4592</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FibroGen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 8, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>April 14, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy and Safety of FG-4592 treating anemia in dialysis and non-dialysis chronic kidney disease patients</outcome_measure>
      <outcome_measure>Evaluate FG-4592 doses and dose adjustments.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01630889</url>
  </study>
  <study rank="670">
    <title>Oral Cyclosporine in Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cyclosporine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>January 4, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To identify the safety profile of oral CsA immunotherapy in advanced stage COPD patients, with particular attention to nephrotoxicity, infection risk, and other recognized calcineurin toxicities.</outcome_measure>
      <outcome_measure>To identify the pharmacokinetic-pharmacodynamic relationships of oral CsA using sparse blood sampling measures of drug exposure and biomarkers of an adaptive immune response as endpoints in subjects with advanced stage COPD.</outcome_measure>
      <outcome_measure>To explore the effects of CsA on respiratory function, symptoms, quantitative computed tomographic indices, and markers of bone metabolism.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00974142</url>
  </study>
  <study rank="671">
    <title>Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft-Versus-Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Panobinostat (LBH589)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>H. Lee Moffitt Cancer Center and Research Institute</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 16, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>April 25, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of LBH589 (Phase I)</outcome_measure>
      <outcome_measure>Efficacy of LBH589 (Phase II)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01111526</url>
  </study>
  <study rank="672">
    <title>Benefits of Exercise and Education for Individuals With Parkinson's Disease (BEEP)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Exercise, Education</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Saskatchewan</lead_sponsor>
      <collaborator>Royal University Hospital Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>October 4, 2007</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>all variables measured at baseline, post intervention, months following, and 9 months following.</outcome_measure>
      <outcome_measure>Stanford Self-Efficacy for Managing Chronic Disease</outcome_measure>
      <outcome_measure>The Activities-specific Balance Confidence (ABC) Scale</outcome_measure>
      <outcome_measure>Timed Up and Go Test(TUG)</outcome_measure>
      <outcome_measure>Northwestern University Disability Scale:</outcome_measure>
      <outcome_measure>Schwab &amp; England ADL Scale:) independence in ADL</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire - Short Form (PDQ - 8):</outcome_measure>
      <outcome_measure>Beliefs about Symptom Specific Expectancies:</outcome_measure>
      <outcome_measure>Social and Physical Activities Questionnaire:</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00167453</url>
  </study>
  <study rank="673">
    <title>Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">18F- DTBZ</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 15, 2014</first_received>
    <start_date>March 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>January 11, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02039024</url>
  </study>
  <study rank="674">
    <title>Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Life Threatening Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Imatinib mesylate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>15 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>185</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>February 2001</start_date>
    <completion_date>January 2007</completion_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases</outcome_measure>
      <outcome_measure>To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease</outcome_measure>
      <outcome_measure>To assess the safety and tolerability of Imatinib mesylate</outcome_measure>
      <outcome_measure>To evaluate the pharmacokinetic profile of Imatinib mesylate</outcome_measure>
      <outcome_measure>To assess, where feasible, the functional significance of relevant signal-transduction components in target tissues</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00154388</url>
  </study>
  <study rank="675">
    <title>Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adult Polyglucosan Body Disease</condition>
      <condition>Glycogen Brancher Enzyme Deficiency</condition>
      <condition>Glycogen Storage Disease Type IV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Triheptanoin</intervention>
      <intervention type="Dietary Supplement">Vegetable Oil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baylor Research Institute</lead_sponsor>
      <collaborator>Ultragenyx Pharmaceutical Inc</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 24, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>January 12, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Distance traveled in six minute walk test</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00947960</url>
  </study>
  <study rank="676">
    <title>Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stem Cell Leukemia of Unclear Lineage</condition>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">extracorporeal photopheresis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Kansas</lead_sponsor>
      <collaborator>Mallinckrodt</collaborator>
      <collaborator>University of Kansas Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 27, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>March 31, 2015</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Presence/absence of grade II-IV acute Graft versus Host Disease (aGVHD)</outcome_measure>
      <outcome_measure>proportion of patients who develop chronic Graft versus Host Disease (cGVHD) and experience relapse of primary disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01174940</url>
  </study>
  <study rank="677">
    <title>Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PRX-03140</intervention>
      <intervention type="Drug">Donepezil</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Epix Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>236</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 30, 2008</first_received>
    <start_date>May 2008</start_date>
    <last_updated>July 28, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive subscale.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00693004</url>
  </study>
  <study rank="678">
    <title>Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Laser light (U-Step Walking Stabilizer with laser light)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Parkinson's Disease Research, Education, and Clinical Center, Philadelphia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 21, 2011</first_received>
    <start_date>June 2003</start_date>
    <completion_date>April 2005</completion_date>
    <last_updated>December 30, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to complete walking task</outcome_measure>
      <outcome_measure>Number of steps</outcome_measure>
      <outcome_measure>Number of freezing episodes</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01502995</url>
  </study>
  <study rank="679">
    <title>Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK239512</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 24, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>October 11, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.</outcome_measure>
      <outcome_measure>Pharmacodynamics measured by computerized cognitive tests and validated clinical rating scales. Also investigating the Pharmacokineticsat trough concentrations (Cmin) after GSK239512 repeat dosing on days 8, 15, 22 and 29 and 15.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00675090</url>
  </study>
  <study rank="680">
    <title>Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">daclizumab</intervention>
      <intervention type="Drug">methylprednisolone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dana-Farber Cancer Institute</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>February 5, 2003</first_received>
    <start_date>October 2002</start_date>
    <last_updated>February 6, 2009</last_updated>
    <last_verified>December 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00053976</url>
  </study>
  <study rank="681">
    <title>Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">ABT-126</intervention>
      <intervention type="Drug">donepezil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>274</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 24, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>January 29, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ADAS-Cog - Alzheimer's Disease Assessment Scale Cognition portion</outcome_measure>
      <outcome_measure>MMSE, QoL-AD, CIBIC-plus, NPI, CSDD, ADAS-Cog (13 item) and ADCS-ADL. Note: Acronyms are fully defined in the area titled Detailed Description.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00948909</url>
  </study>
  <study rank="682">
    <title>Autologous Stem Cell Transplant for Refractory Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">mobilization of stem cells to prepare for Leukapheresis</intervention>
      <intervention type="Other">Leukapheresis- Collection of stem cells</intervention>
      <intervention type="Drug">Preparative regimen 4-6 weeks after Leukapheresis</intervention>
      <intervention type="Other">Stem Cell Transplant</intervention>
      <intervention type="Drug">Low-dose IL-2 administration</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nationwide Children's Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <max_age>29 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 21, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>April 21, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary endpoint of the study is feasibility and safety of the autologous HSCT and low dose IL-2 post-HSCT, as evaluated by day +100 TRM (transplant related mortality) and incidence of severe toxicity.</outcome_measure>
      <outcome_measure>Secondary endpoints are evaluations of the effects of HSCT on clinical and laboratory manifestations of Crohn's Disease, i.e. frequency of and types of transplant related complications that were observed.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02676622</url>
  </study>
  <study rank="683">
    <title>G-CSF to Treat Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">G-CSF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 25, 2001</first_received>
    <start_date>October 2001</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>September 26, 2015</last_updated>
    <last_verified>June 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00025805</url>
  </study>
  <study rank="684">
    <title>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-957</intervention>
      <intervention type="Other">Placebo for ABT-957</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 18, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>June 14, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic evaluation of the two ABT-957 diastereomers</outcome_measure>
      <outcome_measure>Number of subjects with adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02220738</url>
  </study>
  <study rank="685">
    <title>Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-354</intervention>
      <intervention type="Drug">ABT-354</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 23, 2013</first_received>
    <start_date>July 2013</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>December 9, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Vital signs</outcome_measure>
      <outcome_measure>ECG (electrocardiogram)</outcome_measure>
      <outcome_measure>Neurological exam</outcome_measure>
      <outcome_measure>Laboratory tests</outcome_measure>
      <outcome_measure>Number of subject with adverse events</outcome_measure>
      <outcome_measure>C-SSRS (Columbia-Suicide Severity Rating Scale)</outcome_measure>
      <outcome_measure>Pharmacokinetic parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01908010</url>
  </study>
  <study rank="686">
    <title>Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glycogen Storage Disease Type II</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Myozyme</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 1, 2005</first_received>
    <start_date>June 2005</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>February 4, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Long-term Safety and Efficacy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00125879</url>
  </study>
  <study rank="687">
    <title>Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">CT-P13</intervention>
      <intervention type="Biological">Remicade</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Celltrion</lead_sponsor>
      <collaborator>Hospira, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 24, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>February 11, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy evaluated by Assessment of Crohn's disease activity index -70 response</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02096861</url>
  </study>
  <study rank="688">
    <title>The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Device">active tDCS</intervention>
      <intervention type="Drug">Sertraline</intervention>
      <intervention type="Device">sham tDCS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cheng-Kung University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2016</first_received>
    <start_date>August 2015</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>September 27, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change of Unified Parkinson's Disease Rating Scale among different weeks</outcome_measure>
      <outcome_measure>Change of Hoehn and Yahr scale among different weeks</outcome_measure>
      <outcome_measure>Change of Hamilton Rating Scale for Depression among different weeks</outcome_measure>
      <outcome_measure>Change of Taiwanese Depression Questionnaire among different weeks</outcome_measure>
      <outcome_measure>Change of Global Assessment of Functioning among different weeks</outcome_measure>
      <outcome_measure>Change of clinical global impression among different weeks</outcome_measure>
      <outcome_measure>Change of finger tapping test among different weeks</outcome_measure>
      <outcome_measure>Change of continuous performance task among different weeks</outcome_measure>
      <outcome_measure>Change of Wisconsin Card Sorting Test among different weeks</outcome_measure>
      <outcome_measure>Change of Wechsler Memory Scale - Revised among different weeks</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02917122</url>
  </study>
  <study rank="689">
    <title>Cimzia Versus Mesalamine for Crohn's Recurrence</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cimzia</intervention>
      <intervention type="Drug">Mesalamine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Milton S. Hershey Medical Center</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 25, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>July 8, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical recurrence rates of Crohn's disease</outcome_measure>
      <outcome_measure>Endoscopic recurrence of Crohn's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01696942</url>
  </study>
  <study rank="690">
    <title>A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">AAV-hAADC-2</intervention>
      <intervention type="Genetic">AAV-hAADC-2</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 28, 2005</first_received>
    <start_date>November 2004</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>December 2, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The safety and tolerability of intrastriatal administration of AAV-hAADC-2 as measured by Adverse Events in subjects with mid- to late-stage Parkinson's Disease.</outcome_measure>
      <outcome_measure>The effect of AAV-hAADC-2 on clinical status as recorded in subject diaries, by clinical assessment, and daily levodopa requirement.</outcome_measure>
      <outcome_measure>The relationship between the dose of AAV-hAADC-2 vector infused and the resulting level of striatal AADC expression by FMT-PET imaging.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00229736</url>
  </study>
  <study rank="691">
    <title>Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PF-04360365</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 30, 2009</first_received>
    <start_date>March 2010</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>September 25, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Fractional Clearance rate of ABeta peptide in CSF</outcome_measure>
      <outcome_measure>Area under the ratio of CSF labeled/unlabeled ABETA time curve from onset of clearance to 36h following start of infusion</outcome_measure>
      <outcome_measure>PF-04360365 concentrations and ABETA concentrations in plasma and CSF</outcome_measure>
      <outcome_measure>Ratio of labeled/unlabeled leucine in plasma and CSF post labeled leucine administration</outcome_measure>
      <outcome_measure>Adverse events, vital signs, clinical labs, electrocardiograms, physical / neurologic examinations, Columbia Suicide Severity Rating Scale, MRI</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01005862</url>
  </study>
  <study rank="692">
    <title>A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">200 mg Ceftaroline fosamil</intervention>
      <intervention type="Drug">600 mg Ceftaroline fosamil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>August 10, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>February 16, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetics of Ceftaroline after intravenous infusion of Ceftaroline Fosamil in patients with end-stage renal disease and a matched control population with normal renal function to characterise the clearance of Ceftaroline.</outcome_measure>
      <outcome_measure>Pharmacokinetics of Ceftaroline after intravenous infusion of Ceftaroline fosamil in patients with end-stage renal disease and a matched control population with normal renal function to characterise the clearance of Ceftaroline.</outcome_measure>
      <outcome_measure>Pharmacokinetics of Ceftaroline after intravenous infusion of Ceftaroline fosamil in patients with end stage renal diseaseand to characterise the clearance of Ceftaroline.</outcome_measure>
      <outcome_measure>Safety and tolerability in terms of adverse events, laboratory data, physical examinations, ECG and vital signs.</outcome_measure>
      <outcome_measure>Pharmacokinetics of Ceftaroline M-1 after intravenous infusion of Ceftaroline fosamil in patients with end-stage renal disease and a matched control population with normal renal function to characterise the clearance of Ceftaroline.</outcome_measure>
      <outcome_measure>Pharmacokinetics of Ceftaroline M-1 after intravenous infusion of Ceftaroline fosamil in patients with end stage renal disease and to characterise the clearance of Ceftaroline.</outcome_measure>
      <outcome_measure>Pharmacokinetics of Ceftaroline fosamil after intravenous infusion of Ceftaroline fosamil in patients with end-stage renal disease and a matched control population with normal renal function to characterise the clearance of Ceftaroline.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01664065</url>
  </study>
  <study rank="693">
    <title>A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Fabry Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Agalsidase beta</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 30, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 16, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>April 1, 2015</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156</outcome_measure>
      <outcome_measure>Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Left Ventricular Mass (LVM) at Week 156</outcome_measure>
      <outcome_measure>Change From Baseline in LVM at Week 156</outcome_measure>
      <outcome_measure>Number of Participants in Overall Cardiac Function Assessment and Clinical Symptoms at Week 156: Change From Baseline in Cardiac Function Test</outcome_measure>
      <outcome_measure>Percent Change From Baseline in GL-3 Plasma Levels at Week 156</outcome_measure>
      <outcome_measure>Change From Baseline in Short Form (36) Health Survey (SF-36) Scores at Week 156</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00140621</url>
  </study>
  <study rank="694">
    <title>Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Lung Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Minimal intervention</intervention>
      <intervention type="Behavioral">Enhanced Intervention</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Iowa</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>954</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 7, 2007</first_received>
    <start_date>March 2008</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>August 18, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ADEs</outcome_measure>
      <outcome_measure>Medication appropriateness</outcome_measure>
      <outcome_measure>Complications related to medications, including the number of hospital readmissions, unscheduled visits to emergency departments or urgent care facilities, and physician visits related to a medication problem or ADE</outcome_measure>
      <outcome_measure>Cost-effectiveness of the minimal or enhanced treatment compared to usual care</outcome_measure>
      <outcome_measure>Number of medications</outcome_measure>
      <outcome_measure>Complete medication list</outcome_measure>
      <outcome_measure>Community physician and pharmacist surveys</outcome_measure>
      <outcome_measure>Medication adherence</outcome_measure>
      <outcome_measure>Barriers to patient adherence</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00513903</url>
  </study>
  <study rank="695">
    <title>An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesenchymal stromal cells (MSC) for infusion</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>R.P.Herrmann</lead_sponsor>
      <collaborator>The Queen Elizabeth Hospital</collaborator>
      <collaborator>Concord Hospital</collaborator>
      <collaborator>Sir Charles Gairdner Hospital</collaborator>
      <collaborator>The Alfred</collaborator>
      <collaborator>Royal Perth Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 22, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>June 7, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical response to MSC: Reduction of Crohn's disease Activity score by 100 points or more at six weeks post start of therapy</outcome_measure>
      <outcome_measure>Incidence of infusional toxicity</outcome_measure>
      <outcome_measure>Induction of remission</outcome_measure>
      <outcome_measure>Improved quality of life</outcome_measure>
      <outcome_measure>Endoscopic improvement.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01090817</url>
  </study>
  <study rank="696">
    <title>Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft-Versus-Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pentostatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ohio State University Comprehensive Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>July 2003</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>April 25, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the response rate (complete and partial) to treatment with pentostatin in steroid-refractory acute GVHD (graft-versus-host disease).</outcome_measure>
      <outcome_measure>Investigate the pharmacokinetics of pentostatin in patients with acute GVHD to correlate the response with area under the curve (AUC).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00201786</url>
  </study>
  <study rank="697">
    <title>Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anemia, Sickle Cell</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Magnesium Pidolate, Hydroxyurea</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St. Jude Children's Research Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Years</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 1, 2005</first_received>
    <start_date>November 2004</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>February 23, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To estimate the maximum tolerated dose of magnesium pidolate in combination with hydroxyurea in patients with sickle cell disease who have been on a therapeutic dose of hydroxyurea for at least six months.</outcome_measure>
      <outcome_measure>To document the toxicity of the combination of hydroxyurea and magnesium pidolate.</outcome_measure>
      <outcome_measure>To investigate the effect of the combination of hydroxyurea and magnesium on hematological parameters and red cell metabolism.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00143572</url>
  </study>
  <study rank="698">
    <title>A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Kidney Disease, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methoxy polyethylene glycol-epoetin beta</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>241</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 25, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>May 5, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>March 16, 2016</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Modification of Diet in Renal Disease With 4 Variables (MDRD-4)</outcome_measure>
      <outcome_measure>Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)</outcome_measure>
      <outcome_measure>Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Month 24</outcome_measure>
      <outcome_measure>Change From Baseline in Serum Creatinine Concentration at Month 24</outcome_measure>
      <outcome_measure>Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Month 24</outcome_measure>
      <outcome_measure>Change From Baseline in Serum Cystatin C Concentration at Month 24</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01194154</url>
  </study>
  <study rank="699">
    <title>Metformin in Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Metformin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St George's, University of London</lead_sponsor>
      <collaborator>Medical Research Council</collaborator>
      <collaborator>British Lung Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 23, 2010</first_received>
    <start_date>January 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>May 6, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Capillary glucose concentration</outcome_measure>
      <outcome_measure>COPD Assessment Test score</outcome_measure>
      <outcome_measure>Exacerbation of Chronic Pulmonary Disease Tool (EXACT) score</outcome_measure>
      <outcome_measure>Time to discharge</outcome_measure>
      <outcome_measure>Recurrent exacerbation, readmission, and death rate</outcome_measure>
      <outcome_measure>Insulin requirement during hospitalisation period</outcome_measure>
      <outcome_measure>Haemoglobin A1c</outcome_measure>
      <outcome_measure>C-reactive protein concentration</outcome_measure>
      <outcome_measure>Body mass index</outcome_measure>
      <outcome_measure>Waist circumference</outcome_measure>
      <outcome_measure>Forced expiratory volume in 1 second</outcome_measure>
      <outcome_measure>Fructosamine</outcome_measure>
      <outcome_measure>Interleukin 6</outcome_measure>
      <outcome_measure>Interleukin 8</outcome_measure>
      <outcome_measure>Tumor necrosis factor alpha</outcome_measure>
      <outcome_measure>Interferon gamma</outcome_measure>
      <outcome_measure>8-isoprostane</outcome_measure>
      <outcome_measure>Total carbonyl stress</outcome_measure>
      <outcome_measure>Glutathione reduced vs oxidised</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01247870</url>
  </study>
  <study rank="700">
    <title>A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">carbidopa and levodopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IMPAX Laboratories, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 13, 2014</first_received>
    <start_date>November 2015</start_date>
    <last_updated>August 9, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>&quot;Off&quot; time per the Assessment of Subject's Motor State</outcome_measure>
      <outcome_measure>Duration of effect estimated using the timepoint at which an improvement of at least 4 points in the MDS-UPDRS Part III score from predose is first observed and continuing until the timepoint at which the improvement is no longer observed</outcome_measure>
      <outcome_measure>Change from predose value in the number of finger-taps at each timepoint</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02271503</url>
  </study>
  <study rank="701">
    <title>Stop Infliximab in Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 25, 2007</first_received>
    <start_date>December 2005</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>July 22, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Relapse of Crohn's disease assessed by a CDAI &gt; 250 or a CDAI between 150 and 250 at two consecutive weeks, with an increase of at least 70 points over baseline.</outcome_measure>
      <outcome_measure>Evaluation of demographic, clinical and endoscopic factors predictive of relapse of Crohn's disease after stopping infliximab, with univariate and multivariate analysis.</outcome_measure>
      <outcome_measure>Tolerance and safety of infliximab retreatment in patients experiencing a relapse.</outcome_measure>
      <outcome_measure>predictive factors of short term-relapse (&lt;2 months) after stopping infliximab, in the follow up of the patients.</outcome_measure>
      <outcome_measure>Clinical response to infliximab retreatment, assessed 4 weeks after retreatment using CDAI. A clinical response is defined by a 70 points drop (and at least 25%) as compared to relapse CDAI.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00571337</url>
  </study>
  <study rank="702">
    <title>A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mild-to-moderate Alzheimer's Disease</condition>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB-742457 15mg</intervention>
      <intervention type="Drug">SB-742457 35mg</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">donepezil 5-10mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>684</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>March 15, 2012</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in cognition and function after 24 weeks.</outcome_measure>
      <outcome_measure>Change in cognition and function after 12, 24, 36 and 48 weeks. Safety and tolerability. Pharmacokinetics and exploratory pharmacogenetics.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00710684</url>
  </study>
  <study rank="703">
    <title>Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Phoressor II (IOMED)</intervention>
      <intervention type="Device">Phoressor II (IOMED)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 6, 2004</first_received>
    <start_date>March 2003</start_date>
    <last_updated>November 22, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>August 31, 2012</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Gait Speed Before and After Real and Sham tDCS.</outcome_measure>
      <outcome_measure>UPDRS Total Scores Before and After Real tDCS Course and After Sham tDCS Course.</outcome_measure>
      <outcome_measure>UPDRS Motor Scores Before and After Real tDCS Course and After Sham tDCS Course.</outcome_measure>
      <outcome_measure>Bradykinesia Measure Before and After Real and Sham tDCS.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00082342</url>
  </study>
  <study rank="704">
    <title>A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus Type 2, Kidney Disease, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aleglitazar</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 2, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>January 2019</completion_date>
    <last_updated>November 1, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to the first occurrence of either component of the composite endpoint: end stage renal disease or cardiovascular death</outcome_measure>
      <outcome_measure>Time to the first occurrence of any component of major adverse cardiovascular event composite (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)</outcome_measure>
      <outcome_measure>Time to the first occurrence of any component of macrovascular composite (CV death, non fatal myocardial infarction, hospitalization for unstable angina, non fatal stroke)</outcome_measure>
      <outcome_measure>Time to the first occurrence of any component of composite outcome of end-stage renal disease and all-cause mortality</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01893242</url>
  </study>
  <study rank="705">
    <title>Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Safinamide</intervention>
      <intervention type="Drug">Safinamide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Newron</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>227</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 21, 2008</first_received>
    <start_date>June 2005</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>March 21, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time from baseline to intervention (e.g., increase in dose of DA-agonist; addition of another DA-agonist, levodopa, or other PD therapy; or discontinuation due to lack of efficacy); or time from baseline to the last follow up, if the event did not occur</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00642889</url>
  </study>
  <study rank="706">
    <title>Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mild Cognitive Impairment Due to Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">Pioglitazone placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Takeda</lead_sponsor>
      <collaborator>Zinfandel Pharmaceuticals Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>65 Years</min_age>
    <max_age>83 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>July 2019</completion_date>
    <last_updated>January 15, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) for placebo-treated, high-risk, non-Hispanic/Latino Caucasian subjects versus placebo-treated, low-risk, non-Hispanic/Latino Caucasian subjects</outcome_measure>
      <outcome_measure>Time to diagnosis of MCI due to AD for pioglitazone-treated, non-Hispanic/Latino Caucasian subjects versus placebo-treated non-Hispanic/Latino, Caucasian subjects in the high-risk stratum</outcome_measure>
      <outcome_measure>Change from baseline in cognitive decline on composite score on the cognitive test battery</outcome_measure>
      <outcome_measure>Change from baseline in instrumental activities of daily living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI])</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01931566</url>
  </study>
  <study rank="707">
    <title>Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Safinamide</intervention>
      <intervention type="Drug">Safinamide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Newron</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>269</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 21, 2008</first_received>
    <start_date>December 2004</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>March 24, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>UPDRS Section III (Motor Examination [ME]) total score at Baseline, each post-baseline visit and Endpoint (Visit 8 [Week 24]).</outcome_measure>
      <outcome_measure>UPDRS Section III (ME) item (&amp; total) scores.CGI Change from Baseline score.UPDRS Section II (ADL) item (&amp; total) scores.CGI Severity of Illness score. H&amp;Y Staging.All above at each visit and Endpoint (LOCF). Cogtest PD battery score each visit</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00643045</url>
  </study>
  <study rank="708">
    <title>A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">AST-120</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Kureha Corporation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1020</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 11, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>March 2, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>February 15, 2015</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>The Development of a Component of a Quadruple Composite Endpoint (Initiation of Dialysis, Kidney Transplant, Doubling of sCr, or Death), Other Measures of Renal Function</outcome_measure>
      <outcome_measure>Vitamins and Folate Levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00500682</url>
  </study>
  <study rank="709">
    <title>Disease Management for Smoking Cessation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Smoking Cessation</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">High intensity disease management</intervention>
      <intervention type="Behavioral">Low intensity disease management</intervention>
      <intervention type="Other">Comparison group</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Kansas Medical Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 23, 2007</first_received>
    <start_date>June 2009</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>November 23, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>7-day point prevalence abstinence from cigarettes</outcome_measure>
      <outcome_measure>Number of quit attempts</outcome_measure>
      <outcome_measure>Progress in stage of change</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00440115</url>
  </study>
  <study rank="710">
    <title>A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline 40 mg</intervention>
      <intervention type="Drug">Istradefylline 20 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Hakko Kirin Pharma, Inc.</lead_sponsor>
      <collaborator>Kyowa Hakko Kirin Company, Limited</collaborator>
      <collaborator>Kyowa Kirin Pharmaceutical Development, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>609</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 18, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>July 12, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy variable is change from Baseline in the total hours of awake time per day spent in the OFF state.</outcome_measure>
      <outcome_measure>Total hours of ON time per day without troublesome dyskinesia;</outcome_measure>
      <outcome_measure>UPDRS Motor Examination Score (Part III);</outcome_measure>
      <outcome_measure>UPDRS Activities of Daily Living (ADL) score (Part II);</outcome_measure>
      <outcome_measure>UPDRS Mentation, Behaviour and Mood (Part I)</outcome_measure>
      <outcome_measure>Total UPDRS (Parts I + II + III);</outcome_measure>
      <outcome_measure>PGI-I scale</outcome_measure>
      <outcome_measure>Sleep time in hours per day based upon 24-hour diaries.</outcome_measure>
      <outcome_measure>Percentage of awake time per day spent in the OFF state</outcome_measure>
      <outcome_measure>Percentage of ON time per day without troublesome dyskinesia.</outcome_measure>
      <outcome_measure>Total hours of ON time and percentage of ON time per day (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia)</outcome_measure>
      <outcome_measure>Montreal Cognitive Assessment (MoCA)</outcome_measure>
      <outcome_measure>Beck Depression Inventory (BDI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01968031</url>
  </study>
  <study rank="711">
    <title>Effect of Polyphenols on Peripheral Vascular Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">dark chocolate with crossover to milk chocolate</intervention>
      <intervention type="Dietary Supplement">milk chocolate with crossover to dark chocolate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Roma La Sapienza</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>September 12, 2013</first_received>
    <start_date>October 2010</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>September 17, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>endothelial function assessed by flow mediated dilation (FMD)</outcome_measure>
      <outcome_measure>Oxidative stress markers</outcome_measure>
      <outcome_measure>Maximal walking distance</outcome_measure>
      <outcome_measure>Ankle Brachial Index (ABI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01947712</url>
  </study>
  <study rank="712">
    <title>Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">PAZ-417</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <first_received>August 15, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>August 3, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>This study is the measurement of a biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD).</outcome_measure>
      <outcome_measure>To measure both amyloid beta peptide 42 (Ab42) and PAZ-417 in both plasma and CSF and assess safety using the results of physical examinations, vital sign measurements, ECGs, cardiac telemetry, standard laboratory tests and collection of AES.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00739037</url>
  </study>
  <study rank="713">
    <title>Naltrexone for Impulse Control Disorders in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Impulse Control Disorder</condition>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 15, 2010</first_received>
    <start_date>November 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 13, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>March 10, 2015</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Assessed as Very Much Improved or Much Improved Based on the Clinical Global Impression-Improvement (CGI-I) Scale</outcome_measure>
      <outcome_measure>Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01052831</url>
  </study>
  <study rank="714">
    <title>A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">E5555 50 mg</intervention>
      <intervention type="Drug">E5555 100 mg</intervention>
      <intervention type="Drug">E5555 200 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Co., Ltd.</lead_sponsor>
      <collaborator>Eisai Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 4, 2007</first_received>
    <start_date>October 2007</start_date>
    <last_updated>May 9, 2013</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG</outcome_measure>
      <outcome_measure>Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00540670</url>
  </study>
  <study rank="715">
    <title>Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimers Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">123-I MNI-187 Injection and Imaging Procedures</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 3, 2007</first_received>
    <start_date>April 2007</start_date>
    <last_updated>January 17, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the dynamic uptake and washout of 123-I MNI-187</outcome_measure>
      <outcome_measure>Blood metabolite characterization of 123-I MNI-187 in healthy and AD subjects to determine the metabolic fate and nature of metabolites; Evaluate the test/retest reproducibility of 123-I MNI-187 and SPECT in AD subjects and healthy controls</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00456417</url>
  </study>
  <study rank="716">
    <title>Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SRA-333</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 6, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>April 2005</completion_date>
    <last_updated>September 3, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the safety and tolerability of multiple ascending fixed oral dose in subject with mild to moderate Alzheimer's Disease</outcome_measure>
      <outcome_measure>To assess the pharmacokinetics and pharmacodynamics of multiple ascending fixed dose.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00151333</url>
  </study>
  <study rank="717">
    <title>GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK1605786A</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">GSK1605786A</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>229</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 3, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>March 13, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Remission (CDAI score less than 150 points)</outcome_measure>
      <outcome_measure>Corticosteroid-free remission</outcome_measure>
      <outcome_measure>Remission in subjects who were in remission at baseline</outcome_measure>
      <outcome_measure>Remission at end of treatment</outcome_measure>
      <outcome_measure>Clinical response (CDAI decrease of at least 100 points)</outcome_measure>
      <outcome_measure>Induction of remission in subjects who were not in remission at baseline</outcome_measure>
      <outcome_measure>Change from baseline in CDAI score</outcome_measure>
      <outcome_measure>Safety outcomes</outcome_measure>
      <outcome_measure>Health outcomes</outcome_measure>
      <outcome_measure>Biomarkers</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01316939</url>
  </study>
  <study rank="718">
    <title>Investigating the Safety of srTMS in the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Magstim Rapid Magnetic Stimulator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 24, 2003</first_received>
    <start_date>June 2003</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>April 16, 2009</last_updated>
    <last_verified>April 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Testing the safety limit (SL) of 50 Hz srTMS.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00063284</url>
  </study>
  <study rank="719">
    <title>A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TVP-1012</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Takeda</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>244</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 9, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 29, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III total score</outcome_measure>
      <outcome_measure>MDS-UPDRS Part II + Part III total score</outcome_measure>
      <outcome_measure>MDS-UPDRS Part I total score</outcome_measure>
      <outcome_measure>MDS-UPDRS Part II total score</outcome_measure>
      <outcome_measure>MDS-UPDRS Part III total score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02337725</url>
  </study>
  <study rank="720">
    <title>Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">B-CIT and SPECT imaging</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>396</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>November 22, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>May 13, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess progression of DAT loss during a 70 month interval</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00404170</url>
  </study>
  <study rank="721">
    <title>Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PF-04360365 1 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 3 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 5 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 10 mg/kg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 11, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>July 24, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To examine the safety and tolerability of a single dose of PF-04360365 in subjects with mild-to-moderate AD.</outcome_measure>
      <outcome_measure>To characterize the pharmacokinetic profile of PF-04360365 following administration of an IV infusion in subjects with mild-to-moderate AD.</outcome_measure>
      <outcome_measure>To evaluate the relationship of PF-04360365 plasma exposure and Aβ plasma exposure.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00733642</url>
  </study>
  <study rank="722">
    <title>Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibrutinib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pharmacyclics LLC.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 11, 2014</first_received>
    <start_date>July 2014</start_date>
    <last_updated>April 13, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Phase 1b: Number of dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib</outcome_measure>
      <outcome_measure>Phase 2 (Efficacy): Overall cGVHD response rate defined as the proportion of evaluable subjects who achieve a [NIH-defined Complete Response (CR) and Partial Response (PR)] over all subjects who were treated with RP2D</outcome_measure>
      <outcome_measure>Failure Free Survival (FFS)</outcome_measure>
      <outcome_measure>Change in symptom burden by the Lee cGVHD Symptom Scale</outcome_measure>
      <outcome_measure>Corticosteroid requirement changes over Time</outcome_measure>
      <outcome_measure>Number of subjects with Adverse Events (AE) as a measure of safety and tolerability of ibrutinib</outcome_measure>
      <outcome_measure>Determine the plasma pharmacokinetics of ibrutinib and the metabolite, PCI-45227</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02195869</url>
  </study>
  <study rank="723">
    <title>Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">CERE-120: Adeno-Associated Virus Delivery of Neurturin</intervention>
      <intervention type="Procedure">Sham Surgery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ceregene</lead_sponsor>
      <collaborator>Sangamo Biosciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 25, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>March 2018</completion_date>
    <last_updated>October 27, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in UPDRS Part III Motor Examination in the &quot;Off&quot; state</outcome_measure>
      <outcome_measure>Incidence, relatedness, severity, and duration of treatment-emergent adverse events</outcome_measure>
      <outcome_measure>Changes from baseline in clinical laboratory tests, vital signs, weight, and examination findings</outcome_measure>
      <outcome_measure>Clinically significant changes from baseline in brain imaging results</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00985517</url>
  </study>
  <study rank="724">
    <title>Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">beclomethasone dipropionate</intervention>
      <intervention type="Drug">methylprednisolone</intervention>
      <intervention type="Drug">prednisone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>August 5, 2002</first_received>
    <start_date>April 2002</start_date>
    <completion_date>January 2005</completion_date>
    <last_updated>May 29, 2013</last_updated>
    <last_verified>December 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00043147</url>
  </study>
  <study rank="725">
    <title>A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Congenital Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Motavizumab</intervention>
      <intervention type="Biological">Palivizumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MedImmune LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <max_age>24 Months</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1236</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>October 1, 2007</first_received>
    <start_date>October 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>February 14, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>January 11, 2012</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Reporting Adverse Events Through Study Day 150</outcome_measure>
      <outcome_measure>Number of Subjects Reporting Serious Adverse Events Through Study Day 150</outcome_measure>
      <outcome_measure>Number of Subjects Reporting Laboratory Adverse Events</outcome_measure>
      <outcome_measure>The Number of Subjects Hospitalized for RSV Infection.</outcome_measure>
      <outcome_measure>The Number of Subjects With RSV Outpatient MA-LRI for Season 2 Only.</outcome_measure>
      <outcome_measure>Number of Subjects Who Had Anti-motavizumab Antibodies Detected</outcome_measure>
      <outcome_measure>Mean Trough Serum Concentration of Motavizumab at Pre-dose 1</outcome_measure>
      <outcome_measure>Mean Trough Serum Concentration of Motavizumab at 30 Days Post-dose 1</outcome_measure>
      <outcome_measure>Mean Trough Serum Concentration of Motavizumab at 30 Days Post-dose 2</outcome_measure>
      <outcome_measure>Mean Trough Serum Concentration of Motavizumab at 30 Days Post-dose 3</outcome_measure>
      <outcome_measure>Mean Trough Serum Concentration of Motavizumab at 30 Days Post-dose 4</outcome_measure>
      <outcome_measure>Mean Trough Serum Concentrations of Motavizumab in Subjects Who Underwent Cardiac Surgery With Cardiopulmonary Bypass</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00538785</url>
  </study>
  <study rank="726">
    <title>Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Treatment of Dry Eye Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Restasis, Refresh Plus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Innovative Medical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 30, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>July 29, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Dry Eye disease</outcome_measure>
      <outcome_measure>efficacy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00567177</url>
  </study>
  <study rank="727">
    <title>Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Adalimumab</intervention>
      <intervention type="Biological">Placebo for adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 13, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>April 8, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>March 9, 2016</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Serum Adalimumab Concentration at Week 8</outcome_measure>
      <outcome_measure>Number of Participants With Potentially Significant Hematology Parameters During Administration of Adalimumab</outcome_measure>
      <outcome_measure>Number of Participants With Potentially Significant Clinical Chemistry Parameters During Administration of Adalimumab</outcome_measure>
      <outcome_measure>Number of Participants With Potentially Significant Vital Signs Parameters During Administration of Adalimumab</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Clinical Remission (Crohn's Disease Activity Index [CDAI] &lt; 150) Every 2 Weeks up to Week 26</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Clinical Response (CDAI Decrease ≥ 70 From Week 0) Every 2 Weeks up to Week 26</outcome_measure>
      <outcome_measure>CDAI: Mean Change From Baseline to Each Visit</outcome_measure>
      <outcome_measure>High-sensitivity C-reactive Protein (hsCRP): Median Change From Baseline (Week 0) to Week 26</outcome_measure>
      <outcome_measure>Fecal Calprotectin: Change From Baseline (Week 0) to Week 8</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02015793</url>
  </study>
  <study rank="728">
    <title>Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Infliximab</intervention>
      <intervention type="Drug">AZA</intervention>
      <intervention type="Drug">Placebo Prednisolone</intervention>
      <intervention type="Drug">Prednisolone</intervention>
      <intervention type="Drug">AZA</intervention>
      <intervention type="Biological">Placebo Infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 21, 2008</first_received>
    <start_date>November 2003</start_date>
    <completion_date>January 2005</completion_date>
    <last_updated>April 21, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the therapeutic efficacy of repeated infliximab infusions in order to maintain Crohn's disease remission (Crohn's disease Activity Index [CDAI] &lt;=150) at the end of the study.</outcome_measure>
      <outcome_measure>Tolerability evaluation (labs parameters, vital signs, adverse events).</outcome_measure>
      <outcome_measure>Quality of life assessment, by IBDQ questionnaire.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00796250</url>
  </study>
  <study rank="729">
    <title>Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Low dose naltrexone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Santa Barbara Cottage Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 11, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>November 19, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>An increase in the subjects inflammatory bowel disease questionnaire score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01810185</url>
  </study>
  <study rank="730">
    <title>Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
      <condition>Pulmonary Hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxyurea</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ann &amp; Robert H Lurie Children's Hospital of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <max_age>25 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 10, 2006</first_received>
    <start_date>July 2006</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>March 28, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>February 18, 2013</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tricuspid Regurgitant Jet Velocity</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00350844</url>
  </study>
  <study rank="731">
    <title>Coenzyme Q10 in Huntington's Disease (HD)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">coenzyme Q10</intervention>
      <intervention type="Other">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>University of Rochester</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>609</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 4, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>February 29, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>December 7, 2015</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))</outcome_measure>
      <outcome_measure>Change in Total Functional Capacity (TFC) Score From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Functional Checklist Score From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Independence Scale Score From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Total Motor Score From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Behavioral Frequency Score From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Behavioral Frequency x Severity Score From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Verbal Fluency Test From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Stroop Interference Test - Color Naming From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Stroop Interference Test - Word Reading From Baseline to Month 60</outcome_measure>
      <outcome_measure>Change in Stroop Interference Test - Interference From Baseline to Month 60</outcome_measure>
      <outcome_measure>Time to a Two-Point Decline in TFC Score or Death</outcome_measure>
      <outcome_measure>Time to a Three-Point Decline in TFC Score or Death</outcome_measure>
      <outcome_measure>Number Completing Study at Assigned Dosage Level</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00608881</url>
  </study>
  <study rank="732">
    <title>A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Paget's Disease of Bone</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alendronate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 30, 2007</first_received>
    <start_date>October 2001</start_date>
    <completion_date>October 2002</completion_date>
    <last_updated>February 12, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2002</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months</outcome_measure>
      <outcome_measure>MK0217 will be safely tolerated</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00480662</url>
  </study>
  <study rank="733">
    <title>Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Multidisciplinary Care</intervention>
      <intervention type="Other">Usual Care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>Stichting Nuts Ohra</collaborator>
      <collaborator>Porticus</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>301</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>August 20, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>November 4, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Parkinson's Disease Quality of Life Questionnaire (PDQL)</outcome_measure>
      <outcome_measure>AMC Linear Disability Score (ALDS)</outcome_measure>
      <outcome_measure>SF-36 (secundary;utility score)</outcome_measure>
      <outcome_measure>UPDRS Motor Examination (part III)(secondary)</outcome_measure>
      <outcome_measure>UPDRS Complications of therapy (part IV)(tertiary)</outcome_measure>
      <outcome_measure>SPDDS(tertiary)</outcome_measure>
      <outcome_measure>Modified MACTAR scale(tertiary)</outcome_measure>
      <outcome_measure>Parkinson Activity Scale(tertiary)</outcome_measure>
      <outcome_measure>Costs (secondary)</outcome_measure>
      <outcome_measure>Frequency of falls (tertiary)</outcome_measure>
      <outcome_measure>Freezing of Gait Questionnaire (tertiary)</outcome_measure>
      <outcome_measure>Falls Efficacy Scale (tertiary)</outcome_measure>
      <outcome_measure>Non-Motor Symptom Assessment Scale and Quest for Parkinson's Disease (tertiary)</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (tertiary)</outcome_measure>
      <outcome_measure>Caregiver burden assessed with BELA-A-k (secondary), SF-36 (tertiary), and HADS (tertiary)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00518791</url>
  </study>
  <study rank="734">
    <title>A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine hydrobromide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>387</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 10, 2005</first_received>
    <start_date>July 1997</start_date>
    <completion_date>December 1998</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to the end of treatment in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores</outcome_measure>
      <outcome_measure>Change from baseline in ADAS-cog/13, DAD and NPI scores to the end of treatment; Incidence of adverse events; Pittsburgh Sleep Scale score; Changes in laboratory tests, ECGs and physical examinations</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00253227</url>
  </study>
  <study rank="735">
    <title>NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CoQ10</intervention>
      <intervention type="Drug">GPI 1485</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>195</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 23, 2004</first_received>
    <start_date>January 2004</start_date>
    <completion_date>September 2005</completion_date>
    <last_updated>October 31, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2005</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00076492</url>
  </study>
  <study rank="736">
    <title>Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">apomorphine hydrochloride</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Hakko Kirin Company, Limited</lead_sponsor>
      <collaborator>Kyowa Hakko Kirin Co., Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 22, 2008</first_received>
    <start_date>November 2007</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>August 30, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The change (response ratio, raw score change, percent score change) in UPDRS (Unified Parkinson's Disease Rating Scale ) Part 3 score at the maintenance dose level</outcome_measure>
      <outcome_measure>The incidence of adverse events/adverse drug reactions and their nature</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00610103</url>
  </study>
  <study rank="737">
    <title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">E6011</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 23, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of the short-term safety and tolerability of E6011</outcome_measure>
      <outcome_measure>Concentration of E6011 measured over time in blood samples.</outcome_measure>
      <outcome_measure>The number and percentage of participants with anti-E6011 antibodies detected in blood samples over time.</outcome_measure>
      <outcome_measure>The number of screen positives, confirm positives, and relative anti-E6011 levels measured in blood samples from participants.</outcome_measure>
      <outcome_measure>Change from baseline in the percentage of immunohistochemical staining for the CX3CR1+ protein in intestinal tissue over time.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02249078</url>
  </study>
  <study rank="738">
    <title>Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rasagiline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
      <collaborator>H. Lundbeck A/S</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 6, 2010</first_received>
    <start_date>September 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>October 3, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of rasagiline on sleep disturbances in PD patients: Parkinson's Disease Sleep Scale (PDSS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01178047</url>
  </study>
  <study rank="739">
    <title>Oral AGY for Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">AGY</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Igy Inc.</lead_sponsor>
      <collaborator>University of Alberta</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>January 8, 2013</first_received>
    <start_date>May 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>April 20, 2016</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>general safety</outcome_measure>
      <outcome_measure>Symptoms</outcome_measure>
      <outcome_measure>Health Related Quality of Life</outcome_measure>
      <outcome_measure>ATG antibody level</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01765647</url>
  </study>
  <study rank="740">
    <title>Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BF2.649 (pitolisant)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bioprojet</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>268</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 11, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 11, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ESS change (Epworth Sleepiness Scale)</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01036139</url>
  </study>
  <study rank="741">
    <title>Safety and Efficacy of Liraglutide in Parkinson's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Liraglutide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cedars-Sinai Medical Center</lead_sponsor>
      <collaborator>The Cure Parkinson's Trust</collaborator>
      <collaborator>Novo Nordisk A/S</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>25 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>57</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 21, 2016</first_received>
    <start_date>September 2016</start_date>
    <completion_date>February 2019</completion_date>
    <last_updated>November 1, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Motor Function</outcome_measure>
      <outcome_measure>Non-Motor Function</outcome_measure>
      <outcome_measure>Cognitive Function</outcome_measure>
      <outcome_measure>Peripheral Insulin Resistance</outcome_measure>
      <outcome_measure>Total MDS-UPDRS</outcome_measure>
      <outcome_measure>Functional status and quality of life</outcome_measure>
      <outcome_measure>Adverse events frequency</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02953665</url>
  </study>
  <study rank="742">
    <title>Neuroprotection by Cannabinoids in Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</lead_sponsor>
      <collaborator>GW Pharmaceuticals Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 29, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>January 31, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serious Adverse Events reported</outcome_measure>
      <outcome_measure>Changes in the UHDRs Score</outcome_measure>
      <outcome_measure>Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in plasma</outcome_measure>
      <outcome_measure>Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in cerebrospinal fluid.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01502046</url>
  </study>
  <study rank="743">
    <title>A Study With Pentasa in Patients With Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn´s Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pentasa</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ferring Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 13, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>March 15, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>October 3, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 10.</outcome_measure>
      <outcome_measure>Relative Change From Baseline to Week 10 in Fecal Calprotectin</outcome_measure>
      <outcome_measure>Relative Change From Baseline to Each Visit in Serum C-reactive Protein (CRP)</outcome_measure>
      <outcome_measure>Relative Change From Baseline to Each Visit in Inflammatory Bowel Disease Questionnaire (IBDQ) Score</outcome_measure>
      <outcome_measure>Relative Change From Baseline to Each Visit in Work Productivity &amp; Activity Impairment Questionnaire (WPAI_CD) Score Item 5 (Work Productivity)</outcome_measure>
      <outcome_measure>Relative Change From Baseline to Week 10 in Estimated Creatinine Clearance</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00862121</url>
  </study>
  <study rank="744">
    <title>Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sumanirole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>854</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 14, 2003</first_received>
    <start_date>April 2003</start_date>
    <completion_date>September 2004</completion_date>
    <last_updated>June 6, 2006</last_updated>
    <last_verified>June 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in UPDRS (Unified Parkinson's Disease Rating Scale) II + III total scores at end of maintenance, for sumanirole compared to placebo</outcome_measure>
      <outcome_measure>To assess the safety profile of sumanirole and the benefit of sumanirole in quality of life measures compared to placebo</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00058838</url>
  </study>
  <study rank="745">
    <title>Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pramipexole immediate release tablet</intervention>
      <intervention type="Drug">pramipexole extended release tablet</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>475</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 30, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>October 22, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>December 19, 2012</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Unified Parkinsons Disease Rating Scale (UPDRS) Parts II+III Score at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage Off-time During Waking Hours at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Duration of Off-time During Waking Hours at Week 18</outcome_measure>
      <outcome_measure>Responder in Percentage Off-time During Waking Hours at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage On-time Without Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage On-time Without or With Non-troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Duration of On-time Without Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Duration of On-time With Non-troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Duration of On-time Without or With Non-troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in Duration of On-time With Troublesome Dyskinesia at Week 18</outcome_measure>
      <outcome_measure>Clinical Global Impression of Improvement (CGI-I) Responder at Week 18</outcome_measure>
      <outcome_measure>Patient Global Impressions of Improvement (PGI-I) Responder at Week 18</outcome_measure>
      <outcome_measure>Responder in UPDRS Parts II+III Score at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS II Score Separately at Week 18</outcome_measure>
      <outcome_measure>Change From Baseline in UPDRS III Score Separately at Week 18</outcome_measure>
      <outcome_measure>Levodopa (L-Dopa) Introduction During the Study</outcome_measure>
      <outcome_measure>Levodopa (L-Dopa) Dose Change During the Study</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01191944</url>
  </study>
  <study rank="746">
    <title>Bee Venom for the Treatment of Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">bee venom</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 30, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>June 13, 2014</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>UPDRS III scores</outcome_measure>
      <outcome_measure>Evaluate the potential effect of bee venom on disease progression by comparing UPDRS III off scores between treated/placebo group</outcome_measure>
      <outcome_measure>changes in L-Dopa equivalence doses over 12 months</outcome_measure>
      <outcome_measure>Correlate symptom (UPDRS III) progression with nigrostriatal denervation as measured by DaTSCAN</outcome_measure>
      <outcome_measure>Quantify the evolution (appearance, progression or regression) of motor fluctuations over the one year study period by UPDRS IV</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01341431</url>
  </study>
  <study rank="747">
    <title>Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PPI-1019 (APAN)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>PRAECIS Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 27, 2004</first_received>
    <start_date>May 2003</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>September 18, 2006</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Clinical (adverse events, vital signs, ECG) and laboratory (chemistry, hematology) parameters</outcome_measure>
      <outcome_measure>Single dose pharmacokinetic parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00100282</url>
  </study>
  <study rank="748">
    <title>Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clopidogrel</intervention>
      <intervention type="Drug">Clopidogrel</intervention>
      <intervention type="Drug">Clopidogrel</intervention>
      <intervention type="Drug">Clopidogrel</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Takeshi Morimoto</lead_sponsor>
      <collaborator>Kyoto University, Graduate School of Medicine</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 16, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>January 7, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Inhibition of platelet aggregation 24 hours after loading</outcome_measure>
      <outcome_measure>Inhibition of platelet aggregation 7 days after loading</outcome_measure>
      <outcome_measure>Inhibition of platelet aggregation 28 days after loading</outcome_measure>
      <outcome_measure>all cause death</outcome_measure>
      <outcome_measure>cardiac death</outcome_measure>
      <outcome_measure>myocardial infarction</outcome_measure>
      <outcome_measure>stent thrombosis (Academic Research Consortium definition)</outcome_measure>
      <outcome_measure>acute hemorrhagic or ischemic stroke excluding transient ischemic attack</outcome_measure>
      <outcome_measure>bleeding complications (Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO] and Thrombolysis In Myocardial Infarction [TIMI] definition)</outcome_measure>
      <outcome_measure>composite of cardiac death, myocardial infarction and stroke</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01069302</url>
  </study>
  <study rank="749">
    <title>Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Zemplar Capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 20, 2004</first_received>
    <start_date>August 2004</start_date>
    <last_updated>January 17, 2011</last_updated>
    <last_verified>July 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>The efficacy endpoint is achievement of two consecutive &gt; or = 30% decreases from baseline in iPTH levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00091975</url>
  </study>
  <study rank="750">
    <title>Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Autoimmune Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Enteric-coated Mycophenolate Sodium</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 10, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>April 19, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>December 14, 2010</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)</outcome_measure>
      <outcome_measure>Changes in the GI Symptom Severity Subscales After Conversion to Enteric-coated Mycophenolate Sodium</outcome_measure>
      <outcome_measure>Changes in GI-related Quality of Life Index (GIQLI), After Patients Are Converted From MMF to Enteric-coated Mycophenolate Sodium</outcome_measure>
      <outcome_measure>Changes in the GI-related Quality of Life Subscales After Conversion to Enteric-coated Mycophenolate Sodium</outcome_measure>
      <outcome_measure>Changes in Psychological General Well-Being Index (PGWB) After Conversion to Enteric-coated Mycophenolate Sodium</outcome_measure>
      <outcome_measure>Changes in Psychological General Well-Being Index (PGWB) Subscales After Conversion to Enteric-coated Mycophenolate Sodium</outcome_measure>
      <outcome_measure>Overall Treatment Effects for GI Symptoms Assessed by the Physician</outcome_measure>
      <outcome_measure>Overall Treatment Effects for GI Symptoms Assessed by the Patient</outcome_measure>
      <outcome_measure>Overall Treatment Effects for for Health-related Quality of Life Assessed by the Patient</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00351377</url>
  </study>
  <study rank="751">
    <title>Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sumanirole</intervention>
      <intervention type="Drug">ropinirole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 8, 2002</first_received>
    <start_date>December 2001</start_date>
    <completion_date>April 2003</completion_date>
    <last_updated>June 6, 2006</last_updated>
    <last_verified>June 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in UPDRS (Unified Parkinson's Disease Rating Scale) II + III total scores at end of maintenance, for sumanirole compared to placebo</outcome_measure>
      <outcome_measure>To assess the safety profile of sumanirole; the benefit of sumanirole in quality of life measures, and change from baseline in UPDRS II + III total scores at end of maintenance, for sumanirole compared to ropinirole</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00036218</url>
  </study>
  <study rank="752">
    <title>Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Monofer (iron isomaltoside 1000)</intervention>
      <intervention type="Drug">Monofer</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pharmacosmos A/S</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 1, 2010</first_received>
    <start_date>February 2012</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>November 13, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Total serum iron pharmakokinetic parameters</outcome_measure>
      <outcome_measure>Total urine-iron pharmakokinetic parameters</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01213680</url>
  </study>
  <study rank="753">
    <title>AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AC-1204</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Accera, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>66 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>418</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>November 30, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>April 5, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</outcome_measure>
      <outcome_measure>Clock Draw Interpretation Scale (CDIS)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Quality of Life - Alzheimer's Disease (QoL-AD)</outcome_measure>
      <outcome_measure>Resource Utilization in Dementia (RUD-Lite)</outcome_measure>
      <outcome_measure>Incidence of treatment-emergent adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01741194</url>
  </study>
  <study rank="754">
    <title>A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">AST-120</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Kureha Corporation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1015</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 11, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>March 2, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>February 15, 2015</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>The Development of a Component of a Quadruple Composite Endpoint (Initiation of Dialysis, Kidney Transplant, Doubling of sCr, or Death), Other Measures of Renal Function and (QOL: Exploratory)</outcome_measure>
      <outcome_measure>Vitamins and Folate Levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00501046</url>
  </study>
  <study rank="755">
    <title>AMG 181 in Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AMG 181</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amgen</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>254</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 27, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>June 27, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>CDAI remission</outcome_measure>
      <outcome_measure>CDAI response</outcome_measure>
      <outcome_measure>Sustained CDAI remission</outcome_measure>
      <outcome_measure>CDAI change</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01696396</url>
  </study>
  <study rank="756">
    <title>A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Jansky-Bielschowsky Disease</condition>
      <condition>Batten Disease</condition>
      <condition>Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2</condition>
      <condition>CLN2 Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">BMN 190</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioMarin Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 19, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>April 25, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the safety of every other week infusions of BMN 190 based on: vital signs, physical examination, electrocardiogram tests, clinical laboratory tests, adverse events, concomitant medications, immunogenicity tests</outcome_measure>
      <outcome_measure>To evaluate the efficacy of every other week infusions of BMN 190 by monitoring changes in clinical measures as measured by the CLN2 disease rating scale</outcome_measure>
      <outcome_measure>To evaluate the efficacy of every other week infusions of BMN 190 by monitoring changes in clinical measures as measured by magnetic resonance imaging (MRI)</outcome_measure>
      <outcome_measure>To determine the pharmacokinetic (PK) parameters of infused BMN 190 in subjects with CLN2</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01907087</url>
  </study>
  <study rank="757">
    <title>Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-02545920</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">PF-02545920</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 6, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>February 17, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline to Day 28 of Unified Huntington Disease Rating Scale -Total Motor Score (TMS)</outcome_measure>
      <outcome_measure>Change from Baseline to Day28 in fMRI parameter estimates and percent signal change during Monetary Incentive Delay</outcome_measure>
      <outcome_measure>Change from Baseline to Day28 in Grip Strength Incentive Motivation task score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01806896</url>
  </study>
  <study rank="758">
    <title>Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Bone marrow harvesting</intervention>
      <intervention type="Procedure">Liposuction</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UPECLIN HC FM Botucatu Unesp</lead_sponsor>
      <collaborator>Faculdade de Medicina do ABC</collaborator>
      <collaborator>IEP São Lucas - Instituto de Ensino e Pesquisa</collaborator>
      <collaborator>Hemocentro São Lucas</collaborator>
      <collaborator>CordCell</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 24, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>May 21, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Total Pulmonary Capacity</outcome_measure>
      <outcome_measure>Pulmonary morphology</outcome_measure>
      <outcome_measure>Pulmonary function</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02412332</url>
  </study>
  <study rank="759">
    <title>Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bryostatin for Injection</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Blanchette Rockefeller Neurosciences Insitute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 21, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>January 21, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse Events</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale</outcome_measure>
      <outcome_measure>Clinician's Interview Based Impression of Change</outcome_measure>
      <outcome_measure>Clinical Dementia Rating Battery</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living</outcome_measure>
      <outcome_measure>Severe Impairment Battery</outcome_measure>
      <outcome_measure>Hopkins Verbal Learning Test-Revised</outcome_measure>
      <outcome_measure>Temperature</outcome_measure>
      <outcome_measure>Respiratory rate</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Electrocardiogram</outcome_measure>
      <outcome_measure>Physical Exam</outcome_measure>
      <outcome_measure>Hematology</outcome_measure>
      <outcome_measure>Blood chemistry</outcome_measure>
      <outcome_measure>Urinalysis</outcome_measure>
      <outcome_measure>Pharmacokinetics</outcome_measure>
      <outcome_measure>Protein kinase C activity (pharmacodynamics)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00606164</url>
  </study>
  <study rank="760">
    <title>Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adult-Onset Still's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">anakinra</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Helsinki University</lead_sponsor>
      <collaborator>Uppsala University Hospital</collaborator>
      <collaborator>Helse Stavanger HF</collaborator>
      <collaborator>Tampere University Hospital</collaborator>
      <collaborator>Turku University Hospital</collaborator>
      <collaborator>Oulu University Hospital</collaborator>
      <collaborator>Kuopio University Hospital</collaborator>
      <collaborator>Jyväskylä Central Hospital</collaborator>
      <collaborator>Satakunta Central Hospital</collaborator>
      <collaborator>University Hospital, Umeå</collaborator>
      <collaborator>University Hospital, Linkoeping</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 15, 2009</first_received>
    <start_date>December 2005</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>December 15, 2009</last_updated>
    <last_verified>December 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients reaching remission of the disease, after eight weeks of the randomized study treatment (Remission: afebrile and normalization of acute phase reactants)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01033656</url>
  </study>
  <study rank="761">
    <title>Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-Alcoholic Fatty Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">OMACOR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital Southampton NHS Foundation Trust</lead_sponsor>
      <collaborator>National Institute for Health Research, United Kingdom</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 25, 2008</first_received>
    <start_date>November 2009</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>April 14, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in biomarkers for NAFLD and change in liver fat</outcome_measure>
      <outcome_measure>Change in risk factors for cardiovascular disease and type 2 diabetes</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00760513</url>
  </study>
  <study rank="762">
    <title>Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Rheumatoid Arthritis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">infliximab</intervention>
      <intervention type="Drug">DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>AESCA Pharma GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>19 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 27, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>March 18, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>April 3, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Patients in Remission According to Disease Activity Score (DAS) 28 (&lt; 2.6)</outcome_measure>
      <outcome_measure>DAS 28 at Baseline vs at Week 38; Quality of Life; American College of Rheumatology (ACR) Response Disease Progression (X-ray); Effect of Inflammatory Markers on Response and Disease Progression; Assess Simplified Disease Activity Index (SDAI).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00521924</url>
  </study>
  <study rank="763">
    <title>Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">CAD106</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 13, 2006</first_received>
    <start_date>June 2005</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>March 27, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tolerability/safety assessments (physical/neurol.exam., ECG, vital signs, standard and special immunological laboratory evaluations, MRIs, EEGs, AE/SAE monitoring).</outcome_measure>
      <outcome_measure>Antibody titers (IgM and IgM titers against amyloid and carrier protein).</outcome_measure>
      <outcome_measure>Immune response, cognitive and functional assessments</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00411580</url>
  </study>
  <study rank="764">
    <title>Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ALX-0600</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">teduglutide 0.05</intervention>
      <intervention type="Drug">teduglutide 0.2 mg</intervention>
      <intervention type="Drug">Teduglutide 0.05 dose</intervention>
      <intervention type="Drug">teduglutide 0.1 mg dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Shire</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 11, 2003</first_received>
    <start_date>October 2003</start_date>
    <completion_date>September 2005</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy variable is the percentage of subjects who respond to treatment, defined as the percentage of subjects who are in remission (CDAI less than 150) or have a 100-point or greater reduction from baseline in CDAI score at dosing Week 8.</outcome_measure>
      <outcome_measure>The various secondary efficacy variables are based on the CDAI, Inflammatory Bowel Disease Questionnaire (IBDQ), plasma citrulline and laboratory inflammatory markers.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00072839</url>
  </study>
  <study rank="765">
    <title>Bortezomib in Patients With Chronic Graft Versus Host Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bortezomib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, Davis</lead_sponsor>
      <collaborator>Millennium Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 1, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>January 20, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of weekly bortezomib in patients with chronic graft versus host disease panobinostat in combination with cisplatin and pemetrexed</outcome_measure>
      <outcome_measure>cGVHD Response</outcome_measure>
      <outcome_measure>Role of bortezomib on induction of immune tolerance by performing correlative studies</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01672229</url>
  </study>
  <study rank="766">
    <title>N-Acetylcysteine for Neuroprotection in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">N-acetylcysteine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 4, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 31, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>change of cerebral glutathione levels as measured by proton magnetic resonance spectroscopy</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale Parts I-V</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory Questionnaire</outcome_measure>
      <outcome_measure>Hamilton Depression Rating Scale (HAM-D)</outcome_measure>
      <outcome_measure>9-Hole Peg Board Test</outcome_measure>
      <outcome_measure>10-Meter Walk Test</outcome_measure>
      <outcome_measure>oxidative stress markers in cerebrospinal fluid</outcome_measure>
      <outcome_measure>Questionnaire for Impulsive Compulsive Disorders in PD</outcome_measure>
      <outcome_measure>Beck Anxiety Inventory</outcome_measure>
      <outcome_measure>PD quality of life questionnaire</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01470027</url>
  </study>
  <study rank="767">
    <title>DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DHA (Docosahexaenoic Acid)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alzheimer's Disease Cooperative Study (ADCS)</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
      <collaborator>DSM Nutritional Products, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>402</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 22, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>September 15, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>May 28, 2010</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of Change on the ADAS-Cog 11.</outcome_measure>
      <outcome_measure>Rate of Change on CDR-SOB</outcome_measure>
      <outcome_measure>ADCS-ADL</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00440050</url>
  </study>
  <study rank="768">
    <title>A Study of MK0657 in Parkinson's Disease Patients (0657-006)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MK0657</intervention>
      <intervention type="Drug">Comparator: Placebo (unspecified)</intervention>
      <intervention type="Drug">Comparator: levodopa</intervention>
      <intervention type="Drug">Comparator: carbidopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 24, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>January 28, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy will be assessed for up to 8 hours by the Unified Parkinson's Disease Rating Scale-Motor Examination and a modified AIMS dyskinesia scale</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00505843</url>
  </study>
  <study rank="769">
    <title>A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Preladenant 2 mg tablet</intervention>
      <intervention type="Drug">Preladenant 5 mg tablet</intervention>
      <intervention type="Drug">Preladenant 10 mg tablet</intervention>
      <intervention type="Drug">Placebo to Preladenant Tablet</intervention>
      <intervention type="Drug">Rasagiline 1 mg capsule</intervention>
      <intervention type="Drug">Placebo to Rasagiline capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>778</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>January 13, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>January 13, 2016</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Mean &quot;Off&quot; Time</outcome_measure>
      <outcome_measure>Numberof Participants With Systolic Blood Pressure &gt;=180 mm Hg</outcome_measure>
      <outcome_measure>Number of Participants With Diastolic Blood Pressure &gt;=105 mm Hg</outcome_measure>
      <outcome_measure>Number of Participants With Alanine Aminotransferase &gt;=3 Times the Upper Limit of Normal</outcome_measure>
      <outcome_measure>Number of Participants With Aspartate Aminotransferase &gt;=3 Times the Upper Limit of Normal</outcome_measure>
      <outcome_measure>Percentage of Participants With Suicidality</outcome_measure>
      <outcome_measure>Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)</outcome_measure>
      <outcome_measure>Percentage of Participants With &gt;30% Change (Reduction) From Baseline at Week 12 in Mean &quot;Off&quot; Time</outcome_measure>
      <outcome_measure>Change From Baseline at Week 12 in Mean &quot;On&quot; Time Without Troublesome Dyskinesia</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01155466</url>
  </study>
  <study rank="770">
    <title>A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hodgkin's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MDX-060</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 30, 2006</first_received>
    <start_date>November 2005</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall response rate</outcome_measure>
      <outcome_measure>Progression-free survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00284804</url>
  </study>
  <study rank="771">
    <title>Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Granulomatous Disease, Chronic, X-linked, Variant</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Great Ormond Street Hospital for Children NHS Foundation Trust</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <max_age>30 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 23, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>June 1, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall survival following gene therapy</outcome_measure>
      <outcome_measure>Reduction in frequency of infections</outcome_measure>
      <outcome_measure>Long term immune reconstitution</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01381003</url>
  </study>
  <study rank="772">
    <title>Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cx601</intervention>
      <intervention type="Other">Saline solution</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TiGenix S.A.U.</lead_sponsor>
      <collaborator>Cellerix</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>278</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 21, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>November 30, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Combine remission of perianal fistulising Crohn's</outcome_measure>
      <outcome_measure>Efficacy Assessment by week 24</outcome_measure>
      <outcome_measure>Efficacy Assessment by week 52</outcome_measure>
      <outcome_measure>Efficacy Assessment by week 104</outcome_measure>
      <outcome_measure>Safety analysis throughout the study:</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01541579</url>
  </study>
  <study rank="773">
    <title>The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Immunogenicity and Adverse Drug Effect of Vaccines Influenza</condition>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Seasonal influenza vaccine (AdimFlu-S)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cheng-Kung University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 9, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>April 4, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The dynamic change of seroprotection rate related to administration of influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.</outcome_measure>
      <outcome_measure>The safety of the influenza vaccination in patients with chronic kidney disease.</outcome_measure>
      <outcome_measure>The dynamic change of seroconversion rate related to administration of influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.</outcome_measure>
      <outcome_measure>The dynamic change of seroresponse rate related to administration of influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02105519</url>
  </study>
  <study rank="774">
    <title>Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">T-817MA-H</intervention>
      <intervention type="Drug">T-817MA-L</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Toyama Chemical Co., Ltd.</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 4, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>June 22, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC.</outcome_measure>
      <outcome_measure>Clinical Safety</outcome_measure>
      <outcome_measure>Efficacy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02079909</url>
  </study>
  <study rank="775">
    <title>Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diagnostic Imaging</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BAY1006578</intervention>
      <intervention type="Drug">BAY1006578</intervention>
      <intervention type="Drug">BAY1006578</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Piramal Imaging SA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 23, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>January 18, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by different quantification approaches</outcome_measure>
      <outcome_measure>Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by visual analysis and by standard parameters (e.g. Standardized Uptake Values=SUV)</outcome_measure>
      <outcome_measure>Electrocardiogram (ECG)</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Adverse events collection</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01153607</url>
  </study>
  <study rank="776">
    <title>Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Valsartan</intervention>
      <intervention type="Drug">Perindopril</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chinese PLA General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 20, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>November 29, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Homeostasis model of assessment for insulin resistence index (HOMA-IR index)</outcome_measure>
      <outcome_measure>Glomerular filtration rate(eGFR) and Creatinine clearance rate(CCR)</outcome_measure>
      <outcome_measure>Body mass index(BMI)</outcome_measure>
      <outcome_measure>24-h urine protein, urinary albumin-creatinin ration, retinol binding protein</outcome_measure>
      <outcome_measure>Cholesterol, triglycerides, high density lipoprotein, low density lipoprotein</outcome_measure>
      <outcome_measure>Glycosylated hemoglobin</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02299310</url>
  </study>
  <study rank="777">
    <title>Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Congenital Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vasovist</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Guy's Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 24, 2008</first_received>
    <start_date>March 2007</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>July 31, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The improvement of diagnosis of CHD, due to larger coverage of vascular territories, higher spatial resolution, faster acquisition and higher quality of MR-flow measurements using Vasovist in comparison with standard Gd-agent</outcome_measure>
      <outcome_measure>The improvement of image quality will be analysed by measuring the SNR, the CNR, the vessel sharpness. In addition, the overall image quality will be scored by three independent readers (scale: excellent, good, ok, bad)</outcome_measure>
      <outcome_measure>Ventricular volumes measured from the acquired data will be compared with respect to a reference</outcome_measure>
      <outcome_measure>The accuracy (standard deviation) and reproducibility of the flow measurements will be compared using the two different agents</outcome_measure>
      <outcome_measure>No secondary outcome measures.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00668824</url>
  </study>
  <study rank="778">
    <title>Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Trichuris suis ova</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Coronado Biosciences, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>May 17, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>February 26, 2013</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of Adverse Events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01434693</url>
  </study>
  <study rank="779">
    <title>Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NVA237 100 µg</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">NVA237 200 µg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>281</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 1, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>May 14, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>December 23, 2010</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</outcome_measure>
      <outcome_measure>Least Squares Means of Trough Forced Expiratory Volume in One Second (FEV1), by Day</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00510510</url>
  </study>
  <study rank="780">
    <title>Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children 10-16 With Chronic Kidney Disease (CKD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease Stage 3 and 4</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Zemplar (paricalcitol) Capsules</intervention>
      <intervention type="Drug">Placebo capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 13, 2009</first_received>
    <start_date>February 2010</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>May 22, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy-endpoint is the proportion of subjects who achieve two consecutive greater than or equal to 30 percent reductions from baseline in intact parathyroid hormone levels.</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve a final intact parathyroid hormone values within Kidney Disease Outcomes Quality Initiative intact parathyroid hormone target ranges will be evaluated within each Chronic Kidney Disease stage.</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve a final value within the applicable Kidney Disease Outcomes Quality Initiative target ranges for calcium.</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve a final value within the applicable Kidney Disease Outcomes Quality Initiative target ranges for phosphorus.</outcome_measure>
      <outcome_measure>The mean percent change in intact parathyroid hormone from baseline to each post baseline visit (Weeks 2, 4, 8 and 12).</outcome_measure>
      <outcome_measure>The mean change in First Morning Void Urine Albumin/Creatinine Ratio from baseline to each post baseline visit (Weeks 4, 8 and 12).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01020487</url>
  </study>
  <study rank="781">
    <title>A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease Psychosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pimavanserin tartrate (ACP-103)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ACADIA Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 26, 2007</first_received>
    <start_date>July 2007</start_date>
    <last_updated>May 17, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00550238</url>
  </study>
  <study rank="782">
    <title>Escitalopram for the Treatment of Depression in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">escitalopram</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Konkuk University Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 18, 2013</first_received>
    <start_date>November 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>August 12, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in CSDD(Cornell scale for depression in dementia) from baseline after 12 weeks of between treatment groups</outcome_measure>
      <outcome_measure>Change from baseline in CSDD(Cornell scale for depression in dementia) at week 4, 8, 16 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in K-MMSE at week 12 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in ADAS-Cog at week 12 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in NPIQ at week 12 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in S-IADL at week 12 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in GDS-15 at week 4, 8, 12, 16 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in CDR at week 12 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in CDR sum of box at week 12 and 24.</outcome_measure>
      <outcome_measure>Change from baseline in Pittsburgh Sleep Quality Index at week 12 and 24.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01841125</url>
  </study>
  <study rank="783">
    <title>Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">bapineuzumab</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>88 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 2, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>May 3, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>October 14, 2013</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78</outcome_measure>
      <outcome_measure>Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78</outcome_measure>
      <outcome_measure>Change From Baseline in Brain Amyloid Burden at Week 71</outcome_measure>
      <outcome_measure>Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71</outcome_measure>
      <outcome_measure>Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71</outcome_measure>
      <outcome_measure>Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78</outcome_measure>
      <outcome_measure>Divergence of Effect on the DAD Total Scores From Week 39 to Week 78</outcome_measure>
      <outcome_measure>Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)</outcome_measure>
      <outcome_measure>Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)</outcome_measure>
      <outcome_measure>Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)</outcome_measure>
      <outcome_measure>Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)</outcome_measure>
      <outcome_measure>Change From Baseline in Dependence Scale Total Score at Week 78</outcome_measure>
      <outcome_measure>Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)</outcome_measure>
      <outcome_measure>Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)</outcome_measure>
      <outcome_measure>Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)</outcome_measure>
      <outcome_measure>Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)</outcome_measure>
      <outcome_measure>Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00676143</url>
  </study>
  <study rank="784">
    <title>Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Arginine</intervention>
      <intervention type="Drug">Arginine (Loading)</intervention>
      <intervention type="Drug">Arginine (Continuous)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
      <collaborator>Children's Healthcare of Atlanta</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>7 Years</min_age>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 15, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>July 2019</completion_date>
    <last_updated>July 26, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetics of IV arginine, measured by plasma arginine concentration over time</outcome_measure>
      <outcome_measure>Change in nitric oxide metabolites</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration -Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration for Arginine</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration of arginine</outcome_measure>
      <outcome_measure>Apparent clearance of arginine</outcome_measure>
      <outcome_measure>Terminal elimination half-life (t1/2) for arginine</outcome_measure>
      <outcome_measure>Change in red blood cell (RBC) arginine</outcome_measure>
      <outcome_measure>Daily urine arginine</outcome_measure>
      <outcome_measure>Global arginine bioavailability (GABR)</outcome_measure>
      <outcome_measure>Change in asymmetric dimethylarginine (ADMA) levels</outcome_measure>
      <outcome_measure>Modeling nitric oxide (NOx) level versus plasma arginine level</outcome_measure>
      <outcome_measure>Biomarkers of hemolysis</outcome_measure>
      <outcome_measure>Erythrocyte glutathione levels</outcome_measure>
      <outcome_measure>Level of cytokines</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02447874</url>
  </study>
  <study rank="785">
    <title>Leukine (Sargramostim) for Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Procedure">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Procedure">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Procedure">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">MEG</intervention>
      <intervention type="Drug">sargramostim</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Procedure">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Procedure">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Procedure">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Procedure">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">MEG</intervention>
      <intervention type="Procedure">blood draw</intervention>
      <intervention type="Behavioral">physical exam and UPDRS part III assessment</intervention>
      <intervention type="Procedure">Motion Analysis</intervention>
      <intervention type="Procedure">Motion Analysis</intervention>
      <intervention type="Procedure">Motion Analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Howard Gendelman, MD</lead_sponsor>
      <collaborator>Sanofi</collaborator>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>UNeMed</collaborator>
      <collaborator>Nebraska Neuroscience Alliance</collaborator>
      <collaborator>University of Nebraska</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 13, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>May 20, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Change in UPDRS part III score</outcome_measure>
      <outcome_measure>Change in blood analyses results</outcome_measure>
      <outcome_measure>Abnormal findings in physical examination</outcome_measure>
      <outcome_measure>Change in FACS results</outcome_measure>
      <outcome_measure>Change in function of Treg cells</outcome_measure>
      <outcome_measure>Change in magnetoencephalography results</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01882010</url>
  </study>
  <study rank="786">
    <title>A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">RO5313534</intervention>
      <intervention type="Drug">RO5313534</intervention>
      <intervention type="Drug">RO5313534</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>389</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 17, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>November 1, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score</outcome_measure>
      <outcome_measure>CANTAB tests, MMSE total score, ADCS CGIC, Behave-AD-FW, ADCS-ADL, Zarit Burden interview</outcome_measure>
      <outcome_measure>AEs, lab parameters, suicidal risk, concomitant medications, physical and neurological examinations.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00884507</url>
  </study>
  <study rank="787">
    <title>Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine hydrobromide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>973</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 10, 2005</first_received>
    <start_date>March 2001</start_date>
    <completion_date>July 2002</completion_date>
    <last_updated>May 19, 2011</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to end of treatment for controlled release group in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores</outcome_measure>
      <outcome_measure>Change from baseline in ADAS-cog/13, /10, /mem scores, NPI, and ADCS/ADL; safety and tolerability of controlled-release formulation; difference in effects between the controlled-release and immediate-release formulations</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00253214</url>
  </study>
  <study rank="788">
    <title>Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Lymphoproliferative Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">rituximab</intervention>
      <intervention type="Drug">cyclophosphamide</intervention>
      <intervention type="Drug">methylprednisolone</intervention>
      <intervention type="Drug">prednisone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Oncology Group</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <max_age>30 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 6, 2003</first_received>
    <start_date>April 2004</start_date>
    <last_updated>September 14, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>September 17, 2013</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Event-free Survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00066469</url>
  </study>
  <study rank="789">
    <title>Efficacy of Patient Centred Information for Vascular Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Verbal and written information</intervention>
      <intervention type="Other">Verbal and electronic information</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mid Western Regional Hospital, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>March 4, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>March 24, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall improvement in knowledge in a group of patients with vascular disease following the provision of information through verbal, written or electronically based sources.</outcome_measure>
      <outcome_measure>Effectiveness of providing electronically based information to the vascular patient population</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01804972</url>
  </study>
  <study rank="790">
    <title>Effectiveness of Dextrose Injection for Osgood-Schlatter Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Osgood-Schlatter Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Dextrose Injection</intervention>
      <intervention type="Procedure">Lidocaine Injection</intervention>
      <intervention type="Other">Usual Care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Universidad Nacional de Rosario</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>9 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 22, 2011</first_received>
    <start_date>January 2006</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>February 22, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT01300754</url>
  </study>
  <study rank="791">
    <title>Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aricept (donepezil SR 23 mg)</intervention>
      <intervention type="Drug">Aricept (donepezil IR 10 mg)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Inc.</lead_sponsor>
      <collaborator>Eisai Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1467</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2007</first_received>
    <start_date>June 2007</start_date>
    <last_updated>June 26, 2014</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>November 12, 2012</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to Week 24 in SIB Total Score</outcome_measure>
      <outcome_measure>Overall Change From Baseline in Modified CIBIC+ to Week 24</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in ADCS-ADL Total Score</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in MMSE Total Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00478205</url>
  </study>
  <study rank="792">
    <title>A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine hydrobromide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>636</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>November 10, 2005</start_date>
    <completion_date>October 1997</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to the end of treatment in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores</outcome_measure>
      <outcome_measure>Change from baseline to the end of treatment in ADAS-cog/13 and DAD scores; Concentration of drug in blood; PGWB; Health/social care resource use; Incidence of adverse events; Changes in laboratory tests, ECGs and physical examinations</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00253201</url>
  </study>
  <study rank="793">
    <title>A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine hydrobromide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>653</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 10, 2005</first_received>
    <start_date>February 1997</start_date>
    <completion_date>December 1998</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to the end of treatment in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores</outcome_measure>
      <outcome_measure>Change from baseline in ADAS-cog/13 and DAD scores to the end of treatment; concentration of drug in blood; PGWB; Health/social care resource use; Incidence of adverse events; Changes in laboratory tests, ECGs and physical examinations</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00253188</url>
  </study>
  <study rank="794">
    <title>Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-089</intervention>
      <intervention type="Drug">ABT-089</intervention>
      <intervention type="Drug">ABT-089</intervention>
      <intervention type="Drug">ABT-089</intervention>
      <intervention type="Drug">ABT-089</intervention>
      <intervention type="Drug">ABT-089</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>337</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 7, 2007</first_received>
    <start_date>November 2007</start_date>
    <last_updated>August 19, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Pharmacokinetics (how the body handles the study drug)</outcome_measure>
      <outcome_measure>Pharmacodynamic (how the study drug affects cognitive functions such as thinking and memory)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00555204</url>
  </study>
  <study rank="795">
    <title>Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">bapineuzumab</intervention>
      <intervention type="Drug">bapineuzumab</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>901</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 24, 2008</first_received>
    <start_date>June 2008</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>December 4, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>October 22, 2013</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78</outcome_measure>
      <outcome_measure>The Change From Baseline in the Disability Assessment for Demential (DAD) Total Score at Week 78</outcome_measure>
      <outcome_measure>The Change From Baseline in Brain Amyloid Burden at Week 71.</outcome_measure>
      <outcome_measure>The Change From Baseline in Phospho-tau Levels in the Cerebrospinal Fluid (CSF) at Week 71.</outcome_measure>
      <outcome_measure>The Change From Baseline in Brain Volume at Week 71</outcome_measure>
      <outcome_measure>Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78</outcome_measure>
      <outcome_measure>Divergence of Effect on the DAD Total Scores From Week 39 to Week 78</outcome_measure>
      <outcome_measure>Time to Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)</outcome_measure>
      <outcome_measure>Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)</outcome_measure>
      <outcome_measure>Time to Median Placebo Deterioration on DAD Total Score</outcome_measure>
      <outcome_measure>Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis Plan)</outcome_measure>
      <outcome_measure>Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (European Union Analysis Plan)</outcome_measure>
      <outcome_measure>Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)</outcome_measure>
      <outcome_measure>Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (European Union Analysis Plan)</outcome_measure>
      <outcome_measure>Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (US Analysis Plan)</outcome_measure>
      <outcome_measure>Change From Baseline in Dependence Scale Total Score at Week 78</outcome_measure>
      <outcome_measure>Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00667810</url>
  </study>
  <study rank="796">
    <title>A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Advanced Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB BIOSCIENCES GmbH</lead_sponsor>
      <collaborator>Otsuka Pharmaceutical Co., Ltd.</collaborator>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 6, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>May 7, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>March 11, 2014</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (&quot;on&quot; State) Total Score</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of &quot;on&quot; and &quot;Off&quot; State) Total Score</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Treatment Period in Absolute Time Spent &quot;Off&quot;</outcome_measure>
      <outcome_measure>Change From Baseline to the End of the Treatment Period in Time Spent &quot;on&quot; Without Troublesome Dyskinesia</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01723904</url>
  </study>
  <study rank="797">
    <title>A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">MEDI8968 SC for 12 months</intervention>
      <intervention type="Biological">Placebo SC for 12 months</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MedImmune LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>464</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 6, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the effect of MEDI8968 on the rate of acute exacerbations of COPD (AECOPD) in adult subjects with COPD; GOLD II-IV on standard maintenance therapy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01448850</url>
  </study>
  <study rank="798">
    <title>A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Preladenant</intervention>
      <intervention type="Drug">Placebo tablet to match Preladenant</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 10, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>August 18, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>August 18, 2016</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Mean &quot;Off&quot; Time (Hours Per Day) at Week 12</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced an Adverse Event (AE)</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Study Treatment Due to an AE</outcome_measure>
      <outcome_measure>Percentage of Participants With ≥30% Reduction in &quot;Off&quot; Time at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in Mean &quot;On&quot; Time Without Troublesome Dyskinesias (Hours Per Day) at Week 12</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01294800</url>
  </study>
  <study rank="799">
    <title>Alzheimer's Disease Prevention Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Memory Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Estrogen</intervention>
      <intervention type="Drug">Estrogen and Progesterone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute on Aging (NIA)</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>October 29, 1999</start_date>
    <completion_date>September 2007</completion_date>
    <last_updated>November 3, 2010</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00000176</url>
  </study>
  <study rank="800">
    <title>A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">MRI</intervention>
      <intervention type="Other">FDG-PET</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>September 19, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>August 10, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Regional cerebral blood flow, as measured by dASL.</outcome_measure>
      <outcome_measure>Rate of cerebral glucose consumption, MRglc, as measured by fludeoxyglucose-PET (FDG-PET)</outcome_measure>
      <outcome_measure>Resting state functional MRI blood-oxygen-level-dependent (fMRI BOLD) response</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00757939</url>
  </study>
  <study rank="801">
    <title>Lipitor as a Treatment for Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atorvastatin calcium</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for the Study of Aging (ISOA)</lead_sponsor>
      <collaborator>Pfizer</collaborator>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 19, 2001</first_received>
    <start_date>October 2000</start_date>
    <completion_date>August 2004</completion_date>
    <last_updated>November 8, 2006</last_updated>
    <last_verified>November 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00024531</url>
  </study>
  <study rank="802">
    <title>Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rosiglitazone (Extended Release)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 28, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>November 4, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>AUC (0-inf) and Cmax of RSG XR</outcome_measure>
      <outcome_measure>AUC(0-t), t1/2 and tmax for RSG XR</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00688207</url>
  </study>
  <study rank="803">
    <title>Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SR57667B</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sanofi</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>564</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 26, 2005</first_received>
    <start_date>July 2003</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>December 22, 2008</last_updated>
    <last_verified>December 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to disability warranting introduction of Ldopaor a dopamine agonist.</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00228150</url>
  </study>
  <study rank="804">
    <title>Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Relapsed Multiple Myeloma</condition>
      <condition>End-stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carfilzomib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Onyx Therapeutics, Inc.</lead_sponsor>
      <collaborator>Onyx Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>September 6, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>March 31, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>March 31, 2016</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Terminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Clearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Mean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Volume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Clearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Mean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Volume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-389/M14</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-389/M14</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration for Metabolite PR-389/M14</outcome_measure>
      <outcome_measure>Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-389/M14</outcome_measure>
      <outcome_measure>Terminal Half-life (T½) of Metabolite PR-389/M14</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-413/M15</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-413/M15</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-413/M15</outcome_measure>
      <outcome_measure>Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-413/M15</outcome_measure>
      <outcome_measure>Terminal Half-life (T½) of Metabolite PR-413/M15</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-519/M16</outcome_measure>
      <outcome_measure>Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-519/M16</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-519/M16</outcome_measure>
      <outcome_measure>Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-519/M16</outcome_measure>
      <outcome_measure>Terminal Half-life (T½) of Metabolite PR-519/M16</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01949532</url>
  </study>
  <study rank="805">
    <title>Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Physical therapy aimed to move safely</intervention>
      <intervention type="Other">Physical Therapy aimed to improve Physical Activity</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
      <collaborator>ZonMw: The Netherlands Organisation for Health Research and Development</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>700</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 5, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>January 27, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Level of Physical Activity based on the LAPAQ questionnaire</outcome_measure>
      <outcome_measure>One week diary of physical activity</outcome_measure>
      <outcome_measure>Level of Physical Activity based on an activity monitor</outcome_measure>
      <outcome_measure>Physical Fitness (Six Minute Walk Test &amp; Astrand bicycle test)</outcome_measure>
      <outcome_measure>Quality of Life (PDQ-39)</outcome_measure>
      <outcome_measure>Mood and Depression (HADS)</outcome_measure>
      <outcome_measure>Cognition (CANTAB)</outcome_measure>
      <outcome_measure>disease severity ( Nine Hole Peg test, UPDRS)</outcome_measure>
      <outcome_measure>Safety(Falls)</outcome_measure>
      <outcome_measure>Mobility (Timed up and go test)</outcome_measure>
      <outcome_measure>Fatigue (FSS)</outcome_measure>
      <outcome_measure>Medication (questionnaire)</outcome_measure>
      <outcome_measure>Medical Costs (questionnaire)</outcome_measure>
      <outcome_measure>Quality of Sleep (SCOPA-sleep)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00748488</url>
  </study>
  <study rank="806">
    <title>Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Alequel</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hadassah Medical Organization</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 28, 2014</first_received>
    <start_date>January 2008</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>September 21, 2014</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>September 7, 2014</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Improved in Disease Activity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02185183</url>
  </study>
  <study rank="807">
    <title>Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bradykinin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vanderbilt University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 19, 2009</first_received>
    <start_date>December 2003</start_date>
    <last_updated>November 18, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00868855</url>
  </study>
  <study rank="808">
    <title>Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anxiety Disorders</condition>
      <condition>Mood Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Single Diagnosis Treatment Protocol</intervention>
      <intervention type="Behavioral">Unified Protocol (UP)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boston University</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 12, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>January 14, 2016</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Anxiety Disorders Interview Schedule for DSM-IV-Lifetime Version</outcome_measure>
      <outcome_measure>Clinical Global Impression Severity (CGI-S) and Improvement Scales (CGI-I)</outcome_measure>
      <outcome_measure>Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scale (SIGH-A and SIGH-D)</outcome_measure>
      <outcome_measure>Mini or Superlite-ADIS-IV</outcome_measure>
      <outcome_measure>Superlite-ADIS-IV</outcome_measure>
      <outcome_measure>Yale-Brown Obsessive Compulsive Scale Interview (Y-BOCS)</outcome_measure>
      <outcome_measure>Panic Disorder Severity Scale (PDSS)</outcome_measure>
      <outcome_measure>Liebowitz Social Anxiety Scale (LSAS)</outcome_measure>
      <outcome_measure>Generalized Anxiety Disorder Severity Scale (GADSS)</outcome_measure>
      <outcome_measure>Post-Traumatic Stress Disorder (PTSD) Symptom Scale-Interview Version (PSS-I)</outcome_measure>
      <outcome_measure>Beck Depression Inventory (BDI-II)</outcome_measure>
      <outcome_measure>Beck Anxiety Inventory (BAI)</outcome_measure>
      <outcome_measure>Overall Anxiety Sensitivity and Impairment Scale (OASIS)</outcome_measure>
      <outcome_measure>Work and Social Adjustment Scale (WSAS)</outcome_measure>
      <outcome_measure>Credibility/Expectancy Questionnaire</outcome_measure>
      <outcome_measure>Rand-modified, Medical Outcomes Study 36-item Short-Form Health Survey (Rand-MOS-SF-36)</outcome_measure>
      <outcome_measure>University of Rhode Island Change Assessment</outcome_measure>
      <outcome_measure>Homework Compliance Scale</outcome_measure>
      <outcome_measure>Anxiety Sensitivity Index</outcome_measure>
      <outcome_measure>Anxiety Control Questionnaire Revised (ACQ-R)</outcome_measure>
      <outcome_measure>Behavioral Inhibition/Behavioral Activation Scale (BIS/BAS)</outcome_measure>
      <outcome_measure>Eysenck Personality Questionnaire-Revised-Short Form (EPQR-S)</outcome_measure>
      <outcome_measure>Emotion Regulation Questionnaire (ERQ)</outcome_measure>
      <outcome_measure>Eysenck Personality Questionnaire-Revised - Short Form (EPQR-S)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01243606</url>
  </study>
  <study rank="809">
    <title>Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">PET/CT</intervention>
      <intervention type="Drug">F-18 FPCIT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Asan Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 30, 2007</first_received>
    <start_date>November 2006</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>January 11, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>diagnostic sensitivity and specificity, and acute complication</outcome_measure>
      <outcome_measure>correlation of specific striatal uptake to non specific uptake ratio of F-18 FPCIT and clinical sererity (H&amp;Y stage)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00468078</url>
  </study>
  <study rank="810">
    <title>A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-04236921 SC injection</intervention>
      <intervention type="Drug">PF-04236921 SC injection</intervention>
      <intervention type="Drug">PF-04236921 SC injection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 31, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>December 14, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>September 14, 2015</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg</outcome_measure>
      <outcome_measure>The CDAI-70 Response Rate at Week 8 in Participants Who Received Placebo and PF-04236921 200 mg</outcome_measure>
      <outcome_measure>The CDAI-70 Response Rate at Week 12 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg</outcome_measure>
      <outcome_measure>The CDAI-70 Response Rate at Week 12 in Participants Who Received Placebo and PF-04236921 200 mg</outcome_measure>
      <outcome_measure>The CDAI-70 Response Rate Over Time in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg</outcome_measure>
      <outcome_measure>The CDAI-70 Response Rate Over Time in Participants Who Received Placebo and PF-04236921 200 mg</outcome_measure>
      <outcome_measure>The CDAI Remission Rate Over Time in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg</outcome_measure>
      <outcome_measure>The CDAI Remission Rate Over Time in Participants Who Received Placebo and PF-04236921 200 mg</outcome_measure>
      <outcome_measure>The CDAI-100 Response Rate Over Time in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg</outcome_measure>
      <outcome_measure>The CDAI-100 Response Rate Over Time in Participants Who Received Placebo and PF-04236921 200 mg</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score Over Time in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg</outcome_measure>
      <outcome_measure>Change From Baseline in CDAI Score Over Time in Participants Who Received Placebo and PF-04236921 200 mg</outcome_measure>
      <outcome_measure>Percentages of Participants With Confirmed Positive Anti-drug Antibodies (ADAs)</outcome_measure>
      <outcome_measure>Percentages of Participants With Confirmed Positive Neutralizing Antibodies (NAbs)</outcome_measure>
      <outcome_measure>Serum PF-04236921 Concentration Over Time</outcome_measure>
      <outcome_measure>Number of Participants Who Withdrew From the Study Due to Treatment-emergent Adverse Events (AEs)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01287897</url>
  </study>
  <study rank="811">
    <title>A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-03654746</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 7, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 16, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>April 9, 2014</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Clinically Significant Vital Sign Abnormalities</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Significant Laboratory Test Abnormalities</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Significant Change From Baseline in Physical Examination</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Baseline</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 5</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 10</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 15</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 20</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 25</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 30</outcome_measure>
      <outcome_measure>Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Follow-up</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 5</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 10</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 15</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 20</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 25</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 30</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Follow-up</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 5</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 10</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 15</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 20</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 25</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 30</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Follow-up</outcome_measure>
      <outcome_measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for PF-03654746</outcome_measure>
      <outcome_measure>Maximum Serum Concentration (Cmax) for PF-03654746</outcome_measure>
      <outcome_measure>Time to Reach Maximum Observed Serum Concentration (Tmax) for PF-03654746</outcome_measure>
      <outcome_measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for Donepezil</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for Donepezil</outcome_measure>
      <outcome_measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Donepezil</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01028911</url>
  </study>
  <study rank="812">
    <title>Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Isradipine CR 5mg</intervention>
      <intervention type="Drug">Isradipine CR 10mg</intervention>
      <intervention type="Drug">Isradipine CR 20mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
      <collaborator>Northwestern University Dixon Fund</collaborator>
      <collaborator>The Parkinson Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 26, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>April 16, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>October 2, 2012</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.</outcome_measure>
      <outcome_measure>Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale</outcome_measure>
      <outcome_measure>Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale</outcome_measure>
      <outcome_measure>Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale</outcome_measure>
      <outcome_measure>Efficacy: Change in Modified Hoehn &amp; Yahr Scale</outcome_measure>
      <outcome_measure>Efficacy: Change in Modified Schwab &amp; England Independence Scale</outcome_measure>
      <outcome_measure>Efficacy: Change in Beck Depression Inventory II (BDI-II)</outcome_measure>
      <outcome_measure>Efficacy: Change in Montreal Cognitive Assessment</outcome_measure>
      <outcome_measure>Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)</outcome_measure>
      <outcome_measure>Vital Signs: Change in Systolic Standing</outcome_measure>
      <outcome_measure>Vital Signs: Change in Systolic Supine</outcome_measure>
      <outcome_measure>Vital Signs: Change in Diastolic Standing</outcome_measure>
      <outcome_measure>Vital Signs: Change in Diastolic Supine</outcome_measure>
      <outcome_measure>Vital Signs: Change in Pulse Standing</outcome_measure>
      <outcome_measure>Vital Signs: Change in Pulse Supine</outcome_measure>
      <outcome_measure>Common Adverse Events: Oedema Peripheral</outcome_measure>
      <outcome_measure>Common Adverse Events: Dizziness</outcome_measure>
      <outcome_measure>Common Adverse Events: Nasopharyngitis</outcome_measure>
      <outcome_measure>Common Adverse Events: Headache</outcome_measure>
      <outcome_measure>Common Adverse Events: Constipation</outcome_measure>
      <outcome_measure>Common Adverse Events: Fatigue</outcome_measure>
      <outcome_measure>Common Adverse Events: Nausea</outcome_measure>
      <outcome_measure>Common Adverse Events: Upper Respiratory Tract Infection</outcome_measure>
      <outcome_measure>Common Adverse Events: Depression</outcome_measure>
      <outcome_measure>Common Adverse Events: Somnolence</outcome_measure>
      <outcome_measure>Common Adverse Events: Insomnia</outcome_measure>
      <outcome_measure>Common Adverse Events: Dyspepsia</outcome_measure>
      <outcome_measure>Common Adverse Events: Diarrhoea</outcome_measure>
      <outcome_measure>Common Adverse Events: Sinusitis</outcome_measure>
      <outcome_measure>Common Adverse Events: Back Pain</outcome_measure>
      <outcome_measure>Common Adverse Events: Hypotension</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00909545</url>
  </study>
  <study rank="813">
    <title>Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Memantine</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 28, 2007</first_received>
    <start_date>April 2006</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>April 30, 2009</last_updated>
    <last_verified>April 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>This is an exploratory study. The primary efficacy point will be global impressions.</outcome_measure>
      <outcome_measure>Analyses will be computed for the categorical dependent variables (DV): spirograph, pouring, subjective ADL, observed tremor, global assessment by examiner, global assessment by patient, and subjective assessment by patient scores.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00646204</url>
  </study>
  <study rank="814">
    <title>Treatments for Insomnia in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Insomnia</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Light box (Litebook company)</intervention>
      <intervention type="Behavioral">CBT and sleep hygiene</intervention>
      <intervention type="Drug">Doxepin and Zopiclone</intervention>
      <intervention type="Device">Light box ( Litebook company)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>McGill University Health Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 19, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>April 15, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SCOPA sleep scale</outcome_measure>
      <outcome_measure>Actigraphy</outcome_measure>
      <outcome_measure>Daily sleep dairy</outcome_measure>
      <outcome_measure>Insomnia severity Index (ISI)</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index (PSQI)</outcome_measure>
      <outcome_measure>Parkinson's Disease Sleep Scale (PDSS)</outcome_measure>
      <outcome_measure>Clinical global impression of change</outcome_measure>
      <outcome_measure>The Krupp Fatigue Severity Scale</outcome_measure>
      <outcome_measure>Beck depression index</outcome_measure>
      <outcome_measure>Adherence to treatment</outcome_measure>
      <outcome_measure>Severity of motor manifestations (UPDRS)</outcome_measure>
      <outcome_measure>Quality of life (PDQ-39)</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Sleep Hygiene Index</outcome_measure>
      <outcome_measure>Dysfunctional Beliefs and Attitudes about Sleep, a brief version ( DBAS 16)</outcome_measure>
      <outcome_measure>Epworth Sleepiness Scale (ESS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01489982</url>
  </study>
  <study rank="815">
    <title>Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dotarem</intervention>
      <intervention type="Drug">Gadovist</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Guerbet</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>189</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>December 3, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>November 14, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>November 14, 2012</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Intra-patient Accuracy (Percent Agreement), On-site Data</outcome_measure>
      <outcome_measure>Intra-patient Accuracy, in Off-site Readings</outcome_measure>
      <outcome_measure>Specificity</outcome_measure>
      <outcome_measure>Sensitivity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01026389</url>
  </study>
  <study rank="816">
    <title>Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Granulomatous Disease</condition>
      <condition>Communicable Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gene Therapy Method for CGD</intervention>
      <intervention type="Device">Isolex 300i Magnetic Cell Selector</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 1999</first_received>
    <start_date>June 1995</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>September 26, 2015</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00001476</url>
  </study>
  <study rank="817">
    <title>Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tolvaptan (OPC-41061)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1371</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 6, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>May 13, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment difference in the change of eGFR from pre-treatment baseline to post-treatment follow-up, normalized (divided) by each subject's treatment duration</outcome_measure>
      <outcome_measure>Treatment difference in annualized slope of eGFR calculated for individual subjects using an appropriate baseline and available, post-randomization, on-treatment assessments</outcome_measure>
      <outcome_measure>Plasma tolvaptan and metabolites, including DM-4103 plasma concentrations</outcome_measure>
      <outcome_measure>Uosm and urine specific gravity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02160145</url>
  </study>
  <study rank="818">
    <title>Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dry Eye Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">P-321 Ophthalmic Solution</intervention>
      <intervention type="Drug">P-321 Ophthalmic Solution placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Parion Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>53</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 28, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>May 1, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subjects with adverse events</outcome_measure>
      <outcome_measure>Changes from baseline in 14 days in visual acuity.</outcome_measure>
      <outcome_measure>Change from baseline at 28 days in visual acuity for Cohort 4 only.</outcome_measure>
      <outcome_measure>Changes from baseline at 14 days in corneal staining.</outcome_measure>
      <outcome_measure>Changes from baseline at 28 days in corneal staining for cohort 4 only.</outcome_measure>
      <outcome_measure>Changes from baseline at 14 days in conjunctival staining.</outcome_measure>
      <outcome_measure>Changes from baseline at 28 days in conjunctival staining for Cohort 4 only.</outcome_measure>
      <outcome_measure>Changes from baseline at 14 days in intraocular pressure.</outcome_measure>
      <outcome_measure>Changes from baseline at 28 days in intraocular pressure. for Cohort 4 only.</outcome_measure>
      <outcome_measure>Changes from baseline at 14 days in ophthalmoscopy.</outcome_measure>
      <outcome_measure>Changes from baseline at 28 days in ophthalmoscopy for Cohort 4 only.</outcome_measure>
      <outcome_measure>Measure plasma P-321 concentrations</outcome_measure>
      <outcome_measure>Measure urine concentrations of P-321</outcome_measure>
      <outcome_measure>Measure tear concentrations of P-321</outcome_measure>
      <outcome_measure>Measure plasma P-321 concentrations in Cohort 4</outcome_measure>
      <outcome_measure>Measure urine concentrations of P-321 in Cohort 4</outcome_measure>
      <outcome_measure>Measure tear concentrations of P-321 in Cohort 4</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02242032</url>
  </study>
  <study rank="819">
    <title>the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thyroid Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chinese herbs-I</intervention>
      <intervention type="Drug">chinese herbs-II</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tianjin Medical University Cancer Institute and Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 7, 2013</first_received>
    <start_date>June 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>February 14, 2016</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>diameter，number of the tumor</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01873014</url>
  </study>
  <study rank="820">
    <title>Cannabidiol for Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cannabidiol</intervention>
      <intervention type="Drug">placebo in drops</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Meir Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 20, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>April 13, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>reduction of 70 points in CDAI</outcome_measure>
      <outcome_measure>change in quality of life during the study</outcome_measure>
      <outcome_measure>any adverse events during study period</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01037322</url>
  </study>
  <study rank="821">
    <title>A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 18, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>July 2005</completion_date>
    <last_updated>September 24, 2014</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tolerability of rotigotine as determined by the total number of subjects completing the trial.</outcome_measure>
      <outcome_measure>Effect on symptoms and other variables.</outcome_measure>
      <outcome_measure>Safety.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00242008</url>
  </study>
  <study rank="822">
    <title>A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">infliximab or placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centocor, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>306</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>June 2000</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>April 26, 2010</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Reduction in the number of draining fistulas</outcome_measure>
      <outcome_measure>Complete fistula response (no draining fistula).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00207766</url>
  </study>
  <study rank="823">
    <title>Predictive Value of the &quot;Cytocapacity Test&quot; Patients With Lymphoproliferative Diseases and High-dose Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hodgkin's Disease</condition>
      <condition>Non-Hodgkin Lymphomas</condition>
      <condition>Multiple Myelomas</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">lenograstim</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>WiSP Wissenschaftlicher Service Pharma GmbH</lead_sponsor>
      <collaborator>Ludwig-Maximilians - University of Munich</collaborator>
      <collaborator>Chugai Pharma GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>169</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 10, 2010</first_received>
    <start_date>May 2003</start_date>
    <completion_date>December 2004</completion_date>
    <last_updated>March 10, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of infections</outcome_measure>
      <outcome_measure>Time to platelet engraftment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01085058</url>
  </study>
  <study rank="824">
    <title>Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Extracorporeal Photopheresis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>4 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 7, 2002</first_received>
    <start_date>November 2002</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>September 26, 2015</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Determination of response rate including degree of improvement; steroid sparing effect; types of cGVHD problems which respond to this therapy; assessment of problems or side effects or adverse events associated with the procedure.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00048789</url>
  </study>
  <study rank="825">
    <title>Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chagas Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Benznidazole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Drugs for Neglected Diseases</lead_sponsor>
      <collaborator>Medecins Sans Frontieres, Netherlands</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 1, 2012</first_received>
    <start_date>April 2011</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>August 30, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary endpoints are: - A positive or negative PCR at baseline (BL) among serology positive patients.</outcome_measure>
      <outcome_measure>- Identification of the optimal relationship between sensitivity and feasibility at baseline.</outcome_measure>
      <outcome_measure>- Identification of the optimal relationship between sensitivity and Identification of the optimal relationship between sensitivity and feasibility at End Of Treatment (EOT)</outcome_measure>
      <outcome_measure>- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at EOT - to be estimated using 1) the current sampling schedule (CS), the most sensitive one and the optimal one.</outcome_measure>
      <outcome_measure>- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at 6 and 12 months follow-up - to be estimated using 1) the current sampling schedule (CS) and the optimal one (based on EOT data).</outcome_measure>
      <outcome_measure>- Relative reduction [(parasite count at baseline - parasite count at EOT, 6 and 12 months)/parasite count at baseline] of parasitemia - to be evaluated through parasite load at EOT, 6 and 12 months through quantitative PCR.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01678599</url>
  </study>
  <study rank="826">
    <title>Lisuride Patch to Treat Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intravenous Levodopa</intervention>
      <intervention type="Drug">Lisuride Transdermal System</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 6, 2004</first_received>
    <start_date>August 2004</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>October 25, 2007</last_updated>
    <last_verified>March 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change in parkinsonian severity variance.</outcome_measure>
      <outcome_measure>Change in dyskinesia severity.</outcome_measure>
      <outcome_measure>Change in antiparkinsonian efficacy half-time for levodopa.</outcome_measure>
      <outcome_measure>Change in parkinsonian severity.</outcome_measure>
      <outcome_measure>Change in optimal oral levodopa requirement.</outcome_measure>
      <outcome_measure>Change in patient diary rating.</outcome_measure>
      <outcome_measure>Change in daytime somnolence.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00089622</url>
  </study>
  <study rank="827">
    <title>Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Intravenous injection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Royan Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>25 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 17, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>January 3, 2016</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>mass formation</outcome_measure>
      <outcome_measure>Creatinin</outcome_measure>
      <outcome_measure>GFR</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02195323</url>
  </study>
  <study rank="828">
    <title>A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease Psychosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pimavanserin tartrate (ACP-103)</intervention>
      <intervention type="Drug">Pimavanserin tartrate (ACP-103)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ACADIA Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>298</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2007</first_received>
    <start_date>June 2007</start_date>
    <last_updated>February 6, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>February 6, 2014</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antipsychotic Efficacy</outcome_measure>
      <outcome_measure>Motor Symptoms Change From Baseline (Negative = Improvement)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00477672</url>
  </study>
  <study rank="829">
    <title>Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Gaucher Disease, Type 1</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">GA-GCB (velaglucerase alfa)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Shire</lead_sponsor>
      <collaborator>Shire Human Genetic Therapies, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 23, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>August 4, 2010</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants Who Experienced at Least One Adverse Event</outcome_measure>
      <outcome_measure>Change From Baseline to Week 53 in Hemoglobin Concentration</outcome_measure>
      <outcome_measure>Percent Change From Baseline to Week 53 in Platelet Count</outcome_measure>
      <outcome_measure>Percent Change From Baseline to Week 51 in Normalized Liver Volume</outcome_measure>
      <outcome_measure>Percent Change From Baseline to Week 51 in Normalized Spleen Volume</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00478647</url>
  </study>
  <study rank="830">
    <title>Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Azithromycin + Metronidazole</intervention>
      <intervention type="Drug">Metronidazole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Prof. Arie Levine</lead_sponsor>
      <collaborator>Wolfson Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>73</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 12, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 6, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle)</outcome_measure>
      <outcome_measure>Normalization of CRP ( CRP ≤0.5 mg/dL).</outcome_measure>
      <outcome_measure>Fecal calprotectin at 8 weeks .</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01596894</url>
  </study>
  <study rank="831">
    <title>Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Lesch-Nyhan Disease</condition>
      <condition>Self-injurious Behavior</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ecopipam</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Psyadon Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 14, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 5, 2015</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Behavior Problems Inventory - Self-Injurious Behavior Subscale</outcome_measure>
      <outcome_measure>Effect of Ecopipam Withdrawal and Maintenance</outcome_measure>
      <outcome_measure>Safety Summary of Ecopipam in Patients With Lesch-Nyhan Disease: Total Number of Serious and Non-Serious Adverse Events Experienced During 3 Double-blind Crossover Periods</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01751802</url>
  </study>
  <study rank="832">
    <title>HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
      <condition>Gluten</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Gluten challenge.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oslo University Hospital</lead_sponsor>
      <collaborator>South-Eastern Norway Regional Health Authority</collaborator>
      <collaborator>University of Oslo</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>April 6, 2010</first_received>
    <start_date>September 2006</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>September 18, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HLA-DQ2-tetramer response after gluten challenge</outcome_measure>
      <outcome_measure>Mucosal responses to 3 day gluten challenge.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01100099</url>
  </study>
  <study rank="833">
    <title>A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-04447943</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 1, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>August 5, 2010</last_updated>
    <last_verified>August 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>vital signs</outcome_measure>
      <outcome_measure>ECGs</outcome_measure>
      <outcome_measure>Physical and Neurological examinations</outcome_measure>
      <outcome_measure>Laboratory tests</outcome_measure>
      <outcome_measure>adverse events</outcome_measure>
      <outcome_measure>Plasma concentrations of PF 04447943 over time</outcome_measure>
      <outcome_measure>Plasma concentrations of donepezil over time</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00988598</url>
  </study>
  <study rank="834">
    <title>Study and Treatment of Post Lyme Disease (STOP-LD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lyme Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Antibiotics</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>November 2, 1999</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>August 26, 2010</last_updated>
    <last_verified>November 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00000937</url>
  </study>
  <study rank="835">
    <title>Enhancing the Secondary Prevention of Coronary Artery Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Disease</condition>
      <condition>Ischemic Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Evidence summaries endorsed by local opinion leaders</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Alberta</lead_sponsor>
      <collaborator>Heart and Stroke Foundation of Canada</collaborator>
      <collaborator>Alberta Heritage Foundation for Medical Research</collaborator>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>480</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 25, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Composite measure representing improvement in cholesterol-related secondary prevention consisting of (1) provision of a statin sample (2) provision of a statin prescription or (3) dosage increase of a statin within the first 6 months post-angiogram.</outcome_measure>
      <outcome_measure>Provision of other proven efficacious medications for coronary artery disease by 6 months including ACE inhibitors, beta-blockers and antiplatelet agents.</outcome_measure>
      <outcome_measure>Changes in the provision of other lipid lowering medications.</outcome_measure>
      <outcome_measure>Smoking rates - receipt of smoking cessation advice/nicotine replacement products/bupropion.</outcome_measure>
      <outcome_measure>Repeat fasting lipid panel within 6 months post-angiogram.</outcome_measure>
      <outcome_measure>Proportion of patients achieving target LDL-C of 2.0mmol/l or less.</outcome_measure>
      <outcome_measure>Clinical events including myocardial infarction, stroke, admissions for coronary artery disease, total hospitalizations and mortality.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00175240</url>
  </study>
  <study rank="836">
    <title>Albuterol in Individuals With Late Onset Pompe Disease (LOPD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pompe Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albuterol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 8, 2013</first_received>
    <start_date>June 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>February 11, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>Change in forced vital capacity at 3 months</outcome_measure>
      <outcome_measure>Change in 6 minute walk test in 6 months.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01859624</url>
  </study>
  <study rank="837">
    <title>Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">carbidopa, levodopa, entacapone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>184</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 31, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>June 2006</completion_date>
    <last_updated>November 22, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Quality of life assessment</outcome_measure>
      <outcome_measure>Symptom control change from baseline</outcome_measure>
      <outcome_measure>Change from baseline in number of wearing-off symptoms</outcome_measure>
      <outcome_measure>Change from baseline in proportion of patients experiencing wearing-off</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00143026</url>
  </study>
  <study rank="838">
    <title>Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Cognitive Decline Due to Alzheimer Disease</condition>
      <condition>Mild Cognitive Impairment Due to Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naproxen</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Douglas Mental Health University Institute</lead_sponsor>
      <collaborator>McGill University</collaborator>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>December 19, 2015</first_received>
    <start_date>August 2012</start_date>
    <completion_date>December 2019</completion_date>
    <last_updated>March 3, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status</outcome_measure>
      <outcome_measure>Composite Alzheimer Progression Score (APS) derived from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease</outcome_measure>
      <outcome_measure>frequency and severity of treatment-emergent adverse events</outcome_measure>
      <outcome_measure>ratio of total and protein-bound naproxen concentrations as well as kinetics of drug accumulation and washout</outcome_measure>
      <outcome_measure>biomarkers of inflammatory processes</outcome_measure>
      <outcome_measure>CSF biomarkers of AD pathogenesis</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02702817</url>
  </study>
  <study rank="839">
    <title>Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatic Veno-Occlusive Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 30, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>November 17, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>AT-III level before 5th dose of AT-III</outcome_measure>
      <outcome_measure>AT-III level before 9th dose</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01886248</url>
  </study>
  <study rank="840">
    <title>A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPM 962</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 27, 2012</first_received>
    <start_date>January 2005</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>February 3, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maintenance Dose of the SPM962</outcome_measure>
      <outcome_measure>Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters</outcome_measure>
      <outcome_measure>Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy</outcome_measure>
      <outcome_measure>UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy</outcome_measure>
      <outcome_measure>UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy</outcome_measure>
      <outcome_measure>UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy</outcome_measure>
      <outcome_measure>UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.</outcome_measure>
      <outcome_measure>UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.</outcome_measure>
      <outcome_measure>UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy</outcome_measure>
      <outcome_measure>Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy</outcome_measure>
      <outcome_measure>Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01634243</url>
  </study>
  <study rank="841">
    <title>Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">piribedil</intervention>
      <intervention type="Drug">pramipexole or ropinirole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Desitin Arzneimittel GmbH</lead_sponsor>
      <collaborator>FGK Clinical Research GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 3, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>May 23, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy variable will be the 'median reaction time during the second 15 minutes (minutes 16-30)' of the subtest 'vigilance', visual test condition 'moving bar', of the Test battery for Attention Performances (TAP) at end of treatment.</outcome_measure>
      <outcome_measure>Other vigilance parameters of the TAP test</outcome_measure>
      <outcome_measure>Other neuropsychological tests: Test of verbal fluency (RWT), Verbal learning memory test (VLMT), Stroop test (FWIT)</outcome_measure>
      <outcome_measure>Epworth Sleepiness Scale (ESS)</outcome_measure>
      <outcome_measure>Parkinson's Disease Sleeping Scale (PDSS)</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) subscores I to IV and total score</outcome_measure>
      <outcome_measure>Parkinson's disease quality of life questionnaire (PDQ-39)</outcome_measure>
      <outcome_measure>Clinical Global Impressions (CGI) (except item 3.2)</outcome_measure>
      <outcome_measure>Patient Global Impression (PGI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01007864</url>
  </study>
  <study rank="842">
    <title>Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ropinirole prolonged release/extended release(PR/XR)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 9, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>April 11, 2013</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>November 16, 2009</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Food Effects on Cmax and Cmin of SKF101468 (Ropinirole) and Its Metabolites</outcome_measure>
      <outcome_measure>Food Effects on AUC0-24 of SKF101468 (Ropinirole) and Its Metabolites</outcome_measure>
      <outcome_measure>Food Effects on Tmax of SKF101468 (Ropinirole) and Its Metabolites</outcome_measure>
      <outcome_measure>Plasma Trough Concentrations of SKF101468 (Ropinirole) and Its Metabolites</outcome_measure>
      <outcome_measure>Total Score in the Japanese UPDRS Part III</outcome_measure>
      <outcome_measure>Change From Baseline in the Japanese UPDRS Part III</outcome_measure>
      <outcome_measure>Percent Change From Baseline in the Japanese UPDRS Part III</outcome_measure>
      <outcome_measure>Percentage of Responders of the Total Score in the Japanese UPDRS Total Score in Part III</outcome_measure>
      <outcome_measure>Total Score in the Japanese UPDRS Part I</outcome_measure>
      <outcome_measure>Change From Baseline in the Japanese UPDRS Part I</outcome_measure>
      <outcome_measure>Percent Change From Baseline in the Japanese UPDRS Part I</outcome_measure>
      <outcome_measure>Total Score in the Japanese UPDRS Part II</outcome_measure>
      <outcome_measure>Change From Baseline in the Japanese UPDRS Part II</outcome_measure>
      <outcome_measure>Percent Change From Baseline in the Japanese UPDRS Part II</outcome_measure>
      <outcome_measure>Total Score in the Japanese UPDRS Part IV</outcome_measure>
      <outcome_measure>Change From Baseline in the Japanese UPDRS Part IV</outcome_measure>
      <outcome_measure>Percent Change From Baseline in the Japanese UPDRS Part IV</outcome_measure>
      <outcome_measure>Summary of the Modified Hoehn &amp; Yahr Criteria Stages</outcome_measure>
      <outcome_measure>Number of Participants Scored as Responders on the Clinician's Global Impression (CGI) Scale</outcome_measure>
      <outcome_measure>Percentage of Participants Who Remained in the Study on the Indicated Days</outcome_measure>
      <outcome_measure>Change From Baseline in Albumin, Total Protein, and Hemoglobin at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Total Bilirubin, Blood Urea Nitrogen, and Creatinine at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Blood Urea Nitrogen, Cholesterol, Chloride, Potassium, and Sodium at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Prolactin at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Hematocrit at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Platelet Count and White Blood Cell Count at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Red Blood Cell Count at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Urinalysis Data</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in 12-Lead Electrocardiogram (ECG) Findings at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Supine and Standing Systolic and Diastolic Blood Pressure at Weeks 16 and 52</outcome_measure>
      <outcome_measure>Change From Baseline in Supine and Standing Pulse Rate at Weeks 16 and 52</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00434304</url>
  </study>
  <study rank="843">
    <title>A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Gaucher Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Taliglucerase alfa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Protalix</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 4, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>June 20, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>November 6, 2015</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hemoglobin</outcome_measure>
      <outcome_measure>Chitotriosidase</outcome_measure>
      <outcome_measure>Spleen Volume</outcome_measure>
      <outcome_measure>Platelet Count</outcome_measure>
      <outcome_measure>Liver Volume</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01411228</url>
  </study>
  <study rank="844">
    <title>Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ropinirole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 26, 2006</first_received>
    <start_date>June 2003</start_date>
    <completion_date>December 2004</completion_date>
    <last_updated>August 30, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Mean change from baseline in awake time &quot;off&quot; at Week 24 LOCF (last observation carried forward).</outcome_measure>
      <outcome_measure>Mean change from baseline in:</outcome_measure>
      <outcome_measure>amount and percent of awake time spent &quot;on&quot;</outcome_measure>
      <outcome_measure>percent awake time spent &quot;off&quot;</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS) total motor score</outcome_measure>
      <outcome_measure>UPDRS Activities of Daily Living score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00381472</url>
  </study>
  <study rank="845">
    <title>Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Flaxseed</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dr. Grant Pierce</lead_sponsor>
      <collaborator>St. Boniface General Hospital Research Centre</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>October 28, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 23, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>December 4, 2014</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary Outcome Measures Include the Following Events: (All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions.)</outcome_measure>
      <outcome_measure>Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00781950</url>
  </study>
  <study rank="846">
    <title>Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fudan University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 25, 2008</first_received>
    <start_date>November 2008</start_date>
    <last_updated>May 26, 2010</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Hoehn &amp; Yahr scale</outcome_measure>
      <outcome_measure>Schwab &amp; England score</outcome_measure>
      <outcome_measure>The liver kidney deficiency scale score by Traditional Chinese Medicine standard</outcome_measure>
      <outcome_measure>Dose of levodopa per day</outcome_measure>
      <outcome_measure>Dose of dopamine Agonists per day</outcome_measure>
      <outcome_measure>Parkinson disease sleep scale (PDSS)</outcome_measure>
      <outcome_measure>Assessment of autonomic dysfunction in Parkinson disease (SCOPA-AUT)</outcome_measure>
      <outcome_measure>Changes in laboratory indexes as safety assessment, including red blood cell(RBC), white blood cell(WBC), platelet(PLT), alanine transaminase(ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), creatinine(Cr) in blood samples, ect.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00629161</url>
  </study>
  <study rank="847">
    <title>Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cerebrolysin + donepezil</intervention>
      <intervention type="Drug">Cerebrolysin + placebo</intervention>
      <intervention type="Drug">Donepezil + placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ever Neuro Pharma GmbH</lead_sponsor>
      <collaborator>acromion GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>51 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>217</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 7, 2009</first_received>
    <start_date>October 2004</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>June 4, 2009</last_updated>
    <last_verified>June 2009</last_verified>
    <firstreceived_results_date>April 7, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28</outcome_measure>
      <outcome_measure>Clinical Interview-Based Impression of Change (CIBIC+) Score</outcome_measure>
      <outcome_measure>Change From Baseline for ADAS-COG+</outcome_measure>
      <outcome_measure>ADAS-COG+ Responders</outcome_measure>
      <outcome_measure>Change From Baseline for Original ADAS-COG</outcome_measure>
      <outcome_measure>CIBIC+ Score</outcome_measure>
      <outcome_measure>CIBIC+ Responders</outcome_measure>
      <outcome_measure>Clinical Interview-Based Impression of Severity (CIBIS+) Score</outcome_measure>
      <outcome_measure>Change From Baseline for Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)</outcome_measure>
      <outcome_measure>Change From Baseline in Total Score for Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Combined Responders, i.e. Response in ADAS-COG+ and CIBIC+</outcome_measure>
      <outcome_measure>Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry , Urinalysis, Electrocardiogram [ECG])</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00911807</url>
  </study>
  <study rank="848">
    <title>Study of the Efficacy of AT1001 (Larazotide Acetate) to Treat Celiac Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Larazotide acetate (AT1001)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alba Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>72 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 27, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>July 12, 2012</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response to gluten</outcome_measure>
      <outcome_measure>Anti-transglutaminase</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00889473</url>
  </study>
  <study rank="849">
    <title>An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entacapone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 7, 2005</first_received>
    <start_date>February 2003</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>November 22, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events during the long term treatment (maximum 3 years)</outcome_measure>
      <outcome_measure>Blood pressure at every 12 weeks</outcome_measure>
      <outcome_measure>Laboratory test at every 16 weeks</outcome_measure>
      <outcome_measure>ECG at every 16 weeks</outcome_measure>
      <outcome_measure>On time based on patient diary (up to 104 weeks)</outcome_measure>
      <outcome_measure>UPDRS score at every 16 weeks</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00237263</url>
  </study>
  <study rank="850">
    <title>A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GCS-100</intervention>
      <intervention type="Drug">Placebo, Saline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>La Jolla Pharmaceutical Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 25, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in estimated glomerular filtration rate (eGFR) from baseline relative to placebo after administration of GCS-100 for 8 weeks in patients with chronic kidney disease (CKD) and baseline eGFR of 15 - 44 mL/min/1.73m2</outcome_measure>
      <outcome_measure>Number of adverse events as a measure of safety and tolerability of GCS-100 administered for 8 weeks relative to placebo in patients with CKD</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01843790</url>
  </study>
  <study rank="851">
    <title>European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">3APS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bellus Health Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>930</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <first_received>September 14, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>December 7, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00217763</url>
  </study>
  <study rank="852">
    <title>A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ticagrelor</intervention>
      <intervention type="Drug">Clopidogrel</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>130 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>16415</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>November 20, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 25, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time from randomization to first occurrence of any event in the composite of cardiovascular death, myocardial infarction and ischemic stroke</outcome_measure>
      <outcome_measure>Time from randomisation to first occurrence of any event in the composite of CV death, MI, ischemic stroke and ALI</outcome_measure>
      <outcome_measure>Time from randomization to occurrence of cardiovascular death</outcome_measure>
      <outcome_measure>Time from randomization to occurrence of myocardial infarction</outcome_measure>
      <outcome_measure>Time from randomization to occurrence of all-cause mortality</outcome_measure>
      <outcome_measure>Time from randomization to occurrence of composite of cardiovascular death, myocardial infarction and all-cause stroke (ischaemic or haemorrhagic)</outcome_measure>
      <outcome_measure>Time from randomisation to occurrence of ALI</outcome_measure>
      <outcome_measure>Time from randomisation to occurrence of lower extremity revascularization</outcome_measure>
      <outcome_measure>Time from randomisation to occurrence of any revascularisation (coronary, peripheral [limb, mesenteric, renal, carotid and other])</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01732822</url>
  </study>
  <study rank="853">
    <title>An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab 10 mg/kg</intervention>
      <intervention type="Drug">Infliximab 5 mg/kg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centocor, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 22, 2005</first_received>
    <start_date>May 1996</start_date>
    <completion_date>February 1998</completion_date>
    <last_updated>November 3, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 1998</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with 50% or more reduction from baseline in the number of open fistulae at Week 3</outcome_measure>
      <outcome_measure>Percentage of patients achieving a complete response at week 52</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00269841</url>
  </study>
  <study rank="854">
    <title>Effect of LY450139 on the Long Term Progression of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY450139</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1537</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 11, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>March 13, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>November 6, 2013</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks</outcome_measure>
      <outcome_measure>LY450139 Population Pharmacokinetics: Clearance of LY450139</outcome_measure>
      <outcome_measure>LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug</outcome_measure>
      <outcome_measure>Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks</outcome_measure>
      <outcome_measure>Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00594568</url>
  </study>
  <study rank="855">
    <title>Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Graft-versus-host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rituximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northside Hospital, Inc.</lead_sponsor>
      <collaborator>Blood and Marrow Transplant Group of Georgia</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 12, 2010</first_received>
    <start_date>April 2011</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>March 22, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>December 16, 2015</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of Complete Response of cGVHD to Treatment.</outcome_measure>
      <outcome_measure>Rate of Overall Response of cGVHD to Treatment</outcome_measure>
      <outcome_measure>Rate of Partial Response of cGVHD to Treatment</outcome_measure>
      <outcome_measure>Requirement for Systemic Corticosteroid Use</outcome_measure>
      <outcome_measure>Time to Immunosuppression Withdrawal</outcome_measure>
      <outcome_measure>Incidence of Overall Survival</outcome_measure>
      <outcome_measure>Duration of Systemic Corticosteroid Use</outcome_measure>
      <outcome_measure>Incidence of Disease-free Survival</outcome_measure>
      <outcome_measure>Incidence of Non-relapse Mortality</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01161628</url>
  </study>
  <study rank="856">
    <title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MT-1303</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 8, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 4, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability of single dose of MT-1303 assessed by number of participants with adverse events</outcome_measure>
      <outcome_measure>Peak plasma concentration (Cmax) of MT-1303 and its metabolite</outcome_measure>
      <outcome_measure>Area under the plasma concentration versus time curve (AUC) of MT-1303 and its metabolite</outcome_measure>
      <outcome_measure>Pharmacodynamic effect of MT-1303 on lymphocyte count</outcome_measure>
      <outcome_measure>Exploratory parameter : C-reactive protein (CRP)</outcome_measure>
      <outcome_measure>Exploratory parameter :Erythrocyte sedimentation (ESR)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01666327</url>
  </study>
  <study rank="857">
    <title>Antioxidant Supplementation in Patients With Kashin-Beck Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kashin-Beck Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Biological Antioxidant Supplementation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Innovative Humanitarian Solutions</lead_sponsor>
      <collaborator>University of Houston - Victoria</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>9 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2006</first_received>
    <start_date>July 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>February 12, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Score on FLACC or Word Graphic pain rating scale at 3, 6, 9 months</outcome_measure>
      <outcome_measure>Increase in serum selenium concentrations at 6 months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00376025</url>
  </study>
  <study rank="858">
    <title>Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Razadyne ER</intervention>
      <intervention type="Drug">Aricept</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>Ortho-McNeil Neurologics, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 28, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>April 9, 2013</last_updated>
    <last_verified>June 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Brain activity patterns, as collected via functional magnetic resonance imaging (fMRI), at rest and associated with task performance after 4 weeks of low-dose treatment and after 8-weeks of higher-dose treatment.</outcome_measure>
      <outcome_measure>Differences in cognitive testing and functional status at pre-treatment baseline and after completion of the 12-week treatment trial.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00369603</url>
  </study>
  <study rank="859">
    <title>A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>139</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 31, 2006</start_date>
    <completion_date>October 1999</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Hourly mean heart rates and PR intervals during each of the 24-hour Holter monitoring periods; Twenty-four hour mean, minimum and maximum heart rates and PR intervals during each of the 24-hour Holter monitoring periods</outcome_measure>
      <outcome_measure>Pharmacokinetics and other safety parameters including ECG parameters were other parameters of interest.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00309725</url>
  </study>
  <study rank="860">
    <title>Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Everolimus-eluting stent (Xience)</intervention>
      <intervention type="Device">Zotarolimus-eluting stent (Endeavor Resolute)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Deutsches Herzzentrum Muenchen</lead_sponsor>
      <collaborator>Technische Universität München</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>650</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 10, 2008</first_received>
    <start_date>December 2007</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>July 1, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of major adverse cardiac event defined as a composite of death, myocardial infarction and target lesion revascularization.</outcome_measure>
      <outcome_measure>Angiographic restenosis at follow-up coronary angiography.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00598637</url>
  </study>
  <study rank="861">
    <title>Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine 5 and 10 cm^2 patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>208</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 19, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>April 10, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>December 15, 2010</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Regardless Whether They Completed the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Compliant to the 10 cm^2 Patch</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 24</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Trail-making Test Part A Score at Week 24</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score at Week 24</outcome_measure>
      <outcome_measure>Change From Baseline in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Physician</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Caregiver</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Mini-Zarit Inventory Score of Caregiver Burden at Week 24</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00561392</url>
  </study>
  <study rank="862">
    <title>EPI-743 for Mitochondrial Respiratory Chain Diseases</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mitochondrial Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">EPI-743</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Edison Pharmaceuticals Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Year</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>87</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 7, 2011</first_received>
    <start_date>February 2010</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>March 18, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in neuromuscular function from baseline to 13 weeks</outcome_measure>
      <outcome_measure>Number of subjects experiencing adverse events</outcome_measure>
      <outcome_measure>Change in Newcastle Pediatric Mitochondrial Disease Score from baseline at 13 weeks</outcome_measure>
      <outcome_measure>Pharmacokinetics of EPI-743 after first dose and at steady state</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01370447</url>
  </study>
  <study rank="863">
    <title>High and Low Dose Treatment of Carbidopa in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbidopa-Levodopa</intervention>
      <intervention type="Drug">Carbidopa- Levodopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oregon Health and Science University</lead_sponsor>
      <collaborator>Parkinson Disease Research, Education and Clinical Center at Portland VA Hospital</collaborator>
      <collaborator>RJG Foundation</collaborator>
      <collaborator>Oregon Clinical and Translational Research Institute</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 2, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>November 28, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Bradykinesia, assessed by alternate finger tapping</outcome_measure>
      <outcome_measure>Pharmacokinetics of levodopa</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00745277</url>
  </study>
  <study rank="864">
    <title>Robotic Locomotor Experience Applied to Parkinson's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Lokomat®</intervention>
      <intervention type="Device">Treadmill</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliero Universitaria Maggiore della Carita</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 23, 2011</first_received>
    <start_date>October 2010</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>September 26, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>6 minute walking test</outcome_measure>
      <outcome_measure>10 meter walking test</outcome_measure>
      <outcome_measure>Time Up and Go test</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01302184</url>
  </study>
  <study rank="865">
    <title>12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">KW-6002 (istradefylline)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Kirin Pharmaceutical Development, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 3, 2007</first_received>
    <start_date>April 2002</start_date>
    <completion_date>June 2003</completion_date>
    <last_updated>July 12, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa.</outcome_measure>
      <outcome_measure>To establish the efficacy of 40 mg/day istradefylline for reducing motor symptoms and improving activities of daily living (ADL) in subjects with advanced PD treated with levodopa/carbidopa.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00456586</url>
  </study>
  <study rank="866">
    <title>Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amantadine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 15, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>March 30, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Timed Up and Go (TUG)</outcome_measure>
      <outcome_measure>modified Timed Up and Go (mTUG)</outcome_measure>
      <outcome_measure>Analysis of Motor Functioning using the Parkinson's Home Diaries</outcome_measure>
      <outcome_measure>Freezing of Gait Questionnaire</outcome_measure>
      <outcome_measure>Clinical Global Impression (CGI)</outcome_measure>
      <outcome_measure>Parkinson's Disease Questionnaire-39 (PDQ-39)</outcome_measure>
      <outcome_measure>Gait Analysis Testing</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS)</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Drug Safety and Tolerability Analysis</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01652534</url>
  </study>
  <study rank="867">
    <title>Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">683699</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 18, 2005</first_received>
    <start_date>October 2004</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>April 10, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who are responders at Week 6.</outcome_measure>
      <outcome_measure>- Proportion of subjects with response at other timepoints. - Proportion of subjects in remission. - Average rate of response for the CDAI score. - Mean change from baseline in CDAI score Improvement in Quality of Life.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00101946</url>
  </study>
  <study rank="868">
    <title>Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Spondyloarthritis</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Alberta</lead_sponsor>
      <collaborator>Abbott</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 31, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>September 14, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy outcome measure will be the Ankylosing Spondylitis Assessment Study group 20 (ASAS 20) response at 24 weeks.</outcome_measure>
      <outcome_measure>ASAS 20 response</outcome_measure>
      <outcome_measure>ASAS 40, 50, 70, 5/6 responses</outcome_measure>
      <outcome_measure>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</outcome_measure>
      <outcome_measure>Bath Ankylosing Spondylitis Functional Index (BASFI)</outcome_measure>
      <outcome_measure>Patient Global Assessment of arthritic and CD-related disease activity</outcome_measure>
      <outcome_measure>Total Back Pain</outcome_measure>
      <outcome_measure>Nocturnal Back Pain</outcome_measure>
      <outcome_measure>Erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP)</outcome_measure>
      <outcome_measure>Patient Acceptable Symptom State (PASS) assessments</outcome_measure>
      <outcome_measure>Spinal mobility assessment</outcome_measure>
      <outcome_measure>Enthesitis assessment</outcome_measure>
      <outcome_measure>Crohn's Disease Activity Index (CDAI)</outcome_measure>
      <outcome_measure>Short form 36 (SF-36™)</outcome_measure>
      <outcome_measure>Helplessness scale</outcome_measure>
      <outcome_measure>Spondyloarthritis Research Consortium of Canada Magnetic Resonance Imaging Index (SPARCC MRI)</outcome_measure>
      <outcome_measure>Serum biomarkers matrix metalloproteinase 3 (MMP3), vascular endothelial growth factor (VEGF), DKK-1, Wnt, RANKL, OPG and cytokines (e.g. IL17, IL23, IL18)</outcome_measure>
      <outcome_measure>Bowel permeability</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00972218</url>
  </study>
  <study rank="869">
    <title>Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Galantamine (Reminyl®)</intervention>
      <intervention type="Drug">Placebo/Galantamine (Reminyl®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ludwig-Maximilians - University of Munich</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 29, 2007</first_received>
    <start_date>September 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>August 29, 2007</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00523666</url>
  </study>
  <study rank="870">
    <title>Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cogane™ (PYM50028)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Phytopharm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 2, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>August 20, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To investigate the safety and tolerability of Cogane™ oral solution</outcome_measure>
      <outcome_measure>To investigate the pharmacokinetic profile of Cogane™ and its metabolites</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00875316</url>
  </study>
  <study rank="871">
    <title>Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rasagiline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 19, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>December 10, 2013</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>June 14, 2013</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Modified Fatigue Impact Scale (MFIS)</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS)</outcome_measure>
      <outcome_measure>Multidimensional Fatigue Inventory (MFIS)</outcome_measure>
      <outcome_measure>PD Quality of Life Scale (PDQ39)</outcome_measure>
      <outcome_measure>Paced Auditory Serial Addition Test (PASAT)</outcome_measure>
      <outcome_measure>Finger Tapping</outcome_measure>
      <outcome_measure>Hand-grip Strength</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01168596</url>
  </study>
  <study rank="872">
    <title>HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastroesophageal Reflux</condition>
      <condition>Heartburn</condition>
      <condition>Dyspepsia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Esomeprazole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 24, 2005</first_received>
    <start_date>April 2005</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>March 25, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline after 6 months in the level of ki-67 expression and histological markers of esophageal epithelial acid-related disease after acid-suppressive therapy with esomeprazole</outcome_measure>
      <outcome_measure>Changes in immunohistochemical markers of esophageal epithelial acid-related disease after 6 months treatment with different levels of acid suppression with esomeprazole</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00243724</url>
  </study>
  <study rank="873">
    <title>The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Certolizumab Pegol</intervention>
      <intervention type="Drug">Certolizumab Pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Celltech</lead_sponsor>
      <collaborator>UCB Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 29, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>March 3, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>June 28, 2013</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects in Clinical Remission at Week 62</outcome_measure>
      <outcome_measure>Absolute Pediatric Crohn's Disease Activity Index (PCDAI) Scores at Week 62</outcome_measure>
      <outcome_measure>Change in Pediatric Crohn's Disease Activity Index (PCDAI) Scores From Week 0 to the End of the Study (Week 62)</outcome_measure>
      <outcome_measure>Percentage of Subjects Achieving Clinical Response From Week 0 to the End of the Study (Week 62)</outcome_measure>
      <outcome_measure>C-Reactive Protein (CRP) Levels at Week 62</outcome_measure>
      <outcome_measure>Change in C-Reactive Protein (CRP) Levels From Week 0 to the End of the Study (Week 62)</outcome_measure>
      <outcome_measure>Erythrocyte Sedimentation Rate (ESR) at Week 62</outcome_measure>
      <outcome_measure>Change in Erythrocyte Sedimentation Rate (ESR) From Week 0 to the End of the Study (Week 62)</outcome_measure>
      <outcome_measure>Change in Growth Scores (Tanner Stage [Assessing Puberty]) From Week 0 to the End of the Study (Week 62)</outcome_measure>
      <outcome_measure>Percentage of Subjects Who Initiated Steroid Tapering</outcome_measure>
      <outcome_measure>Percentage of Subjects in Corticosteroid-free Remission at the End of the Study</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00899678</url>
  </study>
  <study rank="874">
    <title>Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Disease</condition>
      <condition>Chronic Kidney Disease</condition>
      <condition>Chronic Renal Disease</condition>
      <condition>Hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">exercise aerobic</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of Pelotas</lead_sponsor>
      <collaborator>Ministry of Health, Brazil</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>June 30, 2010</first_received>
    <start_date>September 2011</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 1, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression of renal disease</outcome_measure>
      <outcome_measure>quality of life</outcome_measure>
      <outcome_measure>efficacy of physical exercise on blood pressure</outcome_measure>
      <outcome_measure>Effects of exercise on endothelial progenitor cells in pre-dialysis patients</outcome_measure>
      <outcome_measure>Ankle Brachial Pressure Index</outcome_measure>
      <outcome_measure>blood lipids</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01155128</url>
  </study>
  <study rank="875">
    <title>A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
      <condition>HEMOGLOBIN SS</condition>
      <condition>Hemoglobin S Beta-0 Thalassemia</condition>
      <condition>Inflammation</condition>
      <condition>Quality of Life</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)</intervention>
      <intervention type="Other">Placebo Capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Thomas Jefferson University</lead_sponsor>
      <collaborator>Drexel University</collaborator>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <max_age>19 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 14, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>October 22, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine whether supplementation with LOVAZA will exert an anti-inflammatory effect by decreasing levels of the inflammatory biomarker high sensitivity C Reactive Protein (hsCRP) in children and adolescents with Sickle Cell Disease (SCD).</outcome_measure>
      <outcome_measure>To determine whether supplementation with LOVAZA will increase health-associated quality of life (QoL) responses as they relate to clinical vasocclusive events (VOC) in children and adolescents with Sickle Cell Disease (SCD).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01202812</url>
  </study>
  <study rank="876">
    <title>Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Raynaud's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SLx-2101</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kadmon Corporation, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 11, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>March 2008</completion_date>
    <last_updated>January 26, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Raynaud's condition scores after 14 days of SLx-2101</outcome_measure>
      <outcome_measure>Safety and tolerability</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00528242</url>
  </study>
  <study rank="877">
    <title>Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rosiglitazone XR (extended release) oral tablets</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 6, 2006</first_received>
    <start_date>December 2004</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>January 10, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in global and regional cerebral glucose metabolism/Cerebral Metabolic Rate for glucose (CMRglu) as measured by the ratio of Ki to K1</outcome_measure>
      <outcome_measure>Changes in global and regional CMRglu as measured by [18F]FDG uptake.</outcome_measure>
      <outcome_measure>Global changes in brain structure from baseline as measured by structural MRI from baseline.Vital signs and ECGs.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00334568</url>
  </study>
  <study rank="878">
    <title>Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">E5555</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>720</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 5, 2006</first_received>
    <start_date>September 2007</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>December 1, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability - especially the risk of bleeding</outcome_measure>
      <outcome_measure>Incidence of major adverse cardiovascular events; the effect on platelet aggregation inhibition. Exploratory Outcome Measure: effects on endovascular inflammatory processes</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00312052</url>
  </study>
  <study rank="879">
    <title>Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive Training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Kansas</lead_sponsor>
      <collaborator>Alzheimer's Association</collaborator>
      <collaborator>University of Kansas Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>January 28, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>October 2, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Composite score of 5 cognitive tests including 1)WAIS digit span, 2) word fluency, 3) trail making test-A 4) Rey Osterrieth complex figure and 5) MMSE</outcome_measure>
      <outcome_measure>Brain activity during functional brain imaging</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00611312</url>
  </study>
  <study rank="880">
    <title>The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thyroid Eye Disease</condition>
      <condition>Ocular Hypertension</condition>
      <condition>Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prostaglandin Analog</intervention>
      <intervention type="Drug">Timolol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 16, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 19, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in appearance of facial periorbital region at 12 months.</outcome_measure>
      <outcome_measure>Change from baseline in Hertel exophthalmometry at 12 and 24 months.</outcome_measure>
      <outcome_measure>Change from baseline in intraocular pressure at 12 and 24 months.</outcome_measure>
      <outcome_measure>Change from baseline in appearance of facial periorbital region at 24 months.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01927406</url>
  </study>
  <study rank="881">
    <title>A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammation</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NNC0114-0006</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novo Nordisk A/S</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>53</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 13, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>February 17, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Crohn's disease activity index (CDAI)</outcome_measure>
      <outcome_measure>Change in CDAI</outcome_measure>
      <outcome_measure>Clinical remission, defined as CDAI of less than 150</outcome_measure>
      <outcome_measure>Change in the inflammatory bowel disease questionnaire (IBDQ) score</outcome_measure>
      <outcome_measure>Changes in the Short Form Health Survey (SF-36v2) physical and mental component scores</outcome_measure>
      <outcome_measure>Incidence of adverse events (AEs)</outcome_measure>
      <outcome_measure>Incidence of anti-NNC0114-0006 antibodies</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01751152</url>
  </study>
  <study rank="882">
    <title>Minocycline in Patients With Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Minocycline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>63</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 24, 2002</first_received>
    <start_date>September 2001</start_date>
    <completion_date>August 2003</completion_date>
    <last_updated>March 24, 2015</last_updated>
    <last_verified>December 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00029874</url>
  </study>
  <study rank="883">
    <title>Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Age Related Macular Degeneration</condition>
      <condition>Central Retinal Vein Occlusion</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ziv-aflibercept drug</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rafic Hariri University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>16 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 14, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>June 23, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Ziv-aflibercept in retinal diseases with poor vision: Safety monitoring by OCT and visual acuity</outcome_measure>
      <outcome_measure>OCT retinal structure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02173873</url>
  </study>
  <study rank="884">
    <title>Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease.</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paracalcitol</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 30, 2012</first_received>
    <start_date>June 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>October 1, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Endothelial function measurement</outcome_measure>
      <outcome_measure>Endothelial function and plasma/serum and genetic biomarkers of bone mineral disorders in CKD (BMD-CKD) and renin angiotensin-aldosteron system (RAS).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01680198</url>
  </study>
  <study rank="885">
    <title>Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aliskiren</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>March 29, 2012</first_received>
    <start_date>June 2010</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>March 29, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Measure: Pharmacokinetics of aliskiren: Area under the concentration-time curve from time zero to 48- hour post-dose (AUC(0-48hrs)), from time zero to the last measurable concentration sampling time (AUClast), from time zero to infinity (AUCinf)</outcome_measure>
      <outcome_measure>Pharmacokinetics of aliskiren: Maximum (peak) observed blood and urine drug concentration (Cmax) after single dose administration</outcome_measure>
      <outcome_measure>Pharmacokinetics of aliskiren: Time to reach maximum (peak) blood and urine drug concentration (Tmax) and elimination half-life (t1/2) after single dose administration</outcome_measure>
      <outcome_measure>Effect of timing of hemodialysis on the PK of aliskiren in End Stage Renal Disease (ESRD) patients</outcome_measure>
      <outcome_measure>Number of patients with adverse events, serious adverse events and death</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01568775</url>
  </study>
  <study rank="886">
    <title>A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastroesophageal Reflux Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">E3810</intervention>
      <intervention type="Drug">E3810</intervention>
      <intervention type="Drug">E3810</intervention>
      <intervention type="Drug">E3810</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Co., Ltd.</lead_sponsor>
      <collaborator>Eisai Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>317</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 24, 2014</first_received>
    <start_date>September 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>September 28, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of non-recurrence according to endoscopic findings (modified Los Angeles Classification) after the 52nd week of the maintenance therapy period</outcome_measure>
      <outcome_measure>Rate of non-recurrence according to endoscopic findings (modified Los Angeles Classification) after the12th and 24th week of the maintenance therapy period</outcome_measure>
      <outcome_measure>Period between randomization and recurrence of disease</outcome_measure>
      <outcome_measure>Incidence of heartburn (daytime / nighttime) during the maintenance therapy period</outcome_measure>
      <outcome_measure>Frequency of heartburn (daytime / nighttime) during the maintenance therapy period</outcome_measure>
      <outcome_measure>Severity of heartburn (daytime / nighttime) during the maintenance therapy period</outcome_measure>
      <outcome_measure>Incidence of sleep disorders during the maintenance therapy period</outcome_measure>
      <outcome_measure>Frequency of sleep disorders during the maintenance therapy period</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02135107</url>
  </study>
  <study rank="887">
    <title>The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Everolimus Eluting Stent or Zotalolimus Eluting Stent</intervention>
      <intervention type="Drug">ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>75 Years</min_age>
    <max_age>84 Years</max_age>
    <age_groups>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 3, 2012</first_received>
    <start_date>August 2010</start_date>
    <last_updated>January 9, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Major Adverse Cardiac Event</outcome_measure>
      <outcome_measure>cardiac or non-cardiac major adverse event</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01508663</url>
  </study>
  <study rank="888">
    <title>Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5745</intervention>
      <intervention type="Drug">Placebo to match GS-5745</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 28, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>February 9, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events, change from screening in laboratory tests and vital signs, and development of immunogenicity after dosing</outcome_measure>
      <outcome_measure>PK parameters of GS-5745 as measured by AUC and Cmax</outcome_measure>
      <outcome_measure>PK parameters of GS-5745 as measured by Tmax, Clast, Tlast, Ctau, λz, CL, and Vz</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02077465</url>
  </study>
  <study rank="889">
    <title>Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
      <intervention type="Drug">Placebo Patch</intervention>
      <intervention type="Drug">L-dopa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
      <collaborator>UCB Trading (Shanghai) Co. Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>346</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 18, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>January 29, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>October 8, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Percentage of Responders From Baseline to the End of the Doubleblind Maintenance Period</outcome_measure>
      <outcome_measure>Percent Change in Absolute Time Spent &quot;Off&quot; From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Percent Change in Relative Time Spent &quot;Off&quot; From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Absolute Time Spent &quot;on&quot; From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Relative Time Spent &quot;on&quot; From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Percent Change in Absolute Time Spent &quot;on&quot; From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Percent Change in Relative Time Spent &quot;on&quot; From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in the Number of &quot;Off&quot; Periods From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Status of the Subject (on) After Wake-up With Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Status of the Subject (on) After Wake-up Without Troublesome Dyskinesia From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Status of the Subject (Off) After Wake-up From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During &quot;on&quot; Periods From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01646255</url>
  </study>
  <study rank="890">
    <title>Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">rosiglitazone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 26, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>October 26, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Long term safety and tolerability of rosiglitazone (RSG) XR.</outcome_measure>
      <outcome_measure>Long-term efficacy of RSG XR in terms of orientation, memory (recent and immediate), concentration, language and praxis.</outcome_measure>
      <outcome_measure>Frequency of serious adverse events.</outcome_measure>
      <outcome_measure>Percentage of subjects with adverse event of edema</outcome_measure>
      <outcome_measure>Change from baseline in vital signs. Frequency of vital signs of clinical concern.</outcome_measure>
      <outcome_measure>Change from baseline in weight.</outcome_measure>
      <outcome_measure>Frequency of clinical chemistry (including lipids) and hematology parameters of clinical concern.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00381238</url>
  </study>
  <study rank="891">
    <title>Efficiency of Physiotherapeutic Care in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">ParkNet</intervention>
      <intervention type="Other">Usual Care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>ZonMw: The Netherlands Organisation for Health Research and Development</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>708</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 24, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>September 1, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Modified MACTAR scale</outcome_measure>
      <outcome_measure>Parkinson Activity Scale (secondary)</outcome_measure>
      <outcome_measure>Costs</outcome_measure>
      <outcome_measure>Proportion of correct referrals (tertiary)</outcome_measure>
      <outcome_measure>Quality of physiotherapy(tertiary)</outcome_measure>
      <outcome_measure>Incidence of Falls (tertiary)</outcome_measure>
      <outcome_measure>ALDS (tertiary)</outcome_measure>
      <outcome_measure>SF-36 (tertiary)</outcome_measure>
      <outcome_measure>EQ-5D (tertiary)</outcome_measure>
      <outcome_measure>Satisfaction of patients and professionals (tertiary)</outcome_measure>
      <outcome_measure>Self Assessment Disability Scale (tertiary)</outcome_measure>
      <outcome_measure>Freezing of Gait Questionnaire {tertiary}</outcome_measure>
      <outcome_measure>6 meter walk test {tertiary}</outcome_measure>
      <outcome_measure>4x3 meter walk test (tertiary)</outcome_measure>
      <outcome_measure>Single leg stance (tertiary)</outcome_measure>
      <outcome_measure>Posture and Gait score (tertiary)</outcome_measure>
      <outcome_measure>Timed Up and Go (tertiary)</outcome_measure>
      <outcome_measure>Falls Efficacy Scale {tertiary}</outcome_measure>
      <outcome_measure>9-hole pegboard test {tertiary}</outcome_measure>
      <outcome_measure>Health Anxiety and Depression Scale (tertiary)</outcome_measure>
      <outcome_measure>Physical activities assessed with the LAPAQ questionnaire (tertiary)</outcome_measure>
      <outcome_measure>Caregiver burden assessed with the Care Giver Strain Index (tertiary)</outcome_measure>
      <outcome_measure>PDQ-39 (Mobility Scale)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00330694</url>
  </study>
  <study rank="892">
    <title>Safety Study of AT1001 to Treat Celiac Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AT-1001</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alba Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 9, 2006</first_received>
    <start_date>January 2006</start_date>
    <completion_date>February 2006</completion_date>
    <last_updated>October 10, 2006</last_updated>
    <last_verified>October 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To demonstrate the safety and tolerance of single, oral doses of AT-1001 in celiac disease subjects that are gluten-free and in remission</outcome_measure>
      <outcome_measure>To determine whether quantifiable AT-1001 concentrations are present in plasma following single oral doses and to characterize the pharmacokinetic behavior of AT-1001 in celiac disease subjects that are gluten-free and in remission</outcome_measure>
      <outcome_measure>To evaluate the effects of single doses of AT-1001 on intestinal permeability ratios and zonulin levels following single, oral challenge doses of gluten (2.5 gm) by utilizing urinary lactulose and mannitol, and serum zonulin concentrations as biomarkers.</outcome_measure>
      <outcome_measure>Self-reported measures of GI discomfort</outcome_measure>
      <outcome_measure>Pharmacokinetic Measures</outcome_measure>
      <outcome_measure>Pharmacodynamic Measures</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00386165</url>
  </study>
  <study rank="893">
    <title>Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Stimulation</intervention>
      <intervention type="Procedure">Stimulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Heinrich-Heine University, Duesseldorf</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 14, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>September 10, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of stimulation of GPI versus GPR (UHDRS Scale)</outcome_measure>
      <outcome_measure>Effect of treatment on cognitive functions (neuropsychological tests)</outcome_measure>
      <outcome_measure>Effects of treatment on electrophysiological tests</outcome_measure>
      <outcome_measure>Effects of treatment on functional scale (functional ability, dependence scale, TFC)</outcome_measure>
      <outcome_measure>Progression of disease (motor UHDRS)</outcome_measure>
      <outcome_measure>Effect of treatment on striatal atrophy (CT Scans)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00902889</url>
  </study>
  <study rank="894">
    <title>Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Graves Disease</condition>
      <condition>Hyperthyroidism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Potassium Iodide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Massachusetts, Worcester</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 22, 2009</first_received>
    <start_date>April 2005</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>October 9, 2015</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Blood Loss During Surgery</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00946296</url>
  </study>
  <study rank="895">
    <title>Efficacy, Safety, and Tolerability of GS-4997 in Participants With Diabetic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-4997</intervention>
      <intervention type="Drug">Placebo to match GS-4997</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>334</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 26, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>August 30, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in estimated glomerular filtration rate (eGFR) from baseline at Week 48</outcome_measure>
      <outcome_measure>Proportion of participants achieving at least a 30% reduction from baseline in albuminuria at Week 48</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02177786</url>
  </study>
  <study rank="896">
    <title>The Effect of Donepezil on Gait and Balance in Parkinson's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Donepezil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oregon Health and Science University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 12, 2012</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>January 25, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sensory organization test</outcome_measure>
      <outcome_measure>iTUG- measuring walking gait using inertial sensors</outcome_measure>
      <outcome_measure>Concentration and Memory</outcome_measure>
      <outcome_measure>Sensory Organization Test</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01521117</url>
  </study>
  <study rank="897">
    <title>A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ASP0777</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 6, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>November 17, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number and percentage of subjects with adverse events</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment of AUC, maximum concentration (Cmax), minimum concentration (Cmin) and time to maximum concentration (tmax) through analysis of blood samples</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01406145</url>
  </study>
  <study rank="898">
    <title>An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rivastigmine Transdermal Patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>868</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 14, 2005</first_received>
    <start_date>February 2003</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability as measured by adverse events, vital signs and skin irritation for up to 28 weeks treatment</outcome_measure>
      <outcome_measure>Change in cognition from baseline (week 24 of the double blind phase) at week 52</outcome_measure>
      <outcome_measure>Clinical global impression of change from baseline at week 52</outcome_measure>
      <outcome_measure>Change in activities of daily living from baseline at week 52</outcome_measure>
      <outcome_measure>Change in behavioral symptoms from baseline at week 52</outcome_measure>
      <outcome_measure>Change in executive function from baseline at week 52</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00219232</url>
  </study>
  <study rank="899">
    <title>Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PolyPill</intervention>
      <intervention type="Other">Minimal care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
      <collaborator>Golestan University of Medical Science</collaborator>
      <collaborator>University of Birmingham</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>7000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>December 14, 2010</first_received>
    <start_date>February 2011</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>May 6, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to first major cardiovascular event</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Fasting blood sugar, total cholesterol, HDL-C and LDL-C</outcome_measure>
      <outcome_measure>Number of Subjects Developing Adverse Events</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Rate of major cardiovascular events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01271985</url>
  </study>
  <study rank="900">
    <title>Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HEMOGLOBIN SC DISEASE</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mg Pidolate</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>Texas Children's Hospital</collaborator>
      <collaborator>Boston Children’s Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 26, 2002</first_received>
    <start_date>January 2001</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>November 15, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Evaluation of whether treatment with oral Mg pidolate decreases the number of painful crises.</outcome_measure>
      <outcome_measure>Evaluation of tolerance of long-term treatment with oral Mg pidolate.</outcome_measure>
      <outcome_measure>To find out if treatment with oral Mg pidolate increases the intracellular Mg content of erythrocytes.</outcome_measure>
      <outcome_measure>Evaluations of the effect of Mg pidolate therapy on the K-Cl cotransport activity and RBC hydration status</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00040456</url>
  </study>
  <study rank="901">
    <title>Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tolvaptan (OPC-41061)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 25, 2014</first_received>
    <start_date>September 2014</start_date>
    <last_updated>November 1, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety variables</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02251275</url>
  </study>
  <study rank="902">
    <title>Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">adalimumab</intervention>
      <intervention type="Biological">adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>945</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 8, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>October 6, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>July 24, 2009</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5.</outcome_measure>
      <outcome_measure>Number of Participants Who Were Responders at Week 20 of Treatment. A Responder Was Defined as a Participant Who Had a Decrease of 3 or More on the HBI.</outcome_measure>
      <outcome_measure>Number of Participants Who Had a Reduction in Number of Draining Fistulas of at Least 50% From Baseline to Week 20</outcome_measure>
      <outcome_measure>Number of Participants Who Had Extra-intestinal Manifestations (EIM) at Baseline and Resolution by Week 20.</outcome_measure>
      <outcome_measure>Mean Change in Total Score of Short Inflammatory Bowel Disease Questionnaire (SIBDQ) From Baseline to Week 20</outcome_measure>
      <outcome_measure>Mean Change in Percent Work Time Missed Due to Crohn's Disease From Baseline to Week 20 of Treatment</outcome_measure>
      <outcome_measure>Mean Change in Percent Impairment While Working From Baseline to Week 20 of Treatment</outcome_measure>
      <outcome_measure>Mean Change in Overall Work Productivity and Activity Impairment Score From Baseline to Week 20</outcome_measure>
      <outcome_measure>Mean Change in Activity Impairment Score From Baseline to Week 20</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00409617</url>
  </study>
  <study rank="903">
    <title>Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hodgkin's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vinblastine sulfate</intervention>
      <intervention type="Drug">Dacarbazine</intervention>
      <intervention type="Drug">Filgrastim</intervention>
      <intervention type="Drug">Bleomycin sulfate</intervention>
      <intervention type="Drug">Doxorubicin hydrochloride</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>Amgen</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>November 2, 1999</start_date>
    <completion_date>February 1999</completion_date>
    <last_updated>May 22, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00000626</url>
  </study>
  <study rank="904">
    <title>Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Frontotemporal Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">florbetapir 18F</intervention>
      <intervention type="Drug">18F-FDG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Avid Radiopharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>June 27, 2013</first_received>
    <start_date>September 2009</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>September 16, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>September 10, 2014</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Qualitative Amyloid Image Assessment</outcome_measure>
      <outcome_measure>Quantitative Amyloid Image Assessment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01890343</url>
  </study>
  <study rank="905">
    <title>Primary Prevention of Allergic Disease in Early Child by Lactobacillus Reuteri</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Allergic Conditions</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Lactobacillus reuteri</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Linkoeping University</lead_sponsor>
      <collaborator>BioGaia AB, Sweden</collaborator>
      <collaborator>The Ekhaga Foundation, Sweden</collaborator>
      <collaborator>The Heart and Lung foundation, Sweden</collaborator>
      <collaborator>The Research Council for the South-East Sweden</collaborator>
      <collaborator>The Swedish Asthma and Allergy Association, Sweden</collaborator>
      <collaborator>The Swedish Research Council</collaborator>
      <collaborator>University Hospital, Linkoeping</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>232</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 27, 2011</first_received>
    <start_date>February 2001</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>March 19, 2014</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Allergic disease</outcome_measure>
      <outcome_measure>Sensitization</outcome_measure>
      <outcome_measure>IgE-associated allergic disease</outcome_measure>
      <outcome_measure>Lactobacillus reuteri colonization in stool and breast milk</outcome_measure>
      <outcome_measure>Cytokines in breast milk</outcome_measure>
      <outcome_measure>Th1 and Th2- associated chemokines in blood samples</outcome_measure>
      <outcome_measure>Microbial composition in stool samples</outcome_measure>
      <outcome_measure>Allergic disease at 7 years of age</outcome_measure>
      <outcome_measure>Prevalence of caries in primary dentition at 8 years of age</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01285830</url>
  </study>
  <study rank="906">
    <title>Adaptive Support Ventilation in the Weaning of COPD</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Disease, Chronic Obstructive</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Comparison of two different modes for weaning from mechanical ventilation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>97</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <first_received>August 31, 2009</first_received>
    <start_date>April 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>May 26, 2010</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Weaning duration</outcome_measure>
      <outcome_measure>Weaning success</outcome_measure>
      <outcome_measure>Length of stay in the ICU</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00969605</url>
  </study>
  <study rank="907">
    <title>Ketasyn in Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ketasyn™ (AC-1202)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Accera, Inc.</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 1, 2005</first_received>
    <start_date>October 2004</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>December 30, 2008</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Changes measured by Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at all 5 visits</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change (ADCS-CGIC) at visits 2 through 5</outcome_measure>
      <outcome_measure>Mini-Mental State Exam (MMSE) at all 5 visits</outcome_measure>
      <outcome_measure>Changes measured by Electrocardiogram (ECG) at visits 1 and 5</outcome_measure>
      <outcome_measure>Beta-Hydroxybutyrate pre-dose levels at all 5 visits</outcome_measure>
      <outcome_measure>Beta-Hydroxybutyrate 2-hour post-dose levels at visits 2, 3, and 4</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00142805</url>
  </study>
  <study rank="908">
    <title>Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Drug: EVP-6124</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FORUM Pharmaceuticals Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>403</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 21, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>May 2, 2016</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog-13) to Day 182</outcome_measure>
      <outcome_measure>Change from Baseline in the Clinical Dementia Rating Sum of the Boxes (CDR-SB) to Day 182</outcome_measure>
      <outcome_measure>Safety and tolerability of EVP-6124 or Placebo in Subjects with AD</outcome_measure>
      <outcome_measure>Change from Baseline in activities of daily living using the Disability Assessment for Dementia (DAD)</outcome_measure>
      <outcome_measure>Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Change from Baseline in the Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change from Baseline in the Controlled Oral Word Association Test (COWAT)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01969136</url>
  </study>
  <study rank="909">
    <title>Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Drug: EVP-6124</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FORUM Pharmaceuticals Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>474</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 21, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>May 2, 2016</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog-13) to Day 182</outcome_measure>
      <outcome_measure>Change from Baseline in the Clinical Dementia Rating Sum of the Boxes (CDR-SB) to Day 182</outcome_measure>
      <outcome_measure>Safety and tolerability of EVP-6124 or Placebo in Subjects with AD</outcome_measure>
      <outcome_measure>Change from Baseline in activities of daily living using the Disability Assessment for Dementia (DAD)</outcome_measure>
      <outcome_measure>Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Change from Baseline in the Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change from Baseline in the Controlled Oral Word Association Test (COWAT)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01969123</url>
  </study>
  <study rank="910">
    <title>Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Stem Cell Transplantation</condition>
      <condition>Bone Marrow Transplantation</condition>
      <condition>Peripheral Blood Stem Cell Transplantation</condition>
      <condition>Allogeneic Transplantation,</condition>
      <condition>Genetic Diseases</condition>
      <condition>Thalassemia</condition>
      <condition>Pediatrics</condition>
      <condition>Diamond-Blackfan Anemia</condition>
      <condition>Combined Immune Deficiency</condition>
      <condition>Wiskott-Aldrich Syndrome</condition>
      <condition>Chronic Granulomatous Disease</condition>
      <condition>X-linked Lymphoproliferative Disease</condition>
      <condition>Metabolic Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cyclophosphamide Dose Level 1</intervention>
      <intervention type="Drug">Cyclophosphamide Dose Level 2</intervention>
      <intervention type="Drug">Cyclophosphamide Dose Level 3</intervention>
      <intervention type="Drug">Cyclophosphamide Dose Level 4</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Hospital Los Angeles</lead_sponsor>
      <collaborator>Lucile Packard Children's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 21, 2015</first_received>
    <start_date>February 2007</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>May 11, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>January 29, 2016</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Neutrophil Engraftment (=/&gt;500 Cells/uL) and Platelet Engraftment (&gt;20K Cell/uL) at 30 Days</outcome_measure>
      <outcome_measure>Number of Participants With Disease Recurrence at 1 Year Post-transplant</outcome_measure>
      <outcome_measure>Number of Participants Who Developed Severe Mucositis, Veno-occlusive Disease (VOD), Toxicity of the Kidney, Liver, or Gastrointestinal (GI) Tract up to 1 Year Post-transplant</outcome_measure>
      <outcome_measure>Number of Participants Who Developed Graft-Versus-Host-Disease (GVHD) as Determined by the Glucksberg Scale</outcome_measure>
      <outcome_measure>Number of Participants Who Were Disease Progression-Free and Death-Free at 1 Year Post-transplant</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02512679</url>
  </study>
  <study rank="911">
    <title>Dose-Dependent Effect of Thiazide in Dent's Disease Hypercalciuria</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dent's Disease</condition>
      <condition>Nephrolithiasis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydrochlorothiazide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>3 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 12, 2008</first_received>
    <start_date>July 2003</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>March 17, 2008</last_updated>
    <last_verified>July 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>to investigate the dose-dependent benefit/risk ratio of low (6.25 mg/day), intermediate (12.5 mg/day) and high (25 mg/day) doses of hydrochlorothiazide</outcome_measure>
      <outcome_measure>clinical events (cramps, symptomatic dehydration, acute weight loss)</outcome_measure>
      <outcome_measure>Biological : acute renal failure (estimated GFR), hypokalemia, hyperkalemia, hyponatremia, biological signs of extra cellular dehydration (protides, hematocrit, plasma active renin, plasma aldosterone)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00638482</url>
  </study>
  <study rank="912">
    <title>The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune Inner Ear Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">gevokizumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>XOMA (US) LLC</lead_sponsor>
      <collaborator>Feinstein Institute for Medical Research</collaborator>
      <collaborator>National Institute on Deafness and Other Communication Disorders (NIDCD)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 20, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>February 2, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improved hearing threshold, as defined by an improvement in either the PTA (Pure Tone Average) of &gt;=5 dB (Decibel), or 12% in the WRS (Word Recognition Score)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01950312</url>
  </study>
  <study rank="913">
    <title>Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ACC-001 + QS-21</intervention>
      <intervention type="Biological">ACC-001</intervention>
      <intervention type="Biological">QS-21</intervention>
      <intervention type="Drug">Placebo: Phosphate buffered saline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
      <collaborator>Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 24, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>May 6, 2014</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104</outcome_measure>
      <outcome_measure>GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104</outcome_measure>
      <outcome_measure>Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00479557</url>
  </study>
  <study rank="914">
    <title>A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">risperidone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 3, 2006</first_received>
    <start_date>March 2002</start_date>
    <completion_date>March 2003</completion_date>
    <last_updated>May 20, 2011</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change in Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) psychotic symptom cluster score from baseline and intermediate visits to study end (Week 9) compared with placebo.</outcome_measure>
      <outcome_measure>Changes in BEHAVE-AD total, subscales and items scores, changes in CMAI aggressiveness and non-aggressiveness item scores and changes in CGI-C from baseline and intermediate visits to study end (Week 9) compared with placebo. Safety evaluations.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00287742</url>
  </study>
  <study rank="915">
    <title>A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Pelvic Inflammatory Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Moxifloxacin (Avelox, BAY12-8039)</intervention>
      <intervention type="Drug">Levofloxacin &amp; Metronidazole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bayer</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>460</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 27, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>September 2, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>September 1, 2009</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population</outcome_measure>
      <outcome_measure>Clinical Response 7 to 14 Days After Completion of Study Drug Therapy on Intent To Treat (ITT) Population</outcome_measure>
      <outcome_measure>Clinical Response on Treatment for Per Protocol Population</outcome_measure>
      <outcome_measure>Clinical Response on Treatment for Intent To Treat Population</outcome_measure>
      <outcome_measure>Bacteriological Response at Test Of Cure (TOC) Visit Microbiologically Valid</outcome_measure>
      <outcome_measure>Bacteriological Response at Test Of Cure (TOC) Visit in Intent To Treat Population With Causative Organism</outcome_measure>
      <outcome_measure>Clinical Response at Follow-up Visit on Per Protocol Population</outcome_measure>
      <outcome_measure>Clinical Response at Follow-up Visit on Intent To Treat Population</outcome_measure>
      <outcome_measure>Bacteriological Response at Follow-up Visit Microbiologically Valid</outcome_measure>
      <outcome_measure>Bacteriological Response at Follow-up Visit in Intent To Treat Population With Causative Organism</outcome_measure>
      <outcome_measure>Number of Subjects Who Received Alternative Medicine</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00453349</url>
  </study>
  <study rank="916">
    <title>Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Allopurinol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Dundee</lead_sponsor>
      <collaborator>NHS Tayside</collaborator>
      <collaborator>British Heart Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 18, 2010</first_received>
    <start_date>February 2011</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>March 24, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Onset of claudication pain</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Anti-oxidant effects</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01147705</url>
  </study>
  <study rank="917">
    <title>The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">probiotics</intervention>
      <intervention type="Dietary Supplement">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Baruch Padeh Medical Center, Poriya</lead_sponsor>
      <collaborator>Ministry of Health, Israel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>March 1, 2010</first_received>
    <start_date>December 2012</start_date>
    <last_updated>August 10, 2011</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Truelove and Witts Classification of Ulcerative Colitis</outcome_measure>
      <outcome_measure>Crohn's disease activity index (CDAI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01078935</url>
  </study>
  <study rank="918">
    <title>Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">doxycycline</intervention>
      <intervention type="Drug">rifampicin</intervention>
      <intervention type="Drug">Placebo matched to doxycycline</intervention>
      <intervention type="Drug">Placebo matched to Rifampin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hamilton Health Sciences Corporation</lead_sponsor>
      <collaborator>The Physicians' Services Incorporated Foundation</collaborator>
      <collaborator>McMaster University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 20, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>July 27, 2010</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical Dementia Rating scale</outcome_measure>
      <outcome_measure>Standardized Alzheimer's disease Assessment Scale -cognitive subscale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00439166</url>
  </study>
  <study rank="919">
    <title>Study of IRX4204 for Treatment of Early Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IRX4204</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Io Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 7, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>May 7, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>striatal binding ratio (SBR)</outcome_measure>
      <outcome_measure>Total Motor and UPDRS scores</outcome_measure>
      <outcome_measure>Safety including hematology and chemistry laboratories, vital signs, and adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02438215</url>
  </study>
  <study rank="920">
    <title>Virtual Exercises in Patients With Parkinson's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Patients With Parkinson's Disease.</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Virtual exercises</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Faculdade Evangelica do Parana</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 23, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>October 4, 2015</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Functional exercise capacity</outcome_measure>
      <outcome_measure>Fatigue</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02023034</url>
  </study>
  <study rank="921">
    <title>Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">Rotigotine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>349</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 18, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>April 9, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>October 25, 2013</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to the End of Maintenance in Total Nonmotor Symptoms Scale (NMSS) Score</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in Total Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in Health-related Quality of Life (HRQL) Measured by a 39-item Parkinson's Disease Questionnaire (PDQ-39)</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Cardiovascular</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Sleep/Fatigue</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Mood/Cognition</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Perception/Hallucinations</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Attention/Memory,</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Gastrointestinal Tract</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Urinary</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Sexual Function</outcome_measure>
      <outcome_measure>Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Miscellaneous</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01300819</url>
  </study>
  <study rank="922">
    <title>Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BF2.649 (Pitolisant)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bioprojet</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>273</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 9, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 11, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ESS change (Epworth Sleepiness Scale) versus baseline</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01066442</url>
  </study>
  <study rank="923">
    <title>A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Disease, Chronic Obstructive</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CNTO 6785</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>187</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 17, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>June 6, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in prebronchodilator (before taking an inhaled bronchodilator) Forced Expiratory Volume in 1 second (FEV1) at Week 16</outcome_measure>
      <outcome_measure>Change from baseline in postbronchodilator (after taking an inhaled bronchodilator) Forced Expiratory Volume in 1 second (FEV1) at Week 16</outcome_measure>
      <outcome_measure>Change from baseline in weekly average number of occasions in a day that rescue medication is used at Week 16</outcome_measure>
      <outcome_measure>Change from baseline in EXAcerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms™ (E-RS™) at Week 16</outcome_measure>
      <outcome_measure>Change from baseline at Week 16 in total score of the St George's respiratory questionnaire for Chronic Obstructive Pulmonary Disease (COPD) participants (SGRQ-C)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01966549</url>
  </study>
  <study rank="924">
    <title>Topical Cyclosporine and Disease Progression</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Disease Progression</condition>
      <condition>Disease Severity</condition>
      <condition>Staining</condition>
      <condition>Schirmers</condition>
      <condition>OSDI</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Restasis</intervention>
      <intervention type="Drug">Endura</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Innovative Medical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 3, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>September 23, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Disease Severity</outcome_measure>
      <outcome_measure>Staining</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00567983</url>
  </study>
  <study rank="925">
    <title>Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Memantine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Florida Atlantic University</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 17, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>August 7, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>September 20, 2013</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint).</outcome_measure>
      <outcome_measure>Fuld Object Memory Evaluation</outcome_measure>
      <outcome_measure>Rey Complex Figure Test</outcome_measure>
      <outcome_measure>Trail Making Test - Part A</outcome_measure>
      <outcome_measure>Trail Making Test - Part B</outcome_measure>
      <outcome_measure>Mini Mental Status Exam</outcome_measure>
      <outcome_measure>Useful Field of View</outcome_measure>
      <outcome_measure>Motor Free Visual Perception Test - Visual Closure Subtest</outcome_measure>
      <outcome_measure>Cognitive Dementia Rating Scale</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00476008</url>
  </study>
  <study rank="926">
    <title>DIM as a Treatment for Thyroid Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Proliferative Thyroid Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Diindolylmethane (DIM)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The New York Eye &amp; Ear Infirmary</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>April 30, 2013</first_received>
    <start_date>November 2006</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>April 30, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evidence of objective and quantifiable changes in thyroid size as a resalt of the oral administration of DIM, confirmed by pre- and post- DIM treatment ultrasounds</outcome_measure>
      <outcome_measure>Evidence of DIM's effect on estrogen metabolites, confirmed by plasma and urine analysis</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01846364</url>
  </study>
  <study rank="927">
    <title>High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">4-Aminosalicylic acid</intervention>
      <intervention type="Drug">PASER placebo granules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Jacobus Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 2, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>October 14, 2008</last_updated>
    <last_verified>October 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response, as defined by a reduction of the CDAI score of &gt;70 points by 4 weeks compared with baseline</outcome_measure>
      <outcome_measure>Rate of remission as defined by the decrease in CDAI &gt; 100 points and total CDAI &lt; 150 by 4 weeks</outcome_measure>
      <outcome_measure>Rate of response as defined by a reduction in HBI to less than 5 by 4 weeks</outcome_measure>
      <outcome_measure>Rate of remission as defined by the decrease in HBI to less than 3 by 4 weeks</outcome_measure>
      <outcome_measure>Time to response and/or remission including time to change in HBI, according to elements of the daily patient diary</outcome_measure>
      <outcome_measure>Increase in IBDQ to greater than 170 and the time to score above 170</outcome_measure>
      <outcome_measure>The change from baseline in the patient's general sense of disease activity as recorded in the individual daily diary</outcome_measure>
      <outcome_measure>Absence of night time stools, if they were present on entry, and time to disappearance</outcome_measure>
      <outcome_measure>Time to normalization of all other components in the diary</outcome_measure>
      <outcome_measure>Change in Hgb, ESR, CRP, platelet count, calprotectin from baseline and time to normalization</outcome_measure>
      <outcome_measure>Change in global physician assessment of disease activity from baseline to study completion</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00417690</url>
  </study>
  <study rank="928">
    <title>Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Quality of Life</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Resonator Device</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>pico-tesla Magnetic Therapies, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 13, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 13, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in PDQ-39 single index score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00863226</url>
  </study>
  <study rank="929">
    <title>A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">6R-BH4 (sapropterin dihydrochloride)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioMarin Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>15 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 7, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>September 4, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the safety of oral 6R-BH4 administered in escalating doses to subjects with sickle cell disease (SCD)</outcome_measure>
      <outcome_measure>To evaluate changes in physiological and biochemical markers of endothelial function in subjects with SCD receiving escalating doses of oral 6R-BH4</outcome_measure>
      <outcome_measure>Tertiary Outcome: To evaluate changes in clinical measures of SCD in subjects receiving oral 6R-BH4 for up to 2 years</outcome_measure>
      <outcome_measure>Tertiary Outcome: To evaluate changes in the 6-minute walk (6MW) test in subjects receiving oral 6R-BH4 for up to 2 years</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00445978</url>
  </study>
  <study rank="930">
    <title>Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Disease</condition>
      <condition>Cardiovascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cholate testing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
      <collaborator>University of Colorado, Denver</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>June 24, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>May 2018</completion_date>
    <last_updated>August 2, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Liver Function</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02506335</url>
  </study>
  <study rank="931">
    <title>The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">gemfibrozil</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
      <collaborator>Parke-Davis</collaborator>
      <collaborator>Fournier Labs</collaborator>
    </sponsors>
    <gender>Male</gender>
    <max_age>73 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2531</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 25, 2006</first_received>
    <start_date>June 1991</start_date>
    <completion_date>August 1999</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 1998</primary_completion_date>
    <outcome_measures>
      <outcome_measure>incidence of nonfatal myocardial infarction or death from coronary heart disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00283335</url>
  </study>
  <study rank="932">
    <title>Study to Evaluate SPI-1005 in Adults With Meniere's Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Meniere's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPI-1005</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sound Pharmaceuticals, Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>19 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 2, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>June 9, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability of SPI-1005 using histories, physical exams, and clinical measures.</outcome_measure>
      <outcome_measure>Plasma Ebselen levels of SPI-1005 before, during, and after 21 days of dosing</outcome_measure>
      <outcome_measure>Plasma Selenium levels before, during, and after 21 days of dosing</outcome_measure>
      <outcome_measure>Impact on Sensorineural Hearing Loss</outcome_measure>
      <outcome_measure>Impact on Speech Discrimination</outcome_measure>
      <outcome_measure>Impact on Tinnitus</outcome_measure>
      <outcome_measure>Impact on Vertigo</outcome_measure>
      <outcome_measure>Pharmacodynamic response</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02603081</url>
  </study>
  <study rank="933">
    <title>Improving Health Habits in Impoverished Populations</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes</condition>
      <condition>Chronic Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Self-Care Stimulating Disease Prevention Program</intervention>
      <intervention type="Behavioral">Fighting Cancer with Advice</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>December 5, 2007</first_received>
    <start_date>November 2008</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>June 6, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum glycosylated hemoglobin, heart rate recovery step test</outcome_measure>
      <outcome_measure>Total Cholesterol, BMI, waist circumference, healthy eating, physical activity, perceived health status, patient satisfaction, mood</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00569595</url>
  </study>
  <study rank="934">
    <title>Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Behçet's Disease</condition>
      <condition>Uveitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intravitreal Infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 26, 2015</first_received>
    <start_date>January 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Best Corrected Visual Acuity in logMAR</outcome_measure>
      <outcome_measure>Central Foveal Thickness in microns by Optical Coherence Tomography</outcome_measure>
      <outcome_measure>Electroretinogram a and b waves amplitudes in microvolts</outcome_measure>
      <outcome_measure>Vitritis severity graded 0-3</outcome_measure>
      <outcome_measure>Electroretinogram a and b waves implicit times in milliseconds</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02620618</url>
  </study>
  <study rank="935">
    <title>Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY2886721</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>March 21, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>January 7, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to 12 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations</outcome_measure>
      <outcome_measure>Change from baseline to 26 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations</outcome_measure>
      <outcome_measure>Change from baseline in plasma amyloid beta (Aβ)1-40 and Aβ1-42 concentrations</outcome_measure>
      <outcome_measure>Change from baseline to 26 weeks in Neuropsychological Test Battery (NTB)</outcome_measure>
      <outcome_measure>Change from baseline to 26 weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</outcome_measure>
      <outcome_measure>Change from baseline to 26 weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)</outcome_measure>
      <outcome_measure>Change from baseline to 26 weeks in Mini Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Change from baseline in cerebrospinal fluid (CSF) tau and phosphorylated tau (ptau) 181 concentrations</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01561430</url>
  </study>
  <study rank="936">
    <title>A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Galantamine HBr</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xian-Janssen Pharmaceutical Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>215</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 24, 2008</first_received>
    <start_date>March 2004</start_date>
    <completion_date>February 2005</completion_date>
    <last_updated>May 18, 2011</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Primary endpoint (ADAS-cog/11) decreased 5.4 ± 6.4 and 4 .0 ± 7.3 in galantamine and Donepezil group respectively after 16-week treatment from baseline of 22.5 ± 9.3 and 23.3 ± 9.7 respectively, showing the non-inferiority in term of efficacy.</outcome_measure>
      <outcome_measure>Secondary endpoint is responder rate. It showed 78% responder rate in galantamine group and 58% responder rate in Donepezil group after 16 weeks.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00645190</url>
  </study>
  <study rank="937">
    <title>Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atorvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>77</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>June 9, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>July 20, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>improvement of endothelial dysfunction with endo-PAT2000</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00917527</url>
  </study>
  <study rank="938">
    <title>Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease (CHD)</condition>
      <condition>CHD Risk-Equivalent Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">anacetrapib</intervention>
      <intervention type="Drug">Comparator: placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 23, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>November 29, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in Low Density Lipoprotein Cholesterol</outcome_measure>
      <outcome_measure>Number of participants with hepatitis-related adverse experiences</outcome_measure>
      <outcome_measure>Number of participants with Alanine Transaminase consecutive elevations greater than or equal to 3xULN (Upper Limit of Normal)</outcome_measure>
      <outcome_measure>Number of participants with Aspartate Aminotransferase consecutive elevations greater than or equal to 3xULN</outcome_measure>
      <outcome_measure>Number of participants with Creatine Phosphokinase elevations greater than or equal to 10xULN</outcome_measure>
      <outcome_measure>Number of participants with Creatine Phosphokinase elevations greater than or equal 10xULN with muscle symptoms</outcome_measure>
      <outcome_measure>Number of participants with sodium, chloride, or bicarbonate elevations greater than ULN</outcome_measure>
      <outcome_measure>Number of participants with reduction in potassium levels less than LLN (Lower Limit of Normal)</outcome_measure>
      <outcome_measure>Number of participants with myalgia</outcome_measure>
      <outcome_measure>Number of participants with rhabdomyolysis</outcome_measure>
      <outcome_measure>Number of participants with pre-specified adjudicated cardiovascular serious adverse events</outcome_measure>
      <outcome_measure>Number of participants with death from any cause</outcome_measure>
      <outcome_measure>Number of participants with significant increase in Blood Pressure</outcome_measure>
      <outcome_measure>Change from baseline in High Density Lipoprotein Cholesterol</outcome_measure>
      <outcome_measure>Change from baseline in non-High Density Lipoprotein Cholesterol</outcome_measure>
      <outcome_measure>Change from baseline in Apolipoprotein B</outcome_measure>
      <outcome_measure>Change from baseline in Apolipoprotein A-1</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00685776</url>
  </study>
  <study rank="939">
    <title>Huperzine A in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Huperzine A</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute on Aging (NIA)</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
      <collaborator>Neuro-Hitech</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 26, 2004</first_received>
    <start_date>April 2004</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>February 19, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00083590</url>
  </study>
  <study rank="940">
    <title>Methylphenidate and Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">methylphenidate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oregon Health and Science University</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 31, 2006</first_received>
    <start_date>July 2004</start_date>
    <last_updated>September 3, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Time &quot;on&quot; defined by tapping speed</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00359723</url>
  </study>
  <study rank="941">
    <title>A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TPI-287 2 mg/m2</intervention>
      <intervention type="Drug">TPI-287 6.3 mg/m2</intervention>
      <intervention type="Drug">TPI-287 20 mg/m2</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>82 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <first_received>October 14, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>December 5, 2016</last_updated>
    <last_verified>December 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum tolerated dose of TPI-287</outcome_measure>
      <outcome_measure>TPI-287 levels in blood plasma and cerebrospinal fluid</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01966666</url>
  </study>
  <study rank="942">
    <title>Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NVA237</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>460</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 27, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>July 16, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 3, 2014</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Trough Forced Expiratory Volume in One Second (FEV1)</outcome_measure>
      <outcome_measure>Transition Dyspnea Index (TDI) Score</outcome_measure>
      <outcome_measure>Change From Baseline in Daily Rescue Medication Use (Number of Puffs)</outcome_measure>
      <outcome_measure>24h Trough FEV1</outcome_measure>
      <outcome_measure>FEV1 and Forced Vital Capacity (FVC)</outcome_measure>
      <outcome_measure>Peak FEV1</outcome_measure>
      <outcome_measure>Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose</outcome_measure>
      <outcome_measure>Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)</outcome_measure>
      <outcome_measure>Time to First Moderate or Severe COPD Exacerbation</outcome_measure>
      <outcome_measure>Number of Moderate and Severe COPD Exacerbations</outcome_measure>
      <outcome_measure>The Total Score of the St George's Respiratory Questionnaire (SGRQ)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01566604</url>
  </study>
  <study rank="943">
    <title>Computer-Based Training for Mild Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Computer-based Cognitive Training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Posit Science Corporation</lead_sponsor>
      <collaborator>University of California, San Francisco</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 27, 2006</first_received>
    <start_date>September 2004</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>May 13, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective of this trial will be to assess the feasibility of using computer-based</outcome_measure>
      <outcome_measure>cognitive training in an a population with early Alzheimer's Disease.</outcome_measure>
      <outcome_measure>A standardized set of neuropsychological assessments will be conducted pre- and post-</outcome_measure>
      <outcome_measure>compuer-based training.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00319891</url>
  </study>
  <study rank="944">
    <title>Transpulmonary Thermodilution Measurements in Patients With Heart Diseases</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Device">PiCCO Catheter (Pulsiocath 5F)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 2, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>June 25, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cardiac Output, Preload values (GEDV)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02035007</url>
  </study>
  <study rank="945">
    <title>A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Gaucher Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Taliglucerase alfa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Protalix</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>2 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 26, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>November 10, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>October 28, 2014</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hemoglobin</outcome_measure>
      <outcome_measure>Chitotriosidase</outcome_measure>
      <outcome_measure>Spleen Volume</outcome_measure>
      <outcome_measure>Platelet Count</outcome_measure>
      <outcome_measure>Chemokine (C-C Motif) Ligand 18 (CCL18)</outcome_measure>
      <outcome_measure>Liver Volume</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01132690</url>
  </study>
  <study rank="946">
    <title>Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Indacaterol 150 μg</intervention>
      <intervention type="Drug">Salmeterol 50 μg</intervention>
      <intervention type="Drug">Placebo to Indacaterol</intervention>
      <intervention type="Drug">Placebo to Salmeterol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1002</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 4, 2007</first_received>
    <start_date>November 2007</start_date>
    <last_updated>July 22, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>July 22, 2011</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment</outcome_measure>
      <outcome_measure>St. George's Respiratory Questionnaire (SGRQ) Total Score After 12 Weeks of Treatment</outcome_measure>
      <outcome_measure>Percentage of COPD &quot;Days of Poor Control&quot; During 26 Weeks of Treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00567996</url>
  </study>
  <study rank="947">
    <title>Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifabutin, Clarithromycin, and Clofazimine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medstar Health Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 6, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>March 2008</completion_date>
    <last_updated>August 7, 2007</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Clinical remission by a decline in Crohns disease activity index to &lt;151</outcome_measure>
      <outcome_measure>Clinical improvement using inflammatory bowel disease quality of life questionnaire</outcome_measure>
      <outcome_measure>Endoscopic improvement using Crohn's disease endoscopic activity index</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00513552</url>
  </study>
  <study rank="948">
    <title>An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK1605786A</intervention>
      <intervention type="Drug">GSK1605786A</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>255</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 16, 2012</first_received>
    <start_date>November 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>March 6, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects achieving clinical response at Week 12</outcome_measure>
      <outcome_measure>Proportion of subjects in clinical remission at Week 12</outcome_measure>
      <outcome_measure>Proportion of subjects with clinical response at both Week 8 and Week 12</outcome_measure>
      <outcome_measure>Proportion of subjects with clinical remission at both Week 8 and Week 12</outcome_measure>
      <outcome_measure>Proportion of subjects with clinical response at Week 8</outcome_measure>
      <outcome_measure>C-reactive protein concentration</outcome_measure>
      <outcome_measure>Faecal calprotectin</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01536418</url>
  </study>
  <study rank="949">
    <title>Efficacy and Safety of Filgrastim in Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">G-CSF; filgrastim</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of South Florida</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 8, 2011</first_received>
    <start_date>June 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>November 26, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>June 29, 2012</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01617577</url>
  </study>
  <study rank="950">
    <title>Exercise Interventions in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Exercise Programme</intervention>
      <intervention type="Behavioral">Hand Writing programme</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oxford Brookes University</lead_sponsor>
      <collaborator>National Institute for Health Research, United Kingdom</collaborator>
      <collaborator>Royal Berkshire NHS Foundation Trust (participant identification centre)</collaborator>
      <collaborator>Nuffield Orthopaedic Centre NHS Trust (participant identification centre)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 15, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>October 20, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Two minute walk from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Two minute walk from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Two minute walk from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Time Up and Go (TUG) from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Nine hole peg test from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in SF-36 from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in EQ-5D from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Prescribed medication from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Blood Pressure from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Body Mass Index from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in aerobic fitness from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Leg power from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Grip Strength from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Disease Status from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in Non-motor symptoms from baseline at 3 months</outcome_measure>
      <outcome_measure>change in reported Physical Activity from baseline at 3 months</outcome_measure>
      <outcome_measure>Change measured physical activity from baseline at 3 months</outcome_measure>
      <outcome_measure>Process Evaluation</outcome_measure>
      <outcome_measure>Adherence</outcome_measure>
      <outcome_measure>Change in Time Up and Go (TUG) from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Time Up and Go (TUG) from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Nine hole peg test from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Nine hole peg test from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in SF-36 from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in SF-36 from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in EQ-5D from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in EQ-5D from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Prescribed medication from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Prescribed medication from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Blood Pressure from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Blood Pressure from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Body Mass Index from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in aerobic fitness from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Leg power from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Leg power from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Grip Strength from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Grip Strength from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Disease Status from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Disease Status from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in Non-motor symptoms from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in Non-motor symptoms from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in reported Physical Activity from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in reported Physical Activity from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change measured physical activity from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change measured physical activity from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change in FSS from baseline at 3 months</outcome_measure>
      <outcome_measure>Change in FSS from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change in FSS from 6 months at 12 months</outcome_measure>
      <outcome_measure>Change upper limb function from baseline at 3 months</outcome_measure>
      <outcome_measure>Change upper limb function from 3 months at 6 months</outcome_measure>
      <outcome_measure>Change upper limb function from 6 months at 12 months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01439022</url>
  </study>
  <study rank="951">
    <title>Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">KW-6500</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Hakko Kirin Company, Limited</lead_sponsor>
      <collaborator>Kyowa Hakko Kirin Co., Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 7, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>August 30, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The incidence of adverse events after administration of KW-6500</outcome_measure>
      <outcome_measure>Time to expression of the ON state, continuous time of the ON state, raw score change and percent score change in Unified Parkinson's Disease Rating Scale (UPDRS) part III, response ratio, and UPDRS part II score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00955318</url>
  </study>
  <study rank="952">
    <title>A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Dyskinesia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltoprazine HCl</intervention>
      <intervention type="Drug">Eltoprazine HCl</intervention>
      <intervention type="Drug">Eltoprazine HCl</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amarantus BioScience Holdings, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 13, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>April 20, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical impact of dyskinesia measured by total UDysRS (Unified Dyskinesia Rating Scale) score</outcome_measure>
      <outcome_measure>• PD motor symptoms assessed by MDS-UPDRS, diaries and physiological measurement with motion sensor system</outcome_measure>
      <outcome_measure>Dyskinesia severity using physiological motion sensor system</outcome_measure>
      <outcome_measure>Patient function using MDS-UPDRS and UDysRS questionnaires quantify dyskinesia and Parkinsonian motor symptoms.</outcome_measure>
      <outcome_measure>Safety and tolerability: adverse events, physical and neurological exams, safety laboratory values, vital signs and ECG</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02439125</url>
  </study>
  <study rank="953">
    <title>Simvastatin (Zocor) Therapy in Sickle Cell Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Hospital &amp; Research Center Oakland</lead_sponsor>
      <collaborator>Department of Health and Human Services</collaborator>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 26, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>August 20, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>February 11, 2013</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Total Cholesterol Level</outcome_measure>
      <outcome_measure>Change in Hemoglobin Level</outcome_measure>
      <outcome_measure>Change in Serum Creatine Kinase Levels</outcome_measure>
      <outcome_measure>Change in Serum Alanine Transaminase (ALT) Levels</outcome_measure>
      <outcome_measure>Change in Serum Creatinine Levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00508027</url>
  </study>
  <study rank="954">
    <title>Deep Brain Stimulation (DBS) for Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Deep Brain Stimulation (Fornix DBS)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 9, 2008</first_received>
    <start_date>March 2007</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>April 7, 2010</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>memory performance on neuropsychological tests</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00658125</url>
  </study>
  <study rank="955">
    <title>Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease, Idiopathic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPM 962</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>506</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 24, 2005</first_received>
    <start_date>March 2004</start_date>
    <completion_date>July 2005</completion_date>
    <last_updated>September 24, 2014</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2005</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00244387</url>
  </study>
  <study rank="956">
    <title>Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Istradefylline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyowa Hakko Kirin Company, Limited</lead_sponsor>
      <collaborator>Kyowa Hakko Kirin Co., Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>308</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 7, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>August 30, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Reducing the mean total hours of awake time per day spent in the OFF state</outcome_measure>
      <outcome_measure>Reducing the mean percentage of awake time per day spent in the OFF state</outcome_measure>
      <outcome_measure>Mean change in the total hours and the percentage of awake time per day spent in the ON state (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia)</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Change in the Clinical Global Impression - Improvement scale (CGI-I)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00957203</url>
  </study>
  <study rank="957">
    <title>A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Memantine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
      <collaborator>Huntington Society of Canada</collaborator>
      <collaborator>Huntington Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 20, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>March 17, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Utility of TRACK-HD study endpoints in a clinical trial setting</outcome_measure>
      <outcome_measure>Neuropsychiatric and Cognitive Test Scores</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01458470</url>
  </study>
  <study rank="958">
    <title>Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5745</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>187</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 27, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>September 2020</completion_date>
    <last_updated>November 15, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving clinical response at Week 8</outcome_measure>
      <outcome_measure>Proportion of participants achieving endoscopic response at Week 8</outcome_measure>
      <outcome_measure>Proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission at Week 8</outcome_measure>
      <outcome_measure>Proportion of participants achieving mucosal healing at Week 8</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02405442</url>
  </study>
  <study rank="959">
    <title>Different Doses of IVIG for Kawasaki Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kawasaki Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IVIG (1g/kg,once)</intervention>
      <intervention type="Drug">IVIG (1g/kg,twice)</intervention>
      <intervention type="Drug">IVIG (2g/kg.once)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Hospital of Fudan University</lead_sponsor>
      <collaborator>Shanghai Children's Medical Center</collaborator>
      <collaborator>Children's Hospital of Shanghai Jiaotong University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Month</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>547</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 7, 2015</first_received>
    <start_date>January 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 8, 2016</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The fever days of KD patients</outcome_measure>
      <outcome_measure>incidence of coronary artery lesions(CAL)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02439996</url>
  </study>
  <study rank="960">
    <title>Amitiza in Constipation Associated With PD (Parkinson's Disease)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LUBIPROSTONE</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>University of South Florida</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 21, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>July 18, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>February 12, 2016</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline to End of Study</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00908076</url>
  </study>
  <study rank="961">
    <title>Effects of Talampanel on Patients With Advanced Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dyskinesias</condition>
      <condition>Parkinson Disease</condition>
      <condition>Movement Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">talampanel</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Pharmaceutical Industries</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 8, 2002</first_received>
    <start_date>December 2006</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>April 11, 2011</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2007</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00036296</url>
  </study>
  <study rank="962">
    <title>Autologous Bone Marrow Stem Cell Transplantation for Hip Osteonecrosis in Sickle Cell Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Avascular Necrosis of Femur Head</condition>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Stem Cell Graft Group</intervention>
      <intervention type="Biological">Autologous bone marrow stem cell</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of Bahia</lead_sponsor>
      <collaborator>Hospital Universitário Professor Edgard Santos</collaborator>
      <collaborator>Oswaldo Cruz Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 15, 2015</first_received>
    <start_date>August 2006</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Harris Hip Score of 10 points or more</outcome_measure>
      <outcome_measure>Numeric pain intensity scale (0-10)</outcome_measure>
      <outcome_measure>Disease progression defined as progression to a fractural stage of osteonecrosis</outcome_measure>
      <outcome_measure>Reoperation rate</outcome_measure>
      <outcome_measure>Radiological progression</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02448121</url>
  </study>
  <study rank="963">
    <title>National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">minocycline</intervention>
      <intervention type="Drug">creatine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>195</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 23, 2003</first_received>
    <start_date>May 2003</start_date>
    <completion_date>July 2005</completion_date>
    <last_updated>January 19, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2005</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00063193</url>
  </study>
  <study rank="964">
    <title>Development of NIC5-15 in the Treatment of Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NIC5-15</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
      <collaborator>Humanetics Corporation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 4, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>November 1, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic analysis, Safety Assessments including vital signs, physical exam, Symptom Checklist (see below), complete blood count, serum chemistries, urinalysis, and electrocardiogram, Symptom Checklist, ADAScog</outcome_measure>
      <outcome_measure>Clinician's Global Impression of Change (ADCS-CGIC), Mini-Mental Status Exam (MMSE), Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory, Insulin Sensitivity and Secretion, Biomarkers. APO-E genotyping.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00470418</url>
  </study>
  <study rank="965">
    <title>Neural Correlates In Mild Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">donepezil HCl (Aricept)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Inc.</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 23, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>May 6, 2009</last_updated>
    <last_verified>May 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Functional magnetic resonance imaging to identify neural correlates of cognitive improvement after 3 months of donepezil HCl in subjects w/ mild AD, using the Functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion</outcome_measure>
      <outcome_measure>Mini Mental State Exam, Alzheimer's Disease Assess,emt Scale-cognitive subscale, Neuropsychiatric Inventory and Instrumental Activities of Daily Living scales at screen and week 12.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00477659</url>
  </study>
  <study rank="966">
    <title>Minocycline in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Mild Cognitive Impairment</condition>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Minocycline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Huntington Medical Research Institutes</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 25, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>September 23, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>October 25, 2012</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</outcome_measure>
      <outcome_measure>Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).</outcome_measure>
      <outcome_measure>Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01463384</url>
  </study>
  <study rank="967">
    <title>Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Levodopa (drug), intraduodenal administration</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Akershus</lead_sponsor>
      <collaborator>Solvay Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 6, 2006</first_received>
    <start_date>January 2006</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>December 29, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Marginal cost per QALY of replacing conventional treatment with intraduodenal levodopa</outcome_measure>
      <outcome_measure>Quality of life at three, six, nine and twelve months(Assessed by Nottingham Health Profile (NHP), Parkinson Disease Questionnaire (PDQ39), 15D Quality of life)</outcome_measure>
      <outcome_measure>Parkinson related function at three, six, nine and twelve months(UPDRS, Hoehn and Yahr scores, Schwab and England)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00272688</url>
  </study>
  <study rank="968">
    <title>GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DMXB-A</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>CoMentis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 19, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>April 2007</completion_date>
    <last_updated>April 18, 2007</last_updated>
    <last_verified>December 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>CDR</outcome_measure>
      <outcome_measure>ADAS-cog</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00414622</url>
  </study>
  <study rank="969">
    <title>Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End-Stage Renal Disease</condition>
      <condition>Stage 5 Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telavancin</intervention>
      <intervention type="Procedure">Pharmacokinetic Blood Sampling</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
      <collaborator>Theravance Biopharma Antibiotics, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>March 12, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>March 25, 2016</last_updated>
    <last_verified>March 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic Parameters of Telavancin</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02392208</url>
  </study>
  <study rank="970">
    <title>MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MK0249</intervention>
      <intervention type="Drug">Comparator: Placebo (unspecified)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 9, 2007</first_received>
    <start_date>November 2006</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>January 28, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>October 25, 2010</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Week 4 Change From Baseline in Computerized Neuropsychological Test Battery (CNTB): Short CNTB Summary Score.</outcome_measure>
      <outcome_measure>Week 4 Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): ADAS-Cog Total Score</outcome_measure>
      <outcome_measure>Week 4 Change From Baseline in Cognition Summary Score (CSS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00420420</url>
  </study>
  <study rank="971">
    <title>Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">masitinib (AB1010)</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AB Science</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 11, 2009</first_received>
    <start_date>February 2006</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>May 21, 2013</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>change from baseline in ADAS-Cog</outcome_measure>
      <outcome_measure>change from baseline in CIBIC-plus</outcome_measure>
      <outcome_measure>change from baseline in CDR</outcome_measure>
      <outcome_measure>change from baseline in MMSE</outcome_measure>
      <outcome_measure>change from baseline in NPI</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00976118</url>
  </study>
  <study rank="972">
    <title>The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Caffeine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sheba Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>November 27, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>February 24, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Flow-mediated dilation (FMD) as surrogate of brachial artery endothelial function</outcome_measure>
      <outcome_measure>Markers of inflammation such as hs-CRP, Il6, homocysteine, serum caffeine level</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00564824</url>
  </study>
  <study rank="973">
    <title>Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">donepezil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vanderbilt University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>December 5, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 15, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in brain activation patterns as measured in an fMRI.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00408525</url>
  </study>
  <study rank="974">
    <title>Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SLV308</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Solvay Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 22, 2005</first_received>
    <start_date>October 2005</start_date>
    <last_updated>January 29, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00134251</url>
  </study>
  <study rank="975">
    <title>Safety Study of GCS-100 to Treat Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GCS-100</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>La Jolla Pharmaceutical Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 26, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>June 19, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of Safety</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01717248</url>
  </study>
  <study rank="976">
    <title>Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Etanercept</intervention>
      <intervention type="Dietary Supplement">Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Life Extension Foundation Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>60 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>October 5, 2012</first_received>
    <start_date>February 2010</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>May 10, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference in effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Mini-Mental Status Examination (MMSE) score.</outcome_measure>
      <outcome_measure>Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) score.</outcome_measure>
      <outcome_measure>Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Montreal Cognitive Assessment (MoCA) score.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01716637</url>
  </study>
  <study rank="977">
    <title>A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rituximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 8, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>September 6, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The efficacy of the combination of rituximab and prednisone as initial therapy for C-GVHD, which is defined as discontinuation of immunosuppressive therapy at 12 months with resolution of reversible manifestations of C-GVHD</outcome_measure>
      <outcome_measure>To determine the response rate to treatment, defined as complete response plus partial response (PR) for rituximab and prednisone</outcome_measure>
      <outcome_measure>To determine the rate of recurrent C-GVHD following initial therapy with rituximab and prednisone</outcome_measure>
      <outcome_measure>To determine the relapse rate of the underlying malignancy for which the allo-SCT was performed from time of study registration after treatment with rituximab and prednisone</outcome_measure>
      <outcome_measure>To determine the rate of infection requiring treatment with anti-bacterial, anti-fungal or anti-viral therapy from time of study registration after treatment with rituximab and prednisone</outcome_measure>
      <outcome_measure>To determine overall survival of treated patients from time of study registration to a maximum of 3 years following study registration for patients receiving rituximab and prednisone</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01066598</url>
  </study>
  <study rank="978">
    <title>Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Paget's Disease of Bone</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Zoledronic acid</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 15, 2008</first_received>
    <start_date>October 2008</start_date>
    <last_updated>April 23, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of patients who achieve therapeutic response (a reduction of at least 75% from baseline in total Serum Alkaline Phosphatase (SAP) excess or normalization of SAP.</outcome_measure>
      <outcome_measure>The percent change from baseline in total Serum Alkaline Phosphatase (SAP).</outcome_measure>
      <outcome_measure>The percent change from baseline in serum cross-linked C-telopeptide of type I collagen (CTX).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00774020</url>
  </study>
  <study rank="979">
    <title>Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">CERE-120: AAV2-NTN</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ceregene</lead_sponsor>
      <collaborator>Sangamo Biosciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 11, 2005</first_received>
    <start_date>June 2005</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>September 2, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00252850</url>
  </study>
  <study rank="980">
    <title>A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Certolizumab Pegol (CDP870)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>604</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <first_received>September 8, 2005</first_received>
    <start_date>December 2003</start_date>
    <completion_date>May 2005</completion_date>
    <last_updated>September 6, 2013</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>In the population with CRP ≥ 10 mg/L at baseline</outcome_measure>
      <outcome_measure>Clinical response at week 6</outcome_measure>
      <outcome_measure>Clinical response at week 6 and week 26</outcome_measure>
      <outcome_measure>In the population with CRP ≥ 10 mg/L at baseline - % patients in clinical remission at Week 6; % patients in clinical remission at both Week 6 and Week 26; % patients with IBDQ response at Week 6; % patients with IBDQ response at both Week 6 and Week 2</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00152490</url>
  </study>
  <study rank="981">
    <title>Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pramipexole</intervention>
      <intervention type="Drug">Bromocriptine</intervention>
      <intervention type="Drug">Placebo pramipexole</intervention>
      <intervention type="Drug">Placebo bromocriptine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>315</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 20, 2014</first_received>
    <start_date>April 1999</start_date>
    <last_updated>June 20, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2000</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in total score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)</outcome_measure>
      <outcome_measure>Change from baseline in total score of UPDRS Part III (Motor Examination)</outcome_measure>
      <outcome_measure>Changes from baseline in sores of individual items on UPDRS Part II</outcome_measure>
      <outcome_measure>Changes from baseline in scores of individual items on UPDRS Part III</outcome_measure>
      <outcome_measure>Change from baseline in area under the curve (AUC) in the UPDRS Part II score</outcome_measure>
      <outcome_measure>Change from baseline in area under the curve (AUC) in the UPDRS Part III score</outcome_measure>
      <outcome_measure>Change from baseline in total score of UPDRS Part I (mentation, behaviour and mood)</outcome_measure>
      <outcome_measure>Change from baseline in total score of UPDRS Part IV (complications of therapy)</outcome_measure>
      <outcome_measure>Change from baseline in total score of UPDRS Part I-III</outcome_measure>
      <outcome_measure>Change from baseline in total score of UPDRS Part I-IV</outcome_measure>
      <outcome_measure>Change from baseline in Modified Hoehn &amp; Yahr stage</outcome_measure>
      <outcome_measure>Clinical global impression of efficacy</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)</outcome_measure>
      <outcome_measure>Number of patients with abnormal changes in laboratory parameters</outcome_measure>
      <outcome_measure>Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02172573</url>
  </study>
  <study rank="982">
    <title>A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AVE8112</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Michael J. Fox Foundation for Parkinson's Research</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 26, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>October 2, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Tolerated Dose (MTD)</outcome_measure>
      <outcome_measure>Pharmacodynamics</outcome_measure>
      <outcome_measure>Pharmacokinetics</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01803945</url>
  </study>
  <study rank="983">
    <title>Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chagas Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Benznidazole</intervention>
      <intervention type="Drug">Posaconazole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Universitari Vall d'Hebron Research Institute</lead_sponsor>
      <collaborator>Hospital Vall d'Hebron</collaborator>
      <collaborator>Tropical Medicine and International Health Unit Drassanes. Barcelona</collaborator>
      <collaborator>International Health Unit Metropolitana Nord. Santa Coloma.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 20, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 9, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Parasitological cure measured by a real time PCR in blood sample</outcome_measure>
      <outcome_measure>Parasitological cure measured by real time PCR in blood sample</outcome_measure>
      <outcome_measure>Safety and tolerability of both drugs</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01162967</url>
  </study>
  <study rank="984">
    <title>Effect of Robot-assisted Gait Training on Freezing of Gait in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Lokomat</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>January 7, 2009</first_received>
    <start_date>October 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>September 18, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Freezing of Gait</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00819949</url>
  </study>
  <study rank="985">
    <title>Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dementia</condition>
      <condition>Alzheimer Disease</condition>
      <condition>Mental Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">risperidone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>473</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 2, 2002</first_received>
    <start_date>December 2000</start_date>
    <completion_date>January 2003</completion_date>
    <last_updated>January 31, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to end of treatment (Week 8) in Psychosis Cluster Score of Pathology from the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) Rating Scale and Clinical Global Impression (CGI).</outcome_measure>
      <outcome_measure>Change in BEHAVE-AD total score and subscales (other than Psychosis Cluster subscale) from baseline; improvement in CGI scores during treatment; incidence of adverse events throughout study.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00034762</url>
  </study>
  <study rank="986">
    <title>A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PRT-201</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Proteon Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 22, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>April 8, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the safety of a single topical dose of PRT-201.</outcome_measure>
      <outcome_measure>Primary graft patency</outcome_measure>
      <outcome_measure>Secondary graft patency.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01001351</url>
  </study>
  <study rank="987">
    <title>Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Budesonide/formoterol (Symbicort® Turbuhaler®)</intervention>
      <intervention type="Drug">Tiotropium (SpirivaTM)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>793</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 27, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>March 25, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>June 18, 2014</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pre-dose FEV1</outcome_measure>
      <outcome_measure>Post-dose FEV1 at 5 Minutes</outcome_measure>
      <outcome_measure>Post-dose FEV1 at 60 Minutes</outcome_measure>
      <outcome_measure>Pre-dose FVC</outcome_measure>
      <outcome_measure>Post-dose FVC at 5 Minutes</outcome_measure>
      <outcome_measure>Post-dose FVC at 60 Minutes</outcome_measure>
      <outcome_measure>Pre-dose IC</outcome_measure>
      <outcome_measure>Post-dose IC at 60 Minutes</outcome_measure>
      <outcome_measure>Pre-dose PEF in Last Week of Treatment</outcome_measure>
      <outcome_measure>Pre-dose PEF in First Week of Treatment</outcome_measure>
      <outcome_measure>Pre-dose PEF in Whole Treatment Period</outcome_measure>
      <outcome_measure>Post-dose PEF in Last Week of Treatment</outcome_measure>
      <outcome_measure>Post-dose PEF in First Week of Treatment</outcome_measure>
      <outcome_measure>Post-dose PEF in Whole Treatment Period</outcome_measure>
      <outcome_measure>Use of Reliever Medication During Day in the Last Week on Treatment</outcome_measure>
      <outcome_measure>Use of Reliever Medication During Day in the First Week on Treatment</outcome_measure>
      <outcome_measure>Use of Reliever Medication During Day in the Whole Treatment Period</outcome_measure>
      <outcome_measure>Use of Reliever Medication During Night in the Last Week on Treatment</outcome_measure>
      <outcome_measure>Use of Reliever Medication During Night in the First Week on Treatment</outcome_measure>
      <outcome_measure>Use of Reliever Medication During Night in the Whole Treatment Period</outcome_measure>
      <outcome_measure>Change in COPD Symptoms - Breathing</outcome_measure>
      <outcome_measure>Change in COPD Symptoms - Cough</outcome_measure>
      <outcome_measure>Change in COPD Symptoms - Sputum</outcome_measure>
      <outcome_measure>COPD Exacerbations</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01397890</url>
  </study>
  <study rank="988">
    <title>A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Donepezil (Aricept)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>249</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 27, 2008</first_received>
    <start_date>October 2002</start_date>
    <completion_date>October 2004</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-severe) total score</outcome_measure>
      <outcome_measure>Change from baseline in Severe Impairment Battery (SIB) total score</outcome_measure>
      <outcome_measure>Change from baseline in SIB total score</outcome_measure>
      <outcome_measure>Change from baseline in Neuropsychiatric Inventory (NPI) total score</outcome_measure>
      <outcome_measure>Change from inclusion in Mini Mental State Examination (MMSE) total score</outcome_measure>
      <outcome_measure>Change from baseline in Clinical Global Impression of Improvement (CGI-I) score</outcome_measure>
      <outcome_measure>Adverse events and laboratory value changes</outcome_measure>
      <outcome_measure>Change from baseline in modified ADCS-ADL-severe total score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00630851</url>
  </study>
  <study rank="989">
    <title>Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lymphoproliferative Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">therapeutic allogeneic lymphocytes</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Edinburgh</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 9, 2002</first_received>
    <start_date>March 2001</start_date>
    <last_updated>December 18, 2013</last_updated>
    <last_verified>June 2002</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Complete response</outcome_measure>
      <outcome_measure>Partial response</outcome_measure>
      <outcome_measure>Stable disease</outcome_measure>
      <outcome_measure>Progressive disease</outcome_measure>
      <outcome_measure>Time to complete remission</outcome_measure>
      <outcome_measure>Survival at 2 years</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00033475</url>
  </study>
  <study rank="990">
    <title>OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gaucher Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">OGT 918</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>4 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 9, 2002</first_received>
    <start_date>July 2002</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>September 26, 2015</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00041535</url>
  </study>
  <study rank="991">
    <title>Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">paricalcitol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>216</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 25, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>December 20, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>November 7, 2011</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels</outcome_measure>
      <outcome_measure>The Proportion of Subjects Achieving a Final Intact Parathyroid Hormone Value Between 150 and 300 pg/mL</outcome_measure>
      <outcome_measure>The Change From Baseline to the Final Observation in Intact Parathyroid Hormone Value</outcome_measure>
      <outcome_measure>The Change From Baseline to the Final Observation in Calcium</outcome_measure>
      <outcome_measure>The Change From Baseline to the Final Observation in Calcium-phosphorus Product</outcome_measure>
      <outcome_measure>The Change From Baseline to the Final Observation in the Vital Sign of Systolic Blood Pressure</outcome_measure>
      <outcome_measure>The Change From Baseline to the Final Observation in the Vital Sign of Diastolic Blood Pressure</outcome_measure>
      <outcome_measure>The Change From Baseline to the Final Observation in the Vital Sign of Heart Rate</outcome_measure>
      <outcome_measure>The Proportion of Subjects With 2 Consecutive Calcium Measurements Greater Than 11.0 mg/dL (2.75 mmol/L)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01071070</url>
  </study>
  <study rank="992">
    <title>Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nerve Growth Factor</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>NsGene A/S</lead_sponsor>
      <collaborator>Karolinska Institutet</collaborator>
      <collaborator>Stockholm County Council, Sweden</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 14, 2010</first_received>
    <start_date>January 2008</start_date>
    <last_updated>July 15, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01163825</url>
  </study>
  <study rank="993">
    <title>The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mild to Severe Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Donepezil HCl</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eisai Inc.</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>97</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 6, 2007</first_received>
    <start_date>January 2008</start_date>
    <last_updated>October 29, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>MMSE (Mini Mental State Examination).</outcome_measure>
      <outcome_measure>CAS (Caregiver Activity Survey), NPI-8( Neuropsychiatric Inventory), ADRQl (Alzheimer Disease-related Quality of Life), and DAD (Disability Assessment in Dementia)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00571064</url>
  </study>
  <study rank="994">
    <title>A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Graft vs Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ASEDs</intervention>
      <intervention type="Drug">Saline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
      <collaborator>The EMMES Corporation</collaborator>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 23, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>October 26, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>May 24, 2016</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Participants Who Experienced a ≥ 50% Reduction in the Combined Score of the Modified Oxford Punctate Keratopathy Grading and the NIH/National Eye Institute (NEI) Visual Analogue Scale in the Study Eye From Baseline to Month 3.</outcome_measure>
      <outcome_measure>Number of Systemic and Ocular Toxicities and Adverse Events</outcome_measure>
      <outcome_measure>Number of Participants Withdrawn From the Study Treatment Due to Vision Loss, Adverse Events or Treatment Failure</outcome_measure>
      <outcome_measure>Mean Change in the Combined Score of the Modified Oxford Punctate Keratopathy Grading and the NIH Visual Analogue Scale in the Study Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the Combined Score of the Modified Oxford Punctate Keratopathy Grading and the NIH Visual Analogue Scale in the Fellow Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the Combined Score of the Modified Oxford Punctate Keratopathy Grading and the NIH Visual Analogue Scale in the Study Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the Combined Score of the Modified Oxford Punctate Keratopathy Grading and the NIH Visual Analogue Scale in the Fellow Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the Chronic Ocular GVHD Composite Assessment Scale (CAS) Score in the Study Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the Chronic Ocular GVHD Composite Assessment Scale (CAS) Score in the Fellow Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the Chronic Ocular GVHD Composite Assessment Scale (CAS) Score in the Study Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the Chronic Ocular GVHD Composite Assessment Scale (CAS) Score in the Fellow Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) in the Study Eye at 3 Months Compared to Baseline.</outcome_measure>
      <outcome_measure>Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) in the Fellow Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) in the Study Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) in the Fellow Eye at 6 Months Compared to Baseline.</outcome_measure>
      <outcome_measure>Mean Change in Tear Stability (Tear Break-up Time) in the Study Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Tear Stability (Tear Break-up Time) in the Fellow Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Tear Stability (Tear Break-up Time) in the Study Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Tear Stability (Tear Break-up Time) in the Fellow Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Tear Composition (Tear Osmolarity) in the Study Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Tear Composition (Tear Osmolarity) in the Study Eye at 6 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Tear Composition (Tear Osmolarity) in the Fellow Eye at 3 Months Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in Tear Composition (Tear Osmolarity) in the Fellow Eye at 6 Months Compared to Baseline</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01972438</url>
  </study>
  <study rank="995">
    <title>Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lymphoproliferative Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MEDI-507</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MedImmune LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 22, 2005</first_received>
    <start_date>April 2004</start_date>
    <last_updated>June 12, 2007</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To determine the maximum tolerated dose (MTD) or the optimal biological dose</outcome_measure>
      <outcome_measure>(OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with</outcome_measure>
      <outcome_measure>CD-2 positive lymphoproliferative disorders.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00123942</url>
  </study>
  <study rank="996">
    <title>Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CVT-301</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Acorda Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 23, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>May 4, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in average Unified Parkinson's Disease Rating Scale Part III motor score</outcome_measure>
      <outcome_measure>Time to resolution of OFF episode to an ON state.</outcome_measure>
      <outcome_measure>To characterize the safety (including pulmonary safety)of CVT-301 when used chronically to provide relief from OFF episodes.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01777555</url>
  </study>
  <study rank="997">
    <title>Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ACC-001 3 μg/ QS-21 50 μg</intervention>
      <intervention type="Biological">ACC-001 10 μg/ QS-21 50 μg</intervention>
      <intervention type="Other">Placebo- Phosphate buffered saline (PBS)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
      <collaborator>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>63</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 22, 2010</first_received>
    <start_date>February 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>January 28, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>February 9, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest (ROIs)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01227564</url>
  </study>
  <study rank="998">
    <title>ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Leuprolide acetate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Voyager Pharmaceutical Corporation</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 25, 2003</first_received>
    <start_date>March 2003</start_date>
    <completion_date>February 2006</completion_date>
    <last_updated>December 10, 2009</last_updated>
    <last_verified>February 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2006</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00063310</url>
  </study>
  <study rank="999">
    <title>PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">L-citrulline tablets, 1000 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Angiogenix</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 21, 2006</start_date>
    <last_updated>June 21, 2006</last_updated>
    <last_verified>June 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>PK and PD responses to L-citrulline</outcome_measure>
      <outcome_measure>Endpoints will be determined as change from baseline</outcome_measure>
      <outcome_measure>Assessment of safety and tolerability of L-citrulline,</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00343954</url>
  </study>
  <study rank="1000">
    <title>Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coat's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">anecortave acetate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Manhattan Eye, Ear &amp; Throat Hospital</lead_sponsor>
      <collaborator>Alcon Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>March 2002</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>October 23, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>to investigate the use of anecortave acetate in coats's disease</outcome_measure>
      <outcome_measure>mean change in ETDRS visual acuity , OCT, leakage in FA compared at baseline at month 24.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00211315</url>
  </study>
</search_results>
